<!DOCTYPE html>
<html lang="en">

  <head>
    <meta charset="utf-8">
    </meta>
    <title>Metadata reference</title>
  </head>

  <body>
    <h1>Metadata reference</h1>
    <div id="tocContainer">
      <ul>
        <li><a href="#package">Package ID</a></li>
        <li><a href="#trackedEntityTypes">Tracked Entity Types</a></li>
        <li><a href="#trackedEntityAttributes">Tracked Entity Attributes</a></li>
        <li><a href="#programs">Programs</a></li>
        <li><a href="#programRules">Program Rules</a></li>
        <li><a href="#programIndicators">Program Indicators</a></li>
        <li><a href="#constants">Constants</a></li>
        <li><a href="#dataElements">Data Elements</a></li>
        <li><a href="#dataElementGroups">Data Element Groups</a></li>
        <li><a href="#categoryCombos">Category Combos</a></li>
        <li><a href="#categories">Categories</a></li>
        <li><a href="#categoryOptions">Category Options</a></li>
        <li><a href="#categoryOptionCombos">Category Option Combos</a></li>
        <li><a href="#optionSets">Option Sets</a></li>
        <li><a href="#options">Options</a></li>
        <li><a href="#indicatorGroups">Indicator Groups</a></li>
        <li><a href="#indicators">Indicators</a></li>
        <li><a href="#indicatorTypes">Indicator Types</a></li>
        <li><a href="#programIndicatorGroups">Program Indicator Groups</a></li>
        <li><a href="#userGroups">User Groups</a></li>
      </ul>
    </div>
    <h2>Package info</h2>
    <table>
      <tr>
        <th>Property</th>
        <td>Value</td>
      </tr>
      <tr>
        <th>Code</th>
        <td>TB</td>
      </tr>
      <tr>
        <th>Type</th>
        <td>DRS</td>
      </tr>
      <tr>
        <th>Version</th>
        <td>TRACKER</td>
      </tr>
      <tr>
        <th>DHIS2 version</th>
        <td>V0.9.0</td>
      </tr>
      <tr>
        <th>Created</th>
        <td>DHIS2.33</td>
      </tr>
      <tr>
        <th>Identifier</th>
        <td>TB_DRS_TRACKER_V0.9.0_DHIS2.33_2020-10-01T11:06</td>
      </tr>
    </table>
    <h2 id="trackedEntityTypes">Tracked entity types</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Person</td>
        <td>2020-08-13</td>
        <td>MCPQUTHX1Ze</td>
      </tr>
    </table>
    <h3>Tracked Entity Type - Tracked Entity Type Attributes</h3>
    <table>
      <tr>
        <th>Tracked Entity Type</th>
        <th>Tracked Entity Type Attribute</th>
      </tr>
      <tr>
        <td>Person</td>
        <td>gqLw62UZlrD</td>
      </tr>
      <tr>
        <td>Person</td>
        <td>hKZ9AJpnVcG</td>
      </tr>
      <tr>
        <td>Person</td>
        <td>loHxNJH4IvV</td>
      </tr>
      <tr>
        <td>Person</td>
        <td>qb8PkSObwqh</td>
      </tr>
    </table>
    <h2 id="trackedEntityAttributes">Tracked entity attributes</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Code</th>
        <th>Description</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Cluster ID</td>
        <td></td>
        <td></td>
        <td>2020-06-26</td>
        <td>aOrGt5JE0gV</td>
      </tr>
      <tr>
        <td>Family name</td>
        <td></td>
        <td>Family name of the patient</td>
        <td>2020-08-13</td>
        <td>aW66s2QSosT</td>
      </tr>
      <tr>
        <td>Patient DRS ID</td>
        <td></td>
        <td></td>
        <td>2020-06-26</td>
        <td>BdvE9shT6GX</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td></td>
        <td>Sex of Person</td>
        <td>2020-08-13</td>
        <td>CklPZdOd6H1</td>
      </tr>
      <tr>
        <td>Location of Residence</td>
        <td></td>
        <td>The location (coordinates) of the place of residence</td>
        <td>2020-08-04</td>
        <td>f038nOc9uRF</td>
      </tr>
      <tr>
        <td>Administrative Area of Residence</td>
        <td></td>
        <td></td>
        <td>2020-07-30</td>
        <td>ljHL8NnSEAD</td>
      </tr>
      <tr>
        <td>Date of birth (age)</td>
        <td></td>
        <td>Date of birth plus calculated age</td>
        <td>2020-09-24</td>
        <td>mAWcalQYYyk</td>
      </tr>
      <tr>
        <td>TB Registration Number</td>
        <td></td>
        <td></td>
        <td>2020-06-29</td>
        <td>ntelZthDPpR</td>
      </tr>
      <tr>
        <td>Country of origin</td>
        <td></td>
        <td>Patient's country of origin</td>
        <td>2020-06-26</td>
        <td>PBdqXh8Nvuj</td>
      </tr>
      <tr>
        <td>Patient DRS Serial Number</td>
        <td></td>
        <td></td>
        <td>2020-06-26</td>
        <td>Qj7EXFIXcyc</td>
      </tr>
      <tr>
        <td>Health Facility Code</td>
        <td></td>
        <td>From master facility list</td>
        <td>2020-08-04</td>
        <td>sWn0CERcUYj</td>
      </tr>
      <tr>
        <td>Given name</td>
        <td></td>
        <td>The name of the patient or initials</td>
        <td>2020-08-13</td>
        <td>TfdH5KvFmMy</td>
      </tr>
      <tr>
        <td>Address (current)</td>
        <td></td>
        <td>Current home address of the patient</td>
        <td>2020-09-24</td>
        <td>VCtm2pySeEV</td>
      </tr>
      <tr>
        <td>Date of birth is estimated</td>
        <td></td>
        <td></td>
        <td>2020-09-24</td>
        <td>Z1rLc1rVHK8</td>
      </tr>
    </table>
    <h2 id="programs">Programs</h2>
    <h3>Anti-Tuberculosis Drugs Resistance Survey (DRS)</h3>
    <table>
      <tr>
        <th>Property</th>
        <td>Value</td>
      </tr>
      <tr>
        <th>Name</th>
        <td>Anti-Tuberculosis Drugs Resistance Survey (DRS)</td>
      </tr>
      <tr>
        <th>Tracked Entity Type:</th>
        <td>Person</td>
      </tr>
      <tr>
        <th>Last updated:</th>
        <td>2020-06-29</td>
      </tr>
      <tr>
        <th>UID:</th>
        <td>KYzHf1Ta6C4</td>
      </tr>
    </table>
    <h4>Program Stages</h4>
    <table>
      <tr>
        <th>Program Stage</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>2020-09-24</td>
        <td>GcwlzpdiI9M</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>2020-09-24</td>
        <td>GkWDp4w0oLP</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>2020-09-24</td>
        <td>mKxKBtIDl6q</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>2020-09-24</td>
        <td>oHeGGP8b2jT</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>2020-09-24</td>
        <td>ucGVfFax931</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>2020-09-24</td>
        <td>Y6qhyXKY6k5</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>2020-09-24</td>
        <td>ZVfK21voZUN</td>
      </tr>
    </table>
    <h4>Program Stage - Program Stage Section - Data Element</h4>
    <table>
      <tr>
        <th>Program Stage</th>
        <th>Program Stage Section</th>
        <th>Data Element</th>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Screening Test Results for HIV</td>
        <td>TB DRS CIF: HIV Test Date</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Screening Test Results for HIV</td>
        <td>TB DRS CIF: HIV Test Result</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CIF: Bacteriological Confirmation - Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CIF: Bacteriological Confirmation - Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CIF: Specimen 1 Microscopy Test Result</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CIF: Specimen 2 Microscopy Test Result</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CIF: Date of Xpert MTB/RIF Initial Screening Test</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Initial Bacteriological Confirmation of TB Reported by the Enrolling Facility</td>
        <td>TB DRS CIF: Xpert MTB/RIF Initial Screening Result</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - Control Question</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - Injections for TB</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - length of sickness - weeks</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - Names of Drugs</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - Other Symptoms of Lung Disease</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - Prior Symptoms</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - Sputum Examinations</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Provided by Patient</td>
        <td>TB DRS CIF: Treatment History - Tuberculosis Drugs</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Based on Medical Records</td>
        <td>TB DRS CIF: Treatment History - Prior TB Registration</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Treatment History Based on Medical Records</td>
        <td>TB DRS CIF: Treatment History - Previous TB Registration Number</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Final Treatment History Decision</td>
        <td>TB DRS CIF: Treatment History - Treatment Over 1 Month</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Final Treatment History Decision</td>
        <td>TB DRS CIF: Treatment History - Outcome</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Final Treatment History Decision</td>
        <td>TB DRS CIF: Treatment History - CIF Officer Name</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Final Treatment History Decision</td>
        <td>TB DRS CIF: Treatment History - Outcome Other</td>
      </tr>
      <tr>
        <td>CIF</td>
        <td>Final Treatment History Decision</td>
        <td>TB DRS CIF: Treatment History - Regimen</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>Sample Shipment</td>
        <td>TB DRS CS: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>Sample Shipment</td>
        <td>TB DRS CS: Date of Samples Arrival at NRL</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>Sample Shipment</td>
        <td>TB DRS CS: Date Samples Shipped to NRL</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Sample 1 Collection Date</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Sample 1 DRS ID</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Sample 1 Additive</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Sample 2 Collection Date</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Sample 2 DRS ID</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Sample 2 Additive</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Sample 3 Collection Date</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Sample 3 DRS ID</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Sample 3 Additive</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Specify Other (Sample 1)</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Specify Other (Sample 2)</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Specify Other (Sample 3)</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Specify Other (Sample 4)</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Sample 4 Collection Date</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Sample 4 DRS ID</td>
      </tr>
      <tr>
        <td>Collection and shipment of DRS samples to NRL</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Sample 4 Additive</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sample Rejected or Lost</td>
        <td>TB DRS LAB: Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Date of Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Final Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of Final Initial DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of Final Initial DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of Final Subsequent DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of Final Subsequent DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Specimen Type used for LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Date of LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Final LPA (RIF/INH) Result - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Final LPA (RIF/INH) Result - H</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Date of LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Fluoroquinolones</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Am/Cm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - H</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - H</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Culture in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Culture in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Initial DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Initial DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sample Rejected or Lost</td>
        <td>TB DRS LAB: Sample Rejected or Lost</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Subsequent DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Subsequent DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Bdq </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Storage Only</td>
        <td>TB DRS LAB: Storage Only</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Cfz </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Targeted Gene Sequencing</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Dlm </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Ultra Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Ultra Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>DRS Sample 1</td>
        <td>TB DRS CS: Sample 1 DRS ID</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Date of Targeted Gene Sequencing Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Date of Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Bdq </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Cfz </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Dlm </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Bdq </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Cfz </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Dlm </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - FQ</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - FQ</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: LPA (FQ/2LI) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: LPA (RIF/INH) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Comments and Remarks</td>
        <td>TB DRS LAB: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Specimen Type used for LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 1</td>
        <td>Sample 1: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Km</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>DRS Sample 2</td>
        <td>TB DRS CS: Sample 2 DRS ID</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sample Rejected or Lost</td>
        <td>TB DRS LAB: Sample Rejected or Lost</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Date of Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Final Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Ultra Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Ultra Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Culture in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Culture in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Initial DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of Final Initial DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Initial DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of Final Initial DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Subsequent DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Subsequent DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Bdq </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Cfz </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Dlm </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Bdq </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Cfz </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Dlm </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Bdq </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Cfz </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Dlm </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of Final Subsequent DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of Final Subsequent DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: LPA (FQ/2LI) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: LPA (RIF/INH) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Date of LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Date of LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Specimen Type used for LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Specimen Type used for LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Am/Cm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Fluoroquinolones</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Km</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Final LPA (RIF/INH) Result - H</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Final LPA (RIF/INH) Result - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Targeted Gene Sequencing</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Date of Targeted Gene Sequencing Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - H</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - FQ</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Date of Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - H</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - FQ</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Storage Only</td>
        <td>TB DRS LAB: Storage Only</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Comments and Remarks</td>
        <td>TB DRS LAB: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 2</td>
        <td>Sample 2: NRL - Sample Rejected or Lost</td>
        <td>TB DRS LAB: Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>DRS Sample 3</td>
        <td>TB DRS CS: Sample 3 DRS ID</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: Sample Rejected or Lost</td>
        <td>TB DRS LAB: Sample Rejected or Lost</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: Sample Rejected or Lost</td>
        <td>TB DRS LAB: Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Date of Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Final Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Ultra Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Ultra Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Culture in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Culture in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Initial DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Initial DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of Final Initial DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of Final Initial DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Bdq </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Cfz </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Dlm </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Subsequent DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Subsequent DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Bdq </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Cfz </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Dlm </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Bdq </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Cfz </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Dlm </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of Final Subsequent DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of Final Subsequent DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: LPA (FQ/2LI) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: LPA (RIF/INH) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Date of LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Date of LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Specimen Type used for LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Specimen Type used for LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Am/Cm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Fluoroquinolones</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Km</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Final LPA (RIF/INH) Result - H</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Final LPA (RIF/INH) Result - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Targeted Gene Sequencing</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Date of Targeted Gene Sequencing Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - H</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - FQ</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Date of Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - H</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - FQ</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Storage Only</td>
        <td>TB DRS LAB: Storage Only</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 3</td>
        <td>Sample 3: NRL - Comments and Remarks</td>
        <td>TB DRS LAB: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>DRS Sample 4</td>
        <td>TB DRS CS: Sample 4 DRS ID</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: Sample Rejected or Lost</td>
        <td>TB DRS LAB: Sample Rejected or Lost</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: Sample Rejected or Lost</td>
        <td>TB DRS LAB: Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Sputum Smear Microscopy</td>
        <td>TB Lab: Date of Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Final Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra Quantitative Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Ultra Test</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Ultra Test Result</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Culture in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Culture in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Initial DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Initial DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of Final Initial DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of Final Initial DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Bdq </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Cfz </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Dlm </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Subsequent DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Subsequent DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Bdq </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Cfz </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Dlm </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Bdq </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Cfz </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Dlm </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - H CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - H CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Lfx</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Lzd </td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Mfx CB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Mfx CC</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of Final Subsequent DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of Final Subsequent DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: LPA (FQ/2LI) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: LPA (RIF/INH) - MTB</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Date of LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Date of LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Specimen Type used for LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Specimen Type used for LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Am/Cm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Fluoroquinolones</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Km</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Final LPA (RIF/INH) Result - H</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Final LPA (RIF/INH) Result - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Targeted Gene Sequencing</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Date of Targeted Gene Sequencing Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - H</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - FQ</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Date of Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Am</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Bdq</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Cfz</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Dlm</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - E</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Eto</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - H</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Lzd</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - FQ</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pa</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Z</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - R</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Storage Only</td>
        <td>TB DRS LAB: Storage Only</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>NRL - DRS Sample 4</td>
        <td>Sample 4: NRL - Comments and Remarks</td>
        <td>TB DRS LAB: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL: Date Samples Shipped to Supranational Laboratory (SRL)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL: Samples Shipped to SRL</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL: Date of Samples Arrival at SRL</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL: DRS ID</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>Sample Processing at SRL</td>
        <td>TB DRS SRL - Reasons for not Shipping Samples to SRL</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Culture in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Culture in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of Final Initial DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of Final Initial DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of Final Subsequent DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of Final Subsequent DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Date of LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Date of LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Sputum Smear Microscopy</td>
        <td>TB Lab: Date of Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Date of Targeted Gene Sequencing Results</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Test</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Ultra Test</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB DRS LAB: Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Culture in Solid Media (e.g. LJ)</td>
        <td>TB DRS LAB: Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Am/Cm</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - E</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Fluoroquinolones</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Km</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Final LPA (RIF/INH) Result - H</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Final LPA (RIF/INH) Result - R</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Sputum Smear Microscopy</td>
        <td>TB DRS LAB: Final Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Am</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Bdq </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Cfz </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Dlm </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - E</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - H CB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - H CC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Lfx</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Lzd </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Mfx CB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Mfx CC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - R</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST LM - Z</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Am</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Bdq</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Cfz</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Dlm</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Test Result</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Ultra Test Result</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - E</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - H CB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Initial DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Initial DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - H CC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Lfx</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Lzd</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Mfx CB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Mfx CC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - R</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST SM - Z</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Am</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Bdq </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Cfz </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Dlm </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - E</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - H CB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - H CC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Lfx</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Lzd </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Mfx CB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Mfx CC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - R</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST LM - Z</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Am</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Bdq </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Cfz </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Dlm </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - E</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - H CB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - H CC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Lfx</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Lzd </td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Mfx CB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Mfx CC</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - R</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST SM - Z</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: LPA (FQ/2LI) - MTB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: LPA (RIF/INH) - MTB</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Sample/s Rejected or Lost</td>
        <td>TB DRS LAB: Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Sample/s Rejected or Lost</td>
        <td>TB DRS LAB: Sample Rejected or Lost</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Fluoroquinolones / Second-line Injectables)</td>
        <td>TB Lab: Specimen Type used for LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: LPA (Rifampicin / Isoniazid)</td>
        <td>TB Lab: Specimen Type used for LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Sputum Smear Microscopy</td>
        <td>TB Lab: Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Storage Only</td>
        <td>TB DRS LAB: Storage Only</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Subsequent DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Subsequent DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing</td>
        <td>TB DRS LAB: Targeted Gene Sequencing</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Am</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Bdq</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Cfz</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Dlm</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - E</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Eto</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - H</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Lzd</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - FQ</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pa</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Z</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - R</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Targeted Gene Sequencing</td>
        <td>TB DRS LAB: TGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Date of Results</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Am</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Bdq</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Cfz</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Dlm</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - E</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Eto</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - H</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Lzd</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - FQ</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pa</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Z</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing - Genotypic Resistance Profiling</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - R</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>File Upload Section</td>
        <td>TB DRS SRL: Import .csv</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Comments and Remarks</td>
        <td>TB DRS SRL: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Whole Genome Sequencing</td>
        <td>TB DRS LAB: WGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF</td>
        <td>TB DRS LAB: Xpert MTB/RIF Quantitative Result</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>SRL</td>
        <td>SRL: Xpert MTB/RIF Ultra</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra Quantitative Result</td>
      </tr>
    </table>
    <h2 id="programIndicators">Program Indicators</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Code</th>
        <th>Description</th>
        <th>Analytics Type</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - H CC susceptible</td>
        <td>Sub DST SM: new patients - H CC susceptible</td>
        <td></td>
        <td>Subsequent DST SM - new patients susceptible to H CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>A4tOZ6DtOz6</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Z contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Z cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>A6hImpJUCnp</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Dlm resistant</td>
        <td>Sub DST SM: new patients - Dlm resistant</td>
        <td></td>
        <td>Subsequent DST SM - New patients resistant to Dlm</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>A9gJNpnubW6</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - E resistant</td>
        <td>Sub DST LM: prev patients - E resistant</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients resistant to E</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>AAaf1N6q9Kc</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - H CB contaminated/indeterminate</td>
        <td>Sub DST SM: patients - H CB cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - patients - H CB contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>abdl4RkyzwL</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Lzd contaminated</td>
        <td>Sub DST LM: samples - Lzd contaminated</td>
        <td></td>
        <td>Subsequent DST LM - Lzd - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ADNg2qsAAcK</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Bdq resistant</td>
        <td>Sub DST SM: samples - Bdq resistant</td>
        <td></td>
        <td>Subsequent DST SM - Bdq - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>adnY7HmKOSi</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Mfx CB contaminated</td>
        <td>Sub DST LM: samples - Mfx CB contaminated</td>
        <td></td>
        <td>Subsequent DST LM - Mfx CB - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Ae5XHffdlOT</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Mfx CB susceptible</td>
        <td>Init DST SM: prev patients - Mfx CB susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>aEQVSqDQ91m</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: new patients - Km resistant</td>
        <td>LPA FQ/2LI: new patients - Km resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by LPA FQ/2LI. Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>afmIU4uXULr</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - E susceptible</td>
        <td>Sub DST LM: prev patients - E susceptible</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients susceptible to E</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ahmEPvvLdlB</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Cfz susceptible</td>
        <td>Sub DST LM: samples - Cfz susceptible</td>
        <td></td>
        <td>Subsequent DST LM - Cfz - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>AhU8qnVRvyB</td>
      </tr>
      <tr>
        <td>Missing data: age</td>
        <td>Missing data: age</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>AIhr0Sqq0Nl</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - H CC indeterminate</td>
        <td>Sub DST LM: samples - H CC indeterminate</td>
        <td></td>
        <td>Subsequent DST LM - H CC - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Aiy6br5cVtS</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Mfx CC indeterminate</td>
        <td>Init DST SM: samples - Mfx CC indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>AJ626bsdSe7</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - H CC contaminated</td>
        <td>Sub DST LM: samples - H CC contaminated</td>
        <td></td>
        <td>Subsequent DST LM - H CC - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>aLoApEYPHN8</td>
      </tr>
      <tr>
        <td>Culture SM: previously treated patients - contaminated</td>
        <td>Culture SM: prev patients - contaminated</td>
        <td></td>
        <td>Number of previously treated patients with result "contaminated" (cumulative). If more than one sample is examined per patient, "contaminated" result is recorded if all samples are contaminated. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>aLyPlwg2jot</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - R contaminated</td>
        <td>Sub DST SM: samples - R contaminated</td>
        <td></td>
        <td>Subsequent DST SM - R - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>AnE9y3CTG55</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Dlm susceptible</td>
        <td>Sub DST SM: patients - Dlm susceptible</td>
        <td></td>
        <td>Subsequent DST SM - patients susceptible to Dlm</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>AoNRpuKHFIA</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Mfx CC resistant</td>
        <td>Sub DST SM: prev patients - Mfx CC resistant</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients resistant to Mfx CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ap5DhakUaof</td>
      </tr>
      <tr>
        <td>Culture LM: 1 day</td>
        <td>Culture LM: 1d</td>
        <td></td>
        <td>Number of samples with 1 day turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>apEsA0h0WnR</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Mfx CB susceptible</td>
        <td>Sub DST SM: new patients - Mfx CB susceptible</td>
        <td></td>
        <td>Subsequent DST SM - new patients susceptible to Mfx CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>APrBMG15JPD</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - H CC susceptible</td>
        <td>Sub DST SM: patients - H CC susceptible</td>
        <td></td>
        <td>Subsequent DST SM - patients susceptible to H CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>aqiSmfOO1Y8</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - R resistant</td>
        <td>Sub DST LM: new patients - R resistant</td>
        <td></td>
        <td>Subsequent DST LM - New patients resistant to R</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>aQYGSuGN2yc</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: patients - INH indeterminate</td>
        <td>LPA RIF/INH: patients - INH indeterminate</td>
        <td></td>
        <td>LPA RIF/INH - INH indeterminate patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>aRT2098p8t3</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Z indeterminate</td>
        <td>Sub DST LM: samples - Z indeterminate</td>
        <td></td>
        <td>Subsequent DST LM - Z - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ASk2lczUEoC</td>
      </tr>
      <tr>
        <td>Samples: 10 days</td>
        <td>Collection arrival interval: 10d</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>asvQqsKFI4O</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Mfx CC resistant</td>
        <td>Sub DST LM: prev patients - Mfx CC resistant</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients resistant to Mfx CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ATlmsxFz21i</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Lfx contaminated</td>
        <td>Init DST SM: samples - Lfx contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ATMaMtQexcy</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Cfz contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Cfz cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - patients - Cfz contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>AUZxWKFQOIK</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Z contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Z cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients - Z contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>aW1dvUXmJzF</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Lfx susceptible</td>
        <td>Sub DST LM: samples - Lfx susceptible</td>
        <td></td>
        <td>Subsequent DST LM - Lfx - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>AxJiEHXPR4O</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - H CC resistant</td>
        <td>Init DST SM: samples - H CC resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>AZuK40TqYeX</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - R resistant</td>
        <td>Init DST LM: prev patients - R resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>B5d9eKm8nRR</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Lzd resistant</td>
        <td>Sub DST SM: prev patients - Lzd resistant</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients resistant to Lzd</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>b5ipTVVUxgZ</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - H CB resistant</td>
        <td>Sub DST SM: prev patients - H CB resistant</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients resistant to H CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>B9veWJCIhm3</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Bdq contaminated/indeterminate</td>
        <td>Init DST SM: patients - Bdq cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>BaMzkG7QFr3</td>
      </tr>
      <tr>
        <td>Samples with inoculation date for subsequent DST LM</td>
        <td>Sub DST LM: samples - inoculation date</td>
        <td></td>
        <td>Samples with inoculation date for subsequent DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>BAx8oO7z3BL</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - E resistant</td>
        <td>Init DST SM: samples - E resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>BBfev9dl9RM</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Z resistant</td>
        <td>Init DST LM: patients - Z resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>bbvugBgfLh0</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Cfz resistant</td>
        <td>Sub DST LM: new patients - Cfz resistant</td>
        <td></td>
        <td>Subsequent DST LM - New patients resistant to Cfz</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Bd06WGYcdgI</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Lzd susceptible</td>
        <td>Sub DST SM: prev patients - Lzd susceptible</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients susceptible to Lzd</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>BDa3bpSHQfR</td>
      </tr>
      <tr>
        <td>Samples with result for LPA RIF/INH</td>
        <td>LPA RIF/INH: samples - result</td>
        <td></td>
        <td>Samples with result for LPA RIF/INH</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>bE3YcdNxA3g</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Dlm resistant</td>
        <td>Init DST LM: patients - Dlm resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>belqKaig0KY</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Am contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Am cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - new patients - Am contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>bg6znd2CWYH</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Mfx CC susceptible</td>
        <td>Init DST SM: new patients - Mfx CC susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>bibTiiTflBW</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - H CB susceptible</td>
        <td>Sub DST LM: samples - H CB susceptible</td>
        <td></td>
        <td>Subsequent DST LM - H CB - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>BifclMTmRC8</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Bdq contaminated/indeterminate</td>
        <td>Init DST LM: patients - Bdq cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>bIHg1wvFPuX</td>
      </tr>
      <tr>
        <td>Culture LM: new patients - NTM detected</td>
        <td>Culture LM: new patients - NTM</td>
        <td></td>
        <td>Number of new patients with result "NTM" (cumulative). If more than one sample is examined per patient, "NTM" result is recorded if at least one sample has NTM and no MTB is detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>Bl0VfF5WWxe</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - H CC contaminated/indeterminate</td>
        <td>Init DST SM: patients - H CC cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>bLhO4Hh4j7O</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Am contaminated</td>
        <td>Init DST LM: samples - Am contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>bNdyJEAQZYH</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Lzd susceptible</td>
        <td>Sub DST SM: patients - Lzd susceptible</td>
        <td></td>
        <td>Subsequent DST SM - patients susceptible to Lzd</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>booODOHpIFb</td>
      </tr>
      <tr>
        <td>Samples with result for LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - result</td>
        <td></td>
        <td>Samples with result for LPA FQ/2LI</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>BP1h0h5Fcsc</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Mfx CB susceptible</td>
        <td>Sub DST SM: patients - Mfx CB susceptible</td>
        <td></td>
        <td>Subsequent DST SM - patients susceptible to Mfx CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>bPfqNC7BOgJ</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: previously treated patients - Am/Cm resistant</td>
        <td>LPA FQ/2LI: prev patients - Am/Cm resistant</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested resistant to the applicable drug by LPA FQ/2LI. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>BpRbOc95EiZ</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Bdq contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Bdq cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - patients - Bdq contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>bPWnbBZ4zc1</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Am contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Am cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - patients - Am contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>BQ8ftQEraa4</td>
      </tr>
      <tr>
        <td>Culture SM: patients - contaminated</td>
        <td>Culture SM: patients - contaminated</td>
        <td></td>
        <td>Number of patients with result "contaminated" (cumulative). If more than one sample is examined per patient, "contaminated" result is recorded if all samples are contaminated. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>BRoeNFPYHhT</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Am contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Am cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - patients - Am contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>bSe8cLu9vaB</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Mfx CB resistant</td>
        <td>Init DST LM: prev patients - Mfx CB resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>BTG0cxe1miz</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Lfx susceptible</td>
        <td>Init DST LM: prev patients - Lfx susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>btPg6w5CrOs</td>
      </tr>
      <tr>
        <td>Patients with invalid LPA RIF/INH result</td>
        <td>LPA RIF/INH: patients - invalid result</td>
        <td></td>
        <td>Patients with invalid LPA RIF/INH result</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>bUSPnAIXlHM</td>
      </tr>
      <tr>
        <td>Days between sample collection and culture inoculation LM</td>
        <td>Culture LM: collection-inoculation interval</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>BwTuzAmHJY2</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - E susceptible</td>
        <td>Init DST LM: samples - E susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>BXayDcGzAQ5</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - H CB susceptible</td>
        <td>Sub DST LM: prev patients - H CB susceptible</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients susceptible to H CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>bxokCBL7Fa6</td>
      </tr>
      <tr>
        <td>Started culture SM tests</td>
        <td>Culture SM: started tests</td>
        <td></td>
        <td>Number of started culture SM tests</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>bXTRrrObrqh</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - H CB resistant</td>
        <td>Init DST LM: patients - H CB resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>bxVekLXvoG6</td>
      </tr>
      <tr>
        <td>Microscopy: previously treated patients - negative</td>
        <td>Microscopy: prev patients - negative</td>
        <td></td>
        <td>Previously treated patients - microscopy negative</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>by5T3Wqf1Yx</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Mfx CC indeterminate</td>
        <td>Sub DST SM: samples - Mfx CC indeterminate</td>
        <td></td>
        <td>Subsequent DST SM - Mfx CC - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>bYFSgzsh4y2</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Dlm resistant</td>
        <td>Sub DST LM: prev patients - Dlm resistant</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients resistant to Dlm</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>bYO87TQdvrx</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Dlm contaminated/indeterminate</td>
        <td>Init DST LM: patients - Dlm cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>BZapNkxbmGh</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Mfx CC contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Mfx CC cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - new patients - Mfx CC contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>BzfUTfps4gS</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Bdq contaminated</td>
        <td>Init DST LM: samples - Bdq contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>bZiq1qPRaJM</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: samples - invalid</td>
        <td>Xpert MTB/RIF U: samples - invalid</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra - Invalid</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>bZYLsyngaPn</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Mfx CB susceptible</td>
        <td>Init DST LM: new patients - Mfx CB susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>c0Z8dcZwA9o</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Am resistant</td>
        <td>Init DST SM: new patients - Am resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>C2bwEfFwiBX</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Cfz susceptible</td>
        <td>Init DST SM: new patients - Cfz susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>c2PFlkVS4Zz</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: 2 days</td>
        <td>LPA RIF/INH: 2d</td>
        <td></td>
        <td>Number of samples with 2 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>c2pvFmOjpxD</td>
      </tr>
      <tr>
        <td>Patients with inoculation date for culture SM</td>
        <td>Culture SM: patients - inoculation date</td>
        <td></td>
        <td>Patients with inoculation date for culture SM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>c5whDMhSvRT</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Mfx CB resistant</td>
        <td>Sub DST SM: new patients - Mfx CB resistant</td>
        <td></td>
        <td>Subsequent DST SM - New patients resistant to Mfx CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>c7A83DBkpom</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Bdq resistant</td>
        <td>Init DST LM: new patients - Bdq resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>c9iFIVVuVMD</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: samples - error</td>
        <td>Xpert MTB/RIF: samples - Error</td>
        <td></td>
        <td>Xpert MTB/RIF - Error</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>CBzjrquAv7v</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - R susceptible</td>
        <td>Init DST LM: prev patients - R susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ccIrRzBwp6v</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Lzd contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Lzd cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>CCqP9jWQpAH</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 5 days</td>
        <td>Xpert MTB/RIF U: 5d</td>
        <td></td>
        <td>Number of samples with 5 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Ccxbjmjx4DF</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - R contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - R cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - new patients - R contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>cD6yomdezwR</td>
      </tr>
      <tr>
        <td>Culture LM: samples - MTB</td>
        <td>Culture LM: samples - MTB</td>
        <td></td>
        <td>Number of samples with result "MTB" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>CgDIb7hgosn</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: patients - RIF susceptible</td>
        <td>LPA RIF/INH: patients - RIF susceptible</td>
        <td></td>
        <td>LPA RIF/INH - RIF susceptible patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>CHMTFoEGDYW</td>
      </tr>
      <tr>
        <td>Samples with inoculation date for initial DST SM</td>
        <td>Init DST SM: samples - inoculation date</td>
        <td></td>
        <td>Samples with inoculation date for initial DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>cJ9JXbZ0itN</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - Am/Cm indeterminate</td>
        <td>LPA FQ/2LI: samples - Am/Cm indeterminate</td>
        <td></td>
        <td>LPA FQ/2LI - Am/Cm - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>cjamO4QmiQl</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Dlm resistant</td>
        <td>Init DST LM: prev patients - Dlm resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ckCldwmEQAl</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 1 day</td>
        <td>Xpert MTB/RIF U: 1d</td>
        <td></td>
        <td>Number of samples with 1 day turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>CkH4cl9Ip25</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: samples - no result</td>
        <td>Xpert MTB/RIF U: samples - no result</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra - No result</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>cKlPzK4efeq</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Bdq contaminated</td>
        <td>Init DST SM: samples - Bdq contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>cKpRfFeeqeK</td>
      </tr>
      <tr>
        <td>Patients with invalid LPA FQ/2LI result</td>
        <td>LPA FQ/2LI: patients - invalid result</td>
        <td></td>
        <td>Patients with invalid LPA FQ/2LI result</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>cMcje1sf4Pn</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: previously treated patients - INH indeterminate</td>
        <td>LPA RIF/INH: prev patients - INH indeterminate </td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA RIF/INH. Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA RIF/INH on multiple samples. Condition: previously treated patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>coaXGRyCvbg</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - H CC contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - H CC cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>cOFUIqdayX1</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Mfx CC resistant</td>
        <td>Init DST LM: new patients - Mfx CC resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>CR1sEF01MvB</td>
      </tr>
      <tr>
        <td>Culture LM: 9 days</td>
        <td>Culture LM: 9d</td>
        <td></td>
        <td>Number of samples with 9 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>CtUD7DpDhUt</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: new patients - Am/Cm indeterminate</td>
        <td>LPA FQ/2LI: new patients - Am/Cm indeterminate</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by LPA FQ/2LI. Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA FQ/2LI on multiple samples. Condition: new patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>CVHpNLwyPw9</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Z resistant</td>
        <td>Sub DST SM: samples - Z resistant</td>
        <td></td>
        <td>Subsequent DST SM - Z - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>cVY0RGqdI69</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: patients - MTB not detected</td>
        <td>Xpert MTB/RIF: patients - MTB not detected</td>
        <td></td>
        <td>Xpert MTB/RIF - patients with MTB not detected</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>CWCpPgb2Y2r</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - E contaminated/indeterminate</td>
        <td>Init DST SM: patients - E cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>cyJiS3rV7KV</td>
      </tr>
      <tr>
        <td>Culture LM: 2 days</td>
        <td>Culture LM: 2d</td>
        <td></td>
        <td>Number of samples with 2 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>cyOnOSTFAny</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Lzd contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Lzd cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - patients - Lzd contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>cYQnmEGAuSH</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Am contaminated</td>
        <td>Sub DST LM: samples - Am contaminated</td>
        <td></td>
        <td>Subsequent DST LM - Am - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>D1txAWeoz5n</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Cfz contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Cfz cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>d2CN7zcwQq2</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Bdq contaminated</td>
        <td>Sub DST LM: samples - Bdq contaminated</td>
        <td></td>
        <td>Subsequent DST LM - Bdq - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>D2XDPZzaKjH</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Am resistant</td>
        <td>Init DST LM: samples - Am resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>D4I7CFxNoxO</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Dlm susceptible</td>
        <td>Init DST LM: prev patients - Dlm susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>d4K0yZYr5sf</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - E resistant</td>
        <td>Init DST SM: prev patients - E resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>d5iwto9PKqu</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Dlm indeterminate</td>
        <td>Init DST LM: samples - Dlm indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>d5VDVBgpNff</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Mfx CB resistant</td>
        <td>Sub DST LM: samples - Mfx CB resistant</td>
        <td></td>
        <td>Subsequent DST LM - Mfx CB - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>D74MdAoARVD</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Cfz contaminated</td>
        <td>Init DST LM: samples - Cfz contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>D9GN83zB1tB</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Mfx CB contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Mfx CB cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients - Mfx CB contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>dBGD2K40yW9</td>
      </tr>
      <tr>
        <td>Samples: 2 days</td>
        <td>Collection arrival interval: 2d</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>DCpjfspBzJb</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Lfx indeterminate</td>
        <td>Init DST LM: samples - Lfx indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>dCXS1Srtvzz</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - R susceptible</td>
        <td>Sub DST SM: samples - R susceptible</td>
        <td></td>
        <td>Subsequent DST SM - R - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>dEk1wwgfnnD</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Dlm resistant</td>
        <td>Init DST SM: new patients - Dlm resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>DesYHcLzFQQ</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Mfx CC contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Mfx CC cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>dflTpUL9TOd</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - Km indeterminate</td>
        <td>LPA FQ/2LI: samples - Km indeterminate</td>
        <td></td>
        <td>LPA FQ/2LI - Km - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>dFWU6kNKodU</td>
      </tr>
      <tr>
        <td>Days between sample collection and culture inoculation SM</td>
        <td>Culture SM: collection-inoculation interval</td>
        <td></td>
        <td>Number of days between sample collection date and inoculation date. Added value used to calculate mean.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>dGKwqxO3eKj</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - H CC resistant</td>
        <td>Init DST LM: new patients - H CC resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>dh2mOeE0ieM</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: 9 days</td>
        <td>LPA RIF/INH: 9d</td>
        <td></td>
        <td>Number of samples with 9 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Dh7a17admqQ</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - H CC susceptible</td>
        <td>Init DST SM: prev patients - H CC susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>dhS0qZCbUgr</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: 5 days</td>
        <td>LPA RIF/INH: 5d</td>
        <td></td>
        <td>Number of samples with 5 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>dIx2cpCkvtj</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Lfx resistant</td>
        <td>Sub DST LM: samples - Lfx resistant</td>
        <td></td>
        <td>Subsequent DST LM - Lfx - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>djuou80be4X</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Mfx CC resistant</td>
        <td>Sub DST LM: samples - Mfx CC resistant</td>
        <td></td>
        <td>Subsequent DST LM - Mfx CC - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>dkKIGNb3BPe</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Dlm indeterminate</td>
        <td>Sub DST SM: samples - Dlm indeterminate</td>
        <td></td>
        <td>Subsequent DST SM - Dlm - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>dlC6LusCW5i</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Mfx CB contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Mfx CB cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>DmK5rIflVja</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Mfx CC susceptible</td>
        <td>Init DST LM: samples - Mfx CC susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>dNbYkrR3zua</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Lzd indeterminate</td>
        <td>Init DST LM: samples - Lzd indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>doQ3NVOHYPH</td>
      </tr>
      <tr>
        <td>Patients with negative HIV status</td>
        <td>HIV: negative</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>dOXNXZWb32d</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Mfx CC indeterminate</td>
        <td>Init DST LM: samples - Mfx CC indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>DQ6TpILpwGm</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Z susceptible</td>
        <td>Init DST LM: patients - Z susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>DQiw76Xw1r4</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Bdq susceptible</td>
        <td>Init DST LM: samples - Bdq susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>DTPsQiXmWTp</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Lfx resistant</td>
        <td>Init DST SM: new patients - Lfx resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>dU8neclU24g</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Cfz indeterminate</td>
        <td>Sub DST LM: samples - Cfz indeterminate</td>
        <td></td>
        <td>Subsequent DST LM - Cfz - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>dvBHjZYq37O</td>
      </tr>
      <tr>
        <td>Days between sample collection and Xpert MTB/RIF Ultra test</td>
        <td>Xpert MTB/RIF U: collection-test interval</td>
        <td></td>
        <td>Number of days between sample collection date and test date. Added value used to calculate mean.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>DVMln9sMq2c</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - R contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - R cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>DXmiExPcVmJ</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Lzd susceptible</td>
        <td>Sub DST SM: new patients - Lzd susceptible</td>
        <td></td>
        <td>Subsequent DST SM - new patients susceptible to Lzd</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>dZ0rHB1EkHD</td>
      </tr>
      <tr>
        <td>Samples: 8 days</td>
        <td>Collection arrival interval: 8d</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>dZ3RPo7vpmD</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Bdq susceptible</td>
        <td>Init DST SM: samples - Bdq susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>dZZHJma1Kge</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Am contaminated/indeterminate</td>
        <td>Init DST SM: patients - Am cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>e0cJcbD47aQ</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - R susceptible</td>
        <td>Init DST SM: new patients - R susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>e0gi9i7AftL</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: patients - RIF indeterminate </td>
        <td>Xpert MTB/RIF U: patients - RIF indeterminate</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra - RIF indeterminate patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>e33nRsNWbUl</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - H CB susceptible</td>
        <td>Init DST SM: samples - H CB susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>E4zdpgEfh2D</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Z susceptible</td>
        <td>Sub DST SM: new patients - Z susceptible</td>
        <td></td>
        <td>Subsequent DST SM - new patients susceptible to Z</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>e9RjhGOu3Fz</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Mfx CB susceptible</td>
        <td>Init DST LM: patients - Mfx CB susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>EAwBFKFUQcM</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 0 days</td>
        <td>Xpert MTB/RIF U: 0d</td>
        <td></td>
        <td>Number of samples with 0 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>EbYQHywJJT7</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Mfx CC indeterminate</td>
        <td>Sub DST LM: samples - Mfx CC indeterminate</td>
        <td></td>
        <td>Subsequent DST LM - Mfx CC - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>eCIxImB6qsO</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - R contaminated</td>
        <td>Sub DST LM: samples - R contaminated</td>
        <td></td>
        <td>Subsequent DST LM - R - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ecuAlCQqOV0</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - H CB susceptible</td>
        <td>Sub DST SM: new patients - H CB susceptible</td>
        <td></td>
        <td>Subsequent DST SM - new patients susceptible to H CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>EELFTduH3M9</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - R contaminated/indeterminate</td>
        <td>Sub DST SM: patients - R cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - patients - R contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>EEQ0GjzL3Xl</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Lfx indeterminate</td>
        <td>Sub DST SM: samples - Lfx indeterminate</td>
        <td></td>
        <td>Subsequent DST SM - Lfx - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>EfhWg7dKNsv</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Lzd susceptible</td>
        <td>Init DST SM: new patients - Lzd susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>EGNwXUQWIKb</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Mfx CB resistant</td>
        <td>Init DST SM: prev patients - Mfx CB resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>EhnADaDfnTB</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Z contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Z cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - patients - Z contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>eHQizAJZuXK</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - R resistant</td>
        <td>Sub DST SM: prev patients - R resistant</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients resistant to R</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>EICJmQVZa2a</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - H CC susceptible</td>
        <td>Sub DST LM: samples - H CC susceptible</td>
        <td></td>
        <td>Subsequent DST LM - H CC - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>eId8rqyJur9</td>
      </tr>
      <tr>
        <td>Culture LM: new patients - contaminated</td>
        <td>Culture LM: new patients - contaminated</td>
        <td></td>
        <td>Number of new patients with result "contaminated" (cumulative). If more than one sample is examined per patient, "contaminated" result is recorded if all samples are contaminated. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>elHXs7QIHeg</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Z contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Z cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>elpk5h0qKHQ</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Lzd resistant</td>
        <td>Init DST LM: prev patients - Lzd resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>eLzDUToUdCS</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: 6 days</td>
        <td>LPA FQ/2LI: 6d</td>
        <td></td>
        <td>Number of samples with 6 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>eMQxOQjYOAk</td>
      </tr>
      <tr>
        <td>Culture LM: patients - no growth</td>
        <td>Culture LM: patients - no growth</td>
        <td></td>
        <td>Number of patients with result "no growth" (cumulative). If more than one sample is examined per patient, "no growth" result is recorded if at least one sample has no growth and MTB or NTM are not detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>emvCVU7nSyP</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Mfx CC susceptible</td>
        <td>Sub DST LM: new patients - Mfx CC susceptible</td>
        <td></td>
        <td>Subsequent DST LM - new patients susceptible to Mfx CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>enpdoV1nHk0</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Lzd susceptible</td>
        <td>Init DST LM: patients - Lzd susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>eohX6MLy3Pz</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Lzd contaminated/indeterminate</td>
        <td>Init DST SM: patients - Lzd cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ePD0F8obRs8</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - H CC susceptible</td>
        <td>Sub DST LM: prev patients - H CC susceptible</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients susceptible to H CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>EPdS0YCH90B</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Bdq susceptible</td>
        <td>Sub DST LM: prev patients - Bdq susceptible</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients susceptible to Bdq</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>EpspNpkl2xy</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - H CB contaminated/indeterminate</td>
        <td>Init DST LM: new patients - H CB cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>epZELbYw3Dp</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: new patients - INH susceptible</td>
        <td>LPA RIF/INH: new patients - INH susceptible</td>
        <td></td>
        <td>LPA RIF/INH - new INH susceptible patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>eqA9DYBlpOk</td>
      </tr>
      <tr>
        <td>Culture SM: 0 days</td>
        <td>Culture SM: 0d</td>
        <td></td>
        <td>Number of samples with 0 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>EqAuIAkWriW</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Bdq susceptible</td>
        <td>Sub DST LM: new patients - Bdq susceptible</td>
        <td></td>
        <td>Subsequent DST LM - new patients susceptible to Bdq</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>erA6BTudlqi</td>
      </tr>
      <tr>
        <td>Samples with inoculation date for culture SM</td>
        <td>Culture SM: samples - inoculation date</td>
        <td></td>
        <td>Samples with inoculation date for culture SM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>eSmBD2Ihlyp</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - R resistant</td>
        <td>Sub DST LM: prev patients - R resistant</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients resistant to R</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>eSVL9Sr7zpp</td>
      </tr>
      <tr>
        <td>Patients with inoculation date for subsequent DST SM</td>
        <td>Sub DST SM: patients - inoculation date</td>
        <td></td>
        <td>Patients with inoculation date for subsequent DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>EtO96EwY8GU</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - E contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - E cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>EtQJDbQppQI</td>
      </tr>
      <tr>
        <td>Culture SM: patients - MTB detected</td>
        <td>Culture SM: patients - MTB</td>
        <td></td>
        <td>Number of patients with result "MTB" (cumulative). If more than one sample is examined per patient, "MTB" result is recorded if at least one sample has MTB detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>EU2sU2GqFEJ</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Z resistant</td>
        <td>Init DST SM: new patients - Z resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>EUoIM0Gbjcq</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Z resistant</td>
        <td>Sub DST SM: patients - Z resistant</td>
        <td></td>
        <td>Subsequent DST SM - patients resistant to Z</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>EvcKhBk9htx</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Dlm resistant</td>
        <td>Init DST SM: patients - Dlm resistant</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Ew0ZLYwvP0N</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Lfx resistant</td>
        <td>Init DST SM: patients - Lfx resistant</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>exwSqqUbu1i</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: patients - Km susceptible</td>
        <td>LPA FQ/2LI: patients - Km susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by LPA FQ/2LI. No resistance detected by LPA FQ/2LI on multiple samples. Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>EXziKxYBfcC</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Cfz resistant</td>
        <td>Init DST LM: new patients - Cfz resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>eZ7eIDHaYnM</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Am indeterminate</td>
        <td>Init DST SM: samples - Am indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>f5iJzjQNKc0</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 9 days</td>
        <td>Xpert MTB/RIF U: 9d</td>
        <td></td>
        <td>Number of samples with 9 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>F790gdBXKhI</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Lfx contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Lfx cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients - Lfx contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>F7BmHiwjier</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - R contaminated/indeterminate</td>
        <td>Init DST LM: new patients - R cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>f7CKyOdJg01</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Cfz resistant</td>
        <td>Init DST SM: samples - Cfz resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>F8DmuEmfrYR</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Dlm contaminated</td>
        <td>Sub DST SM: samples - Dlm contaminated</td>
        <td></td>
        <td>Subsequent DST SM - Dlm - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>f8OaQON8Jug</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Lzd contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Lzd cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>F9aDDuk2zH7</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - H CB resistant</td>
        <td>Init DST SM: patients - H CB resistant</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>FaO1ALEZbWD</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: previously treated patients - Km susceptible</td>
        <td>LPA FQ/2LI: prev patients - Km susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by LPA FQ/2LI. No resistance detected by LPA FQ/2LI on multiple samples. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>FBfIl9ERVVt</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - H CB resistant</td>
        <td>Init DST LM: prev patients - H CB resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>fcxcyNcQjzi</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: new patients - E resistant</td>
        <td>LPA FQ/2LI: new patients - E resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by LPA FQ/2LI. Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>fE6l4xcNtLq</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: patients - Km indeterminate</td>
        <td>LPA FQ/2LI: patients - Km indeterminate</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by LPA FQ/2LI. Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA FQ/2LI on multiple samples. Condition: test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>FeaSAdlKno2</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF - patients - RS</td>
        <td>Xpert MTB/RIF: patients - RS</td>
        <td></td>
        <td>Patients with test result for Xpert MTB/RIF - MTB, RIF susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>FEiqi1Eorpi</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - H CB resistant</td>
        <td>Init DST SM: prev patients - H CB resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>fEZeFn8VTpk</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - H CC resistant</td>
        <td>Init DST LM: samples - H CC resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>FFBHhpROVU4</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Lzd contaminated/indeterminate</td>
        <td>Init DST LM: patients - Lzd cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ffqUD3Dxlfs</td>
      </tr>
      <tr>
        <td>Culture SM: 7 days</td>
        <td>Culture SM: 7d</td>
        <td></td>
        <td>Number of samples with 7 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>fFuaaoUS5fC</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Lfx susceptible</td>
        <td>Sub DST LM: patients - Lfx susceptible</td>
        <td></td>
        <td>Subsequent DST LM - patients susceptible to Lfx</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Fgoss6VRywe</td>
      </tr>
      <tr>
        <td>Patients with positive HIV status</td>
        <td>HIV: positive</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>FGsZGC28X8R</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Mfx CC contaminated/indeterminate</td>
        <td>Init DST SM: patients - Mfx CC cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>FHU4eNjE5FD</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - Km susceptible</td>
        <td>LPA FQ/2LI: samples - Km susceptible</td>
        <td></td>
        <td>LPA FQ/2LI - Km - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>fI46ToIG10v</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Bdq susceptible</td>
        <td>Init DST LM: prev patients - Bdq susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>FI5yCrIHoow</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Z contaminated/indeterminate</td>
        <td>Init DST SM: patients - Z cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>fIbds4Nfw1i</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - H CB contaminated</td>
        <td>Init DST SM: samples - H CB contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>fITjLSEGjiq</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Mfx CC susceptible</td>
        <td>Init DST LM: new patients - Mfx CC susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>fkSqKvpD6PA</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - H CB susceptible</td>
        <td>Init DST SM: patients - H CB susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>fkva9qgQzv1</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - E resistant</td>
        <td>LPA FQ/2LI: samples - E resistant</td>
        <td></td>
        <td>LPA FQ/2LI - E - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>FLYNb9akyHF</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - R susceptible</td>
        <td>Sub DST LM: new patients - R susceptible</td>
        <td></td>
        <td>Subsequent DST LM - new patients susceptible to R</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>fmtrEnAYaRK</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Dlm susceptible</td>
        <td>Sub DST SM: samples - Dlm susceptible</td>
        <td></td>
        <td>Subsequent DST SM - Dlm - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>FMvbZg2LHhV</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Am susceptible</td>
        <td>Sub DST SM: samples - Am susceptible</td>
        <td></td>
        <td>Subsequent DST SM - Am - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>FNMPwjQNg4U</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Am resistant</td>
        <td>Init DST LM: patients - Am resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>FNvQMKWecPh</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Bdq resistant</td>
        <td>Sub DST LM: prev patients - Bdq resistant</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients resistant to Bdq</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>FNYTBE2wcLm</td>
      </tr>
      <tr>
        <td>Samples: 9 days</td>
        <td>Collection arrival interval: 9d</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>fO3ji8wgXlM</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Mfx CC resistant</td>
        <td>Init DST LM: patients - Mfx CC resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>fOxfV0W9xb1</td>
      </tr>
      <tr>
        <td>Patients with result for Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF U: patients - result</td>
        <td></td>
        <td>Patients with result for Xpert MTB/RIF Ultra</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>fpV3tkYm9rn</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Lzd resistant</td>
        <td>Init DST SM: new patients - Lzd resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>fpXisLGhJfK</td>
      </tr>
      <tr>
        <td>Culture LM: previously treated patients - MTB detected</td>
        <td>Culture LM: prev patients - MTB</td>
        <td></td>
        <td>Number of previously treated patients with result "MTB" (cumulative). If more than one sample is examined per patient, "MTB" result is recorded if at least one sample has MTB detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>fq4aooEypot</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Am resistant</td>
        <td>Sub DST SM: patients - Am resistant</td>
        <td></td>
        <td>Subsequent DST SM - patients resistant to Am</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>FRGmGDJHpkM</td>
      </tr>
      <tr>
        <td>Culture SM: 8 days</td>
        <td>Culture SM: 8d</td>
        <td></td>
        <td>Number of samples with 8 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>FrIJvXbBKJ9</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Bdq contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Bdq cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - new patients - Bdq contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>frJyeMsmKYo</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Dlm resistant</td>
        <td>Sub DST LM: samples - Dlm resistant</td>
        <td></td>
        <td>Subsequent DST LM - Dlm - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>fUdI3Clnew1</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Cfz susceptible</td>
        <td>Sub DST SM: patients - Cfz susceptible</td>
        <td></td>
        <td>Subsequent DST SM - patients susceptible to Cfz</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>fxAlrUlm1GU</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - R resistant</td>
        <td>Sub DST LM: samples - R resistant</td>
        <td></td>
        <td>Subsequent DST LM - R - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>fYERuvsUVki</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Mfx CC resistant</td>
        <td>Sub DST LM: patients - Mfx CC resistant</td>
        <td></td>
        <td>Subsequent DST LM - patients resistant to Mfx CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>fyw7CVbbp5r</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Am resistant</td>
        <td>Init DST SM: prev patients - Am resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>FzvIunVITV7</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - R susceptible</td>
        <td>Sub DST SM: prev patients - R susceptible</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients susceptible to R</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>g3oYfS8eQAq</td>
      </tr>
      <tr>
        <td>Microscopy: patients - positive</td>
        <td>Microscopy: patients - positive</td>
        <td></td>
        <td>Patients - microscopy positive</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>G3yAX5ER7E3</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - H CB susceptible</td>
        <td>Init DST LM: patients - H CB susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>G5dwFp4FeUI</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Cfz susceptible</td>
        <td>Init DST SM: prev patients - Cfz susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>g8HOqnoSNJ9</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Cfz contaminated</td>
        <td>Sub DST LM: samples - Cfz contaminated</td>
        <td></td>
        <td>Subsequent DST LM - Cfz - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>g9Sp1K9EgQZ</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: new patients - E indeterminate</td>
        <td>LPA FQ/2LI: new patients - E indeterminate</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by LPA FQ/2LI. Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA FQ/2LI on multiple samples. Condition: new patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>GAPMlTbDkXb</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Am susceptible</td>
        <td>Sub DST SM: prev patients - Am susceptible</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients susceptible to Am</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Gc2umtqZ1lY</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Cfz indeterminate</td>
        <td>Init DST LM: samples - Cfz indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>GCHhMllhJcW</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Mfx CB susceptible</td>
        <td>Sub DST SM: samples - Mfx CB susceptible</td>
        <td></td>
        <td>Subsequent DST SM - Mfx CB - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>GCpLmFiy28k</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Am resistant</td>
        <td>Sub DST LM: prev patients - Am resistant</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients resistant to Am</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>gCQxWn0enit</td>
      </tr>
      <tr>
        <td>Samples with result for Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - result</td>
        <td></td>
        <td>Samples with result for Xpert MTB/RIF</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>GCs58vwZsyf</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - H CC resistant</td>
        <td>Sub DST SM: new patients - H CC resistant</td>
        <td></td>
        <td>Subsequent DST SM - New patients resistant to H CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>GDUhrJPqy6w</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 6 days</td>
        <td>Xpert MTB/RIF: 6d</td>
        <td></td>
        <td>Number of samples with 6 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>GGmlMcmL9hd</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - E contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - E cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>GGmrn3hUfJ1</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Lzd resistant</td>
        <td>Sub DST LM: samples - Lzd resistant</td>
        <td></td>
        <td>Subsequent DST LM - Lzd - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>GGor2BR1Yq1</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Bdq resistant</td>
        <td>Sub DST SM: patients - Bdq resistant</td>
        <td></td>
        <td>Subsequent DST SM - patients resistant to Bdq</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>gHTL2er7krj</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: 10+ days</td>
        <td>LPA FQ/2LI: 10+d</td>
        <td></td>
        <td>Number of samples with 10+ days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>GLQZXhtNL52</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Bdq indeterminate</td>
        <td>Sub DST SM: samples - Bdq indeterminate</td>
        <td></td>
        <td>Subsequent DST SM - Bdq - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>GLSkgEz1sfT</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Mfx CB contaminated</td>
        <td>Init DST SM: samples - Mfx CB contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>glxNdJrAU4x</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - E resistant</td>
        <td>Sub DST SM: samples - E resistant</td>
        <td></td>
        <td>Subsequent DST SM - E - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>gnJSzbNuMYw</td>
      </tr>
      <tr>
        <td>Patients with result for Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: patients - result</td>
        <td></td>
        <td>Patients with result for Xpert MTB/RIF</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>gnSeNJoGz9T</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Lfx indeterminate</td>
        <td>Init DST SM: samples - Lfx indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>gpcKhKQvKWR</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Mfx CC contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Mfx CC cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - new patients - Mfx CC contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>GPMaGbyEjG4</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - Am/Cm resistant</td>
        <td>LPA FQ/2LI: samples - Am/Cm resistant</td>
        <td></td>
        <td>LPA FQ/2LI - Am/Cm - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>gSD4sqSzgGL</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Dlm contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Dlm cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients - Dlm contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>GStm6UzOQdq</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Bdq resistant</td>
        <td>Init DST LM: patients - Bdq resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>GTJ6K25PdVV</td>
      </tr>
      <tr>
        <td>Enrolled patients</td>
        <td>Enrollments - total</td>
        <td></td>
        <td>Enrollment count</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>gTPmPsKLwdR</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Z indeterminate</td>
        <td>Init DST SM: samples - Z indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>GUWNoDKwVeB</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Mfx CC susceptible</td>
        <td>Sub DST SM: new patients - Mfx CC susceptible</td>
        <td></td>
        <td>Subsequent DST SM - new patients susceptible to Mfx CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>gvvZUXARGg0</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - H CB susceptible</td>
        <td>Init DST SM: new patients - H CB susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>gwJnPsEhIvZ</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: samples - invalid</td>
        <td>Xpert MTB/RIF: samples - invalid</td>
        <td></td>
        <td>Xpert MTB/RIF - Invalid</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>GxBSEkFVnml</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - E contaminated/indeterminate</td>
        <td>Init DST SM: new patients - E cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>gYdixn3rVl7</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Bdq indeterminate</td>
        <td>Init DST LM: samples - Bdq indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>GYiY3HvV1Gy</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: previously treated patients - RIF indeterminate</td>
        <td>Xpert MTB/RIF U: prev patients - RIF indeterminate</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra - previously treated RIF indeterminate patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>gZCthbeejQI</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - E contaminated</td>
        <td>Sub DST SM: samples - E contaminated</td>
        <td></td>
        <td>Subsequent DST SM - E - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>H0uraA1hI5d</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Am indeterminate</td>
        <td>Sub DST SM: samples - Am indeterminate</td>
        <td></td>
        <td>Subsequent DST SM - Am - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>H185R6OCh9r</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Mfx CC susceptible</td>
        <td>Init DST SM: prev patients - Mfx CC susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>H3TqQeEo9MY</td>
      </tr>
      <tr>
        <td>Culture SM: 10+ days</td>
        <td>Culture SM: 10+d</td>
        <td></td>
        <td>Number of samples with 10+ days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>h3ZPbULlyUP</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - E susceptible</td>
        <td>Init DST SM: samples - E susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>h4iCiDYGYwR</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Bdq resistant</td>
        <td>Init DST SM: samples - Bdq resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>H8hAkVy6cc6</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: 4 days</td>
        <td>LPA FQ/2LI: 4d</td>
        <td></td>
        <td>Number of samples with 4 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>H8hl6NVdcGi</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - E resistant</td>
        <td>Sub DST SM: new patients - E resistant</td>
        <td></td>
        <td>Subsequent DST SM - New patients resistant to E</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>h8kBZ3K0T2d</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - H CB contaminated/indeterminate</td>
        <td>Init DST SM: patients - H CB cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>H9pBIDDmvRF</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Bdq susceptible</td>
        <td>Init DST SM: prev patients - Bdq susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Hb3NQ6s8obq</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: new patients - RIF indeterminate</td>
        <td>Xpert MTB/RIF U: new patients - RIF indeterminate</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra - new RIF indeterminate patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Hbaf9zZw15P</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - H CC contaminated/indeterminate</td>
        <td>Sub DST SM: patients - H CC cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - patients - H CC contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>hcnG8PMuECt</td>
      </tr>
      <tr>
        <td>Culture LM: patients - MTB detected</td>
        <td>Culture LM: patients - MTB</td>
        <td></td>
        <td>Number of patients with result "MTB" (cumulative). If more than one sample is examined per patient, "MTB" result is recorded if at least one sample has MTB detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>hDf5GZVCh6b</td>
      </tr>
      <tr>
        <td>Microscopy: patients - negative</td>
        <td>Microscopy: patients - negative</td>
        <td></td>
        <td>Patients - microscopy negative</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>HDPycwY4BhS</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Dlm susceptible</td>
        <td>Init DST LM: patients - Dlm susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>HdRTHmCBN5P</td>
      </tr>
      <tr>
        <td>Processed LPA RIF/INH samples</td>
        <td>LPA RIF/INH: processed samples</td>
        <td></td>
        <td>Processed LPA RIF/INH samples</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>henuXSapu7A</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: previously treated patients - E indeterminate</td>
        <td>LPA FQ/2LI: prev patients - E indeterminate</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA FQ/2LI. Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA FQ/2LI on multiple samples. Condition: previously treated patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>HfuHrxdatgU</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: new patients - RIF susceptible</td>
        <td>LPA RIF/INH: new patients - RIF susceptible</td>
        <td></td>
        <td>LPA RIF/INH - new RIF susceptible patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>hfYRwQKgaXt</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Cfz resistant</td>
        <td>Sub DST SM: prev patients - Cfz resistant</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients resistant to Cfz</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>hhcHMksqM3z</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: samples - MTB detected, RIF indeterminate</td>
        <td>Xpert MTB/RIF U: samples - RIF indeterminate</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra - MTB detected, RIF indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>hHniKx89xJK</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: 5 days</td>
        <td>LPA FQ/2LI: 5d</td>
        <td></td>
        <td>Number of samples with 5 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>HicWDsLR7Nj</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Am contaminated/indeterminate</td>
        <td>Init DST SM: patients - Am cont/ind - new</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>HJ7yxI5uok5</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - Am/Cm susceptible</td>
        <td>LPA FQ/2LI: samples - Am/Cm susceptible</td>
        <td></td>
        <td>LPA FQ/2LI - Am/Cm - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>HkAV7ShttEV</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - H CC susceptible</td>
        <td>Sub DST SM: samples - H CC susceptible</td>
        <td></td>
        <td>Subsequent DST SM - H CC - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>HkdrJSar6If</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Am susceptible</td>
        <td>Init DST SM: patients - Am susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>hL4mwtjHRFZ</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Lzd resistant</td>
        <td>Sub DST SM: samples - Lzd resistant</td>
        <td></td>
        <td>Subsequent DST SM - Lzd - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>HLrMymgpoqI</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Mfx CB contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Mfx CB cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients - Mfx CB contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>hLYwIBpo278</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Lfx resistant</td>
        <td>Init DST SM: samples - Lfx resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>HNLM0vPGidN</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Lzd indeterminate</td>
        <td>Sub DST SM: samples - Lzd indeterminate</td>
        <td></td>
        <td>Subsequent DST SM - Lzd - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>HqO6R44DBqY</td>
      </tr>
      <tr>
        <td>RR-TB patients</td>
        <td>RR-TB patients</td>
        <td></td>
        <td>RR-TB patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>hQP5qXsaTSB</td>
      </tr>
      <tr>
        <td>Patients with result for culture SM</td>
        <td>Culture SM: patients - result</td>
        <td></td>
        <td>Patients with result for culture SM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>HRT8j3uimEB</td>
      </tr>
      <tr>
        <td>Samples: 10+ days</td>
        <td>Collection arrival interval: 10+d</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>hSScU4CEl4x</td>
      </tr>
      <tr>
        <td>Culture SM: new patients - contaminated</td>
        <td>Culture SM: new patients - contaminated</td>
        <td></td>
        <td>Number of new patients with result "contaminated" (cumulative). If more than one sample is examined per patient, "contaminated" result is recorded if all samples are contaminated. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>HT5df1hXx46</td>
      </tr>
      <tr>
        <td>Patients with invalid Xpert MTB/RIF Ultra result</td>
        <td>Xpert MTB/RIF U: patients - invalid result</td>
        <td></td>
        <td>Patients with invalid Xpert MTB/RIF Ultra result</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>HTBvmWX11N2</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - H CC resistant</td>
        <td>Sub DST LM: prev patients - H CC resistant</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients resistant to H CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>htk2PaBn9n6</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Cfz susceptible</td>
        <td>Sub DST LM: patients - Cfz susceptible</td>
        <td></td>
        <td>Subsequent DST LM - patients susceptible to Cfz</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>HTYSiumflrW</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Mfx CC susceptible</td>
        <td>Sub DST LM: samples - Mfx CC susceptible</td>
        <td></td>
        <td>Subsequent DST LM - Mfx CC - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>HuH9Wbdba4q</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Z susceptible</td>
        <td>Sub DST LM: prev patients - Z susceptible</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients susceptible to Z</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>hvqTrO9xqPC</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Lfx resistant</td>
        <td>Sub DST SM: samples - Lfx resistant</td>
        <td></td>
        <td>Subsequent DST SM - Lfx - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>HxB1sbrTKkv</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - E resistant</td>
        <td>Sub DST LM: patients - E resistant</td>
        <td></td>
        <td>Subsequent DST LM - patients resistant to E</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>HXeaRn0AaLL</td>
      </tr>
      <tr>
        <td>Microscopy: new patients - positive</td>
        <td>Microscopy: new patients - positive</td>
        <td></td>
        <td>New patients - microscopy positive</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>HxgMmSOXRO9</td>
      </tr>
      <tr>
        <td>Culture SM: 4 days</td>
        <td>Culture SM: 4d</td>
        <td></td>
        <td>Number of samples with 4 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>hyoQv9Zr56m</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Bdq susceptible</td>
        <td>Sub DST LM: samples - Bdq susceptible</td>
        <td></td>
        <td>Subsequent DST LM - Bdq - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>hZn5S7DWqzF</td>
      </tr>
      <tr>
        <td>Samples rejected on arrival</td>
        <td>Samples rejected on arrival</td>
        <td></td>
        <td> </td>
        <td>EVENT</td>
        <td>2020-09-04</td>
        <td>hZP8QqW2Hgr</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Mfx CC contaminated</td>
        <td>Sub DST LM: samples - Mfx CC contaminated</td>
        <td></td>
        <td>Subsequent DST LM - Mfx CC - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>HZQG39GLjUK</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - E resistant</td>
        <td>Init DST LM: samples - E resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>hzrdf9T71sf</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Mfx CC contaminated</td>
        <td>Init DST SM: samples - Mfx CC contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>i14osWxv3vs</td>
      </tr>
      <tr>
        <td>Patients with result for subsequent DST LM</td>
        <td>Sub DST LM: patients - result</td>
        <td></td>
        <td>Patients with result for subsequent DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>I4aotZJ6il4</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - H CB indeterminate</td>
        <td>Init DST SM: samples - H CB indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>I64mYichCJ7</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - E susceptible</td>
        <td>Init DST SM: patients - E susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>i7BNLtz6jEk</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - H CC contaminated</td>
        <td>Init DST LM: samples - H CC contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>IAyxc41e5Yy</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Mfx CB contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Mfx CB cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ibm1blKTuPA</td>
      </tr>
      <tr>
        <td>Days between sample collection and LPA FQ/2LI test</td>
        <td>LPA FQ/2LI: collection-test interval</td>
        <td></td>
        <td>Number of days between sample collection date and test date. Added value used to calculate mean.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ibSDbrIrEph</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - H CC resistant</td>
        <td>Init DST SM: prev patients - H CC resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ic0VoKRJi8V</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: new patients - RS</td>
        <td>Xpert MTB/RIF U: new patients - RS</td>
        <td></td>
        <td>New patients with test result for Xpert MTB/RIF Ultra - MTB, RIF susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>IIRJBuBrOTJ</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - H CB susceptible</td>
        <td>Init DST LM: samples - H CB susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ijcH0gNXBx9</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: previously treated patients - RIF indeterminate</td>
        <td>LPA RIF/INH: prev patients - RIF indeterminate </td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA RIF/INH. Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA RIF/INH on multiple samples. Condition: previously treated patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>iK1pi7QPSVA</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: 10+ days</td>
        <td>LPA RIF/INH: 10+d</td>
        <td></td>
        <td>Number of samples with 10+ days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Ik9eYxKo6pQ</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Dlm resistant</td>
        <td>Init DST LM: samples - Dlm resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>iKfKE7FhH9H</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: patients - Am/Cm susceptible</td>
        <td>LPA FQ/2LI: patients - Am/Cm susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by LPA FQ/2LI. No resistance detected by LPA FQ/2LI on multiple samples. Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>IkHjK7xP7Xf</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - E contaminated/indeterminate</td>
        <td>Init DST LM: patients - E cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>IMmK1P6fBva</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 1 day</td>
        <td>Xpert MTB/RIF: 1d</td>
        <td></td>
        <td>Number of samples with 1 day turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>in2GZS5lUD5</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Mfx CB susceptible</td>
        <td>Init DST SM: patients - Mfx CB susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>iNHCjhXr71r</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - E contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - E cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients - E contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>IOIQueZoXmk</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - H CB resistant</td>
        <td>Sub DST LM: patients - H CB resistant</td>
        <td></td>
        <td>Subsequent DST LM - patients resistant to H CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>IpbcHr0Sl5m</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Mfx CB resistant</td>
        <td>Sub DST SM: prev patients - Mfx CB resistant</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients resistant to Mfx CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>IPCjhHOQMWl</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - E contaminated</td>
        <td>Init DST LM: samples - E contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>IQbtsnDkfAq</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: samples - INH resistant</td>
        <td>LPA RIF/INH: samples - INH resistant</td>
        <td></td>
        <td>LPA RIF/INH - INH - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>IQERFALbvVz</td>
      </tr>
      <tr>
        <td>Missing data: TB treatment history</td>
        <td>Missing data: TB Treatment history</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>Ir4RiYE3Nke</td>
      </tr>
      <tr>
        <td>Culture LM: samples - contaminated</td>
        <td>Culture LM: samples - contaminated</td>
        <td></td>
        <td>Number of samples with result "contaminated" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>IV7jORMyeU0</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Cfz contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Cfz cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients - Cfz contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>IWSzulLtcRU</td>
      </tr>
      <tr>
        <td>New patients</td>
        <td>New patients</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>IZ05Ef30nG3</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - R susceptible</td>
        <td>Sub DST LM: samples - R susceptible</td>
        <td></td>
        <td>Subsequent DST LM - R - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>IZmFYcpgXBt</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Z contaminated</td>
        <td>Sub DST SM: samples - Z contaminated</td>
        <td></td>
        <td>Subsequent DST SM - Z - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>j1utfSEDGOO</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Cfz resistant</td>
        <td>Sub DST SM: new patients - Cfz resistant</td>
        <td></td>
        <td>Subsequent DST SM - New patients resistant to Cfz</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>J230BlAaQlK</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Bdq resistant</td>
        <td>Init DST LM: samples - Bdq resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>J3ahtr4IVZn</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - H CB contaminated</td>
        <td>Sub DST LM: samples - H CB contaminated</td>
        <td></td>
        <td>Subsequent DST LM - H CB - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>j3G2AoTFI9u</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Z resistant</td>
        <td>Init DST LM: new patients - Z resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>j3vGe1RQoJ3</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Lzd resistant</td>
        <td>Sub DST SM: new patients - Lzd resistant</td>
        <td></td>
        <td>Subsequent DST SM - New patients resistant to Lzd</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>J3wjJEF8aq0</td>
      </tr>
      <tr>
        <td>Samples: 6 days</td>
        <td>Collection arrival interval: 6d</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>j3X4YEzbRjz</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Z contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Z cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - new patients - Z contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>j89ph75ZaX8</td>
      </tr>
      <tr>
        <td>Previously treated patients (cumulative)</td>
        <td>Previously treated patients (cumulative)</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>J9VPfek4eYG</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Lfx susceptible</td>
        <td>Init DST SM: new patients - Lfx susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>JBEHF7dwqbE</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - H CC resistant</td>
        <td>Init DST LM: patients - H CC resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>JBxsvdKtcZI</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - E susceptible</td>
        <td>Sub DST SM: prev patients - E susceptible</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients susceptible to E</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>JCJ6UNRWuJi</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - H CB contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - H CB cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients - H CB contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>jcm5Bo8ve5A</td>
      </tr>
      <tr>
        <td>Culture SM: 6 days</td>
        <td>Culture SM: 6d</td>
        <td></td>
        <td>Number of samples with 6 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>JCsNAS3pqZZ</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Mfx CB contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Mfx CB cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - new patients - Mfx CB contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>JDINMJYfpt8</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Lfx susceptible</td>
        <td>Sub DST LM: prev patients - Lfx susceptible</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients susceptible to Lfx</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Je3u7mBTONj</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - R resistant</td>
        <td>Init DST SM: prev patients - R resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>jEFlq5DrhmK</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Dlm contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Dlm cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients - Dlm contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>jFmQ13LrhXY</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Mfx CC resistant</td>
        <td>Init DST SM: patients - Mfx CC resistant</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>jGOj77I7ivr</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Mfx CB contaminated/indeterminate</td>
        <td>Init DST LM: patients - Mfx CB cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>jgpxNB7lUtw</td>
      </tr>
      <tr>
        <td>Culture LM: 5 days</td>
        <td>Culture LM: 5d</td>
        <td></td>
        <td>Number of samples with 5 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>JH0XVP5TaUz</td>
      </tr>
      <tr>
        <td>Patients with unknown HIV status</td>
        <td>HIV: unknown</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>jhm47tAnQV8</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Lzd susceptible</td>
        <td>Init DST LM: new patients - Lzd susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>jihuemWnruh</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - H CB susceptible</td>
        <td>Sub DST LM: new patients - H CB susceptible</td>
        <td></td>
        <td>Subsequent DST LM - new patients susceptible to H CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>jIlJF6otQaS</td>
      </tr>
      <tr>
        <td>Patients with invalid Xpert MTB/RIF result</td>
        <td>Xpert MTB/RIF: patients - invalid result</td>
        <td></td>
        <td>Patients with invalid Xpert MTB/RIF result</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>JIZ6X5rD7OK</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - H CB indeterminate</td>
        <td>Sub DST SM: samples - H CB indeterminate</td>
        <td></td>
        <td>Subsequent DST SM - H CB - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>jKYooU49mG4</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - H CB resistant</td>
        <td>Init DST SM: new patients - H CB resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>jmASgzacESm</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Bdq resistant</td>
        <td>Init DST SM: prev patients - Bdq resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>JMJzISQzRK2</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: samples - RIF susceptible</td>
        <td>LPA RIF/INH: samples - RIF susceptible</td>
        <td></td>
        <td>LPA RIF/INH - RIF - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>jnBglStivhT</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - H CC resistant</td>
        <td>Sub DST SM: prev patients - H CC resistant</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients resistant to H CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>JqBF765vRaI</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Bdq susceptible</td>
        <td>Init DST LM: new patients - Bdq susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>jR50rSWqk0y</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: patients - E susceptible</td>
        <td>LPA FQ/2LI: patients - E susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by LPA FQ/2LI. No resistance detected by LPA FQ/2LI on multiple samples. Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>jRlXrgXU6gg</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Mfx CC susceptible</td>
        <td>Sub DST SM: prev patients - Mfx CC susceptible</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients susceptible to Mfx CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>JsAylXp8loj</td>
      </tr>
      <tr>
        <td>Samples: 1 day</td>
        <td>Collection arrival interval: 1d</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>jtos6F8wRKV</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Lfx resistant</td>
        <td>Sub DST LM: prev patients - Lfx resistant</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients resistant to Lfx</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>JuE3ZTRER0P</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 7 days</td>
        <td>Xpert MTB/RIF U: 7d</td>
        <td></td>
        <td>Number of samples with 7 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>jvvRyJ0orNz</td>
      </tr>
      <tr>
        <td>Culture SM: patients - no growth</td>
        <td>Culture SM: patients - no growth</td>
        <td></td>
        <td>Number of patients with result "no growth" (cumulative). If more than one sample is examined per patient, "no growth" result is recorded if at least one sample has no growth and MTB or NTM are not detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>JxcokEnr3xj</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Mfx CB susceptible</td>
        <td>Sub DST LM: new patients - Mfx CB susceptible</td>
        <td></td>
        <td>Subsequent DST LM - new patients susceptible to Mfx CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>JxdzwSOjm8A</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: 1 day</td>
        <td>LPA RIF/INH: 1d</td>
        <td></td>
        <td>Number of samples with 1 day turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>JXTklB80mSZ</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - H CB indeterminate</td>
        <td>Init DST LM: samples - H CB indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>jxvva3VcMqQ</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - R susceptible</td>
        <td>Sub DST SM: patients - R susceptible</td>
        <td></td>
        <td>Subsequent DST SM - patients susceptible to R</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>jyLq8xUOZne</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - H CB contaminated/indeterminate</td>
        <td>Init DST SM: new patients - H CB cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>JzIoXaU5gc7</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: new patients - FQ indeterminate</td>
        <td>LPA FQ/2LI: new patients - FQ indeterminate</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by LPA FQ/2LI. Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA FQ/2LI on multiple samples. Condition: new patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>jZM5koLMnTL</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Bdq susceptible</td>
        <td>Init DST LM: patients - Bdq susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>jZODNlINPVG</td>
      </tr>
      <tr>
        <td>Culture LM: patients - NTM detected</td>
        <td>Culture LM: patients - NTM</td>
        <td></td>
        <td>Number of patients with result "NTM" (cumulative). If more than one sample is examined per patient, "NTM" result is recorded if at least one sample has NTM and no MTB is detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>K0Ni8uEHLXY</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Lzd resistant</td>
        <td>Init DST SM: samples - Lzd resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>K0pjdy1M4eD</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Bdq indeterminate</td>
        <td>Init DST SM: samples - Bdq indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>k1b1mUVqTvK</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Mfx CB contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Mfx CB cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - patients - Mfx CB contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>k1YfISnKxoF</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: previously treated patients - Km resistant</td>
        <td>LPA FQ/2LI: prev patients - Km resistant</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested resistant to the applicable drug by LPA FQ/2LI. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>k3dVli6pjex</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - H CC contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - H CC cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients - H CC contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>K3RhiJId07S</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - E resistant</td>
        <td>Init DST SM: patients - E resistant</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>K59BIxT2i6P</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Am contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Am cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>k6SBsqcv8Pw</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: 8 days</td>
        <td>LPA FQ/2LI: 8d</td>
        <td></td>
        <td>Number of samples with 8 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>KaGNXiu65VF</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Mfx CB susceptible</td>
        <td>Sub DST LM: prev patients - Mfx CB susceptible</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients susceptible to Mfx CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>KBbgHraFGGs</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Cfz susceptible</td>
        <td>Init DST LM: prev patients - Cfz susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>KbOntu5fKTV</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Cfz contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Cfz cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - new patients - Cfz contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>kBPPbfaHHLL</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: patients - FQ resistant</td>
        <td>LPA FQ/2LI: patients - FQ resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by LPA FQ/2LI. Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>KDdD36jnouX</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Z susceptible</td>
        <td>Sub DST LM: new patients - Z susceptible</td>
        <td></td>
        <td>Subsequent DST LM - new patients susceptible to Z</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>kDH4tyBM6FG</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Dlm contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Dlm cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>KDMYnCVSgTk</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - H CB susceptible</td>
        <td>Init DST SM: prev patients - H CB susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>KeCuEyh87Ga</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Lfx resistant</td>
        <td>Sub DST LM: new patients - Lfx resistant</td>
        <td></td>
        <td>Subsequent DST LM - New patients resistant to Lfx</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>kghHkgNoh1r</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - H CB resistant</td>
        <td>Sub DST SM: samples - H CB resistant</td>
        <td></td>
        <td>Subsequent DST SM - H CB - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>kGnLALoufUa</td>
      </tr>
      <tr>
        <td>Culture SM: 5 days</td>
        <td>Culture SM: 5d</td>
        <td></td>
        <td>Number of samples with 5 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>kgPgADkI9De</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - E resistant</td>
        <td>Init DST SM: new patients - E resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>KiRnQZDm9hc</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Z contaminated/indeterminate</td>
        <td>Init DST LM: patients - Z cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>KJe6BdMVXF3</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 4 days</td>
        <td>Xpert MTB/RIF U: 4d</td>
        <td></td>
        <td>Number of samples with 4 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Kk7fwdFUnYo</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Z susceptible</td>
        <td>Sub DST SM: prev patients - Z susceptible</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients susceptible to Z</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Kl1ONdPznGh</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - E contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - E cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients - E contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>kLiVVkPNcEG</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Mfx CB susceptible</td>
        <td>Init DST LM: samples - Mfx CB susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>kn7mJ4XH40C</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Lzd susceptible</td>
        <td>Sub DST SM: samples - Lzd susceptible</td>
        <td></td>
        <td>Subsequent DST SM - Lzd - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>KNZKCM67NGi</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Dlm susceptible</td>
        <td>Init DST LM: samples - Dlm susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>kqrwj0JOJon</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Mfx CB indeterminate</td>
        <td>Init DST SM: samples - Mfx CB indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>kRJlr5MFMSh</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - H CB contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - H CB cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>KVMYPcUq22W</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - R resistant</td>
        <td>Sub DST SM: patients - R resistant</td>
        <td></td>
        <td>Subsequent DST SM - patients resistant to R</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>KW0n6JUuqVn</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Cfz susceptible</td>
        <td>Sub DST LM: new patients - Cfz susceptible</td>
        <td></td>
        <td>Subsequent DST LM - new patients susceptible to Cfz</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>KXylN7DLOAI</td>
      </tr>
      <tr>
        <td>Culture LM: 10 days</td>
        <td>Culture LM: 10d</td>
        <td></td>
        <td>Number of samples with 10 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>l0oQQUpCe0t</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Cfz contaminated/indeterminate</td>
        <td>Init DST SM: patients - Cfz cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>L26pzli6SQ3</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Dlm contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Dlm cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - new patients - Dlm contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>l2og8x5vEYa</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - H CC contaminated</td>
        <td>Init DST SM: samples - H CC contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>L2Sv0Lmeke5</td>
      </tr>
      <tr>
        <td>Culture SM: previously treated patients - NTM detected</td>
        <td>Culture SM: prev patients - NTM</td>
        <td></td>
        <td>Number of previously treated patients with result "NTM" (cumulative). If more than one sample is examined per patient, "NTM" result is recorded if at least one sample has NTM and no MTB is detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>l3xgbTao9qK</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Am contaminated</td>
        <td>Init DST SM: samples - Am contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>l76u70Y8RNm</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: previously treated patients - RS</td>
        <td>Xpert MTB/RIF: prev patients - RS</td>
        <td></td>
        <td>Previously treated patients with test result for Xpert MTB/RIF - MTB, RIF susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>l8EQ2Kz8HMy</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - E resistant</td>
        <td>Sub DST LM: samples - E resistant</td>
        <td></td>
        <td>Subsequent DST LM - E - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>l9hGqsUThxS</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Mfx CC resistant</td>
        <td>Init DST LM: prev patients - Mfx CC resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>l9WK4N0BUzx</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - R resistant</td>
        <td>Init DST SM: new patients - R resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>lAFXVyIOz59</td>
      </tr>
      <tr>
        <td>Days between sample collection and LPA RIF/INH test</td>
        <td>LPA RIF/INH: collection-test interval</td>
        <td></td>
        <td>Number of days between sample collection date and test date. Added value used to calculate mean.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>LaSMRgk7CXT</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Lfx contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Lfx cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>LAsyN6saoOd</td>
      </tr>
      <tr>
        <td>Samples: 3 days</td>
        <td>Collection arrival interval: 3d</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Lb3IQ0ohSpp</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Lzd resistant</td>
        <td>Sub DST LM: patients - Lzd resistant</td>
        <td></td>
        <td>Subsequent DST LM - patients resistant to Lzd</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Lc5HjAi5vyL</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - H CB resistant</td>
        <td>Sub DST SM: new patients - H CB resistant</td>
        <td></td>
        <td>Subsequent DST SM - New patients resistant to H CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>lfHTvcRzmXT</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Bdq susceptible</td>
        <td>Sub DST SM: prev patients - Bdq susceptible</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients susceptible to Bdq</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>LhJkKbrTOOS</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - FQ resistant</td>
        <td>LPA FQ/2LI: samples - FQ resistant</td>
        <td></td>
        <td>LPA FQ/2LI - FQ - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>lHv7SkxUIi0</td>
      </tr>
      <tr>
        <td>Culture SM: 10 days</td>
        <td>Culture SM: 10d</td>
        <td></td>
        <td>Number of samples with 10 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Lje8dx9lWYQ</td>
      </tr>
      <tr>
        <td>Culture LM: 7 days</td>
        <td>Culture LM: 7d</td>
        <td></td>
        <td>Number of samples with 7 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>LKgEs168uwz</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: samples - INH susceptible</td>
        <td>LPA RIF/INH: samples - INH susceptible</td>
        <td></td>
        <td>LPA RIF/INH - INH - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>lmfraes6AwW</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: previously treated patients - INH susceptible</td>
        <td>LPA RIF/INH: prev patients - INH susceptible </td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by LPA RIF/INH. No resistance detected by LPA RIF/INH on multiple samples. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>lMxeHgDnnYU</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: samples - INH indeterminate</td>
        <td>LPA RIF/INH: samples - INH indeterminate</td>
        <td></td>
        <td>LPA RIF/INH - INH - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>lNfI3Vav9ya</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - H CC resistant</td>
        <td>Sub DST SM: samples - H CC resistant</td>
        <td></td>
        <td>Subsequent DST SM - H CC - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>LOLIwqxd2wm</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Lfx contaminated</td>
        <td>Sub DST LM: samples - Lfx contaminated</td>
        <td></td>
        <td>Subsequent DST LM - Lfx - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>lopaZTLHpyB</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Lzd contaminated</td>
        <td>Init DST SM: samples - Lzd contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>lQnrHEMWAee</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Am contaminated</td>
        <td>Sub DST SM: samples - Am contaminated</td>
        <td></td>
        <td>Subsequent DST SM - Am - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>LROUBwdzaVw</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: previously treated patients - RS</td>
        <td>Xpert MTB/RIF U: prrev patients - RS</td>
        <td></td>
        <td>Previously treated patients with test result for Xpert MTB/RIF Ultra - MTB, RIF susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>LRW1AeEUfTs</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Lzd susceptible</td>
        <td>Init DST SM: prev patients - Lzd susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ltuLoYVJ4yN</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - H CC susceptible</td>
        <td>Init DST SM: samples - H CC susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>luMcMB4YiL9</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 10 days</td>
        <td>Xpert MTB/RIF U: 10d</td>
        <td></td>
        <td>Number of samples with 10 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>LuoF6aB4C7j</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Am susceptible</td>
        <td>Init DST LM: samples - Am susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>lvGGYtdHr0u</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Bdq susceptible</td>
        <td>Init DST SM: new patients - Bdq susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>lWEOXjxUbwf</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Lfx resistant</td>
        <td>Init DST SM: prev patients - Lfx resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>lwr3AChFg30</td>
      </tr>
      <tr>
        <td>Samples with result for culture LM</td>
        <td>Culture LM: samples - result</td>
        <td></td>
        <td>Samples with result for culture LM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>lx4tkD2nyiv</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - H CC contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - H CC cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients - H CC contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>LX5Y5X1ijjJ</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - H CB resistant</td>
        <td>Init DST LM: new patients - H CB resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>lxX3YYtafD4</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - E susceptible</td>
        <td>Init DST LM: prev patients - E susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>lyaTr1HCOH2</td>
      </tr>
      <tr>
        <td>Samples with result for culture SM</td>
        <td>Culture SM: samples - result</td>
        <td></td>
        <td>Samples with result for culture SM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>lZ1tOjYHm2t</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Mfx CC resistant</td>
        <td>Sub DST SM: new patients - Mfx CC resistant</td>
        <td></td>
        <td>Subsequent DST SM - New patients resistant to Mfx CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>M2IinLZavHj</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Lzd contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Lzd cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - new patients - Lzd contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>m5nShXZwfvl</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - MTB detected</td>
        <td>LPA FQ/2LI: samples - MTB detected</td>
        <td></td>
        <td>LPA FQ/2LI - MTB detected</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>M65WBBPkgIF</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Mfx CC resistant</td>
        <td>Init DST SM: samples - Mfx CC resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>m6bgoNYcG12</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - H CC contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - H CC cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - new patients - H CC contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>M74bikagdCn</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Mfx CB susceptible</td>
        <td>Sub DST SM: prev patients - Mfx CB susceptible</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients susceptible to Mfx CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>M7Z1bApwb6J</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - H CC resistant</td>
        <td>Init DST SM: new patients - H CC resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>m8N1dCCrsaT</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Am susceptible</td>
        <td>Init DST SM: prev patients - Am susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>M9mlpuwMiJ8</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: previously treated patients - INH resistant</td>
        <td>LPA RIF/INH: prev patients - INH resistant </td>
        <td></td>
        <td>Previously treated patients with at least one sample tested resistant to the applicable drug by LPA RIF/INH. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>m9N36IcoG1l</td>
      </tr>
      <tr>
        <td>Samples: 7 days</td>
        <td>Collection arrival interval: 7d</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>M9QC4zhEcCW</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Bdq contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Bdq cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - new patients - Bdq contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MAfGE8h9nR5</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - E contaminated/indeterminate</td>
        <td>Sub DST LM: patients - E cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - patients - E contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>maRlEPKLrit</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - H CC susceptible</td>
        <td>Init DST SM: new patients - H CC susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>mBK3lYq8HO8</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Mfx CB susceptible</td>
        <td>Init DST SM: new patients - Mfx CB susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>mdIjVH1NUaF</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Mfx CC contaminated</td>
        <td>Init DST LM: samples - Mfx CC contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>Me0P8Hywg5V</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: patients - FQ susceptible</td>
        <td>LPA FQ/2LI: patients - FQ susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by LPA FQ/2LI. No resistance detected by LPA FQ/2LI on multiple samples. Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>mg6xbOMevpk</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Lzd contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Lzd cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients - Lzd contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MGHQjfJcv8i</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Z susceptible</td>
        <td>Init DST SM: samples - Z susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>mgyXxutltWj</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Lfx susceptible</td>
        <td>Sub DST LM: new patients - Lfx susceptible</td>
        <td></td>
        <td>Subsequent DST LM - new patients susceptible to Lfx</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>mI5CLdPFdly</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - E susceptible</td>
        <td>Init DST SM: new patients - E susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>MIDce43XVMU</td>
      </tr>
      <tr>
        <td>Patients with result for LPA RIF/INH</td>
        <td>LPA RIF/INH: patients - result</td>
        <td></td>
        <td>Patients with result for LPA RIF/INH</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MJ93HUyctIa</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: samples - RR</td>
        <td>Xpert MTB/RIF: samples - RR</td>
        <td></td>
        <td>Xpert MTB/RIF - RR</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MJNbrK0Q80m</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - E contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - E cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - new patients - E contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MkaxSDtr5lN</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Bdq resistant</td>
        <td>Sub DST LM: patients - Bdq resistant</td>
        <td></td>
        <td>Subsequent DST LM - patients resistant to Bdq</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MkpDzk0VVOn</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Bdq contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Bdq cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients - Bdq contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Ml5TUmEp9co</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Am susceptible</td>
        <td>Sub DST SM: patients - Am susceptible</td>
        <td></td>
        <td>Subsequent DST SM - patients susceptible to Am</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MlKowimCL4m</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: 1 day</td>
        <td>LPA FQ/2LI: 1d</td>
        <td></td>
        <td>Number of samples with 1 day turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>mmAog6SHRqH</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: samples - RIF indeterminate</td>
        <td>LPA RIF/INH: samples - RIF indeterminate</td>
        <td></td>
        <td>LPA RIF/INH - RIF - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MmgqczjBy4x</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Z contaminated</td>
        <td>Sub DST LM: samples - Z contaminated</td>
        <td></td>
        <td>Subsequent DST LM - Z - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MnhS9zbQTuz</td>
      </tr>
      <tr>
        <td>Culture SM: 2 days</td>
        <td>Culture SM: 2d</td>
        <td></td>
        <td>Number of samples with 2 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>mNIzirHVwvO</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - R indeterminate</td>
        <td>Sub DST LM: samples - R indeterminate</td>
        <td></td>
        <td>Subsequent DST LM - R - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MNQ2cVPKts0</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Z indeterminate</td>
        <td>Sub DST SM: samples - Z indeterminate</td>
        <td></td>
        <td>Subsequent DST SM - Z - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>mqf825wSgBW</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Lzd contaminated</td>
        <td>Init DST LM: samples - Lzd contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>mQmX7NJ2iWr</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Bdq resistant</td>
        <td>Sub DST SM: prev patients - Bdq resistant</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients resistant to Bdq</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MQz9ho7oTxM</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Mfx CB resistant</td>
        <td>Sub DST LM: new patients - Mfx CB resistant</td>
        <td></td>
        <td>Subsequent DST LM - New patients resistant to Mfx CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MRE4oCbTgdp</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Lzd resistant</td>
        <td>Sub DST LM: new patients - Lzd resistant</td>
        <td></td>
        <td>Subsequent DST LM - New patients resistant to Lzd</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>mS4y1f2N2qr</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: patients - FQ indeterminate</td>
        <td>LPA FQ/2LI: patients - FQ indeterminate</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by LPA FQ/2LI. Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA FQ/2LI on multiple samples. Condition: test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>mSoVmSlOATC</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - R contaminated/indeterminate</td>
        <td>Init DST SM: patients - R cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>MT7aEWVXFBf</td>
      </tr>
      <tr>
        <td>Patients with inoculation date for initial DST SM</td>
        <td>Init DST SM: patients - inoculation date</td>
        <td></td>
        <td>Patients with inoculation date for initial DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MTU6QAz2cpX</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - H CC contaminated/indeterminate</td>
        <td>Init DST LM: new patients - H CC cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>mU0CgKC2iWM</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Cfz contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Cfz cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - patients - Cfz contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>mUmuZc4YfoA</td>
      </tr>
      <tr>
        <td>Culture SM: new patients - NTM detected</td>
        <td>Culture SM: new patients - NTM</td>
        <td></td>
        <td>Number of new patients with result "NTM" (cumulative). If more than one sample is examined per patient, "NTM" result is recorded if at least one sample has NTM and no MTB is detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>MuqppHWlVvW</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Z susceptible</td>
        <td>Init DST LM: samples - Z susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>MVspOs3ajZ8</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Am susceptible</td>
        <td>Sub DST LM: prev patients - Am susceptible</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients susceptible to Am</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MwMGpZDEsVq</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Am resistant</td>
        <td>Sub DST LM: samples - Am resistant</td>
        <td></td>
        <td>Subsequent DST LM - Am - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>mWVJ6NngcOg</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Z susceptible</td>
        <td>Sub DST SM: samples - Z susceptible</td>
        <td></td>
        <td>Subsequent DST SM - Z - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>MX0ZgqJRARO</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: patients - Am/Cm indeterminate</td>
        <td>LPA FQ/2LI: patients - Am/Cm indeterminate</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by LPA FQ/2LI. Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA FQ/2LI on multiple samples. Condition: test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>mx7q7B3ZSpH</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: patients - INH susceptible</td>
        <td>LPA RIF/INH: patients - INH susceptible</td>
        <td></td>
        <td>LPA RIF/INH - INH susceptible patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>mXnpYGKvJOJ</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - H CC resistant</td>
        <td>Init DST LM: prev patients - H CC resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>mZ25KRwF5Gy</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: samples - MTB not detected</td>
        <td>Xpert MTB/RIF: samples - MTB not detected</td>
        <td></td>
        <td>Xpert MTB/RIF - MTB not detected</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>n31mFHYciKv</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - FQ susceptible</td>
        <td>LPA FQ/2LI: samples - FQ susceptible</td>
        <td></td>
        <td>LPA FQ/2LI - FQ - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>n6Rrth8edSM</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Lfx contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Lfx cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>N7o1Xqjimlj</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - H CC resistant</td>
        <td>Sub DST LM: samples - H CC resistant</td>
        <td></td>
        <td>Subsequent DST LM - H CC - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>N8T2Ka08phP</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - R indeterminate</td>
        <td>Init DST LM: samples - R indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>NadcebWfg1z</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - H CB contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - H CB cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - new patients - H CB contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>nAG3hPJLNRZ</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: new patients - FQ susceptible</td>
        <td>LPA FQ/2LI: new patients - FQ susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by LPA FQ/2LI. No resistance detected by LPA FQ/2LI on multiple samples. Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>NbEBOhJFhBx</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Z resistant</td>
        <td>Init DST LM: samples - Z resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>nbNPEdgcXHR</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: patients - RIF indeterminate </td>
        <td>Xpert MTB/RIF: patients - RIF indeterminate</td>
        <td></td>
        <td>Xpert MTB/RIF - RIF indeterminate patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ncciXS4015B</td>
      </tr>
      <tr>
        <td>Patients with unknown treatment history (cumulative)</td>
        <td>DRS: unknown treatment history (cumulative)</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>nDbv7VbejeH</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - R resistant</td>
        <td>Init DST SM: samples - R resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>nea65dZOQfp</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Lzd susceptible</td>
        <td>Sub DST LM: new patients - Lzd susceptible</td>
        <td></td>
        <td>Subsequent DST LM - new patients susceptible to Lzd</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>NeWHeUHbtLY</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - H CC resistant</td>
        <td>Sub DST SM: patients - H CC resistant</td>
        <td></td>
        <td>Subsequent DST SM - patients resistant to H CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>nFdMqXBCHgs</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Lfx susceptible</td>
        <td>Sub DST SM: new patients - Lfx susceptible</td>
        <td></td>
        <td>Subsequent DST SM - new patients susceptible to Lfx</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>NfZJb3KTVAO</td>
      </tr>
      <tr>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Xpert MTB/RIF: processed samples</td>
        <td></td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>nhi2Mi5MXVW</td>
      </tr>
      <tr>
        <td>Samples with result for subsequent DST SM</td>
        <td>Sub DST SM: samples - result</td>
        <td></td>
        <td>Samples with result for subsequent DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>NiZZuTnJcqI</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Z susceptible</td>
        <td>Init DST LM: prev patients - Z susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>NJDQNJw2tGD</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 6 days</td>
        <td>Xpert MTB/RIF U: 6d</td>
        <td></td>
        <td>Number of samples with 6 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>NkcFiEE3PpA</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Mfx CB indeterminate</td>
        <td>Sub DST LM: samples - Mfx CB indeterminate</td>
        <td></td>
        <td>Subsequent DST LM - Mfx CB - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>nl8UjHDuOJp</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - R resistant</td>
        <td>Sub DST SM: new patients - R resistant</td>
        <td></td>
        <td>Subsequent DST SM - New patients resistant to R</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>NLogSNyPLrG</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Mfx CC contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Mfx CC cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients - Mfx CC contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>nNgTAOUHVVf</td>
      </tr>
      <tr>
        <td>Patients with valid Xpert MTB/RIF Ultra result</td>
        <td>Xpert MTB/RIF U: patients - valid result</td>
        <td></td>
        <td>Patients with valid test result for Xpert MTB/RIF Ultra</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>nNXqEhYPq12</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: 6 days</td>
        <td>LPA RIF/INH: 6d</td>
        <td></td>
        <td>Number of samples with 6 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>NOwoUDobC82</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Lfx contaminated/indeterminate</td>
        <td>Init DST SM: patients - Lfx cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>npECBAtnX10</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Am susceptible</td>
        <td>Init DST SM: samples - Am susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>nQp5mF3EWSv</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 2 days</td>
        <td>Xpert MTB/RIF U: 2d</td>
        <td></td>
        <td>Number of samples with 2 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>NqXeQze1Q7b</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - R contaminated</td>
        <td>Init DST LM: samples - R contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>NQXMN2Td6gk</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Dlm contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Dlm cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>NQyWPTJyzhL</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - E susceptible</td>
        <td>Sub DST LM: patients - E susceptible</td>
        <td></td>
        <td>Subsequent DST LM - patients susceptible to E</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ntgkubZBIVR</td>
      </tr>
      <tr>
        <td>Culture SM: samples - NTM</td>
        <td>Culture SM: samples - NTM</td>
        <td></td>
        <td>Number of samples with result "NTM" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>NuvmZiORoOd</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Bdq contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Bdq cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - patients - Bdq contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>nvL2apj8ESp</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: previously treated patients - FQ resistant</td>
        <td>LPA FQ/2LI: prev patients - FQ resistant</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested resistant to the applicable drug by LPA FQ/2LI. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>nVrp5WyTpvb</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Lfx susceptible</td>
        <td>Sub DST SM: samples - Lfx susceptible</td>
        <td></td>
        <td>Subsequent DST SM - Lfx - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>nVXSEczhAvM</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 8 days</td>
        <td>Xpert MTB/RIF U: 8d</td>
        <td></td>
        <td>Number of samples with 8 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>NVZjjPEo2QI</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: previously treated patients - FQ indeterminate</td>
        <td>LPA FQ/2LI: prev patients - FQ indeterminate</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA FQ/2LI. Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA FQ/2LI on multiple samples. Condition: previously treated patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>NWJoPKtoVSu</td>
      </tr>
      <tr>
        <td>Patients with result for culture LM</td>
        <td>Culture LM: patients - result</td>
        <td></td>
        <td>Patients with result for culture LM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Nwoz37ThBzC</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - H CB contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - H CB cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>NXVfkJA7wg5</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Bdq susceptible</td>
        <td>Sub DST SM: patients - Bdq susceptible</td>
        <td></td>
        <td>Subsequent DST SM - patients susceptible to Bdq</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>NYBeJuBeqD6</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: patients - E indeterminate</td>
        <td>LPA FQ/2LI: patients - E indeterminate</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by LPA FQ/2LI. Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA FQ/2LI on multiple samples. Condition: test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>nYuAYvmgfbs</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 10+ days</td>
        <td>Xpert MTB/RIF U: 10+d</td>
        <td></td>
        <td>Number of samples with 10+ days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>NyyAfu95mCo</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - R resistant</td>
        <td>Init DST LM: patients - R resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>NyzaBaIm5jS</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Dlm susceptible</td>
        <td>Sub DST SM: prev patients - Dlm susceptible</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients susceptible to Dlm</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>NzGW6C58GkF</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Lfx susceptible</td>
        <td>Init DST LM: patients - Lfx susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>nzj3O4baUVb</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: previously treated patients - RR</td>
        <td>Xpert MTB/RIF: prev patients - RR</td>
        <td></td>
        <td>Previously treated patients with test result for Xpert MTB/RIF - MTB, RIF resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>NZul7fh2R8B</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Dlm indeterminate</td>
        <td>Init DST SM: samples - Dlm indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>O07GF4PWILB</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Bdq contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Bdq cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>o0r6wVvQT1H</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Mfx CC susceptible</td>
        <td>Sub DST LM: patients - Mfx CC susceptible</td>
        <td></td>
        <td>Subsequent DST LM - patients susceptible to Mfx CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>o2vVY3Tou4b</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Am resistant</td>
        <td>Sub DST LM: new patients - Am resistant</td>
        <td></td>
        <td>Subsequent DST LM - New patients resistant to Am</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>o5VfgMGlYLo</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - H CB resistant</td>
        <td>Sub DST LM: samples - H CB resistant</td>
        <td></td>
        <td>Subsequent DST LM - H CB - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>O6It7XLWzij</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Bdq resistant</td>
        <td>Init DST SM: patients - Bdq resistant</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>O6sByxTUSCg</td>
      </tr>
      <tr>
        <td>Days between sample collection and Xpert MTB/RIF test</td>
        <td>Xpert MTB/RIF: collection-test interval</td>
        <td></td>
        <td>Number of days between sample collection date and test date. Added value used to calculate mean.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>O81jVgPRPJZ</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Z resistant</td>
        <td>Sub DST SM: new patients - Z resistant</td>
        <td></td>
        <td>Subsequent DST SM - New patients resistant to Z</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>O9hhMPIUYZO</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Mfx CB contaminated</td>
        <td>Init DST LM: samples - Mfx CB contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>oaIfTkuTRsC</td>
      </tr>
      <tr>
        <td>Culture LM: 3 days</td>
        <td>Culture LM: 3d</td>
        <td></td>
        <td>Number of samples with 3 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>oE4qleMRIsc</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Dlm resistant</td>
        <td>Sub DST LM: patients - Dlm resistant</td>
        <td></td>
        <td>Subsequent DST LM - patients resistant to Dlm</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>OebNebICI0h</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Dlm resistant</td>
        <td>Sub DST SM: prev patients - Dlm resistant</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients resistant to Dlm</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>oeZepiNfmKj</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Bdq susceptible</td>
        <td>Sub DST LM: patients - Bdq susceptible</td>
        <td></td>
        <td>Subsequent DST LM - patients susceptible to Bdq</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>oftX0vZAM9r</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - E susceptible</td>
        <td>Init DST LM: patients - E susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>OlecwgQa57o</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Lzd contaminated</td>
        <td>Sub DST SM: samples - Lzd contaminated</td>
        <td></td>
        <td>Subsequent DST SM - Lzd - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>OLR2G7P2KLX</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Mfx CB susceptible</td>
        <td>Init DST LM: prev patients - Mfx CB susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Olrvc8Jhijd</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: previously treated patients - Km indeterminate</td>
        <td>LPA FQ/2LI: prev patients - Km indeterminate</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA FQ/2LI. Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA FQ/2LI on multiple samples. Condition: previously treated patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>oLyx8mPsMUU</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - E contaminated</td>
        <td>Sub DST LM: samples - E contaminated</td>
        <td></td>
        <td>Subsequent DST LM - E - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>onZWy5SCjZ5</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: new patients - RS</td>
        <td>Xpert MTB/RIF: new patients - RS</td>
        <td></td>
        <td>New patients with test result for Xpert MTB/RIF - MTB, RIF susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>oOTpUbHvOxn</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Cfz contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Cfz cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - new patients - Cfz contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>OQeEjNs3Ho9</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - H CC resistant</td>
        <td>Sub DST LM: patients - H CC resistant</td>
        <td></td>
        <td>Subsequent DST LM - patients resistant to H CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>oqv395bpDv1</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Lfx contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Lfx cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>OSIs8OpyxVO</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Cfz resistant</td>
        <td>Init DST LM: samples - Cfz resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ou4WNqCxMuu</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - H CC contaminated</td>
        <td>Sub DST SM: samples - H CC contaminated</td>
        <td></td>
        <td>Subsequent DST SM - H CC - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>oUz32KzStH0</td>
      </tr>
      <tr>
        <td>Samples: 4 days</td>
        <td>Collection arrival interval: 4d</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>oViP4CReXG4</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 8 days</td>
        <td>Xpert MTB/RIF: 8d</td>
        <td></td>
        <td>Number of samples with 8 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>OVysV7KptVe</td>
      </tr>
      <tr>
        <td>Culture SM: samples - no growth</td>
        <td>Culture SM: samples - no growth</td>
        <td></td>
        <td>Number of samples with result "no growth" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>oXa3DtiSYe0</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: patients - Km resistant</td>
        <td>LPA FQ/2LI: patients - Km resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by LPA FQ/2LI. Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>OxtZda8ABPq</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Cfz resistant</td>
        <td>Init DST SM: new patients - Cfz resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>oyDpKH5EAxE</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - R indeterminate</td>
        <td>Sub DST SM: samples - R indeterminate</td>
        <td></td>
        <td>Subsequent DST SM - R - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>oz7eO5DDvNa</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - H CC resistant</td>
        <td>Init DST SM: patients - H CC resistant</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>P1wRsnQDSoO</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: new patients - Am/Cm resistant</td>
        <td>LPA FQ/2LI: new patients - Am/Cm resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by LPA FQ/2LI. Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>P8GK4wGFFTE</td>
      </tr>
      <tr>
        <td>Sample collection and arrival events</td>
        <td>Collection arrival events, sum</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>P9K7xj7hHgZ</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Bdq resistant</td>
        <td>Init DST LM: prev patients - Bdq resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Pc6xpNNg7LE</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: new patients - Km susceptible</td>
        <td>LPA FQ/2LI: new patients - Km susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by LPA FQ/2LI. No resistance detected by LPA FQ/2LI on multiple samples. Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>PCemW9SgW7M</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: previously treated patients - E resistant</td>
        <td>LPA FQ/2LI: prev patients - E resistant</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested resistant to the applicable drug by LPA FQ/2LI. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>pcyI2L4i2bS</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: 0 days</td>
        <td>LPA FQ/2LI: 0d</td>
        <td></td>
        <td>Number of samples with 0 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>PD1r3kjNsEZ</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 10 days</td>
        <td>Xpert MTB/RIF: 10d</td>
        <td></td>
        <td>Number of samples with 10 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>PdeRbkFtsIC</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Mfx CB contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Mfx CB cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - patients - Mfx CB contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>pDF9ROzD1cb</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: patients - INH resistant</td>
        <td>LPA RIF/INH: patients - INH resistant</td>
        <td></td>
        <td>LPA RIF/INH - INH resistant patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>pDr45R9KiqB</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: samples - MTB detected, RIF indeterminate</td>
        <td>Xpert MTB/RIF: samples - RIF indeterminate</td>
        <td></td>
        <td>Xpert MTB/RIF - MTB detected, RIF indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>PDSh98oi6iG</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Z resistant</td>
        <td>Init DST LM: prev patients - Z resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>pEpZ5PTUhJz</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Bdq contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Bdq cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Pf9TOtsHmci</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Am susceptible</td>
        <td>Init DST LM: prev patients - Am susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>pfmjHNJ9x6R</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Cfz resistant</td>
        <td>Init DST SM: patients - Cfz resistant</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>pg04Amkdg8w</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Lzd contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Lzd cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - patients - Lzd contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>PgBqxJAbupy</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Am susceptible</td>
        <td>Init DST LM: patients - Am susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>phffikkxLSj</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Dlm susceptible</td>
        <td>Sub DST LM: patients - Dlm susceptible</td>
        <td></td>
        <td>Subsequent DST LM - patients susceptible to Dlm</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>phorDunwGXo</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - H CC contaminated/indeterminate</td>
        <td>Init DST SM: new patients - H CC cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>PHv62Yu06oi</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Lfx contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Lfx cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Pi8ayoXTRKO</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - H CB contaminated/indeterminate</td>
        <td>Sub DST LM: patients - H CB cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - patients - H CB contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>PJZO3meSj8D</td>
      </tr>
      <tr>
        <td>New patients (cumulative)</td>
        <td>New patients (cumulative)</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>PK5i0N7y7Ja</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - E contaminated/indeterminate</td>
        <td>Init DST LM: new patients - E cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>pkgY5FqeFjb</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - R resistant</td>
        <td>Init DST LM: new patients - R resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>PL2mZFknpzr</td>
      </tr>
      <tr>
        <td>Patients with inoculation date for subsequent DST LM</td>
        <td>Sub DST LM: patients - inoculation date</td>
        <td></td>
        <td>Patients with inoculation date for subsequent DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>PldVWpl9xeq</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Z contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Z cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - patients - Z contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>pLUGwLLLQMF</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Lzd susceptible</td>
        <td>Init DST LM: prev patients - Lzd susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>plvxpzzpVzo</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Lfx contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Lfx cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - new patients - Lfx contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>pMGwv0JLXEt</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - E susceptible</td>
        <td>Init DST SM: prev patients - E susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>pnT5LoEQyzr</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: patients - MTB not detected</td>
        <td>Xpert MTB/RIF U: patients - MTB not detected</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra - patients with MTB not detected</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Poolb0bKeix</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Dlm susceptible</td>
        <td>Sub DST SM: new patients - Dlm susceptible</td>
        <td></td>
        <td>Subsequent DST SM - new patients susceptible to Dlm</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>PPl4KMHIJT3</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Mfx CC resistant</td>
        <td>Sub DST SM: samples - Mfx CC resistant</td>
        <td></td>
        <td>Subsequent DST SM - Mfx CC - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>PpTb1ERfg3Q</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Z indeterminate</td>
        <td>Init DST LM: samples - Z indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>pqKUQg6IVks</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Cfz susceptible</td>
        <td>Init DST LM: samples - Cfz susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Pr1eRaFDtRG</td>
      </tr>
      <tr>
        <td>Culture LM: samples - No growth</td>
        <td>Culture LM: samples - no growth</td>
        <td></td>
        <td>Number of samples with result "no growth" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>pTDVLacJUAm</td>
      </tr>
      <tr>
        <td>HR-TB patients</td>
        <td>HR-TB patients</td>
        <td></td>
        <td>Patients susceptible to rifampicin and resistant to isoniazid. </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>PTGtgtV5tb2</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Lzd susceptible</td>
        <td>Sub DST LM: prev patients - Lzd susceptible</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients susceptible to Lzd</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>PtpSwoTHmcG</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Z contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Z cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - new patients - Z contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>PUMHNoEubMR</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Cfz contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Cfz cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>pvcjXzf476j</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 5 days</td>
        <td>Xpert MTB/RIF: 5d</td>
        <td></td>
        <td>Number of samples with 5 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>PvKoYkm2MCX</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Am resistant</td>
        <td>Sub DST SM: new patients - Am resistant</td>
        <td></td>
        <td>Subsequent DST SM - New patients resistant to Am</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>pwDBHevJNrL</td>
      </tr>
      <tr>
        <td>Previously treated patients</td>
        <td>Previously treated patients</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>pWkYiiBIzeI</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - H CB resistant</td>
        <td>Sub DST LM: new patients - H CB resistant</td>
        <td></td>
        <td>Subsequent DST LM - New patients resistant to H CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>pXysNcjM76l</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: patients - MTB detected</td>
        <td>LPA RIF/INH: patients - MTB detected</td>
        <td></td>
        <td>LPA RIF/INH - patients with MTB detected</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>pytuZVI0ukZ</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: 4 days</td>
        <td>LPA RIF/INH: 4d</td>
        <td></td>
        <td>Number of samples with 4 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>pYWJoY1zICY</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: previously treated patients - RR</td>
        <td>Xpert MTB/RIF U: prev patients - RR</td>
        <td></td>
        <td>Previously treated patients with test result for Xpert MTB/RIF Ultra - MTB, RIF resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>pzTm4eHbXdp</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: patients - MTB detected</td>
        <td>LPA FQ/2LI: patients - MTB detected</td>
        <td></td>
        <td>Patients with MTB detected in at least one sample by LPA FQ/2LI. Condition: test date.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>q6rKTcc0b4G</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - E susceptible</td>
        <td>Sub DST SM: samples - E susceptible</td>
        <td></td>
        <td>Subsequent DST SM - E - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>q76HsI6ClCd</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Cfz susceptible</td>
        <td>Sub DST SM: prev patients - Cfz susceptible</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients susceptible to Cfz</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>q9KghOGpcdq</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: new patients - RIF resistant</td>
        <td>LPA RIF/INH: new patients - RIF resistant</td>
        <td></td>
        <td>LPA RIF/INH - new RIF resistant patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>qAaqiEtHFgB</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: 7 days</td>
        <td>LPA FQ/2LI: 7d</td>
        <td></td>
        <td>Number of samples with 7 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>QarDtlid8zk</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Lzd contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Lzd cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>QBlVFZk3DBu</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - R indeterminate</td>
        <td>Init DST SM: samples - R indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>QBTDDGn35IH</td>
      </tr>
      <tr>
        <td>Enrolled patients (cumulative)</td>
        <td>Enrollments - cumulative</td>
        <td></td>
        <td>Cumulative enrollment count</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>qd9PbhmNYnR</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Dlm resistant</td>
        <td>Init DST LM: new patients - Dlm resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>QEcUcHVFJho</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: patients - E resistant</td>
        <td>LPA FQ/2LI: patients - E resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by LPA FQ/2LI. Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Qfhf25Oce5X</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - R susceptible</td>
        <td>Init DST LM: samples - R susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>QGjAcTm4uv2</td>
      </tr>
      <tr>
        <td>Missing data: patients with no registered age, gender, HIV test result, or TB treatment history</td>
        <td>Missing data: any key demographics</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>qGLJdB5Qg2I</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: samples - MTB detected</td>
        <td>LPA RIF/INH: samples - MTB detected</td>
        <td></td>
        <td>LPA RIF/INH - MTB detected</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>qgRHOse57eS</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Mfx CB contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Mfx CB cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>QgZ5U6ocKbS</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Mfx CC contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Mfx CC cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>qhTaRzXxdgE</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Cfz contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Cfz cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients - Cfz contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>QjC1EgtnJAD</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Cfz indeterminate</td>
        <td>Sub DST SM: samples - Cfz indeterminate</td>
        <td></td>
        <td>Subsequent DST SM - Cfz - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>QLdY9WHtJDz</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Lfx susceptible</td>
        <td>Init DST SM: patients - Lfx susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>QLOD6SMC2A0</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Mfx CC resistant</td>
        <td>Sub DST LM: new patients - Mfx CC resistant</td>
        <td></td>
        <td>Subsequent DST LM - New patients resistant to Mfx CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>QmGU5r5l9Ab</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Mfx CC susceptible</td>
        <td>Sub DST LM: prev patients - Mfx CC susceptible</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients susceptible to Mfx CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>qoEyqH4wwwm</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Mfx CC resistant</td>
        <td>Init DST SM: prev patients - Mfx CC resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>qogSzR2VXkK</td>
      </tr>
      <tr>
        <td>Samples with result for initial DST SM</td>
        <td>Init DST SM: samples - result</td>
        <td></td>
        <td>Samples with result for initial DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>QPGYhthplln</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: samples - RR</td>
        <td>Xpert MTB/RIF U: samples - RR</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra - RR</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>qQlS4yw9RaV</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: samples - MTB not detected</td>
        <td>Xpert MTB/RIF U: samples - MTB not detected</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra - MTB not detected</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>QSa605mN246</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Z contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Z cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>qtJLBYBxHXE</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Cfz susceptible</td>
        <td>Init DST LM: patients - Cfz susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>qUcV1AsyrjM</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: new patients - RIF indeterminate</td>
        <td>Xpert MTB/RIF: new patients - RIF indeterminate</td>
        <td></td>
        <td>Xpert MTB/RIF - new RIF indeterminate patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>QvrvOrqNR9s</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Cfz resistant</td>
        <td>Sub DST SM: samples - Cfz resistant</td>
        <td></td>
        <td>Subsequent DST SM - Cfz - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>qxFMe08GfWQ</td>
      </tr>
      <tr>
        <td>Patients with result for initial DST LM</td>
        <td>Init DST LM: patients - result</td>
        <td></td>
        <td>Patients with result for initial DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>QXiAL03hJjW</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - R contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - R cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients - R contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>QxlIXjaP09h</td>
      </tr>
      <tr>
        <td>Patients with inoculation date for culture LM</td>
        <td>Culture LM: patients - inoculation date</td>
        <td></td>
        <td>Patients with inoculation date for culture LM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>R1AWAmtWXNh</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: samples - MTB not detected</td>
        <td>LPA RIF/INH: samples - MTB not detected</td>
        <td></td>
        <td>LPA RIF/INH - MTB not detected</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>r1f4FeokEfS</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Lzd susceptible</td>
        <td>Init DST SM: patients - Lzd susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>r35T9E2eN0J</td>
      </tr>
      <tr>
        <td>Culture LM: previously treated patients - no growth</td>
        <td>Culture LM: prev patients - no growth</td>
        <td></td>
        <td>Number of previously treated patients with result "no growth" (cumulative). If more than one sample is examined per patient, "no growth" result is recorded if at least one sample has no growth and MTB or NTM are not detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>R3JPrdIcmjs</td>
      </tr>
      <tr>
        <td>Patients with unknown treatment history</td>
        <td>DRS: unknown treatment history</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>R3QrVqsFhCC</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Cfz susceptible</td>
        <td>Init DST SM: patients - Cfz susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>rAIsq8tQ0rL</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Lzd resistant</td>
        <td>Init DST LM: new patients - Lzd resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>rb5UEJsvHMs</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Dlm contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Dlm cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - patients - Dlm contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>RBicbarJPl4</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Lzd susceptible</td>
        <td>Init DST SM: samples - Lzd susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>RBKOeLO8kFs</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Lfx contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Lfx cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - new patients - Lfx contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>rcICF38L7mE</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - R contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - R cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - new patients - R contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>RCuCuQq8EVw</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Cfz susceptible</td>
        <td>Sub DST LM: prev patients - Cfz susceptible</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients susceptible to Cfz</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>REb86WxR7NW</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - R resistant</td>
        <td>Init DST SM: patients - R resistant</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>RFUHj0EVvIW</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - E indeterminate</td>
        <td>Init DST LM: samples - E indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Rfz2wpp9wsI</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Lzd susceptible</td>
        <td>Init DST LM: samples - Lzd susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>RK2d2KxY2ln</td>
      </tr>
      <tr>
        <td>Samples with result for Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF U: samples- result</td>
        <td></td>
        <td>Samples with result for Xpert MTB/RIF Ultra</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>rkXSq0Sf1Lc</td>
      </tr>
      <tr>
        <td>Culture SM: 1 day</td>
        <td>Culture SM: 1d</td>
        <td></td>
        <td>Number of samples with 1 day turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Rlbs4UiZydq</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Bdq contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Bdq cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>RLMAFAjdM1P</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - H CC susceptible</td>
        <td>Sub DST SM: prev patients - H CC susceptible</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients susceptible to H CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>rMKJMrIdwxU</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: 2 days</td>
        <td>LPA FQ/2LI: 2d</td>
        <td></td>
        <td>Number of samples with 2 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>rnxWrZanCtV</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Bdq contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Bdq cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients - Bdq contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>rocQB4VEATy</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Am susceptible</td>
        <td>Init DST SM: new patients - Am susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>rq7eOFDLmQK</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Mfx CB resistant</td>
        <td>Init DST SM: patients - Mfx CB resistant</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>rQXzjEVe3c2</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Am susceptible</td>
        <td>Init DST LM: new patients - Am susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>RsElKBSc1kB</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Am resistant</td>
        <td>Sub DST SM: samples - Am resistant</td>
        <td></td>
        <td>Subsequent DST SM - Am - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>rShSocJ14lJ</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: 3 days</td>
        <td>LPA FQ/2LI: 3d</td>
        <td></td>
        <td>Number of samples with 3 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>rSrlFohRGM1</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Mfx CB susceptible</td>
        <td>Init DST SM: samples - Mfx CB susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>RTLLeqWAffq</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Am susceptible</td>
        <td>Sub DST SM: new patients - Am susceptible</td>
        <td></td>
        <td>Subsequent DST SM - new patients susceptible to Am</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ruLVyeypubb</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Dlm contaminated</td>
        <td>Init DST SM: samples - Dlm contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>rUvdF2y3yQV</td>
      </tr>
      <tr>
        <td>Culture LM: 8 days</td>
        <td>Culture LM: 8d</td>
        <td></td>
        <td>Number of samples with 8 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>RV2PlhWoox8</td>
      </tr>
      <tr>
        <td>Samples with result for microscopy</td>
        <td>Microscopy: samples - result</td>
        <td></td>
        <td>Samples with result for microscopy</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>rV8cfZVEqZK</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Dlm - contaminated</td>
        <td>Sub DST LM: samples - Dlm - contaminated</td>
        <td></td>
        <td>Subsequent DST LM - Dlm - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>rWJyTJVZl5s</td>
      </tr>
      <tr>
        <td>Culture SM: samples - contaminated</td>
        <td>Culture SM: samples - contaminated</td>
        <td></td>
        <td>Number of samples with result "contaminated" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>RX5YwuS9RbM</td>
      </tr>
      <tr>
        <td>Processed LPA FQ/2LI samples</td>
        <td>LPA FQ/2LI: processed samples</td>
        <td></td>
        <td>Processed LPA FQ/2LI samples</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>rxuYRTJZ2ej</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Z susceptible</td>
        <td>Init DST SM: prev patients - Z susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>RyF9HEzgBBn</td>
      </tr>
      <tr>
        <td>Microscopy: previously treated patients - positive</td>
        <td>Microscopy: prev patients - positive</td>
        <td></td>
        <td>Previously treated patients - microscopy positive</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>RZEpC4Mmmsp</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Am contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Am cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients - Am contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>RZPj0Wrcnxn</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: 7 days</td>
        <td>LPA RIF/INH: 7d</td>
        <td></td>
        <td>Number of samples with 7 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>s2MFQfmgwDR</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Z susceptible</td>
        <td>Sub DST LM: samples - Z susceptible</td>
        <td></td>
        <td>Subsequent DST LM - Z - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>S33osVSK7bu</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Mfx CC contaminated/indeterminate</td>
        <td>Init DST LM: patients - Mfx CC cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>s4ojXwTRVMB</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Cfz resistant</td>
        <td>Init DST SM: prev patients - Cfz resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>s560uws0IhG</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Lfx resistant</td>
        <td>Sub DST SM: new patients - Lfx resistant</td>
        <td></td>
        <td>Subsequent DST SM - New patients resistant to Lfx</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>s8ca1kbNVCy</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: previously treated patients - RIF indeterminate</td>
        <td>Xpert MTB/RIF: prev patients - RIF indeterminate</td>
        <td></td>
        <td>Xpert MTB/RIF - previously treated RIF indeterminate patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>S8lSfngoxu7</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: previously treated patients - FQ susceptible</td>
        <td>LPA FQ/2LI: prev patients - FQ susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by LPA FQ/2LI. No resistance detected by LPA FQ/2LI on multiple samples. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>s9gdW5R4nj1</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Bdq susceptible</td>
        <td>Sub DST SM: new patients - Bdq susceptible</td>
        <td></td>
        <td>Subsequent DST SM - new patients susceptible to Bdq</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>SARbVYz3ovb</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - H CB susceptible</td>
        <td>Sub DST SM: samples - H CB susceptible</td>
        <td></td>
        <td>Subsequent DST SM - H CB - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>SbfRyAQCsp4</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Mfx CB susceptible</td>
        <td>Sub DST LM: patients - Mfx CB susceptible</td>
        <td></td>
        <td>Subsequent DST LM - patients susceptible to Mfx CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>SftNGftUtHI</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - H CC contaminated/indeterminate</td>
        <td>Sub DST LM: patients - H CC cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - patients - H CC contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>sg927BRQATg</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Mfx CC susceptible</td>
        <td>Init DST LM: prev patients - Mfx CC susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>sGLpHvkrJl0</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Mfx CB resistant</td>
        <td>Init DST LM: samples - Mfx CB resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>SGT2z6fisYd</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: samples - RS</td>
        <td>Xpert MTB/RIF U: samples - RS</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra - RS</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>SH0iOmEe0AR</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - R susceptible</td>
        <td>Init DST SM: patients - R susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>sh8xXpr7SOC</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: new patients - INH resistant</td>
        <td>LPA RIF/INH: new patients - INH resistant</td>
        <td></td>
        <td>LPA RIF/INH - new INH resistant patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>sHgmMnlbGOd</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: patients - MTB detected</td>
        <td>Xpert MTB/RIF U: patients - MTB detected</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra - patients with detected MTB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>SJIgoySQSL9</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: new patients - E susceptible</td>
        <td>LPA FQ/2LI: new patients - E susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by LPA FQ/2LI. No resistance detected by LPA FQ/2LI on multiple samples. Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>SjJygt0PwVc</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Dlm indeterminate</td>
        <td>Sub DST LM: samples - Dlm indeterminate</td>
        <td></td>
        <td>Subsequent DST LM - Dlm - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>sJxBmDVVRFI</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Mfx CC contaminated</td>
        <td>Sub DST SM: samples - Mfx CC contaminated</td>
        <td></td>
        <td>Subsequent DST SM - Mfx CC - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>SkrMaOzuaOx</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - Km resistant</td>
        <td>LPA FQ/2LI: samples - Km resistant</td>
        <td></td>
        <td>LPA FQ/2LI - Km - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>SKYQM109VlR</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Am resistant</td>
        <td>Init DST LM: prev patients - Am resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>smBK9aQLZVt</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: previously treated patients - E susceptible</td>
        <td>LPA FQ/2LI: prev patients - E susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by LPA FQ/2LI. No resistance detected by LPA FQ/2LI on multiple samples. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>SmerIApsjMN</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: new patients - INH indeterminate</td>
        <td>LPA RIF/INH: new patients - INH indeterminate</td>
        <td></td>
        <td>LPA RIF/INH - new INH indeterminate patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>SMQaa2FME9m</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Z contaminated</td>
        <td>Init DST SM: samples - Z contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Smx6TYW3634</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Lfx resistant</td>
        <td>Init DST LM: new patients - Lfx resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Sn1Y3lTblQ2</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Mfx CB contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Mfx CB cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>snExB8w3Gcm</td>
      </tr>
      <tr>
        <td>Culture SM: patients - NTM detected</td>
        <td>Culture SM: patients - NTM</td>
        <td></td>
        <td>Number of patients with result "NTM" (cumulative). If more than one sample is examined per patient, "NTM" result is recorded if at least one sample has NTM and no MTB is detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>snFxSirfErx</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - H CB susceptible</td>
        <td>Sub DST LM: patients - H CB susceptible</td>
        <td></td>
        <td>Subsequent DST LM - patients susceptible to H CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>SNTw9Vpw8qb</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: patients - RIF resistant</td>
        <td>LPA RIF/INH: patients - RIF resistant</td>
        <td></td>
        <td>LPA RIF/INH - RIF resistant patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>spav9vMokn2</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: patients - RIF indeterminate</td>
        <td>LPA RIF/INH: patients - RIF indeterminate</td>
        <td></td>
        <td>LPA RIF/INH - RIF indeterminate patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>sPBdvSLlJZY</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Dlm contaminated/indeterminate</td>
        <td>Init DST SM: patients - Dlm cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>sqp1Bv70e3U</td>
      </tr>
      <tr>
        <td>Culture LM: previously treated patients - contaminated</td>
        <td>Culture LM: prev patients - contaminated</td>
        <td></td>
        <td>Number of previously treated patients with result "contaminated" (cumulative). If more than one sample is examined per patient, "contaminated" result is recorded if all samples are contaminated. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>sRaCkGSjiLt</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Lfx contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Lfx cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients - Lfx contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>srZG8NDtJ3h</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - H CC contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - H CC cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - new patients - H CC contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ss7bHfxhLrq</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Lzd susceptible</td>
        <td>Sub DST LM: samples - Lzd susceptible</td>
        <td></td>
        <td>Subsequent DST LM - Lzd - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>stEHUWnoMq5</td>
      </tr>
      <tr>
        <td>Culture LM: 6 days</td>
        <td>Culture LM: 6d</td>
        <td></td>
        <td>Number of samples with 6 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>STuGYEEZ6o5</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - H CB contaminated</td>
        <td>Init DST LM: samples - H CB contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>su6weiXSIti</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Cfz susceptible</td>
        <td>Init DST LM: new patients - Cfz susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>svpfoQw6O39</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Bdq susceptible</td>
        <td>Sub DST SM: samples - Bdq susceptible</td>
        <td></td>
        <td>Subsequent DST SM - Bdq - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>SwmPVQY2FJ3</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Am resistant</td>
        <td>Sub DST SM: prev patients - Am resistant</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients resistant to Am</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>sYiVV33usyC</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - H CB resistant</td>
        <td>Sub DST SM: patients - H CB resistant</td>
        <td></td>
        <td>Subsequent DST SM - patients resistant to H CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>SzYSBtaPujQ</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Mfx CC susceptible</td>
        <td>Sub DST SM: patients - Mfx CC susceptible</td>
        <td></td>
        <td>Subsequent DST SM - patients susceptible to Mfx CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>T1D14wQc6Pe</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Mfx CB resistant</td>
        <td>Init DST SM: samples - Mfx CB resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>t2EcSOcA09t</td>
      </tr>
      <tr>
        <td>Culture LM: new patients - MTB detected</td>
        <td>Culture LM: new patients - MTB</td>
        <td></td>
        <td>Number of new patients with result "MTB" (cumulative). If more than one sample is examined per patient, "MTB" result is recorded if at least one sample has MTB detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>t3qthExhQKL</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Lfx contaminated</td>
        <td>Init DST LM: samples - Lfx contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>tA5pYtchuWU</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Mfx CB contaminated</td>
        <td>Sub DST SM: samples - Mfx CB contaminated</td>
        <td></td>
        <td>Subsequent DST SM - Mfx CB - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>TAJrVlUWA15</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Lfx contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Lfx cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - patients - Lfx contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Tcq1ZiYT7Yq</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Cfz susceptible</td>
        <td>Init DST SM: samples - Cfz susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>tDKHvNwKNRL</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Dlm susceptible</td>
        <td>Sub DST LM: prev patients - Dlm susceptible</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients susceptible to Dlm</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Tegm0xLM4rn</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Mfx CB resistant</td>
        <td>Sub DST SM: patients - Mfx CB resistant</td>
        <td></td>
        <td>Subsequent DST SM - patients resistant to Mfx CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>TePspFbeIA5</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - R contaminated/indeterminate</td>
        <td>Init DST LM: patients - R cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>TeRX9Z45EzR</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Dlm susceptible</td>
        <td>Init DST SM: samples - Dlm susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>thTqoznl0K7</td>
      </tr>
      <tr>
        <td>Culture LM: patients - contaminated</td>
        <td>Culture LM: patients - contaminated</td>
        <td></td>
        <td>Number of patients with result "contaminated" (cumulative). If more than one sample is examined per patient, "contaminated" result is recorded if all samples are contaminated. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>tIgRROcdrWC</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Dlm susceptible</td>
        <td>Sub DST LM: new patients - Dlm susceptible</td>
        <td></td>
        <td>Subsequent DST LM - new patients susceptible to Dlm</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>titK1r1BOlH</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - FQ indeterminate</td>
        <td>LPA FQ/2LI: samples - FQ indeterminate</td>
        <td></td>
        <td>LPA FQ/2LI - FQ - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>tiuKqMsWxrw</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - Error/Invalid/No result</td>
        <td>LPA FQ/2LI: samples - Error/Invalid/No result</td>
        <td></td>
        <td>LPA FQ/2LI - Error/Invalid/No result</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>tja5fRSuTBE</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Z resistant</td>
        <td>Sub DST LM: new patients - Z resistant</td>
        <td></td>
        <td>Subsequent DST LM - New patients resistant to Z</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>tJa81zjWUkG</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - H CB susceptible</td>
        <td>Sub DST SM: patients - H CB susceptible</td>
        <td></td>
        <td>Subsequent DST SM - patients susceptible to H CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>TkKU87tvUfC</td>
      </tr>
      <tr>
        <td>Samples: 0 days</td>
        <td>Collection arrival interval: 0d</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>tLhDS5r25wt</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - E resistant</td>
        <td>Init DST LM: new patients - E resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>tlmQ6gisAGh</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - H CC indeterminate</td>
        <td>Init DST SM: samples - H CC indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ToEpkaCnJuf</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Dlm susceptible</td>
        <td>Init DST LM: new patients - Dlm susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>tois9I4EkY3</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Lfx contaminated/indeterminate</td>
        <td>Init DST LM: patients - Lfx cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>TORYgaK1YUF</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Mfx CB indeterminate</td>
        <td>Init DST LM: samples - Mfx CB indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>TOU4KSWSS1b</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: 3 days</td>
        <td>Xpert MTB/RIF U: 3d</td>
        <td></td>
        <td>Number of samples with 3 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>tqXqhNzjbLK</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - H CC susceptible</td>
        <td>Init DST SM: patients - H CC susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>TSS4Ymmu0qa</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - H CB susceptible</td>
        <td>Init DST LM: new patients - H CB susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>TTy1mozDhty</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Dlm resistant</td>
        <td>Init DST SM: samples - Dlm resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ttyarOal7wI</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Dlm susceptible</td>
        <td>Init DST SM: new patients - Dlm susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>tuFTLk3Q0ss</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 4 days</td>
        <td>Xpert MTB/RIF: 4d</td>
        <td></td>
        <td>Number of samples with 4 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>TUguO2Ynxex</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - H CC indeterminate</td>
        <td>Init DST LM: samples - H CC indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>tuy3A2HETxn</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Am resistant</td>
        <td>Sub DST LM: patients - Am resistant</td>
        <td></td>
        <td>Subsequent DST LM - patients resistant to Am</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>TXzYZ5NUzGE</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: 10 days</td>
        <td>LPA FQ/2LI: 10d</td>
        <td></td>
        <td>Number of samples with 10 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>tYLvtd2eq1T</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Cfz resistant</td>
        <td>Init DST LM: prev patients - Cfz resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>U0KbG9khPd5</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Mfx CC susceptible</td>
        <td>Init DST SM: patients - Mfx CC susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>U4mKeK8i4Hk</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Cfz resistant</td>
        <td>Init DST LM: patients - Cfz resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>U4YZsFclJlk</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Lfx indeterminate</td>
        <td>Sub DST LM: samples - Lfx indeterminate</td>
        <td></td>
        <td>Subsequent DST LM - Lfx - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>U5WRXT9rtyA</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Cfz resistant</td>
        <td>Sub DST SM: patients - Cfz resistant</td>
        <td></td>
        <td>Subsequent DST SM - patients resistant to Cfz</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>U61I4srgNTl</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: 10 days</td>
        <td>LPA RIF/INH: 10d</td>
        <td></td>
        <td>Number of samples with 10 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>u7o1DWalCtg</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - E indeterminate</td>
        <td>LPA FQ/2LI: samples - E indeterminate</td>
        <td></td>
        <td>LPA FQ/2LI - E - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>u8hqJ0vFyDx</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Am susceptible</td>
        <td>Sub DST LM: new patients - Am susceptible</td>
        <td></td>
        <td>Subsequent DST LM - new patients susceptible to Am</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>UBxYSphJOOI</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Lzd resistant</td>
        <td>Init DST LM: patients - Lzd resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Uchb5CJcAOn</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - R susceptible</td>
        <td>Init DST SM: prev patients - R susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>UfEFCBuifbO</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - H CB contaminated</td>
        <td>Sub DST SM: samples - H CB contaminated</td>
        <td></td>
        <td>Subsequent DST SM - H CB - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Ugg2hcmNkv1</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Dlm resistant</td>
        <td>Sub DST SM: samples - Dlm resistant</td>
        <td></td>
        <td>Subsequent DST SM - Dlm - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>uHVdQW61TK6</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - R contaminated/indeterminate</td>
        <td>Init DST SM: new patients - R cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ulABEq4nBsW</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - H CC susceptible</td>
        <td>Init DST LM: samples - H CC susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>uM6AKPkeUwQ</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: 3 days</td>
        <td>LPA RIF/INH: 3d</td>
        <td></td>
        <td>Number of samples with 3 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>uNBJmNEtRBF</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - E susceptible</td>
        <td>Sub DST LM: samples - E susceptible</td>
        <td></td>
        <td>Subsequent DST LM - E - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>UnMZYDDbWef</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - E contaminated/indeterminate</td>
        <td>Sub DST SM: patients - E cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - patients - E contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>uOiAgPqfSca</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - H CC indeterminate</td>
        <td>Sub DST SM: samples - H CC indeterminate</td>
        <td></td>
        <td>Subsequent DST SM - H CC - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Ur2unOu0ABe</td>
      </tr>
      <tr>
        <td>Culture SM: previously treated patients - MTB detected</td>
        <td>Culture SM: prev patients - MTB</td>
        <td></td>
        <td>Number of previously treated patients with result "MTB" (cumulative). If more than one sample is examined per patient, "MTB" result is recorded if at least one sample has MTB detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>UrPUE2i8GAU</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Mfx CC contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Mfx CC cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients - Mfx CC contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>uSojnfuocie</td>
      </tr>
      <tr>
        <td>Culture SM: 9 days</td>
        <td>Culture SM: 9d</td>
        <td></td>
        <td>Number of samples with 9 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>utTgYdaTGrb</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: 9 days</td>
        <td>LPA FQ/2LI: 9d</td>
        <td></td>
        <td>Number of samples with 9 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>uu0066KEVEY</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - E susceptible</td>
        <td>Sub DST SM: patients - E susceptible</td>
        <td></td>
        <td>Subsequent DST SM - patients susceptible to E</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>UuJnpUZEIMt</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Mfx CB contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Mfx CB cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - new patients - Mfx CB contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>uvQVPvXOXSK</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: patients - Am/Cm resistant</td>
        <td>LPA FQ/2LI: patients - Am/Cm resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by LPA FQ/2LI. Condition: MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>uvyU5oBD2oz</td>
      </tr>
      <tr>
        <td>Patients with result for subsequent DST SM</td>
        <td>Sub DST SM: patients - result</td>
        <td></td>
        <td>Patients with result for subsequent DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>uXexeo22Whu</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Lzd contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Lzd cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients - Lzd contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Uy0fdbBkqgV</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Lfx resistant</td>
        <td>Sub DST SM: prev patients - Lfx resistant</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients resistant to Lfx</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>UzmVwVcCDsP</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Cfz resistant</td>
        <td>Sub DST LM: patients - Cfz resistant</td>
        <td></td>
        <td>Subsequent DST LM - patients resistant to Cfz</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>V0x2p9VH7D8</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Dlm resistant</td>
        <td>Sub DST SM: patients - Dlm resistant</td>
        <td></td>
        <td>Subsequent DST SM - patients resistant to Dlm</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>V36JWd4DEwS</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Z susceptible</td>
        <td>Sub DST LM: patients - Z susceptible</td>
        <td></td>
        <td>Subsequent DST LM - patients susceptible to Z</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>V4GWEENoVdy</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: samples - error</td>
        <td>Xpert MTB/RIF U: samples - error</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra - Error</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>v4o5oChYOcF</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Am contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - Am cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients - Am contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>V8h0smTVb4r</td>
      </tr>
      <tr>
        <td>Patients with valid Xpert MTB/RIF result</td>
        <td>Xpert MTB/RIF: patients - valid result</td>
        <td></td>
        <td>Patients with valid test result for Xpert MTB/RIF</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>VBrNPAkO9f1</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: patients - MTB not detected</td>
        <td>LPA FQ/2LI: patients - MTB not detected</td>
        <td></td>
        <td>Patients with MTB not detected in any samples tested by LPA FQ/2LI. Condition: test date.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>VCfBUEMSE8h</td>
      </tr>
      <tr>
        <td>Samples with result for initial DST LM</td>
        <td>Init DST LM: samples - result</td>
        <td></td>
        <td>Samples with result for initial DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>VCucFY6roOu</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Am susceptible</td>
        <td>Sub DST LM: patients - Am susceptible</td>
        <td></td>
        <td>Subsequent DST LM - patients susceptible to Am</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>veREteT6hlg</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Lzd indeterminate</td>
        <td>Init DST SM: samples - Lzd indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>VFwlYCRpKT8</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - R contaminated</td>
        <td>Init DST SM: samples - R contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>VIGJElSLwE6</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - R resistant</td>
        <td>Init DST LM: samples - R resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>VIgX0suMyw3</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Mfx CC resistant</td>
        <td>Init DST LM: samples - Mfx CC resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>vIvpAQtmuvr</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Lfx susceptible</td>
        <td>Init DST LM: samples - Lfx susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>vjf4N8MCOV3</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Lfx susceptible</td>
        <td>Sub DST SM: prev patients - Lfx susceptible</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients susceptible to Lfx</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>vJljhgD71Ny</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Z resistant</td>
        <td>Sub DST LM: patients - Z resistant</td>
        <td></td>
        <td>Subsequent DST LM - patients resistant to Z</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>VkB0mC22R4E</td>
      </tr>
      <tr>
        <td>Samples with inoculation date for culture LM</td>
        <td>Culture LM: samples - inoculation date</td>
        <td></td>
        <td>Samples with inoculation date for culture LM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>vkspdWX0mzd</td>
      </tr>
      <tr>
        <td>Culture SM: previously treated patients - no growth</td>
        <td>Culture SM: prev patients - no growth</td>
        <td></td>
        <td>Number of previously treated patients with result "no growth" (cumulative). If more than one sample is examined per patient, "no growth" result is recorded if at least one sample has no growth and MTB or NTM are not detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>vlhg0jTKrsH</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Cfz indeterminate</td>
        <td>Init DST SM: samples - Cfz indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>vMpjSJHqaNa</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Cfz contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Cfz cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>vnRU4p2WNZH</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Mfx CB resistant</td>
        <td>Init DST SM: new patients - Mfx CB resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>vpFUsKTHw7C</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Dlm susceptible</td>
        <td>Sub DST LM: samples - Dlm susceptible</td>
        <td></td>
        <td>Subsequent DST LM - Dlm - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>VPiRrxWIeAu</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Cfz contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Cfz cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>vPjEMOUrOiA</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Am susceptible</td>
        <td>Sub DST LM: samples - Am susceptible</td>
        <td></td>
        <td>Subsequent DST LM - Am - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>VrkQDJXIDDP</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Am resistant</td>
        <td>Init DST SM: patients - Am resistant</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>VsaE6AEggjD</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: samples - Error/Invalid/No result</td>
        <td>LPA RIF/INH: samples - Error/Invalid/No result</td>
        <td></td>
        <td>LPA RIF/INH - Error/Invalid/No result</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>VsbiIWP2J2F</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - H CB resistant</td>
        <td>Sub DST LM: prev patients - H CB resistant</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients resistant to H CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>vSMBlVfDmft</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - R contaminated/indeterminate</td>
        <td>Sub DST SM: prev patients - R cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients - R contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>VTQkjI3hSkm</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - MTB not detected</td>
        <td>LPA FQ/2LI: samples - MTB not detected</td>
        <td></td>
        <td>LPA FQ/2LI - MTB not detected</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>VVv5IQaPrdI</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - H CB contaminated/indeterminate</td>
        <td>Init DST LM: patients - H CB cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>VvwaGW8ihTk</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - Z resistant</td>
        <td>Sub DST SM: prev patients - Z resistant</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients resistant to Z</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>vWmY0yvNVfc</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Bdq contaminated</td>
        <td>Sub DST SM: samples - Bdq contaminated</td>
        <td></td>
        <td>Subsequent DST SM - Bdq - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>VxJFIFNjhb4</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Mfx CC resistant</td>
        <td>Init DST SM: new patients - Mfx CC resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>VxTMToeTQsg</td>
      </tr>
      <tr>
        <td>Missing data: gender</td>
        <td>Missing data: gender</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>vXwdB7fhkW5</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Mfx CC susceptible</td>
        <td>Init DST SM: samples - Mfx CC susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>vxy56EFkTrH</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Mfx CB resistant</td>
        <td>Sub DST LM: patients - Mfx CB resistant</td>
        <td></td>
        <td>Subsequent DST LM - patients resistant to Mfx CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>vYwZAP4yu5U</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - E indeterminate</td>
        <td>Sub DST SM: samples - E indeterminate</td>
        <td></td>
        <td>Subsequent DST SM - E - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>W0OTsurXcBq</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - E indeterminate</td>
        <td>Init DST SM: samples - E indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>w2AaUjwDGui</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: previously treated patients - Am/Cm indeterminate</td>
        <td>LPA FQ/2LI: prev patients - Am/Cm indeterminate</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by LPA FQ/2LI. Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA FQ/2LI on multiple samples. Condition: previously treated patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>W2V43bhnDpW</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: 8 days</td>
        <td>LPA RIF/INH: 8d</td>
        <td></td>
        <td>Number of samples with 8 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>w3AZnT9pW4i</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Mfx CC resistant</td>
        <td>Sub DST SM: patients - Mfx CC resistant</td>
        <td></td>
        <td>Subsequent DST SM - patients resistant to Mfx CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>W3jcBVNTObT</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Lfx contaminated</td>
        <td>Sub DST SM: samples - Lfx contaminated</td>
        <td></td>
        <td>Subsequent DST SM - Lfx - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>w4Oc9nvJwmg</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Cfz contaminated/indeterminate</td>
        <td>Init DST LM: patients - Cfz cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>W8slaPHit8G</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - E resistant</td>
        <td>Init DST LM: prev patients - E resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>waI6zGdAC0L</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Lfx susceptible</td>
        <td>Init DST LM: new patients - Lfx susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>WAOO1PP801X</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Lfx contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Lfx cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - patients - Lfx contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>WaQFRJ0X8xv</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Am resistant</td>
        <td>Init DST LM: new patients - Am resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Wb7mB8gZmxS</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: 0 days</td>
        <td>LPA RIF/INH: 0d</td>
        <td></td>
        <td>Number of samples with 0 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>WcDv2gi6Pek</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Am indeterminate</td>
        <td>Sub DST LM: samples - Am indeterminate</td>
        <td></td>
        <td>Subsequent DST LM - Am - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>WdtDDovKwwJ</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Am indeterminate</td>
        <td>Init DST LM: samples - Am indeterminate</td>
        <td></td>
        <td>Samples with result "indeterminate" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>weuEp8gEYiA</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Lzd susceptible</td>
        <td>Sub DST LM: patients - Lzd susceptible</td>
        <td></td>
        <td>Subsequent DST LM - patients susceptible to Lzd</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>wfYOu1lx6Qa</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - E susceptible</td>
        <td>Init DST LM: new patients - E susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Wh5ltuI2RdR</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 3 days</td>
        <td>Xpert MTB/RIF: 3d</td>
        <td></td>
        <td>Number of samples with 3 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>wHvQW41KS4c</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Lfx resistant</td>
        <td>Sub DST LM: patients - Lfx resistant</td>
        <td></td>
        <td>Subsequent DST LM - patients resistant to Lfx</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>WiIoqdGvg1M</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Lzd resistant</td>
        <td>Sub DST SM: patients - Lzd resistant</td>
        <td></td>
        <td>Subsequent DST SM - patients resistant to Lzd</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>WjpPcWta7Gz</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Am contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Am cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>wjQ7CrAeA6p</td>
      </tr>
      <tr>
        <td>Culture LM: 10+ days</td>
        <td>Culture LM: 10+d</td>
        <td></td>
        <td>Number of samples with 10+ days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>WJwWEO1wLoD</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - R contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - R cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>WLH2VJO0PkN</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Dlm susceptible</td>
        <td>Init DST SM: prev patients - Dlm susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>wMrYlXritKK</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Z contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Z cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>wnmc8YIahud</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - R susceptible</td>
        <td>Init DST SM: samples - R susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Won3WS3jgBz</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - H CC contaminated/indeterminate</td>
        <td>Init DST LM: patients - H CC cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>WQ2ZlVJAL1d</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: new patients - RR</td>
        <td>Xpert MTB/RIF: new patients - RR</td>
        <td></td>
        <td>New patients with test result for Xpert MTB/RIF - MTB, RIF resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Wq80cCyFEPj</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - E resistant</td>
        <td>Sub DST LM: new patients - E resistant</td>
        <td></td>
        <td>Subsequent DST LM - New patients resistant to E</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>wqHfPAv7vWy</td>
      </tr>
      <tr>
        <td>Culture LM: new patients - no growth</td>
        <td>Culture LM: new patients - no growth</td>
        <td></td>
        <td>Number of new patients with result "no growth" (cumulative). If more than one sample is examined per patient, "no growth" result is recorded if at least one sample has no growth and MTB or NTM are not detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>wQisEHlG43c</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Mfx CC susceptible</td>
        <td>Init DST LM: patients - Mfx CC susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>wSl9gzxcHBr</td>
      </tr>
      <tr>
        <td>Samples with result for subsequent DST LM</td>
        <td>Sub DST LM: samples - result</td>
        <td></td>
        <td>Samples with result for subsequent DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>wsLnXY7LDlA</td>
      </tr>
      <tr>
        <td>Culture LM: previously treated patients - NTM detected</td>
        <td>Culture LM: prev patients - NTM</td>
        <td></td>
        <td>Number of previously treated patients with result "NTM" (cumulative). If more than one sample is examined per patient, "NTM" result is recorded if at least one sample has NTM and no MTB is detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>WTblEFaKYPi</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Bdq contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Bdq cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>WwLq06C7iTC</td>
      </tr>
      <tr>
        <td>Samples with inoculation date for subsequent DST SM</td>
        <td>Sub DST SM: samples - inoculation date</td>
        <td></td>
        <td>Samples tested by subsequent DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>wxKzVyo48o2</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Lfx susceptible</td>
        <td>Init DST SM: prev patients - Lfx susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>WYIKQdnWj8v</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Lfx resistant</td>
        <td>Sub DST SM: patients - Lfx resistant</td>
        <td></td>
        <td>Subsequent DST SM - patients resistant to Lfx</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Wyv5aIEB1Gl</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Lzd indeterminate</td>
        <td>Sub DST LM: samples - Lzd indeterminate</td>
        <td></td>
        <td>Subsequent DST LM - Lzd - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>WzSjzok3JLp</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - R susceptible</td>
        <td>Sub DST LM: prev patients - R susceptible</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients susceptible to R</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>x0BuFyVqp5G</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Lzd contaminated/indeterminate</td>
        <td>Init DST SM: new patients - Lzd cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>X1OWCAaNwhw</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - H CC resistant</td>
        <td>Sub DST LM: new patients - H CC resistant</td>
        <td></td>
        <td>Subsequent DST LM - New patients resistant to H CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>x2pAZdpQDUD</td>
      </tr>
      <tr>
        <td>Culture SM: 3 days</td>
        <td>Culture SM: 3d</td>
        <td></td>
        <td>Number of samples with 3 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>x9RZw5fD8fa</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Mfx CB contaminated/indeterminate</td>
        <td>Init DST SM: patients - Mfx CB cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>XbDlCbLLMWa</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: new patients - RR</td>
        <td>Xpert MTB/RIF U: new patients - RR</td>
        <td></td>
        <td>New patients with test result for Xpert MTB/RIF Ultra - MTB, RIF resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>XBM747hHcXa</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Lfx resistant</td>
        <td>Init DST LM: prev patients - Lfx resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>xCg1UJXJ5Yc</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Cfz contaminated</td>
        <td>Init DST SM: samples - Cfz contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>XCJmxcszJ4E</td>
      </tr>
      <tr>
        <td>Culture SM: new patients - MTB detected</td>
        <td>Culture SM: new patients - MTB</td>
        <td></td>
        <td>Number of new patients with result "MTB" (cumulative). If more than one sample is examined per patient, "MTB" result is recorded if at least one sample has MTB detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>xDByzKWh8B5</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Dlm contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Dlm cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - new patients - Dlm contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>XdE897XapaW</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Mfx CC susceptible</td>
        <td>Sub DST SM: samples - Mfx CC susceptible</td>
        <td></td>
        <td>Subsequent DST SM - Mfx CC - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>xDI1TZpYM8S</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - R resistant</td>
        <td>Sub DST LM: patients - R resistant</td>
        <td></td>
        <td>Subsequent DST LM - patients resistant to R</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>xEEDBnzahPe</td>
      </tr>
      <tr>
        <td>Culture LM: samples - NTM</td>
        <td>Culture LM: samples - NTM</td>
        <td></td>
        <td>Number of samples with result "NTM" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>xFN86BRI9Z6</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - H CB contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - H CB cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients - H CB contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>XGMW0GtBuNg</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - H CC susceptible</td>
        <td>Init DST LM: prev patients - H CC susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>XhNxSlnrws1</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Z susceptible</td>
        <td>Init DST SM: patients - Z susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>xHZKn549ZRN</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Mfx CC contaminated/indeterminate</td>
        <td>Sub DST SM: patients - Mfx CC cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - patients - Mfx CC contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>XjFQ4NnAU7N</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Z resistant</td>
        <td>Init DST SM: prev patients - Z resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>XJom38gElVN</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Dlm susceptible</td>
        <td>Init DST SM: patients - Dlm susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>xjqlj9qGNwf</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Mfx CB resistant</td>
        <td>Init DST LM: patients - Mfx CB resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>xLut6liwpel</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Bdq resistant</td>
        <td>Sub DST SM: new patients - Bdq resistant</td>
        <td></td>
        <td>Subsequent DST SM - New patients resistant to Bdq</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>xLxjI8jmbas</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Bdq resistant</td>
        <td>Sub DST LM: new patients - Bdq resistant</td>
        <td></td>
        <td>Subsequent DST LM - New patients resistant to Bdq</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>xMEWouqClFf</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - H CB susceptible</td>
        <td>Init DST LM: prev patients - H CB susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>xmRYHCLPMTe</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - E resistant</td>
        <td>Init DST LM: patients - E resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>xMXHVJ3TGdP</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: previously treated patients - Am/Cm susceptible</td>
        <td>LPA FQ/2LI: prev patients - Am/Cm susceptible</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by LPA FQ/2LI. No resistance detected by LPA FQ/2LI on multiple samples. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>XmzqEJb0w79</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: samples - E susceptible</td>
        <td>LPA FQ/2LI: samples - E susceptible</td>
        <td></td>
        <td>LPA FQ/2LI - E - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>XNFmjjFC52a</td>
      </tr>
      <tr>
        <td>Missing data: HIV test result</td>
        <td>Missing data: HIV test result</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>XOE7Mzfedq4</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: previously treated patients - RIF resistant</td>
        <td>LPA RIF/INH: prev patients - RIF resistant </td>
        <td></td>
        <td>Previously treated patients with at least one sample tested resistant to the applicable drug by LPA RIF/INH. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>XoQx6SJPRTV</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - R susceptible</td>
        <td>Sub DST LM: patients - R susceptible</td>
        <td></td>
        <td>Subsequent DST LM - patients susceptible to R</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>xPHG0IoL3gy</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Bdq resistant</td>
        <td>Sub DST LM: samples - Bdq resistant</td>
        <td></td>
        <td>Subsequent DST LM - Bdq - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>XqdaRwwmYFx</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Z susceptible</td>
        <td>Init DST SM: new patients - Z susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>XQluYa6a41F</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 9 days</td>
        <td>Xpert MTB/RIF: 9d</td>
        <td></td>
        <td>Number of samples with 9 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>XqOkeUv3qn6</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Mfx CB susceptible</td>
        <td>Sub DST LM: samples - Mfx CB susceptible</td>
        <td></td>
        <td>Subsequent DST LM - Mfx CB - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>xQzcgF6mGZd</td>
      </tr>
      <tr>
        <td>Samples with inoculation date for initial DST LM</td>
        <td>Init DST LM: samples - inoculation date</td>
        <td></td>
        <td>Samples with inoculation date for initial DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>xRHkullgtDD</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Cfz susceptible</td>
        <td>Sub DST SM: new patients - Cfz susceptible</td>
        <td></td>
        <td>Subsequent DST SM - new patients susceptible to Cfz</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>XRPgDH3Z3Fq</td>
      </tr>
      <tr>
        <td>Patients with inoculation date for initial DST LM</td>
        <td>Init DST LM: patients - inoculation date</td>
        <td></td>
        <td>Patients with inoculation date for initial DST LM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>xrpPtTU0Zkc</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - R contaminated/indeterminate</td>
        <td>Sub DST LM: patients - R cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - patients - R contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>xRxkG7NLgxN</td>
      </tr>
      <tr>
        <td>RR-TB patients resistant to FQ</td>
        <td>RR-TB patients resistant to FQ</td>
        <td></td>
        <td>RR-TB patients resistant to FQ</td>
        <td>ENROLLMENT</td>
        <td>2020-09-15</td>
        <td>Xt0NWWZ7DNA</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Dlm resistant</td>
        <td>Sub DST LM: new patients - Dlm resistant</td>
        <td></td>
        <td>Subsequent DST LM - New patients resistant to Dlm</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>XtISOg6IH58</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - H CC susceptible</td>
        <td>Sub DST LM: new patients - H CC susceptible</td>
        <td></td>
        <td>Subsequent DST LM - new patients susceptible to H CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Xvi6xboD8rO</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - H CC contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - H CC cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>xvIpBKT8S5R</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Lzd resistant</td>
        <td>Sub DST LM: prev patients - Lzd resistant</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients resistant to Lzd</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>xWTCtUoYESr</td>
      </tr>
      <tr>
        <td>Culture SM: new patients - no growth</td>
        <td>Culture SM: new patients - no growth</td>
        <td></td>
        <td>Number of new patients with result "no growth" (cumulative). If more than one sample is examined per patient, "no growth" result is recorded if at least one sample has no growth and MTB or NTM are not detected. Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>XZiRvxDYZTg</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: previously treated patients - RIF susceptible</td>
        <td>LPA RIF/INH: prev patients - RIF susceptible </td>
        <td></td>
        <td>Previously treated patients with at least one sample tested susceptible to the applicable drug by LPA RIF/INH. No resistance detected by LPA RIF/INH on multiple samples. Condition: previously treated patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>y0yp20p5Pfr</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Bdq indeterminate</td>
        <td>Sub DST LM: samples - Bdq indeterminate</td>
        <td></td>
        <td>Subsequent DST LM - Bdq - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Y3IoUjmY7AN</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 2 days</td>
        <td>Xpert MTB/RIF: 2d</td>
        <td></td>
        <td>Number of samples with 2 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Y9ecVYqq2wF</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - H CB susceptible</td>
        <td>Sub DST SM: prev patients - H CB susceptible</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients susceptible to H CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YADgwHM5hbx</td>
      </tr>
      <tr>
        <td>Patients with result for LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - result</td>
        <td></td>
        <td>Patients with result for LPA FQ/2LI</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Yb4I8XsLvAC</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Mfx CB indeterminate</td>
        <td>Sub DST SM: samples - Mfx CB indeterminate</td>
        <td></td>
        <td>Subsequent DST SM - Mfx CB - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>yb8FgBYSj32</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Z susceptible</td>
        <td>Sub DST SM: patients - Z susceptible</td>
        <td></td>
        <td>Subsequent DST SM - patients susceptible to Z</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YCmTdM8P0s0</td>
      </tr>
      <tr>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Xpert MTB/RIF U: processed samples</td>
        <td></td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Ydf2CAJR8of</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Z resistant</td>
        <td>Sub DST LM: samples - Z resistant</td>
        <td></td>
        <td>Subsequent DST LM - Z - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>yEIeCX7IwVi</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - E contaminated</td>
        <td>Init DST SM: samples - E contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>YeU707qWYqZ</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Z contaminated</td>
        <td>Init DST LM: samples - Z contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>yFUJCbawmOX</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Mfx CB resistant</td>
        <td>Sub DST SM: samples - Mfx CB resistant</td>
        <td></td>
        <td>Subsequent DST SM - Mfx CB - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YGAd7tN7N6e</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - H CB contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - H CB cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - new patients - H CB contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YgU4PmqMkzP</td>
      </tr>
      <tr>
        <td>Culture LM: 4 days</td>
        <td>Culture LM: 4d</td>
        <td></td>
        <td>Number of samples with 4 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YhbI5N1k81G</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Z resistant</td>
        <td>Sub DST LM: prev patients - Z resistant</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients resistant to Z</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YhxAkBpMTmd</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Am contaminated/indeterminate</td>
        <td>Init DST LM: patients - Am cont/ind</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>yi5Rehcel7M</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Cfz susceptible</td>
        <td>Sub DST SM: samples - Cfz susceptible</td>
        <td></td>
        <td>Subsequent DST SM - Cfz - Susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>yIGqQACwPj5</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Am resistant</td>
        <td>Init DST SM: samples - Am resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>yj67gy58tvc</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: patients - RR</td>
        <td>Xpert MTB/RIF U: patients - RR</td>
        <td></td>
        <td>Patients with test result for Xpert MTB/RIF Ultra - MTB, RIF resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ykeijqKZSTD</td>
      </tr>
      <tr>
        <td>Microscopy: new patients - negative</td>
        <td>Microscopy: new patients - negative</td>
        <td></td>
        <td>New patients - microscopy negative</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>YkUfHLCaQMC</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 10+ days</td>
        <td>Xpert MTB/RIF: 10+d</td>
        <td></td>
        <td>Number of samples with 10+ days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YLgDcklInvQ</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Dlm contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Dlm cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>yLH2B6wc2uR</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - R resistant</td>
        <td>Sub DST SM: samples - R resistant</td>
        <td></td>
        <td>Subsequent DST SM - R - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ylIA0CiL0uz</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: patients - MTB not detected</td>
        <td>LPA RIF/INH: patients - MTB not detected</td>
        <td></td>
        <td>LPA RIF/INH - patients with MTB not detected</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>Ym7g5TyBlyV</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - Am contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - Am cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - new patients - Am contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ymG3jrd4Aba</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: samples - no result</td>
        <td>Xpert MTB/RIF: samples - no result</td>
        <td></td>
        <td>Xpert MTB/RIF - No result</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ymjPwXARDTy</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: samples - RIF resistant</td>
        <td>LPA RIF/INH: samples - RIF resistant</td>
        <td></td>
        <td>LPA RIF/INH - RIF - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>yNQDN6Y7RRv</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - H CB resistant</td>
        <td>Init DST LM: samples - H CB resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>YOEdyHoPgPV</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - E susceptible</td>
        <td>Sub DST SM: new patients - E susceptible</td>
        <td></td>
        <td>Subsequent DST SM - new patients susceptible to E</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YOjNYg1yUIh</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: previously treated patients - E resistant</td>
        <td>Sub DST SM: prev patients - E resistant</td>
        <td></td>
        <td>Subsequent DST SM - previously treated patients resistant to E</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YqnFKRIK0VQ</td>
      </tr>
      <tr>
        <td>Started culture LM tests</td>
        <td>Culture LM: started tests</td>
        <td></td>
        <td>Number of started culture LM tests</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>yqSM0imyakl</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Dlm contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Dlm cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - patients - Dlm contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YRkeyxS2xir</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: patients - RR</td>
        <td>Xpert MTB/RIF: patients - RR</td>
        <td></td>
        <td>Patients with test result for Xpert MTB/RIF - MTB, RIF resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YrnVXhFyLCd</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: samples - RS</td>
        <td>Xpert MTB/RIF: samples - RS</td>
        <td></td>
        <td>Xpert MTB/RIF - RS</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YsIIurLgmPo</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Mfx CB resistant</td>
        <td>Sub DST LM: prev patients - Mfx CB resistant</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients resistant to Mfx CB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YTfcpgyo1OW</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: samples - Cfz contaminated</td>
        <td>Sub DST SM: samples - Cfz contaminated</td>
        <td></td>
        <td>Subsequent DST SM - Cfz - Contaminated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YVm2y4ROVLo</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - H CB resistant</td>
        <td>Init DST SM: samples - H CB resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>yw1mFlZWAMP</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 0 days</td>
        <td>Xpert MTB/RIF: 0d</td>
        <td></td>
        <td>Number of samples with 0 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>yw1VqE1IjSk</td>
      </tr>
      <tr>
        <td>LPA RIF/INH: new patients - RIF indeterminate</td>
        <td>LPA RIF/INH: new patients - RIF indeterminate</td>
        <td></td>
        <td>LPA RIF/INH - new RIF indeterminate patients</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>yw5erBUqN3l</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Dlm resistant</td>
        <td>Init DST SM: prev patients - Dlm resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ywEgFe3CmDN</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Dlm contaminated</td>
        <td>Init DST LM: samples - Dlm contaminated</td>
        <td></td>
        <td>Samples with result "contaminated" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>YWOxEKIW5KB</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: new patients - Am/Cm susceptible</td>
        <td>LPA FQ/2LI: new patients - Am/Cm susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by LPA FQ/2LI. No resistance detected by LPA FQ/2LI on multiple samples. Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>yXTY7DS9wuu</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - E contaminated/indeterminate</td>
        <td>Sub DST SM: new patients - E cont/ind</td>
        <td></td>
        <td>Subsequent DST SM - new patients - E contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>YytrJOimdR2</td>
      </tr>
      <tr>
        <td>Patient's age</td>
        <td>DRS: age</td>
        <td></td>
        <td>Patient's age</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>YZSFxMBLXBq</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: new patients - Km indeterminate</td>
        <td>LPA FQ/2LI: new patients - Km indeterminate</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by LPA FQ/2LI. Result: contaminated/indeterminate. No resistance or susceptibility detected by LPA FQ/2LI on multiple samples. Condition: new patient based on CIF, test date, MTB detected, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Z0nNQL81cpK</td>
      </tr>
      <tr>
        <td>Sample processing events, total</td>
        <td>Sample processing events, total</td>
        <td>events_processing_total</td>
        <td> </td>
        <td>EVENT</td>
        <td>2020-09-21</td>
        <td>Z0pHyvWCUNG</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Lfx susceptible</td>
        <td>Init DST SM: samples - Lfx susceptible</td>
        <td></td>
        <td>Samples with result "susceptible" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Z28tLWyehWi</td>
      </tr>
      <tr>
        <td>Initial DST LM: previously treated patients - Dlm contaminated/indeterminate</td>
        <td>Init DST LM: prev patients - Dlm cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Z4MdCZDK7cg</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Lzd resistant</td>
        <td>Init DST SM: patients - Lzd resistant</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>z4w7a7VHWsr</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Mfx CC contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Mfx CC cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>zB5B6o1lCXQ</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - Lzd contaminated/indeterminate</td>
        <td>Sub DST LM: new patients - Lzd cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - new patients - Lzd contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>zBFap1a5xsV</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Lzd resistant</td>
        <td>Init DST LM: samples - Lzd resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ZBWtuPoGXl6</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Am contaminated/indeterminate</td>
        <td>Init DST LM: new patients - Am cont/ind</td>
        <td></td>
        <td>New patients with at least one sample tested with the applicable drug by initial DST LM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ZCuphHumZGJ</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: 7 days</td>
        <td>Xpert MTB/RIF: 7d</td>
        <td></td>
        <td>Number of samples with 7 days turn-around time between date of sample collection and test date. Condition: date of sample collection, date of samples arrival, test date</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ZcZOvviknKv</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - Lfx resistant</td>
        <td>Init DST LM: patients - Lfx resistant</td>
        <td></td>
        <td>Patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>zD5P8ROnJci</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - R susceptible</td>
        <td>Init DST LM: new patients - R susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>zd6SD8bbBl3</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - E indeterminate</td>
        <td>Sub DST LM: samples - E indeterminate</td>
        <td></td>
        <td>Subsequent DST LM - E - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>zdHSqAwHF7w</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - Mfx CC contaminated/indeterminate</td>
        <td>Sub DST LM: patients - Mfx CC cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - patients - Mfx CC contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>zdJzjF1oAzR</td>
      </tr>
      <tr>
        <td>Days between all lab sample collection and arrival, sum</td>
        <td>Collection-arrival interval - sum</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>ZeEskzvKb72</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Z contaminated/indeterminate</td>
        <td>Sub DST LM: prev patients - Z cont/ind</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients - Z contaminated/indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ZEWoHGVMJHT</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Mfx CB resistant</td>
        <td>Init DST LM: new patients - Mfx CB resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST LM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>zgKh2FOhkSv</td>
      </tr>
      <tr>
        <td>Initial DST SM: new patients - Bdq resistant</td>
        <td>Init DST SM: new patients - Bdq resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ZhWUJgUGMzD</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - Lfx susceptible</td>
        <td>Sub DST SM: patients - Lfx susceptible</td>
        <td></td>
        <td>Subsequent DST SM - patients susceptible to Lfx</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ZiA5jXTrmaY</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Bdq susceptible</td>
        <td>Init DST SM: patients - Bdq susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Zie6OAMjczP</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - Z susceptible</td>
        <td>Init DST LM: new patients - Z susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>zIkLhe4NJc1</td>
      </tr>
      <tr>
        <td>Patients with 1+ test started, cumulative</td>
        <td>Patients with 1+ test started, cumulative</td>
        <td></td>
        <td>At least one test must be started by the end of the reporting period</td>
        <td>ENROLLMENT</td>
        <td>2020-09-04</td>
        <td>zIR9P1JOf0P</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: patients - E resistant</td>
        <td>Sub DST SM: patients - E resistant</td>
        <td></td>
        <td>Subsequent DST SM - patients resistant to E</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ZiVkPofyVfW</td>
      </tr>
      <tr>
        <td>Samples: 5 days</td>
        <td>Collection arrival interval: 5d</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ZkdoPJtDiJ0</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF Ultra: patients - RS</td>
        <td>Xpert MTB/RIF U: patients - RS</td>
        <td></td>
        <td>Patients with test result for Xpert MTB/RIF Ultra - MTB, RIF susceptible</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ZLg4V9cAXmw</td>
      </tr>
      <tr>
        <td>Initial DST LM: new patients - H CC susceptible</td>
        <td>Init DST LM: new patients - H CC susceptible</td>
        <td></td>
        <td>New patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: new patient based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ZlyejogmAYG</td>
      </tr>
      <tr>
        <td>Culture LM: 0 days</td>
        <td>Culture LM: 0d</td>
        <td></td>
        <td>Number of samples with 0 days turn-around time between date of sample collection and inoculation date. Condition: date of sample collection, date of samples arrival, date of inoculation</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ZM7UpCaGTY1</td>
      </tr>
      <tr>
        <td>Patients with result for initial DST SM</td>
        <td>Init DST SM: patients - result</td>
        <td></td>
        <td>Patients with result for initial DST SM</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ZMo9mf0LfWt</td>
      </tr>
      <tr>
        <td>Initial DST SM: samples - Z resistant</td>
        <td>Init DST SM: samples - Z resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST SM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>zN38C55xHYZ</td>
      </tr>
      <tr>
        <td>LPA FQ/2LI: new patients - FQ resistant</td>
        <td>LPA FQ/2LI: new patients - FQ resistant</td>
        <td></td>
        <td>New patients with at least one sample tested resistant to the applicable drug by LPA FQ/2LI. Condition: new patient based on CIF, MTB detected, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>zo63zcpBZCV</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: previously treated patients - Cfz resistant</td>
        <td>Sub DST LM: prev patients - Cfz resistant</td>
        <td></td>
        <td>Subsequent DST LM - previously treated patients resistant to Cfz</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ZONe9AdoHYE</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - Cfz resistant</td>
        <td>Sub DST LM: samples - Cfz resistant</td>
        <td></td>
        <td>Subsequent DST LM - Cfz - Resistant</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>zp3uN4hpm22</td>
      </tr>
      <tr>
        <td>Culture SM: samples - MTB</td>
        <td>Culture SM: samples - MTB</td>
        <td></td>
        <td>Number of samples with result "MTB" (cumulative). Date of final result has to be entered. Date of final result has to be within reporting period.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-18</td>
        <td>ZPXThwLCqnd</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: patients - H CC susceptible</td>
        <td>Sub DST LM: patients - H CC susceptible</td>
        <td></td>
        <td>Subsequent DST LM - patients susceptible to H CC</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>zq6n2KdR9yQ</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: samples - H CB indeterminate</td>
        <td>Sub DST LM: samples - H CB indeterminate</td>
        <td></td>
        <td>Subsequent DST LM - H CB - Indeterminate</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ZQk5pK5QPhu</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - R susceptible</td>
        <td>Init DST LM: patients - R susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>zsxVBbRRx6D</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Mfx CC contaminated/indeterminate</td>
        <td>Init DST SM: prev patients - Mfx CC cont/ind</td>
        <td></td>
        <td>Previously treated patients with at least one sample tested with the applicable drug by initial DST SM. Result: contaminated/indeterminate. No resistance or susceptibility detected by initial DST SM on multiple samples. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>Ztm42od2b6y</td>
      </tr>
      <tr>
        <td>Initial DST LM: samples - Lfx resistant</td>
        <td>Init DST LM: samples - Lfx resistant</td>
        <td></td>
        <td>Samples with result "resistant" for the applicable drug tested by initial DST LM. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ZUax8mb3Fht</td>
      </tr>
      <tr>
        <td>Subsequent DST LM: new patients - E susceptible</td>
        <td>Sub DST LM: new patients - E susceptible</td>
        <td></td>
        <td>Subsequent DST LM - new patients susceptible to E</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>Zvwpbgxmp94</td>
      </tr>
      <tr>
        <td>Initial DST SM: previously treated patients - Lzd resistant</td>
        <td>Init DST SM: prev patients - Lzd resistant</td>
        <td></td>
        <td>Previously treated patient patients with at least one sample tested resistant to the applicable drug by initial DST SM. Condition: previous treatment history based on CIF, test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>zwG40huDp6Q</td>
      </tr>
      <tr>
        <td>Initial DST SM: patients - Z resistant</td>
        <td>Init DST SM: patients - Z resistant</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST SM. No resistance detected by initial DST SM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ZWGzbjgAKMS</td>
      </tr>
      <tr>
        <td>Xpert MTB/RIF: patients - MTB detected</td>
        <td>Xpert MTB/RIF: samples - MTB detected</td>
        <td></td>
        <td>Xpert MTB/RIF - patients with detected MTB</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ZWyfaOl5ga7</td>
      </tr>
      <tr>
        <td>Patients with result for microscopy</td>
        <td>Microscopy: patients - result</td>
        <td></td>
        <td>Patients with result for microscopy</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ZxM3pubMWLI</td>
      </tr>
      <tr>
        <td>Initial DST LM: patients - H CC susceptible</td>
        <td>Init DST LM: patients - H CC susceptible</td>
        <td></td>
        <td>Patients with at least one sample tested susceptible to the applicable drug by initial DST LM. No resistance detected by initial DST LM on multiple samples. Condition: test date, test result.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-25</td>
        <td>ZY5fuX5XP7P</td>
      </tr>
      <tr>
        <td>Subsequent DST SM: new patients - R susceptible</td>
        <td>Sub DST SM: new patients - R susceptible</td>
        <td></td>
        <td>Subsequent DST SM - new patients susceptible to R</td>
        <td>ENROLLMENT</td>
        <td>2020-09-21</td>
        <td>ZZoPud9wM6I</td>
      </tr>
    </table>
    <h4 id="programRules">Program Rules</h4>
    <table>
      <tr>
        <th>Program rule</th>
        <th>Description</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Constant: Hide Mfx CC - Initial DST - SM</td>
        <td>Hide Mfx CC from list of drugs used for Initial DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>a2EZOnGtShT</td>
      </tr>
      <tr>
        <td>Hide "Initial DST - SM" fields</td>
        <td>Hide "Initial DST - SM" fields unless "Initial DST - SM" is selected</td>
        <td>2020-08-29</td>
        <td>adZGFjUODor</td>
      </tr>
      <tr>
        <td>Hide "TGS - genotypic Speciation Results" fields</td>
        <td>Hide "TGS - genotypic speciation results" fields unless "Targeted Gene Sequencing" is selected</td>
        <td>2020-08-29</td>
        <td>AegsTJUK1a2</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Subsequent DST - LM</td>
        <td>Make mandatory: Date of final results - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>aVO554HZRKY</td>
      </tr>
      <tr>
        <td>Hide "Xpert MTB/RIF Ultra quantitative result"</td>
        <td>Hide "Xpert MTB/RIF Ultra quantitative result" unless MTB is detected</td>
        <td>2020-08-29</td>
        <td>aZMgpoSFbJY</td>
      </tr>
      <tr>
        <td>Constant: Hide Dlm - Initial DST - SM</td>
        <td>Hide Dlm from list of drugs used for Initial DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>B5K6hdkZCyR</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Initial DST - SM inoculation date</td>
        <td>Initial DST - SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>B7qKWW0LA3X</td>
      </tr>
      <tr>
        <td>Constant: Hide Lfx - Subsequent DST - SM</td>
        <td>Hide Lfx from list of drugs used for Subsequent DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>b89lO4YuJ1Q</td>
      </tr>
      <tr>
        <td>Make mandatory: Dlm - Initial DST - LM</td>
        <td>Make mandatory: Dlm - Initial DST - LM</td>
        <td>2020-08-29</td>
        <td>BacxHSLs0f3</td>
      </tr>
      <tr>
        <td>Make mandatory: Bdq - Initial DST - SM</td>
        <td>Make mandatory: Bdq - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>bBiHx5Fodad</td>
      </tr>
      <tr>
        <td>CIF - Display guidelines for Microscopy samples in the form</td>
        <td>If initial screening is based on microscopy examination of > 2 samples then add only the 2 samples with the highest bacterial load.</td>
        <td>2020-08-29</td>
        <td>BCkatIfqdYk</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Xpert MTB/RIF Ultra date</td>
        <td>Xpert MTB/RIF Ultra date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>beAbNUR3E6G</td>
      </tr>
      <tr>
        <td>Constant: Hide Dlm - Subsequent DST - LM</td>
        <td>Hide Dlm from list of drugs used for Subsequent DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>bhDFETNiD4W</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Microscopy date</td>
        <td>Microscopy date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>bHJRn7iyMq3</td>
      </tr>
      <tr>
        <td>Constant: Hide "Sample 4" stage</td>
        <td>Hide "Sample 4" stage if not used</td>
        <td>2020-08-29</td>
        <td>BIwvQ6ek8Vu</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx CB - Initial DST - LM</td>
        <td>Make mandatory: Mfx CB - Initial DST - LM</td>
        <td>2020-08-29</td>
        <td>BJEV0tAKjxl</td>
      </tr>
      <tr>
        <td>Date validation: S1 - LPA FQ/2LI date</td>
        <td>LPA FQ/2LI date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>BjqDFhRBzeS</td>
      </tr>
      <tr>
        <td>Constant: Hide Z - Subsequent DST - SM</td>
        <td>Hide Z from list of drugs used for Subsequent DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>bKX5rPBfyfW</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Culture - SM</td>
        <td>Make mandatory: Date of final results - Culture - SM</td>
        <td>2020-08-29</td>
        <td>BlLwKADDmT3</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Culture - SM</td>
        <td>Make mandatory: Date of final results - Culture - SM</td>
        <td>2020-08-29</td>
        <td>bLODvaqP36S</td>
      </tr>
      <tr>
        <td>Constant: Hide Cfz - Subsequent DST - SM</td>
        <td>Hide Cfz from list of drugs used for Subsequent DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>bm4p4dc1JPN</td>
      </tr>
      <tr>
        <td>ENR: Generate DRS Sample 2 ID</td>
        <td>Generate DRS Sample 2 ID</td>
        <td>2020-08-29</td>
        <td>bQ9VZww9wNM</td>
      </tr>
      <tr>
        <td>Date validation: S1 - LPA RIF/INH date</td>
        <td>LPA RIF/INH date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>BSS6VeQyLqW</td>
      </tr>
      <tr>
        <td>Assign Cluster ID</td>
        <td>Assign Cluster ID if Cluster ID is used</td>
        <td>2020-08-24</td>
        <td>BTQvSqCiUl1</td>
      </tr>
      <tr>
        <td>Constant: Hide "CIF - Cluster ID"</td>
        <td>Hide "CIF - Cluster ID" if not used</td>
        <td>2020-08-29</td>
        <td>C0HrM84AAIB</td>
      </tr>
      <tr>
        <td>Constant: Hide Bdq - Initial DST - LM</td>
        <td>Hide Bdq from list of drugs used for Initial DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>c0VHXIVBluv</td>
      </tr>
      <tr>
        <td>Make mandatory: Lzd - Subsequent DST - LM</td>
        <td>Make mandatory: Lzd - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>cdynoioBMJt</td>
      </tr>
      <tr>
        <td>Constant: Hide Mfx CB - Initial DST - SM</td>
        <td>Hide Mfx CB from list of drugs used for Initial DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>cqYWWBueNqe</td>
      </tr>
      <tr>
        <td>ENR: Generate DRS Sample 1 ID</td>
        <td>Generate DRS Sample 1 ID</td>
        <td>2020-08-29</td>
        <td>cryxj5ORjxk</td>
      </tr>
      <tr>
        <td>Assign resistance status - H resistant</td>
        <td>Set the status of resistance to H</td>
        <td>2020-08-21</td>
        <td>CtFIyM0kkWi</td>
      </tr>
      <tr>
        <td>Constant: Hide Z - Subsequent DST - LM</td>
        <td>Hide Z from list of drugs used for Subsequent DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>D6taGou1EWN</td>
      </tr>
      <tr>
        <td>Make mandatory: Cfz - Initial DST - SM</td>
        <td>Make mandatory: Cfz - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>DabO92LrlbZ</td>
      </tr>
      <tr>
        <td>Constant: Hide Lfx - Initial DST - LM</td>
        <td>Hide Lfx from list of drugs used for Initial DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>dll60xcQXpr</td>
      </tr>
      <tr>
        <td>Make mandatory: Date and result fields - Xpert MTB/RIF</td>
        <td>Make mandatory: Date and result fields - Xpert MTB/RIF</td>
        <td>2020-08-29</td>
        <td>dOMPR1GfGUq</td>
      </tr>
      <tr>
        <td>Constant: Hide Bdq - Subsequent DST - SM</td>
        <td>Hide Bdq from list of drugs used for Subsequent DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>DVza0nU07P7</td>
      </tr>
      <tr>
        <td>Hide "TGS drugs tested" section</td>
        <td>Hide "LAB - Targeted Gene Sequencing Drugs Tested" section unless "TGS - Interpretable genetic resistance profiling for MTBc" is available</td>
        <td>2020-08-29</td>
        <td>DW8n3TWamam</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Initial DST - LM inoculation date</td>
        <td>Initial DST - LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>dxr8QD6Cmyu</td>
      </tr>
      <tr>
        <td>Make mandatory: Date and result fields - Microscopy</td>
        <td>Make mandatory: Date and result fields - Microscopy</td>
        <td>2020-08-29</td>
        <td>E3eIHwWlqqo</td>
      </tr>
      <tr>
        <td>Hide "Specify Other" for Sample 3</td>
        <td>Hide "Specify Other" for Sample 3 unless the Answer to "Sample 3 Treatment" is "Other"</td>
        <td>2020-08-29</td>
        <td>eCsM1NkAMj6</td>
      </tr>
      <tr>
        <td>Make mandatory: E - Subsequent DST - LM</td>
        <td>Make mandatory: E - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>edFUeJCPxya</td>
      </tr>
      <tr>
        <td>Make mandatory: Lzd - Initial DST - SM</td>
        <td>Make mandatory: Lzd - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>EDGMArTMHVS</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of inoculation - Initial DST - SM</td>
        <td>Make mandatory: Date of inoculation - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>EivUtCeeRWQ</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of inoculation - Culture - LM</td>
        <td>Make mandatory: Date of inoculation - Culture - LM</td>
        <td>2020-08-29</td>
        <td>eJIAxXkWA4d</td>
      </tr>
      <tr>
        <td>Make mandatory: E - Initial DST - SM</td>
        <td>Make mandatory: E - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>ejOio98LnJP</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Microscopy date</td>
        <td>Microscopy date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>ESZSLZFBYDG</td>
      </tr>
      <tr>
        <td>Date validation: Culture - SM date</td>
        <td>Culture - SM test result date cannot be prior to inoculation date</td>
        <td>2020-08-29</td>
        <td>eWLPwEfUtwl</td>
      </tr>
      <tr>
        <td>Hide "Reasons for sample rejection or loss" fields</td>
        <td>Hide "Reasons for sample rejection or loss" unless "Sample Rejected or Lost" is selected</td>
        <td>2020-08-29</td>
        <td>EydNGX3KeUY</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx CC - Subsequent DST - SM</td>
        <td>Make mandatory: Mfx CC - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>eyEKsDeGI6t</td>
      </tr>
      <tr>
        <td>Hide "Sputum Smear Microscopy" fields</td>
        <td>Hide "Sputum Smear Microscopy Fields" unless "Sputum Smear Microscopy" is selected</td>
        <td>2020-09-24</td>
        <td>fhJpvDBPZWN</td>
      </tr>
      <tr>
        <td>CIF - Assign "Yes" to "Previous TB treatment"</td>
        <td>Assign "Yes" to "TB DRS Treatment History - treatment >1 month" if "Treatment history" & "Prior TB Registration" or "Control Question" & "Prior TB Registration" = Yes </td>
        <td>2020-08-29</td>
        <td>fHu5DLVW1Q2</td>
      </tr>
      <tr>
        <td>Make mandatory: Drugs - LPA FQ/2LI</td>
        <td>Make mandatory: Drugs - LPA FQ/2LI</td>
        <td>2020-08-29</td>
        <td>FlBLt3Rcemi</td>
      </tr>
      <tr>
        <td>Summarise resistance</td>
        <td>Summarise resistance to R, H and FQ</td>
        <td>2020-08-28</td>
        <td>foAWLcAi42q</td>
      </tr>
      <tr>
        <td>Constant: Hide "Subsequent DST - LM" section</td>
        <td>Hide "Subsequent DST - LM" if not used</td>
        <td>2020-08-29</td>
        <td>fVlCUqt0Ps6</td>
      </tr>
      <tr>
        <td>Generate DRS Sample 4 ID</td>
        <td>Generate DRS Sample 4 ID</td>
        <td>2020-02-03</td>
        <td>fVXqShjK1Ue</td>
      </tr>
      <tr>
        <td>Make mandatory: Bdq - Subsequent DST - SM</td>
        <td>Make mandatory: Bdq - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>G0xq3NRQO5E</td>
      </tr>
      <tr>
        <td>Hide "Specify Other" for Sample 1</td>
        <td>Hide "Specify Other" for Sample 1 unless the Answer to "Sample 1 Treatment" is "Other"</td>
        <td>2020-08-29</td>
        <td>g5ttCkqpAas</td>
      </tr>
      <tr>
        <td>Assign previous treatment history status - new</td>
        <td></td>
        <td>2020-08-21</td>
        <td>G8LxV4AyGWa</td>
      </tr>
      <tr>
        <td>Constant: Hide Am - Initial DST - SM</td>
        <td>Hide Am from list of drugs used for Initial DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>GdkouxMOawY</td>
      </tr>
      <tr>
        <td>Assign resistance status - FQ resistant</td>
        <td>Set the status of resistance to FQ</td>
        <td>2020-08-21</td>
        <td>GJOM9Gnw8sA</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Culture - SM inoculation date</td>
        <td>Culture - SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>gJOujE07O8q</td>
      </tr>
      <tr>
        <td>Constant: Hide "3 Step DRS ID"</td>
        <td>Hide "3 Step DRS ID" if full DRS Entry is selected.</td>
        <td>2020-08-29</td>
        <td>gk7OBVBqlXe</td>
      </tr>
      <tr>
        <td>Make mandatory: Am - Initial DST - LM</td>
        <td>Make mandatory: Am - Initial DST - LM</td>
        <td>2020-08-29</td>
        <td>Glh5fxyePph</td>
      </tr>
      <tr>
        <td>Hide "Specify Other" for Sample 4</td>
        <td>Hide "Specify Other" for Sample 4 unless the Answer to "Sample 4 Treatment" is "Other"</td>
        <td>2020-08-29</td>
        <td>GN2dzpXZHFq</td>
      </tr>
      <tr>
        <td>Display treatment history</td>
        <td></td>
        <td>2020-08-21</td>
        <td>GOGFi1CdcC6</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Culture - LM inoculation date</td>
        <td>Culture - LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>GRoxH5Hab8n</td>
      </tr>
      <tr>
        <td>Constant: Hide "Subsequent DST - SM" section</td>
        <td>Hide "Subsequent DST - SM" if not used</td>
        <td>2020-08-29</td>
        <td>GwC6uvcUEdn</td>
      </tr>
      <tr>
        <td>Hide: Subsequent DST LM - "Final results" section</td>
        <td>Hide "Final results" section unless date of final results is entered</td>
        <td>2020-08-29</td>
        <td>gyEgVmikOZo</td>
      </tr>
      <tr>
        <td>ENR: Generate DRS Sample 4 ID</td>
        <td>Generate DRS Sample 4 ID</td>
        <td>2020-08-29</td>
        <td>gzN6Ya5yOFf</td>
      </tr>
      <tr>
        <td>Hide "LPA FQ/2LI" fields</td>
        <td>Hide "LPA FQ/2LI" unless "LPA FQ/2LI" is selected</td>
        <td>2020-08-29</td>
        <td>h8E2btTqxKM</td>
      </tr>
      <tr>
        <td>Constant: Hide Lzd - Initial DST - SM</td>
        <td>Hide Lzd from list of drugs used for Initial DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>H9dJ3ebaaFn</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Xpert MTB/RIF Ultra date</td>
        <td>Xpert MTB/RIF Ultra date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>HH1qknkXBUG</td>
      </tr>
      <tr>
        <td>Constant: Hide Mfx CC Subsequent DST - SM</td>
        <td>Hide Mfx CC from list of drugs used for Subsequent DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>hITJ6mxIPkN</td>
      </tr>
      <tr>
        <td>Constant: Hide Bdq - Subsequent DST - LM</td>
        <td>Hide Bdq from list of drugs used for Subsequent DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>HKS0a7Y4nHT</td>
      </tr>
      <tr>
        <td>CIF - Hide "HIV Test Date"</td>
        <td>Hide "HIV Test Date" if "HIV Test Result" = Unknown</td>
        <td>2020-08-29</td>
        <td>hpkXGVKETRq</td>
      </tr>
      <tr>
        <td>Hide "Xpert MTB/RIF" fields</td>
        <td>Hide "Xpert MTB/RIF" fields unless "Xpert MTB/RIF" is selected</td>
        <td>2020-09-24</td>
        <td>HwGNeimZpes</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Microscopy date</td>
        <td>Microscopy date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>HXmFgxob7SN</td>
      </tr>
      <tr>
        <td>Constant: Hide Am - Initial DST - LM</td>
        <td>Hide Am from list of drugs used for Initial DST - LM if not used</td>
        <td>2020-09-04</td>
        <td>hYQkQaPFuwT</td>
      </tr>
      <tr>
        <td>Constant: Hide E - Initial DST - SM</td>
        <td>Hide E from list of drugs used for Initial DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>hZ46pxd6j0K</td>
      </tr>
      <tr>
        <td>Assign previous treatment history status - previously treated</td>
        <td></td>
        <td>2020-08-21</td>
        <td>I1LXqwouibs</td>
      </tr>
      <tr>
        <td>Hide "WGS drugs tested" section</td>
        <td>Hide "WGS drugs tested" section unless "WGS - interpretable genetic resistance profiling for MTBc" is available</td>
        <td>2020-08-29</td>
        <td>i2OuX4baRcc</td>
      </tr>
      <tr>
        <td>Make mandatory: Z - Initial DST - LM</td>
        <td>Make mandatory: Z - Initial DST - LM</td>
        <td>2020-08-29</td>
        <td>I5cYpaWgJ2F</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Culture - SM inoculation date</td>
        <td>Culture - SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>i5IhobEjIF7</td>
      </tr>
      <tr>
        <td>Hide "WGS - reasons for failed genotypic speciation Results" field</td>
        <td>Hide "WGS - reasons for failed genotypic speciation results" field if genotypic speciation results failed</td>
        <td>2020-08-29</td>
        <td>i7IJAq6Dexs</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Xpert MTB/RIF date</td>
        <td>Xpert MTB/RIF date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>ICGa9EmkMyz</td>
      </tr>
      <tr>
        <td>Hide "Sample 1 Processing Status" Section </td>
        <td>Hide "Sample 1 Processing Status" Section </td>
        <td>2020-06-18</td>
        <td>IiedhV14zKD</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Microscopy date</td>
        <td>Microscopy date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>IKZ3PyXzciJ</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Targeted Gene Sequencing date</td>
        <td>Targeted Gene Sequencing date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>Imp0GenB1u6</td>
      </tr>
      <tr>
        <td>Date validation: Subsequent DST - SM date</td>
        <td>Subsequent DST - SM test result date cannot be prior to inoculation date</td>
        <td>2020-08-29</td>
        <td>is4YEzmgmh9</td>
      </tr>
      <tr>
        <td>Date validation: S4 - WGS date</td>
        <td>WGS date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>iVonvIR1plC</td>
      </tr>
      <tr>
        <td>Constant: Hide R - Initial DST - SM</td>
        <td>Hide R from list of drugs used for Initial DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>ivrzYMSxVnO</td>
      </tr>
      <tr>
        <td>Constant: Hide Lzd - Subsequent DST - LM</td>
        <td>Hide Lzd from list of drugs used for Subsequent DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>IVZAJ5wLIPq</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Targeted Gene Sequencing date</td>
        <td>Targeted Gene Sequencing date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>iyebVEKEkQW</td>
      </tr>
      <tr>
        <td>Hide "Culture - SM" fields</td>
        <td>Hide "Culture - SM" fields unless "Culture - SM" is selected</td>
        <td>2020-08-29</td>
        <td>IYXGAFbCSIP</td>
      </tr>
      <tr>
        <td>Constant: Hide E - Subsequent DST - SM</td>
        <td>Hide E from list of drugs used for Subsequent DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>J4rPKa1u9Nl</td>
      </tr>
      <tr>
        <td>Constant: Hide "Culture - SM" section</td>
        <td>Hide "Culture - SM" if not used</td>
        <td>2020-08-29</td>
        <td>JD4qaeKxKoW</td>
      </tr>
      <tr>
        <td>Make mandatory: Dlm - Initial DST - SM</td>
        <td>Make mandatory: Dlm - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>JhV2ONsXUXh</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Targeted Gene Sequencing date</td>
        <td>Targeted Gene Sequencing date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>jJIHqnStKfp</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Subsequent DST - LM inoculation date</td>
        <td>Subsequent DST - LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>JzMOvveArd9</td>
      </tr>
      <tr>
        <td>Make mandatory: Lzd - Initial DST - LM</td>
        <td>Make mandatory: Lzd - Initial DST - LM</td>
        <td>2020-08-29</td>
        <td>KaNYswej7JI</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx CC - Subsequent DST - LM</td>
        <td>Make mandatory: Mfx CC - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>KCFXXYH4brB</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of inoculation - Culture - SM</td>
        <td>Make mandatory: Date of inoculation - Culture - SM</td>
        <td>2020-08-29</td>
        <td>KI03Jp6b6iV</td>
      </tr>
      <tr>
        <td>Date validation: S2 - WGS date</td>
        <td>WGS date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>KIPA5MWe9lb</td>
      </tr>
      <tr>
        <td>Assign resistance status - R not resistant</td>
        <td>Set the status of resistance to R</td>
        <td>2020-08-21</td>
        <td>KjCSsrBMSMj</td>
      </tr>
      <tr>
        <td>Make mandatory: Drugs - LPA RIF/INH</td>
        <td>Make mandatory: Drugs - LPA RIF/INH</td>
        <td>2020-08-29</td>
        <td>kmCWnyT2VXd</td>
      </tr>
      <tr>
        <td>Make mandatory: R - Subsequent DST - SM</td>
        <td>Make mandatory: R - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>KRjOBaxz4RC</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Targeted Gene Sequencing date</td>
        <td>Targeted Gene Sequencing date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>kvcSmIKtQTe</td>
      </tr>
      <tr>
        <td>Constant: Hide "Patient TB DRS ID"</td>
        <td>Hide "Patient TB DRS ID" if 3-step entry is used.</td>
        <td>2020-08-29</td>
        <td>KXROKuIZZov</td>
      </tr>
      <tr>
        <td>Make mandatory: Am - Subsequent DST - SM</td>
        <td>Make mandatory: Am - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>kY4e1F8QUK1</td>
      </tr>
      <tr>
        <td>Constant: Hide R - Subsequent DST - SM</td>
        <td>Hide R from list of drugs used for Subsequent DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>L8hrzv44viB</td>
      </tr>
      <tr>
        <td>Constant: Hide H CC - Initial DST - LM</td>
        <td>Hide H CC from list of drugs used for Initial DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>lCPmmg8ANPP</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Culture - SM inoculation date</td>
        <td>Culture - SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>ledpI4teXIr</td>
      </tr>
      <tr>
        <td>Constant: Hide "LPA RIF/INH" section</td>
        <td>Hide "LPA (Rifampicin / Isoniazid)" if not used</td>
        <td>2020-08-29</td>
        <td>Lfz435z4iQe</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx CB - Subsequent DST - LM</td>
        <td>Make mandatory: Mfx CB - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>LHB3YSHNtlq</td>
      </tr>
      <tr>
        <td>Constant: Hide Cfz - Subsequent DST - LM</td>
        <td>Hide Cfz from list of drugs used for Subsequent DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>lHG1nvtrf4F</td>
      </tr>
      <tr>
        <td>Date validation: S3 - LPA RIF/INH date</td>
        <td>LPA RIF/INH date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>LK8g9jJHNoc</td>
      </tr>
      <tr>
        <td>Date validation: Initial DST - SM date</td>
        <td>Initial DST - SM test result date cannot be prior to inoculation date</td>
        <td>2020-08-29</td>
        <td>LMK0OKT6432</td>
      </tr>
      <tr>
        <td>CIF - Hide Microscopy test result fields</td>
        <td>Hide Microscopy Test Result fields unless Sputum Smear Microscopy is selected</td>
        <td>2020-08-29</td>
        <td>LnaeeZd9aYe</td>
      </tr>
      <tr>
        <td>Constant: Hide Bdq - Initial DST - SM</td>
        <td>Hide Bdq from list of drugs used for Initial DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>lsbuAFe4LTe</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Initial DST - LM</td>
        <td>Make mandatory: Date of final results - Initial DST - LM</td>
        <td>2020-08-29</td>
        <td>lVGTxVnDNFZ</td>
      </tr>
      <tr>
        <td>ENR: Generate DRS Sample 3 ID</td>
        <td>Generate DRS Sample 3 ID</td>
        <td>2020-08-29</td>
        <td>LyXgAkRoTgM</td>
      </tr>
      <tr>
        <td>SRL: Hide SRL fields</td>
        <td>Hide SRL fields unless Samples shipped to SRL</td>
        <td>2020-08-29</td>
        <td>M0i7NMp24EO</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx CB - Subsequent DST - SM</td>
        <td>Make mandatory: Mfx CB - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>m1eOx8hu8dp</td>
      </tr>
      <tr>
        <td>Make mandatory: Date and result fields - Xpert MTB/RIF Ultra</td>
        <td>Make mandatory: Date and result fields - Xpert MTB/RIF Ultra</td>
        <td>2020-08-29</td>
        <td>M468N9Xb9qn</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Subsequent DST - LM inoculation date</td>
        <td>Subsequent DST - LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>m4eEnHjdCeZ</td>
      </tr>
      <tr>
        <td>Date validation: S4 - LPA RIF/INH date</td>
        <td>LPA RIF/INH date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>M6ZDn0nUt15</td>
      </tr>
      <tr>
        <td>Hide "Culture - LM" fields</td>
        <td>Hide "Culture - LM" fields unless "Culture - LM" is selected</td>
        <td>2020-08-29</td>
        <td>M7Ohl8yE15X</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Xpert MTB/RIF date</td>
        <td>Xpert MTB/RIF date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>MblpuLUQhAN</td>
      </tr>
      <tr>
        <td>Constant: Hide Mfx CC Subsequent DST - LM</td>
        <td>Hide Mfx CC from list of drugs used for Subsequent DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>MdNdxhRQ1Ce</td>
      </tr>
      <tr>
        <td>Constant: Hide R - Initial DST - LM</td>
        <td>Hide R from list of drugs used for Initial DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>MhQJWkudWc9</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Xpert MTB/RIF date</td>
        <td>Xpert MTB/RIF date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>Mjr9rbmQzXl</td>
      </tr>
      <tr>
        <td>Display Patient DRS ID</td>
        <td>Display Patient DRS ID</td>
        <td>2020-08-29</td>
        <td>mKaEauPcWxu</td>
      </tr>
      <tr>
        <td>Constant: Hide E - Subsequent DST - LM</td>
        <td>Hide E from list of drugs used for Subsequent DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>mKB2hn5PfNO</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Initial DST - SM inoculation date</td>
        <td>Initial DST - SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>mKsK1qsEVoF</td>
      </tr>
      <tr>
        <td>Make mandatory: Z - Subsequent DST - LM</td>
        <td>Make mandatory: Z - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>Mm7xMwBoUil</td>
      </tr>
      <tr>
        <td>Make mandatory: Date and result fields - LPA FQ/2LI</td>
        <td>Make mandatory: Date and result fields - LPA FQ/2LI</td>
        <td>2020-08-29</td>
        <td>Ms3vBaROHxR</td>
      </tr>
      <tr>
        <td>Make mandatory: H CB - Initial DST - LM</td>
        <td>Make mandatory: H CB - Initial DST - LM</td>
        <td>2020-08-29</td>
        <td>MtJMGH8LXRM</td>
      </tr>
      <tr>
        <td>CIF - Assign "Yes" to "TB DRS Treatment History - treatment >1 month"</td>
        <td>Assign "Yes" to "TB DRS Treatment History - treatment >1 month" if "Treatment history" & "Prior TB Registration" or "Control Question" & "Prior TB Registration" = Yes </td>
        <td>2020-08-29</td>
        <td>mtSkTzHDV1Z</td>
      </tr>
      <tr>
        <td>Hide "TGS - reasons for failed genotypic speciation results" field</td>
        <td>Hide "TGS - reasons for failed genotypic speciation results" field if genotypic speciation results failed</td>
        <td>2020-08-29</td>
        <td>mUWZalW1I2i</td>
      </tr>
      <tr>
        <td>Make mandatory: Lfx - Initial DST - SM</td>
        <td>Make mandatory: Lfx - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>mzrX55hmaug</td>
      </tr>
      <tr>
        <td>Display current age ( < 2) in the top bar</td>
        <td>Display Age ( <2) in the top bar</td>
        <td>2020-08-21</td>
        <td>N8z9lZls5cB</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Xpert MTB/RIF date</td>
        <td>Xpert MTB/RIF date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>NAlzGYQpSvl</td>
      </tr>
      <tr>
        <td>Hide "Xpert MTB/RIF Ultra" fields</td>
        <td>Hide "Xpert MTB/RIF Ultra" fields unless "Xpert MTB/RIF Ultra" is selected</td>
        <td>2020-09-24</td>
        <td>nd0bwVElmAJ</td>
      </tr>
      <tr>
        <td>Hide "Subsequent DST - LM" fields</td>
        <td>Hide "Subsequent DST - LM" fields unless "Subsequent DST - LM" is selected</td>
        <td>2020-08-29</td>
        <td>Nfkzw58T1On</td>
      </tr>
      <tr>
        <td>Hide "WGS - is interpretable genetic resistance profiling for MTBc available?" field</td>
        <td>Hide "WGS - is interpretable genetic resistance profiling for MTBc available?" field unless "WGS - genotypic speciation results" include MTBc</td>
        <td>2020-08-29</td>
        <td>NMoHHtNiIow</td>
      </tr>
      <tr>
        <td>Assign resistance status - R resistant</td>
        <td>Set the status of resistance to R</td>
        <td>2020-08-21</td>
        <td>NOsuKDnOxVz</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Initial DST - LM inoculation date</td>
        <td>Initial DST - LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>NqUFpBAMZFW</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Culture - LM inoculation date</td>
        <td>Culture - LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>Nw2mqRyiY1O</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Xpert MTB/RIF Ultra date</td>
        <td>Xpert MTB/RIF Ultra date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>o29A6QLMT8p</td>
      </tr>
      <tr>
        <td>Constant: Hide "Culture - LM" section</td>
        <td>Hide "Culture - LM" if not used</td>
        <td>2020-08-29</td>
        <td>O9mMu01lgq9</td>
      </tr>
      <tr>
        <td>Constant: Hide "Sample 2" stage</td>
        <td>Hide "Sample 2" stage if not used</td>
        <td>2020-08-29</td>
        <td>ob26R9u3bye</td>
      </tr>
      <tr>
        <td>Date validation: Initial DST - LM date</td>
        <td>Initial DST - LM test result date cannot be prior to inoculation date</td>
        <td>2020-08-29</td>
        <td>oiqm7VSZwLn</td>
      </tr>
      <tr>
        <td>CIF - Hide "Treatment History - previous treatment registration number"</td>
        <td>Hide "TB DRS Treatment History - previous treatment registration number" unless prior TB registration is "Yes"</td>
        <td>2020-08-29</td>
        <td>OjyDPFPlZ4L</td>
      </tr>
      <tr>
        <td>Assign Patient DRS ID</td>
        <td>Display Patient DRS ID in the Indicator Widget</td>
        <td>2020-08-29</td>
        <td>OmiDOZC8stY</td>
      </tr>
      <tr>
        <td>Constant: Hide Lzd - Initial DST - LM</td>
        <td>Hide Lzd from list of drugs used for Initial DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>onpLkiwFP1Y</td>
      </tr>
      <tr>
        <td>Date validation: S1 - WGS date</td>
        <td>WGS date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>OObCMVzEjkl</td>
      </tr>
      <tr>
        <td>Hide "Initial DST - LM" fields</td>
        <td>Hide "Initial DST - LM" fields unless "Initial DST - LM" is selected</td>
        <td>2020-08-29</td>
        <td>oSEcFhWKeQU</td>
      </tr>
      <tr>
        <td>Constant: Hide Z - Initial DST - LM</td>
        <td>Hide Z from list of drugs used for Initial DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>OtODxIj253U</td>
      </tr>
      <tr>
        <td>Make mandatory: R - Initial DST - SM</td>
        <td>Make mandatory: R - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>OVB1vAnuWEa</td>
      </tr>
      <tr>
        <td>Generate Patient DRS ID</td>
        <td>Generate Patient DRS ID</td>
        <td>2020-02-03</td>
        <td>OVdbdXxA4pw</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Subsequent DST - LM inoculation date</td>
        <td>Subsequent DST - LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>OZcXjJ9SSEa</td>
      </tr>
      <tr>
        <td>Date validation: S3 - WGS date</td>
        <td>WGS date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>P3RSGwbipWV</td>
      </tr>
      <tr>
        <td>Hide "LPA RIF/INH" Fields</td>
        <td>Hide "LPA RIF/INH" unless "LPA RIF/INH" is selected</td>
        <td>2020-08-29</td>
        <td>p7T5h5IhfR8</td>
      </tr>
      <tr>
        <td>Constant: Hide Cfz - Initial DST - LM</td>
        <td>Hide Cfz from list of drugs used for Initial DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>pbOuqeol2Wy</td>
      </tr>
      <tr>
        <td>Constant: Hide "Sputum Smear Microscopy" section</td>
        <td>Hide "Sputum Smear Microscopy" if not used</td>
        <td>2020-08-29</td>
        <td>PcHWmirafV0</td>
      </tr>
      <tr>
        <td>Display current age ( >= 2) in the top bar</td>
        <td>Display Age ( >= 2) in the top bar</td>
        <td>2020-08-21</td>
        <td>PDgCvjHcCVc</td>
      </tr>
      <tr>
        <td>Make mandatory: Cfz - Subsequent DST - LM</td>
        <td>Make mandatory: Cfz - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>PDlfxA7ry9o</td>
      </tr>
      <tr>
        <td>Constant: Hide "CIF - TB Bacteriological Confirmation - Sputum Smear Microscopy"</td>
        <td>Hide "CIF - TB Bacteriological Confirmation - Sputum Smear Microscopy" if not used</td>
        <td>2020-08-29</td>
        <td>pgRQzrtyeoZ</td>
      </tr>
      <tr>
        <td>Hide "Not done" option for Microscopy test</td>
        <td>Hide "Not done" option for Microscopy test</td>
        <td>2020-08-18</td>
        <td>phbh2dN0z3l</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Culture - LM</td>
        <td>Make mandatory: Date of final results - Culture - LM</td>
        <td>2020-08-29</td>
        <td>PkFeM8yXzc9</td>
      </tr>
      <tr>
        <td>Make mandatory: R - Initial DST - LM</td>
        <td>Make mandatory: R - Initial DST - LM</td>
        <td>2020-08-29</td>
        <td>q0XeuO2TB6R</td>
      </tr>
      <tr>
        <td>Constant: Hide "LPA FQ/2LI" section</td>
        <td>Hide "LPA (Fluoroquinolones / Second Line Injectables)" if not used</td>
        <td>2020-08-29</td>
        <td>Q2X5grtVa7h</td>
      </tr>
      <tr>
        <td>Make mandatory: Dlm - Subsequent DST - SM</td>
        <td>Make mandatory: Dlm - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>qAtJIiAnJ2L</td>
      </tr>
      <tr>
        <td>Make mandatory: Date and result fields - LPA RIF/INH</td>
        <td>Make mandatory: Date and result fields - LPA RIF/INH</td>
        <td>2020-08-29</td>
        <td>QbLVLy4wW6g</td>
      </tr>
      <tr>
        <td>Date validation: S4 - LPA FQ/2LI date</td>
        <td>LPA FQ/2LI date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>QeTcwbb2vht</td>
      </tr>
      <tr>
        <td>Hide "Xpert MTB/RIF quantitative result"</td>
        <td>Hide "Xpert MTB/RIF quantitative result" unless MTB is detected</td>
        <td>2020-08-29</td>
        <td>QfW0Fzg0Gj8</td>
      </tr>
      <tr>
        <td>Constant: Hide Dlm - Subsequent DST - SM</td>
        <td>Hide Dlm from list of drugs used for Subsequent DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>QgUL7zDk98e</td>
      </tr>
      <tr>
        <td>Hide "TGS - Is Interpretable genetic resistance profiling for MTBc available?" field</td>
        <td>Hide "TGS - Is Interpretable genetic resistance profiling for MTBc available?" field unless "TGS Genotypic Speciation Results" include MTBc</td>
        <td>2020-08-29</td>
        <td>QhFwiQPkez5</td>
      </tr>
      <tr>
        <td>Assign previous treatment history status - unknown</td>
        <td></td>
        <td>2020-08-21</td>
        <td>qhpY5HIEmj1</td>
      </tr>
      <tr>
        <td>Make mandatory: Lfx - Subsequent DST - LM</td>
        <td>Make mandatory: Lfx - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>qqaDX2cNbrZ</td>
      </tr>
      <tr>
        <td>Hide "Not done" option for Xpert MTB/RIF test</td>
        <td>Hide "Not done" option for Xpert MTB/RIF test</td>
        <td>2020-08-18</td>
        <td>qTkWofwAxS4</td>
      </tr>
      <tr>
        <td>Hide "TGS - reasons for no resistance profiling available" field</td>
        <td>Hide "TGS - reasons for no resistance profiling available" field if "TGS - Interpretable genetic resistance profiling for MTBc" is available</td>
        <td>2020-08-29</td>
        <td>qTNHmDzV7OB</td>
      </tr>
      <tr>
        <td>Make mandatory: E - Initial DST - LM</td>
        <td>Make mandatory: E - Initial DST - LM</td>
        <td>2020-08-29</td>
        <td>qva46czrroD</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Xpert MTB/RIF Ultra date</td>
        <td>Xpert MTB/RIF Ultra date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>qW0p3UsIdxh</td>
      </tr>
      <tr>
        <td>Make mandatory: Cfz - Initial DST - LM</td>
        <td>Make mandatory: Cfz - Initial DST - LM</td>
        <td>2020-08-29</td>
        <td>QYHfhyE0TtC</td>
      </tr>
      <tr>
        <td>CIF - Hide Xpert MTB/RIF</td>
        <td>Hide Xpert MTB/RIF Test fields unless Xpert MTB/RIF is selected</td>
        <td>2020-08-29</td>
        <td>qZ32JJQDYxp</td>
      </tr>
      <tr>
        <td>Make mandatory: H CC - Initial DST - SM</td>
        <td>Make mandatory: H CC - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>R0qK91POcKa</td>
      </tr>
      <tr>
        <td>Make mandatory: R - Subsequent DST - LM</td>
        <td>Make mandatory: R - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>R2YTrbLLnm9</td>
      </tr>
      <tr>
        <td>Constant: Hide "Xpert MTB/RIF Ultra" section</td>
        <td>Hide "Xpert MTB/RIF Ultra" if not used</td>
        <td>2020-08-29</td>
        <td>rBHpHQHMzzY</td>
      </tr>
      <tr>
        <td>Constant: Hide "WGS" section</td>
        <td>Hide "WGS" if not used</td>
        <td>2020-08-29</td>
        <td>reQzgr6rGms</td>
      </tr>
      <tr>
        <td>SRL: Hide "Reasons for not sending results to SRL" field</td>
        <td>Hide SRL - "Reasons for not sending results to SRL" field if shipped or not applicable</td>
        <td>2020-08-29</td>
        <td>RIBNrOhnWFm</td>
      </tr>
      <tr>
        <td>Make mandatory: H CB - Subsequent DST - SM</td>
        <td>Make mandatory: H CB - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>RkS5eOfrRjc</td>
      </tr>
      <tr>
        <td>Constant: Hide "Sample 3" stage</td>
        <td>Hide "Sample 3" stage if not used</td>
        <td>2020-08-29</td>
        <td>rSPDV6Kfj1x</td>
      </tr>
      <tr>
        <td>Hide: Initial DST SM - "Final results" section</td>
        <td>Hide "Final results" section unless date of final results is entered</td>
        <td>2020-08-29</td>
        <td>rv5bDc0loqv</td>
      </tr>
      <tr>
        <td>Constant: Hide "Targeted Gene Sequencing" section</td>
        <td>Hide "Targeted Gene Sequencing" if not used</td>
        <td>2020-08-29</td>
        <td>rxnBSLg9bF1</td>
      </tr>
      <tr>
        <td>Constant: Hide E - Initial DST - LM</td>
        <td>Hide E from list of drugs used for Initial DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>S1mDE2iiUlk</td>
      </tr>
      <tr>
        <td>Constant: Hide H CB - Subsequent DST - LM</td>
        <td>Hide H CB from list of drugs used for Subsequent DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>saKIwUXzmXv</td>
      </tr>
      <tr>
        <td>Constant: Hide Lfx - Subsequent DST - LM</td>
        <td>Hide Lfx from list of drugs used for Subsequent DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>SboB8RbxOjj</td>
      </tr>
      <tr>
        <td>CIF - Hide "Treatment History - Names of Drugs"</td>
        <td>Hide "TB DRS Treatment History - Names of Drugs" unless the answer for "TB DRS Treatment History - Tuberculosis Drugs" is "Yes".</td>
        <td>2020-08-29</td>
        <td>sCdmieN4lT7</td>
      </tr>
      <tr>
        <td>Constant: Hide Z - Initial DST - SM</td>
        <td>Hide Z from list of drugs used for Initial DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>seL9DsDnIO7</td>
      </tr>
      <tr>
        <td>Make mandatory: H CC - Subsequent DST - LM</td>
        <td>Make mandatory: H CC - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>SHyNReZlwD7</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Subsequent DST - SM</td>
        <td>Make mandatory: Date of final results - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>SUrqwc057zV</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of inoculation - Subsequent DST - LM</td>
        <td>Make mandatory: Date of inoculation - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>sx0kyQsEg3c</td>
      </tr>
      <tr>
        <td>Date validation: Subsequent DST - LM date</td>
        <td>Subsequent DST - LM test result date cannot be prior to inoculation date</td>
        <td>2020-08-29</td>
        <td>sx9AorG5zM8</td>
      </tr>
      <tr>
        <td>Constant: Hide SRL stage</td>
        <td>Hide "SRL" if samples are never sent to SRL</td>
        <td>2020-08-29</td>
        <td>SYrJsO8xr6C</td>
      </tr>
      <tr>
        <td>Display previous TB Registration Number</td>
        <td>Display previous TB Registration Number</td>
        <td>2020-08-21</td>
        <td>SzhYub67ji4</td>
      </tr>
      <tr>
        <td>Constant: Hide Mfx CB - Initial DST - LM</td>
        <td>Hide Mfx CB from list of drugs used for Initial DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>tCbPN4u9DVh</td>
      </tr>
      <tr>
        <td>Constant: Hide Am - Subsequent DST - LM</td>
        <td>Hide Am from list of drugs used for Subsequent DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>tin0buEUJWh</td>
      </tr>
      <tr>
        <td>Generate DRS Sample 1 ID</td>
        <td>Generate DRS Sample 1 ID</td>
        <td>2020-02-03</td>
        <td>tJq1UCrpx4p</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of inoculation - initial DST - LM</td>
        <td>Make mandatory: Date of inoculation - initial DST - LM</td>
        <td>2020-08-29</td>
        <td>tlVFPbwLYkY</td>
      </tr>
      <tr>
        <td>Constant: Hide "Initial DST - LM" section</td>
        <td>Hide "Initial DST - LM" if not used</td>
        <td>2020-08-29</td>
        <td>TMFKJbuE519</td>
      </tr>
      <tr>
        <td>Make mandatory: Bdq - Subsequent DST - LM</td>
        <td>Make mandatory: Bdq - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>tQK2uL1SHS9</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx CC - Initial DST - LM</td>
        <td>Make mandatory: Mfx CC - Initial DST - LM</td>
        <td>2020-08-29</td>
        <td>trnwIPTQDem</td>
      </tr>
      <tr>
        <td>Constant: Hide H CC - Subsequent DST - LM</td>
        <td>Hide H CC from list of drugs used for Subsequent DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>tWuhWCgEHBD</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Culture - SM inoculation date</td>
        <td>Culture - SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>txP3vA3nqWB</td>
      </tr>
      <tr>
        <td>Make mandatory: H CC - Initial DST - LM</td>
        <td>Make mandatory: H CC - Initial DST - LM</td>
        <td>2020-08-29</td>
        <td>U3TTAHFB1sb</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Initial DST - LM inoculation date</td>
        <td>Initial DST - LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>u8VNFez3Arg</td>
      </tr>
      <tr>
        <td>Hide: LPA FQ/2LI - FQ, 2LI and E fields</td>
        <td>Hide LPA FQ/2LI - results for FQ, 2LI and E fields unless MTBc is detected</td>
        <td>2020-08-29</td>
        <td>UCz4TkFAacz</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Culture - LM inoculation date</td>
        <td>Culture - LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>UDOQXveS2Uf</td>
      </tr>
      <tr>
        <td>Constant: Hide H CB - Subsequent DST - SM</td>
        <td>Hide H CB from list of drugs used for Subsequent DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>uIOtFwtC1gH</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Initial DST - LM inoculation date</td>
        <td>Initial DST - LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>uISj7gl77sc</td>
      </tr>
      <tr>
        <td>Constant: Hide Cfz - Initial DST - SM</td>
        <td>Hide Cfz from list of drugs used for Initial DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>UnNaEVfXEF2</td>
      </tr>
      <tr>
        <td>Make mandatory: Z - Subsequent DST - SM</td>
        <td>Make mandatory: Z - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>Uo4SWwUgZwU</td>
      </tr>
      <tr>
        <td>Generate DRS Sample 3 ID</td>
        <td>Generate DRS Sample 3 ID</td>
        <td>2020-02-03</td>
        <td>UOtdRCTgYRU</td>
      </tr>
      <tr>
        <td>Assign resistance status - FQ not resistant</td>
        <td>Set the status of resistance to FQ</td>
        <td>2020-08-21</td>
        <td>USloBpR9De6</td>
      </tr>
      <tr>
        <td>Make mandatory: H CB - Subsequent DST - LM</td>
        <td>Make mandatory: H CB - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>UT7qmcqbuLV</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Initial DST - SM</td>
        <td>Make mandatory: Date of final results - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>UYz2rgemOkh</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Culture - LM inoculation date</td>
        <td>Culture - LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>V5hRMgTLguM</td>
      </tr>
      <tr>
        <td>Hide "Subsequent DST - SM" fields</td>
        <td>Hide "Subsequent DST - SM" fields unless "Subsequent DST - SM" is selected</td>
        <td>2020-08-29</td>
        <td>v6MhkRp66X4</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Subsequent DST - LM inoculation date</td>
        <td>Subsequent DST - LM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>v6oyTdBhK6v</td>
      </tr>
      <tr>
        <td>Hide "WGS - reasons for no resistance profiling available" field</td>
        <td>Hide "WGS - reasons for no resistance profiling available" field if "WGS - interpretable genetic resistance profiling for MTBc" is available</td>
        <td>2020-08-29</td>
        <td>vDfzXrPqVKw</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Subsequent DST - SM inoculation date</td>
        <td>Subsequent DST - SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>vG5ehu9fRDu</td>
      </tr>
      <tr>
        <td>Constant: Hide R - Subsequent DST - LM</td>
        <td>Hide R from list of drugs used for Subsequent DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>vgqaTQVEM5r</td>
      </tr>
      <tr>
        <td>Make mandatory: Z - Initial DST - SM</td>
        <td>Make mandatory: Z - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>VhkBA4Q9AA8</td>
      </tr>
      <tr>
        <td>Hide "Specify Other" for Sample 2</td>
        <td>Hide "Specify Other" for Sample 2 unless the Answer to "Sample 2 Treatment" is "Other"</td>
        <td>2020-08-29</td>
        <td>VjTyxzlQNO5</td>
      </tr>
      <tr>
        <td>Constant: Hide Am - Subsequent DST - SM</td>
        <td>Hide Am from list of drugs used for Subsequent DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>vjUK8GGhx3R</td>
      </tr>
      <tr>
        <td>CIF - Hide "Outcome Other"</td>
        <td>Hide "TB DRS TB DRS CIF - Outcome Other" unless Other is selected</td>
        <td>2020-08-29</td>
        <td>vjXTnHT2OtT</td>
      </tr>
      <tr>
        <td>Hide "WGS Genotypic Speciation Results" fields</td>
        <td>Hide "WGS - genotypic speciation results" fields unless "WGS" is selected</td>
        <td>2020-08-29</td>
        <td>VLZOl0DJLS4</td>
      </tr>
      <tr>
        <td>Constant: Hide Dlm - Initial DST - LM</td>
        <td>Hide Dlm from list of drugs used for Initial DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>VMe40J3NnVl</td>
      </tr>
      <tr>
        <td>Make mandatory: Lfx - Subsequent DST - SM</td>
        <td>Make mandatory: Lfx - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>VPXrBFPYhL8</td>
      </tr>
      <tr>
        <td>Make mandatory: Cfz - Subsequent DST - SM</td>
        <td>Make mandatory: Cfz - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>vT5dvGhswAJ</td>
      </tr>
      <tr>
        <td>Hide "WGS" fields</td>
        <td>Hide "WGS" fields unless "WGS" is selected</td>
        <td>2020-08-29</td>
        <td>W8Eq5lh30rL</td>
      </tr>
      <tr>
        <td>Constant: Hide Mfx CB - Subsequent DST - LM</td>
        <td>Hide Mfx CB from list of drugs used for Subsequent DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>wBkYPnKAVOV</td>
      </tr>
      <tr>
        <td>Constant: Hide H CB - Initial DST - LM</td>
        <td>Hide H CB from list of drugs used for Initial DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>wCZHu3exKHT</td>
      </tr>
      <tr>
        <td>Constant: Hide Mfx CC - Initial DST - LM</td>
        <td>Hide Mfx CC from list of drugs used for Initial DST - LM if not used</td>
        <td>2020-08-29</td>
        <td>wE0yhLXQd2Y</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Initial DST - SM inoculation date</td>
        <td>Initial DST - SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>wGuos0ZHWDk</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of inoculation - Subsequent DST - SM</td>
        <td>Make mandatory: Date of inoculation - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>WHgSIxU1wN0</td>
      </tr>
      <tr>
        <td>Make mandatory: Bdq - Initial DST - LM</td>
        <td>Make mandatory: Bdq - Initial DST - LM</td>
        <td>2020-08-29</td>
        <td>wI1b2t9LKQR</td>
      </tr>
      <tr>
        <td>Make mandatory: H CB - Initial DST - SM</td>
        <td>Make mandatory: H CB - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>wSY3LOih3gh</td>
      </tr>
      <tr>
        <td>Make mandatory: Quantitive result - Xpert MTB/RIF</td>
        <td>Make mandatory: Quantitive result - Xpert MTB/RIF</td>
        <td>2020-08-29</td>
        <td>wxBwarZREOz</td>
      </tr>
      <tr>
        <td>Generate DRS Sample 2 ID</td>
        <td>Generate DRS Sample 2 ID</td>
        <td>2020-02-03</td>
        <td>WyhrK5pCVIr</td>
      </tr>
      <tr>
        <td>Constant: Hide H CC - Subsequent DST - SM</td>
        <td>Hide H CC from list of drugs used for Subsequent DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>x7b5voqD5Hf</td>
      </tr>
      <tr>
        <td>Date validation: S4 - Subsequent DST - SM inoculation date</td>
        <td>Subsequent DST - SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>X7P5bqxrcPD</td>
      </tr>
      <tr>
        <td>Constant: Hide "embB" field</td>
        <td>Hide "embB" field if Ethambutol is not being tested</td>
        <td>2020-08-29</td>
        <td>X8QIPW2W05n</td>
      </tr>
      <tr>
        <td>Make mandatory: Quantitive result - Xpert MTB/RIF Ultra</td>
        <td>Make mandatory: Quantitive result - Xpert MTB/RIF Ultra</td>
        <td>2020-08-29</td>
        <td>Xast3F5sYY8</td>
      </tr>
      <tr>
        <td>CIF - Hide "Treatment History - Regimen" and "TB DRS Treatment History - Outcome"</td>
        <td>Hide "Regimen" and "Outcome" fields unless the patient was treated for more than a month</td>
        <td>2020-08-29</td>
        <td>XBOo5soKgDT</td>
      </tr>
      <tr>
        <td>Constant: Hide H CC - Initial DST - SM</td>
        <td>Hide H CC from list of drugs used for Initial DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>xdTQICXUrRr</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx CB - Initial DST - SM</td>
        <td>Make mandatory: Mfx CB - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>xFOl7aDwQ5a</td>
      </tr>
      <tr>
        <td>Constant: Hide Mfx CB - Subsequent DST - SM</td>
        <td>Hide Mfx CB from list of drugs used for Subsequent DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>xly48Oj31dZ</td>
      </tr>
      <tr>
        <td>Date validation: S3 - Subsequent DST - SM inoculation date</td>
        <td>Subsequent DST - SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>XVcJnlHXM6K</td>
      </tr>
      <tr>
        <td>Make mandatory: Dlm - Subsequent DST - LM</td>
        <td>Make mandatory: Dlm - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>xwzc7Ek2K0p</td>
      </tr>
      <tr>
        <td>CIF - Hide treatment history provided by patient</td>
        <td>Hide "Treatment History Provided by Patient" fields if the patient was previously treated for TB</td>
        <td>2020-08-29</td>
        <td>XxpX3sJalg4</td>
      </tr>
      <tr>
        <td>Make mandatory: Lfx - Initial DST - LM</td>
        <td>Make mandatory: Lfx - Initial DST - LM</td>
        <td>2020-08-29</td>
        <td>xYFF40tZ7Qr</td>
      </tr>
      <tr>
        <td>Hide: LPA RIF/INH - R and H result fields</td>
        <td>Hide LPA RIF/INH - R and H result fields unless MTBc is detected</td>
        <td>2020-08-29</td>
        <td>y6QL5z3fXky</td>
      </tr>
      <tr>
        <td>Hide: Subsequent DST SM - "Final results" section</td>
        <td>Hide "Final results" section unless date of final results is entered</td>
        <td>2020-08-29</td>
        <td>yhUxqzLVROr</td>
      </tr>
      <tr>
        <td>Hide: Initial DST LM - "Final results" section</td>
        <td>Hide "Final results" section unless date of final results is entered</td>
        <td>2020-08-29</td>
        <td>yHzbiWa4qnF</td>
      </tr>
      <tr>
        <td>Constant: Hide "Initial DST - SM" section</td>
        <td>Hide "Initial DST - SM" if not used</td>
        <td>2020-08-29</td>
        <td>ykAqcJUSn6T</td>
      </tr>
      <tr>
        <td>Date validation: Culture - LM date</td>
        <td>Culture - LM test result date cannot be prior to inoculation date</td>
        <td>2020-08-29</td>
        <td>YmJNGBTfSM4</td>
      </tr>
      <tr>
        <td>Constant: Hide Lfx - Initial DST - SM</td>
        <td>Hide Lfx from list of drugs used for Initial DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>yMO3HkkVQRA</td>
      </tr>
      <tr>
        <td>Make mandatory: Lzd - Subsequent DST - SM</td>
        <td>Make mandatory: Lzd - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>YnTxPSj9YPl</td>
      </tr>
      <tr>
        <td>Make mandatory: H CC - Subsequent DST - SM</td>
        <td>Make mandatory: H CC - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>Yp1K3LvVoAV</td>
      </tr>
      <tr>
        <td>Constant: Hide "CIF - TB Bacteriological Confirmation - Xpert MTB/RIF"</td>
        <td>Hide "CIF - TB Bacteriological Confirmation - Xpert MTB/RIF" if not used</td>
        <td>2020-08-29</td>
        <td>yPHeTz8frbN</td>
      </tr>
      <tr>
        <td>Constant: Hide Lzd - Subsequent DST - SM</td>
        <td>Hide Lzd from list of drugs used for Subsequent DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>yqL2JNGSCHi</td>
      </tr>
      <tr>
        <td>Make mandatory: E - Subsequent DST - SM</td>
        <td>Make mandatory: E - Subsequent DST - SM</td>
        <td>2020-08-29</td>
        <td>YSi8OAZ4TCq</td>
      </tr>
      <tr>
        <td>Make mandatory: Drugs - E - LPA FQ/2LI</td>
        <td>Make mandatory: Drugs - E - LPA FQ/2LI</td>
        <td>2020-08-29</td>
        <td>yvAZGDsaVga</td>
      </tr>
      <tr>
        <td>Date validation: S3 - LPA FQ/2LI date</td>
        <td>LPA FQ/2LI date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>yYnReZdcksK</td>
      </tr>
      <tr>
        <td>Make mandatory: Date of final results - Culture - LM</td>
        <td>Make mandatory: Date of final results - Culture - LM</td>
        <td>2020-08-29</td>
        <td>yZNR57r3aIm</td>
      </tr>
      <tr>
        <td>Date validation: S2 - LPA RIF/INH date</td>
        <td>LPA RIF/INH date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>Z53n2HnY0hP</td>
      </tr>
      <tr>
        <td>Date validation: S2 - Initial DST - SM inoculation date</td>
        <td>Initial DST - SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>z6ngu8v0Dzy</td>
      </tr>
      <tr>
        <td>Constant: Hide "Xpert MTB/RIF" section</td>
        <td>Hide "Xpert MTB/RIF" if not used</td>
        <td>2020-08-29</td>
        <td>Zckkhc1uLyH</td>
      </tr>
      <tr>
        <td>Constant: Hide H CB - Initial DST - SM</td>
        <td>Hide H CB from list of drugs used for Initial DST - SM if not used</td>
        <td>2020-08-29</td>
        <td>ZcoiBN36Je1</td>
      </tr>
      <tr>
        <td>Make mandatory: Mfx CC - Initial DST - SM</td>
        <td>Make mandatory: Mfx CC - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>zcyK1BiWZcE</td>
      </tr>
      <tr>
        <td>Make mandatory: Am - Subsequent DST - LM</td>
        <td>Make mandatory: Am - Subsequent DST - LM</td>
        <td>2020-08-29</td>
        <td>zLibaa5bqNy</td>
      </tr>
      <tr>
        <td>Assign resistance status - H not resistant</td>
        <td>Set the status of resistance to H</td>
        <td>2020-08-21</td>
        <td>zQRAmSJDkh6</td>
      </tr>
      <tr>
        <td>Make mandatory: Am - Initial DST - SM</td>
        <td>Make mandatory: Am - Initial DST - SM</td>
        <td>2020-08-29</td>
        <td>ZrHT0fLXE9w</td>
      </tr>
      <tr>
        <td>Date validation: S2 - LPA FQ/2LI date</td>
        <td>LPA FQ/2LI date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>ZSH50RCEsmP</td>
      </tr>
      <tr>
        <td>Date validation: S1 - Subsequent DST - SM inoculation date</td>
        <td>Subsequent DST - SM inoculation date cannot be prior to sample collection date</td>
        <td>2020-08-29</td>
        <td>ZWPmho8kwuD</td>
      </tr>
    </table>
    <h4>Program Tracked Entity Attributes</h4>
    <table>
      <tr>
        <th>Tracked Entity Attribute Name</th>
        <th>Last updated</th>
        <th>Program Tracked Entity Attribute UID</th>
        <th>Tracked Entity Attribute UID</th>
      </tr>
      <tr>
        <td>Patient DRS ID</td>
        <td>2020-06-05</td>
        <td>jf47G3ie95T</td>
        <td>BdvE9shT6GX</td>
      </tr>
      <tr>
        <td>Health Facility Code</td>
        <td>2020-06-05</td>
        <td>UJlkDqDxNlG</td>
        <td>sWn0CERcUYj</td>
      </tr>
      <tr>
        <td>Patient DRS Serial Number</td>
        <td>2020-06-05</td>
        <td>rZKv16lFq9y</td>
        <td>Qj7EXFIXcyc</td>
      </tr>
      <tr>
        <td>Cluster ID</td>
        <td>2020-06-05</td>
        <td>iHuT7Jf69il</td>
        <td>aOrGt5JE0gV</td>
      </tr>
      <tr>
        <td>Given name</td>
        <td>2020-06-05</td>
        <td>YVhcTRS789c</td>
        <td>TfdH5KvFmMy</td>
      </tr>
      <tr>
        <td>Family name</td>
        <td>2020-06-05</td>
        <td>yKAmutvvxlx</td>
        <td>aW66s2QSosT</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>2020-06-05</td>
        <td>mdcwEKRScEb</td>
        <td>CklPZdOd6H1</td>
      </tr>
      <tr>
        <td>Date of birth is estimated</td>
        <td>2020-06-05</td>
        <td>jjATJmtN4T4</td>
        <td>Z1rLc1rVHK8</td>
      </tr>
      <tr>
        <td>Date of birth (age)</td>
        <td>2020-06-05</td>
        <td>oBXflxK0OPH</td>
        <td>mAWcalQYYyk</td>
      </tr>
      <tr>
        <td>TB Registration Number</td>
        <td>2020-06-05</td>
        <td>FNMUKiZ2TXa</td>
        <td>ntelZthDPpR</td>
      </tr>
      <tr>
        <td>Administrative Area of Residence</td>
        <td>2020-06-05</td>
        <td>qObTmB2O3iw</td>
        <td>ljHL8NnSEAD</td>
      </tr>
      <tr>
        <td>Location of Residence</td>
        <td>2020-06-05</td>
        <td>tymxPk5geMN</td>
        <td>f038nOc9uRF</td>
      </tr>
      <tr>
        <td>Address (current)</td>
        <td>2020-06-05</td>
        <td>ylfC4Fjo2NN</td>
        <td>VCtm2pySeEV</td>
      </tr>
      <tr>
        <td>Country of origin</td>
        <td>2020-06-05</td>
        <td>ZSreVJc1YHl</td>
        <td>PBdqXh8Nvuj</td>
      </tr>
    </table>
    <h2 id="constants">Constants</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Amikacin</td>
        <td>Subsequent DST in Liquid Media - Am</td>
        <td>2020-09-24</td>
        <td>a4PpEfSutcV</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Pyrazinamide</td>
        <td>Initial DST in Solid Media - Z</td>
        <td>2020-09-24</td>
        <td>aCaNdqUIDZl</td>
      </tr>
      <tr>
        <td>TB-Drugs: LPA (Fluoroquinolones / Second Line Injectables) - Ethambutol</td>
        <td>Ethambutol Result</td>
        <td>2020-08-13</td>
        <td>AiyTLOJHMkl</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Isoniazid CB</td>
        <td>Initial DST in Solid Media - H CB</td>
        <td>2020-09-24</td>
        <td>anpSc1tmlft</td>
      </tr>
      <tr>
        <td>TB-DRS: SRL</td>
        <td>SRL</td>
        <td>2020-08-04</td>
        <td>AUltNkQXzdm</td>
      </tr>
      <tr>
        <td>TB-DRS: Cluster Sampling</td>
        <td>Cluster Sampling</td>
        <td>2020-08-04</td>
        <td>aYPQMlxAZsz</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Linezolid</td>
        <td>Initial DST in Liquid Media - Lzd</td>
        <td>2020-09-24</td>
        <td>aZq11UuXPP6</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Levofloxacin</td>
        <td>Subsequent DST in Liquid Media - Lfx</td>
        <td>2020-09-24</td>
        <td>b1KgVOel21P</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Pyrazinamide</td>
        <td>Subsequent DST in Solid Media - Z</td>
        <td>2020-09-24</td>
        <td>bHPYGfrFNV2</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Delamanid</td>
        <td>Initial DST in Liquid Media - Dlm</td>
        <td>2020-09-24</td>
        <td>BJTzi3WWjhT</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - Subsequent Phenotypic DST in Solid Media (eg. LJ)</td>
        <td>Subsequent Phenotypic DST in SM (eg. LJ)</td>
        <td>2020-09-24</td>
        <td>BpRfvWQcvTo</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Clofazimine</td>
        <td>Subsequent DST in Solid Media - Cfz</td>
        <td>2020-09-24</td>
        <td>bywBn5DxVdi</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra</td>
        <td>2020-09-24</td>
        <td>cFoFDkXKcXC</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Isoniazid CC</td>
        <td>Initial DST in Liquid Media - H CC</td>
        <td>2020-09-24</td>
        <td>cRldkiBh5xv</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Linezolid</td>
        <td>Initial DST in Solid Media - Lzd</td>
        <td>2020-09-24</td>
        <td>CVQR2ZtZWxk</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Moxifloxacin CC</td>
        <td>Subsequent DST in Solid Media - Mfx CC</td>
        <td>2020-09-24</td>
        <td>Czx5FuOqF9i</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Isoniazid CC</td>
        <td>Initial DST in Solid Media - H CC</td>
        <td>2020-09-24</td>
        <td>dAPAScvFPfX</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Moxifloxacin CC</td>
        <td>Initial DST in Liquid Media - Mfx CC</td>
        <td>2020-09-24</td>
        <td>dgjpdQO2Iva</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Amikacin</td>
        <td>Subsequent DST in Solid Media - Am</td>
        <td>2020-09-24</td>
        <td>dTwKm1u2VhY</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Isoniazid CC</td>
        <td>Subsequent DST in Solid Media - H CC</td>
        <td>2020-09-24</td>
        <td>eM3UfUO7W8O</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - LPA (RIF/INH)</td>
        <td>LPA (RIF/INH)</td>
        <td>2020-08-13</td>
        <td>ESUffSPwmju</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Isoniazid CB</td>
        <td>Subsequent DST in Liquid Media - H CB</td>
        <td>2020-09-24</td>
        <td>F9DTb5zl8rS</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Pyrazinamide</td>
        <td>Initial DST in Liquid Media - Z</td>
        <td>2020-09-24</td>
        <td>FDtk4otxDse</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Levofloxacin</td>
        <td>Subsequent DST in Solid Media - Lfx</td>
        <td>2020-09-24</td>
        <td>Fw8wOlTETPt</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Clofazimine</td>
        <td>Initial DST in Liquid Media - Cfz</td>
        <td>2020-09-24</td>
        <td>GL5JTtBvbEC</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - LPA (FQ/2LI)</td>
        <td>LPA (FQ/2LI)</td>
        <td>2020-08-13</td>
        <td>govArZqiFzY</td>
      </tr>
      <tr>
        <td>TB: Treatment - Lists of First-line and Second-line drugs</td>
        <td>First-line and Second-line drugs</td>
        <td>2020-09-24</td>
        <td>GxOlFoUKbHB</td>
      </tr>
      <tr>
        <td>TB-DRS: Bacteriological Confirmation of TB</td>
        <td>Bacteriological Confirmation of TB</td>
        <td>2020-08-04</td>
        <td>gYj2CUoep4O</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF</td>
        <td>2020-08-20</td>
        <td>H4ObQDbhnTA</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Moxifloxacin CC</td>
        <td>Subsequent DST in Liquid Media - Mfx CC</td>
        <td>2020-09-24</td>
        <td>HhKitGif8RV</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - Initial Phenotypic DST in Solid Media (eg. LJ)</td>
        <td>Initial Phenotypic DST in SM (eg. LJ)</td>
        <td>2020-09-24</td>
        <td>HjN2Bgnusyy</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Ethambutol</td>
        <td>Subsequent DST in Liquid Media - E</td>
        <td>2020-09-24</td>
        <td>Ic5asMdbpH8</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - Culture in Solid Media (e.g. LJ)</td>
        <td>TB Culture in Solid Media (e.g. LJ)</td>
        <td>2020-08-13</td>
        <td>iSKEqcuVAui</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Linezolid</td>
        <td>Subsequent DST in Solid Media - Lzd</td>
        <td>2020-09-24</td>
        <td>KIeI2d8xalG</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Bedaquiline</td>
        <td>Initial DST in Liquid Media - Bdq</td>
        <td>2020-09-24</td>
        <td>KjvwSybuWJU</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - Targeted Gene Sequencing</td>
        <td>Targeted Gene Sequencing</td>
        <td>2020-08-18</td>
        <td>KkypNdLNW1f</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Rifampicin</td>
        <td>Subsequent DST in Liquid Media - R</td>
        <td>2020-09-24</td>
        <td>lelJEADYpeI</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Isoniazid CB</td>
        <td>Initial DST in Liquid Media - H CB</td>
        <td>2020-09-24</td>
        <td>lqaf0KfpHGd</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Moxifloxacin CB</td>
        <td>Initial DST in Solid Media - Mfx CB</td>
        <td>2020-09-24</td>
        <td>m4c79OHEKCG</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - Whole Genome Sequencing</td>
        <td>Whole Genome Sequencing</td>
        <td>2020-08-18</td>
        <td>MC7QUDr9YKC</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Linezolid</td>
        <td>Subsequent DST in Liquid Media - Lzd</td>
        <td>2020-09-24</td>
        <td>mU5iEABeF2K</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Ethambutol</td>
        <td>Initial DST in Liquid Media - E</td>
        <td>2020-09-24</td>
        <td>n9zOOsLO0QP</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Clofazimine</td>
        <td>Subsequent DST in Liquid Media - Cfz</td>
        <td>2020-09-24</td>
        <td>Nb6oHqjCCZq</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Levofloxacin</td>
        <td>Initial DST in Solid Media - Lfx</td>
        <td>2020-09-24</td>
        <td>NlOX3oV4gWe</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Moxifloxacin CB</td>
        <td>Subsequent DST in Solid Media - Mfx CB</td>
        <td>2020-09-24</td>
        <td>NvA1K4hFJbc</td>
      </tr>
      <tr>
        <td>TB-DRS: Sample 4 for NRL Processing</td>
        <td>Sample 4 for NRL Processing</td>
        <td>2020-07-30</td>
        <td>NXr7RH56Q1R</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - Initial Phenotypic DST in Liquid Media (eg. Mgit)</td>
        <td>Initial Phenotypic DST in LM (eg. Mgit)</td>
        <td>2020-09-24</td>
        <td>OQxeAIyQUeB</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - Sputum Smear Microscopy</td>
        <td>Sputum Smear Microscopy</td>
        <td>2020-08-20</td>
        <td>q1ah12sKfG3</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Rifampicin</td>
        <td>Initial DST in Solid Media - R</td>
        <td>2020-09-24</td>
        <td>Q67DDsupq7v</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Bedaquiline</td>
        <td>Subsequent DST in Liquid Media - Bdq</td>
        <td>2020-09-24</td>
        <td>QaioqMbO0TX</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Culture in Liquid Media (e.g. MGIT)</td>
        <td>2020-08-13</td>
        <td>qpAseG5vJyS</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Bedaquiline</td>
        <td>Subsequent DST in Solid Media - Bdq</td>
        <td>2020-09-24</td>
        <td>r70ONQRhaHY</td>
      </tr>
      <tr>
        <td>TB-DRS: TB DRS ID</td>
        <td>DRS ID</td>
        <td>2020-08-04</td>
        <td>R9XmbNHMmzn</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Delamanid</td>
        <td>Subsequent DST in Solid Media - Dlm</td>
        <td>2020-09-24</td>
        <td>RFqmLP5W5di</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - LF-LAM</td>
        <td>LF-LAM</td>
        <td>2020-08-13</td>
        <td>riDIK5mvDzW</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Moxifloxacin CC</td>
        <td>Initial DST in Solid Media - Mfx CC</td>
        <td>2020-09-24</td>
        <td>RJNE1o9cw7Y</td>
      </tr>
      <tr>
        <td>TB-DRS: Sample 2 for NRL Processing</td>
        <td>Sample 2 for NRL Processing</td>
        <td>2020-08-04</td>
        <td>rSS2dY6gwLJ</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Isoniazid CB</td>
        <td>Subsequent DST in Solid Media - H CB</td>
        <td>2020-09-24</td>
        <td>s8WPR943gGS</td>
      </tr>
      <tr>
        <td>TB-DRS: Sample 3 for NRL Processing</td>
        <td>Sample 3 for NRL Processing</td>
        <td>2020-07-30</td>
        <td>sqgp1l0s4wp</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Levofloxacin</td>
        <td>Initial DST in Liquid Media - Lfx</td>
        <td>2020-09-24</td>
        <td>t7Okdm8VgDV</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Moxifloxacin CB</td>
        <td>Initial DST in Liquid Media - Mfx CB</td>
        <td>2020-09-24</td>
        <td>UL61U78GWCg</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Rifampicin</td>
        <td>Initial DST in Liquid Media - R</td>
        <td>2020-09-24</td>
        <td>uOJYEwV7XfN</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Bedaquiline</td>
        <td>Initial DST in Solid Media - Bdq</td>
        <td>2020-09-24</td>
        <td>UxcTzMRQsfa</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Delamanid</td>
        <td>Initial DST in Solid Media - Dlm</td>
        <td>2020-09-24</td>
        <td>VUlsMrm4D8k</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Pyrazinamide</td>
        <td>Subsequent DST in Liquid Media - Z</td>
        <td>2020-09-24</td>
        <td>VY15auehssY</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - Subsequent Phenotypic DST in Liquid Media (eg. Mgit)</td>
        <td>Subsequent Phenotypic DST in LM (eg. Mgit)</td>
        <td>2020-09-24</td>
        <td>W8Fm1pJuJPL</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Ethambutol</td>
        <td>Subsequent DST in Solid Media - E</td>
        <td>2020-09-24</td>
        <td>wNxsAieLWYc</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Amikacin</td>
        <td>Initial DST in Liquid Media - Am</td>
        <td>2020-09-24</td>
        <td>x6v8O6EZo0U</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Moxifloxacin CB</td>
        <td>Subsequent DST in Liquid Media - Mfx CB</td>
        <td>2020-09-24</td>
        <td>xfltmyqC3p0</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Amikacin</td>
        <td>Initial DST in Solid Media - Am</td>
        <td>2020-09-24</td>
        <td>XO1V9o5C95J</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Delamanid</td>
        <td>Subsequent DST in Liquid Media - Dlm</td>
        <td>2020-09-24</td>
        <td>Xt5GU9kBD7q</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - TB-LAMP</td>
        <td>TB-LAMP</td>
        <td>2020-08-13</td>
        <td>yF0xR5nDSXa</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Ethambutol</td>
        <td>Initial DST in Solid Media - E</td>
        <td>2020-09-24</td>
        <td>yxPHZFwMTN6</td>
      </tr>
      <tr>
        <td>TB: Laboratory Test - Truenat</td>
        <td>Truenat</td>
        <td>2020-08-13</td>
        <td>zBicQdPbHfj</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Isoniazid CC</td>
        <td>Subsequent DST in Liquid Media - H CC</td>
        <td>2020-09-24</td>
        <td>ZBpqH7xJLBO</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Clofazimine</td>
        <td>Initial DST in Solid Media - Cfz</td>
        <td>2020-09-24</td>
        <td>ZDpLleSK08x</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Rifampicin</td>
        <td>Subsequent DST in Solid Media - R</td>
        <td>2020-09-24</td>
        <td>zJoEjvstp2d</td>
      </tr>
    </table>
    <h2 id="dataElements">Data Elements</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Code</th>
        <th>Description</th>
        <th>Categorycombo</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB Lab: LPA (RIF/INH)</td>
        <td>LPA RIF/INH</td>
        <td></td>
        <td>LPA (RIF/INH)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>a2I7mdEL028</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST SM - H CC</td>
        <td>Subsequent DST SM - H CC</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Isoniazid - critical concentration (H CC), Subsequent DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>A2iF5Ix8pAf</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Reasons for Sample Rejection or Loss</td>
        <td>Reasons for Sample Rejection or Loss</td>
        <td></td>
        <td>Reasons for Sample Rejection or Loss</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>A58cijzgyCn</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - FQ</td>
        <td>FQ - TGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for FQ by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>A8MwWW7rczm</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST LM - Z</td>
        <td>Subsequent DST LM - Z</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Pyrazinamide (Z), Subsequent DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>agZKnJWKdQK</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST LM - Mfx CC</td>
        <td>Lab Subsequent DST LM - Mfx CC</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Moxifloxacin - critical concentration (Mfx CC), Subsequent DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>ASr2gFadIie</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Eto</td>
        <td>Eto - TGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Ethionamide by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>B4PXKvPqTBY</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Solid Media)</td>
        <td>Date of Subsequent DST Inoculation (SM)</td>
        <td></td>
        <td>Date of Subsequent DST Inoculation (Solid Media)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>BMeVWBNe0Id</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST in Solid Media (e.g. LJ)</td>
        <td>Subsequent DST in solid media (e.g. LJ)</td>
        <td></td>
        <td>Subsequent DST in Solid Media (e.g. LJ)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>BNkkWpCKgLR</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Previous TB Registration Number</td>
        <td>Previous TB Registration Number</td>
        <td></td>
        <td>Previous TB Registration Number</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>bOFQuGHR4aW</td>
      </tr>
      <tr>
        <td>TB DRS SRL - Reasons for not Shipping Samples to SRL</td>
        <td>Reasons - no results to SRL</td>
        <td></td>
        <td>Why have Samples not been shipped to SRL</td>
        <td>default</td>
        <td>2020-09-07</td>
        <td>bOuViG0JtyT</td>
      </tr>
      <tr>
        <td>TB Lab: Date of Final Initial DST Results (Solid Media)</td>
        <td>Date of initial DST results (SM)</td>
        <td></td>
        <td>Date of final Initial Phenotypic DST Results (Solid Media)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>bXaGYMAnfNH</td>
      </tr>
      <tr>
        <td>TB DRS CIF: HIV Test Date</td>
        <td>HIV test date</td>
        <td></td>
        <td>HIV test date</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>C03Ya1vvaam</td>
      </tr>
      <tr>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Am/Cm</td>
        <td>LPA FQ/2LI - Am,Cm</td>
        <td></td>
        <td>Final LPA (FQ/2LI) Result for Amikacin/Capreomycin</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>C2owWE9gaoe</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Xpert MTB/RIF Initial Screening Result</td>
        <td>Xpert MTB/RIF Initial Screening Result</td>
        <td></td>
        <td>Xpert MTB/RIF Initial Screening Result</td>
        <td>default</td>
        <td>2020-08-18</td>
        <td>c6w0Nuei0yG</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - H</td>
        <td>H - TGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for H by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>C7sLVfSD0vV</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Solid Media)</td>
        <td>Date of Initial DST Inoculation (SM)</td>
        <td></td>
        <td>Date of Initial Phenotypic DST Inoculation (Solid Media)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>ck7gWJKYi8n</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Sample Rejected or Lost</td>
        <td>Sample Rejected or Lost</td>
        <td></td>
        <td>Sample Rejected or Lost</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>CtMCpcRTKkI</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Specimen 2 Microscopy Test Result</td>
        <td>Specimen 2 Microscopy Result</td>
        <td></td>
        <td>Specimen 2 Microscopy Test Result. If initial screening is based on microscopy examination of > 2 specimens then add only the 2 specimens with the highest bacterail load.</td>
        <td>default</td>
        <td>2020-09-07</td>
        <td>cx2xcrp1e18</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Test</td>
        <td>Xpert MTB/RIF Test</td>
        <td></td>
        <td>Date of Xpert MTB/RIF Test</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>cxi3Lj20Zrg</td>
      </tr>
      <tr>
        <td>TB Lab: Date of LPA (RIF/INH)</td>
        <td>Date of LPA RIF/INH</td>
        <td></td>
        <td>Date of LPA (RIF/INH)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>D4z4o6JR9M0</td>
      </tr>
      <tr>
        <td>TB Lab: Sputum Smear Microscopy</td>
        <td>Sputum Smear Microscopy</td>
        <td></td>
        <td>Sputum Smear Microscopy</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>Dd95Kl4aXZf</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pa</td>
        <td>Pa - WGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Pretomanid by WGS</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>diVqel7EsfP</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST LM - Am</td>
        <td>Initial DST LM - Am</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Amikacin (Am), Initial DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>DjVjz7PNXJA</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Z</td>
        <td>Z - WGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Pyrazinamide by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>dNgpCxvkfBa</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Am</td>
        <td>TGS - Am </td>
        <td></td>
        <td>Genotypic resistance profiling for Amikacin by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-09-07</td>
        <td>Drmi6zCWAeX</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Additional Comments and Remarks</td>
        <td>SRL - additional comments and remarks</td>
        <td></td>
        <td>Additional comments and remarks</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>DSvVcgTucZL</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST SM - Lzd </td>
        <td>Subsequent DST SM - Lzd </td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Linezolid (Lzd), Subsequent DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>DVEEyF5cpjB</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST SM - E</td>
        <td>Subsequent DST SM - E</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Ethambutol (E), Subsequent DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>dwi6P6D2iFg</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST SM - H CC</td>
        <td>Initial DST SM - H CC</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Isoniazid - critical concentration (H CC), Initial DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>dyqHwVB1oij</td>
      </tr>
      <tr>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Fluoroquinolones</td>
        <td>LPA FQ/2LI - FQ</td>
        <td></td>
        <td>Final LPA (FQ/2LI) Result for Fluoroquinolones</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>E61DoZgoPH2</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Bdq</td>
        <td>Bdq - WGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Bedaquiline by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>e7e7q0wadBs</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra Quantitative Result</td>
        <td>Xpert MTB/RIF Ultra quantitative result</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra Quantitative Result</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>e838DsdVAjN</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - R</td>
        <td>R - WGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Rifampicin by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>eAAkJdj12lF</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST LM - H CC</td>
        <td>Subsequent DST LM - H CC</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Isoniazid - critical concentration (H CC), Subsequent DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>Ei5mffgPCHN</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Sputum Smear Microscopy Result</td>
        <td>Sputum Smear Microscopy Result</td>
        <td></td>
        <td>Final Sputum Smear Microscopy Result</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>EJaXeYb8MT3</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - length of sickness - weeks</td>
        <td>Length of sickness</td>
        <td></td>
        <td>For how long has the patient been sick? (number of weeks; for periods less than a week, use decimal)</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>eKEKDJsda40</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST LM - R</td>
        <td>Initial DST LM - R</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Rifampicin (R), Initial DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>ema8JjkIDTz</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Names of Drugs</td>
        <td>Names of Drugs</td>
        <td></td>
        <td>Specify drug/drugs taken:</td>
        <td>default</td>
        <td>2020-06-26</td>
        <td>EsP0jPqdCsi</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST LM - Mfx CB</td>
        <td>Initial DST LM - Mfx CB</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Moxifloxacin CB (Mfx CB), Initial DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>F4fNZ8htdHP</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Bdq</td>
        <td>Bdq - TGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Bedaquiline by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>fhqQzSVeTR1</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Culture Inoculation (Solid Media)</td>
        <td>Date of Culture Inoculation (SM)</td>
        <td></td>
        <td>Date of Culture Inoculation (Solid Media)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>FIY3uk4J7fK</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST SM - R</td>
        <td>Lab Subsequent DST SM - R</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Rifampicin (R), Subsequent DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>FjsunwwqBMk</td>
      </tr>
      <tr>
        <td>TB Lab: Specimen Type used for LPA (FQ/2LI)</td>
        <td>Specimen type - LPA FQ/2LI</td>
        <td></td>
        <td>What specimen type was used for LPA?</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>FKxBceeFNuR</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Outcome</td>
        <td>Outcome</td>
        <td></td>
        <td>What was the outcome of previous treatment?</td>
        <td>default</td>
        <td>2020-08-04</td>
        <td>fkzW5PRBVuI</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Lzd</td>
        <td>Lzd - TGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Linezolid by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>fQifcktAjNe</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 2 Additive</td>
        <td>Sample 2 Additive</td>
        <td></td>
        <td>Sample 2 Additive</td>
        <td>default</td>
        <td>2020-06-26</td>
        <td>FSPdiABIisY</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
        <td>TGS - Interpretable profiling for MTBc</td>
        <td></td>
        <td>Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>FYe5AbkFGjL</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Z</td>
        <td>Z - TGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Pyrazinamide by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>G1zw1rVFH97</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS</td>
        <td>WGS</td>
        <td></td>
        <td>Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>GCEHyuCo1fA</td>
      </tr>
      <tr>
        <td>TB Lab: Final LPA (RIF/INH) Result - R</td>
        <td>LPA RIF/INH - R</td>
        <td></td>
        <td>Final LPA (RIF/INH) Result for Rifampicin</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>Gey1agRf0Kh</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Storage Only</td>
        <td>Storage Only</td>
        <td></td>
        <td>Storage Only</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>gf1mmDm59da</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Dlm</td>
        <td>Dlm - WGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Delamanid by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>GQX1kVD3PCY</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Am</td>
        <td>Am - WGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Amikacin by Whole Genome sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>gtApUJCf41j</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST SM - Dlm </td>
        <td>Subsequent DST SM - Dlm</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Delamanid (Dlm), Subsequent DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>GZ5Vqh8wdI1</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - H</td>
        <td>H - WGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for H by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>h0ESse3Yutp</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Outcome Other</td>
        <td>Outcome Other</td>
        <td></td>
        <td>What was the other outcome of previous treatment?</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>HCBfE6ryH0o</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST SM - Dlm</td>
        <td>Initial DST SM - Dlm</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Delamanid (Dlm), Initial DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>HCLjG26CmTS</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Regimen</td>
        <td>Treatment history: Regimen</td>
        <td></td>
        <td>What type of regimen was the previous treatment?</td>
        <td>default</td>
        <td>2020-07-23</td>
        <td>hHUDjT6cid3</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS Genotypic Speciation Results</td>
        <td>TGS Genotypic speciation results</td>
        <td></td>
        <td>TGS Genotypic Speciation Results</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>hidY602crX8</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Tuberculosis Drugs</td>
        <td>Tuberculosis Drugs</td>
        <td></td>
        <td>Has the patient ever taken tuberculosis drugs for more than one month?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>hkMHdJJMRkD</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST in Liquid Media (e.g. MGIT)</td>
        <td>Initial DST in liquid media (e.g. MGIT)</td>
        <td></td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>HkZ1hGWBqlZ</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST LM - Am</td>
        <td>Subsequent DST LM - Am</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Amikacin (Am), Subsequent DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>IBqX2HMQV4T</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST SM - Mfx CB</td>
        <td>Lab Subsequent DST SM - Mfx CB</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Moxifloxacin - clinical breakpoint (Mfx CB), Subsequent DST SM</td>
        <td>default</td>
        <td>2020-08-13</td>
        <td>iGcMnwWVhKh</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Injections for TB</td>
        <td>Injections for TB</td>
        <td></td>
        <td>Has the patient ever had injections for TB for more than one month?</td>
        <td>default</td>
        <td>2020-06-26</td>
        <td>IkDkBipcHuw</td>
      </tr>
      <tr>
        <td>TB DRS CS: Specify Other (Sample 3)</td>
        <td>Specify Other (Sample 3)</td>
        <td></td>
        <td>Specify other</td>
        <td>default</td>
        <td>2020-06-26</td>
        <td>IQ8pRiFktkT</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST SM - Z</td>
        <td>Lab Subsequent DST SM - Z</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Pyrazinamide (Z), Subsequent DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>J0DefR0gJZV</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST SM - Bdq </td>
        <td>Subsequent DST SM - Bdq </td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Bedaquiline (Bdq), Subsequent DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>jC2yaMqEOPb</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST SM - Bdq</td>
        <td>Initial DST SM - Bdq </td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Bedaquiline (Bdq), Initial DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>jD5CwNpVmb3</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Date of Xpert MTB/RIF Initial Screening Test</td>
        <td>Xpert MTB/RIF Initial Screening Date</td>
        <td></td>
        <td>Date of Xpert MTB/RIF Initial Screening Test</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>jIyPHXFmBZ3</td>
      </tr>
      <tr>
        <td>TB DRS CS: Specify Other (Sample 4)</td>
        <td>Specify Other (Sample 4)</td>
        <td></td>
        <td>Specify other</td>
        <td>default</td>
        <td>2020-06-26</td>
        <td>JkPoMJSKHxt</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 3 Collection Date</td>
        <td>Sample 3 Collection Date</td>
        <td></td>
        <td>Sample 3 Collection Date</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>JpAoAL6Dbmc</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST SM - Mfx CC</td>
        <td>Lab Initial DST SM - Mfx CC</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Moxifloxacin - critical concentration (Mfx CC), Initial DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>Jps4U0wxlyI</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST LM - H CB</td>
        <td>Subsequent DST LM - H CB</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Isoniazid - clinical breakpoint (H CB), Subsequent DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>KJ55m8WkSCO</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Additional Comments and Remarks</td>
        <td>LAB Additional Comments and Remarks</td>
        <td></td>
        <td>Additional comments and remarks</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>KkH3pmsTJ3M</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Bacteriological Confirmation - Sputum Smear Microscopy</td>
        <td>Confirmation - microscopy</td>
        <td></td>
        <td>Bacteriological confirmation of TB by Sputum smear microscopy</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>KMP0CCj6hEC</td>
      </tr>
      <tr>
        <td>TB DRS CS: Specify Other (Sample 1)</td>
        <td>Specify Other (Sample 1)</td>
        <td></td>
        <td>Specify other</td>
        <td>default</td>
        <td>2020-06-26</td>
        <td>kNR9wGWUqnX</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST LM - Lfx</td>
        <td>Initial DST LM - Lfx</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Levofloxacin (Lfx), Initial DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>KWijdprKE8o</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST SM - Mfx CB</td>
        <td>Initial DST SM - Mfx CB</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Moxifloxacin - clinical breakpoint (Mfx CB), Initial DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>LgnTOBA3Fuk</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST SM - Z</td>
        <td>Initial DST SM - Z</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Pyrazinamide (Z), Initial DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>LRfRdS1tsMK</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST SM - E</td>
        <td>Initial DST SM - E</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Ethambutol (E), Initial DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>m1qdvx91gZz</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Culture Inoculation (Liquid Media)</td>
        <td>Date of Culture Inoculation (LM)</td>
        <td></td>
        <td>Date of Culture Inoculation (Liquid Media)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>m7NKGHkiJps</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - CIF Officer Name</td>
        <td>CIF Officer Name </td>
        <td></td>
        <td>Print name of officer responsible for completing the clinical information form</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>m7q2YJoRG5o</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra</td>
        <td>default</td>
        <td>2020-08-13</td>
        <td>MAItgXvlO5L</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Xpert MTB/RIF Test Result</td>
        <td>Xpert MTB/RIF Result</td>
        <td></td>
        <td>Final Xpert MTB/RIF Test Result</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>mdhh8AXcNMe</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Speciation Results</td>
        <td>WGS - Genotypic speciation results</td>
        <td></td>
        <td>WGS - Genotypic Speciation Results</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>MoMwVSDvenr</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 1 Additive</td>
        <td>Sample 1 Additive</td>
        <td></td>
        <td>Sample 1 Additive</td>
        <td>default</td>
        <td>2020-06-26</td>
        <td>mq7gNiLqT24</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Date Samples Shipped to Supranational Laboratory (SRL)</td>
        <td>Date samples shipped to SRL</td>
        <td></td>
        <td>Date samples shipped to SRL</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>mriIhfYxKhd</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 1 Collection Date</td>
        <td>Sample 1 Collection Date</td>
        <td></td>
        <td>Sample 1 Collection Date</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>Mwl0M4rvqBl</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST SM - Cfz</td>
        <td>Initial DST SM - Cfz </td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Clofazimine (Cfz), Initial DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>Na38GSfYww7</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST SM - Am</td>
        <td>Subsequent DST SM - Am</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Amikacin (Am), Subsequent DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>nBVHqtynKKg</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Samples Shipped to SRL</td>
        <td>Samples to SRL</td>
        <td></td>
        <td>Samples shipped to SRL</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>ncuUAcK3obu</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST LM - E</td>
        <td>Initial DST LM - E</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Ethambutol (E), Initial DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>nG3H0zGCpXg</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Liquid Media)</td>
        <td>Date of Initial DST Inoculation (LM)</td>
        <td></td>
        <td>Date of InitialDST Inoculation (Liquid Media)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>ngshCLso7Qs</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST SM - Cfz </td>
        <td>Subsequent DST SM - Cfz </td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Clofazimine (Cfz), Subsequent DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>NIiZmSVFoFD</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 3 Additive</td>
        <td>Sample 3 Additive</td>
        <td></td>
        <td>Sample 3 Additive</td>
        <td>default</td>
        <td>2020-06-26</td>
        <td>nj5kuSbEnnm</td>
      </tr>
      <tr>
        <td>TB DRS CS: Date of Samples Arrival at NRL</td>
        <td>Date of Samples Arrival at NRL</td>
        <td></td>
        <td>Date of samples arrival at NRL</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>nLJ3f34rpYm</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Ultra Test</td>
        <td>Xpert MTB/RIF Ultra Test</td>
        <td></td>
        <td>Date of Xpert MTB/RIF Ultra Test</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>NRUmJNJfvDc</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST LM - H CB</td>
        <td>Initial DST LM - H CB</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Isoniazid - clinical breakpoint (H CB), Initial DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>nulxcFUqHFK</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Specimen 1 Microscopy Test Result</td>
        <td>Specimen 1 Microscopy Result</td>
        <td></td>
        <td>Specimen 1 Microscopy Test Result. If initial screening is based on microscopy examination of > 2 specimens then add only the 2 specimens with the highest bacterail load.</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>nYThQIcbo27</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Final Culture Result (Liquid Media)</td>
        <td>Date of Final Culture Result (LM)</td>
        <td></td>
        <td>Date of Final Culture Result (Liquid Media)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>OBibApuY05j</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Dlm</td>
        <td>Dlm - TGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Delamanid by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>oixCCbTWNYH</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST LM - Bdq </td>
        <td>Initial DST LM - Bdq </td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Bedaquiline (Bdq), Initial DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>oKdArKmQaar</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Other Symptoms of Lung Disease</td>
        <td>Other Symptoms of Lung Disease</td>
        <td></td>
        <td>Did the patient have other symptoms of lung disease prior to this episode (haemoptysis, chest pain, cough)?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>oSUHvzfAOD7</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST LM - E</td>
        <td>Subsequent DST LM - E</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Ethambutol (E), Subsequent DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>oVK7axGLOks</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST LM - H CC</td>
        <td>Initial DST LM - H CC</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Isoniazid - critical concentration (H CC), Initial DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>OXN8xMgpVvC</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST in Solid Media (e.g. LJ)</td>
        <td>Initial DST in solid media (e.g. LJ)</td>
        <td></td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>OZV3tzf7bux</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST LM - Cfz </td>
        <td>Subsequent DST LM - Cfz </td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Clofazimine (Cfz), Subsequent DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>P282EjwlnqS</td>
      </tr>
      <tr>
        <td>TB Lab: Specimen Type used for LPA (RIF/INH)</td>
        <td>Specimen type - LPA RIF/INH</td>
        <td></td>
        <td>What specimen type was used for LPA?</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>p3L4HYkzU4o</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Reasons for No Resistance Profiling Available</td>
        <td>TGS: Reasons for No Resistance Profiling Available</td>
        <td></td>
        <td>Reasons for No Resistance Profiling Available</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>P4qS3sJtCv3</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Culture Result (Solid Media)</td>
        <td>Culture Result (SM)</td>
        <td></td>
        <td>Final Culture Result (Solid Media)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>Pdo9LB4lZ6H</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST SM - Am</td>
        <td>Initial DST SM - Am</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Amikacin (Am), Initial DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>peAahjwkqNX</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Bacteriological Confirmation - Xpert MTB/RIF</td>
        <td>Confirmation: Xpert MTB/RIF</td>
        <td></td>
        <td>Bacteriological confirmation of TB by Xpert MTB/RIF</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>peo25u2dcLt</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History</td>
        <td>DRS: Treatment History</td>
        <td></td>
        <td>Has the patient been previously treated for TB?</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>PjNDfgjWbFC</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Xpert MTB/RIF Quantitative Result</td>
        <td>Xpert MTB/RIF quantitative result</td>
        <td></td>
        <td>Xpert MTB/RIF Quantitative Result</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>pO5nfo8ea4z</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST LM - Lzd </td>
        <td>Subsequent DST LM - Lzd </td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Linezolid (Lzd), Subsequent DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>Ps4JPDTACGB</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST SM - Lfx</td>
        <td>Initial DST SM - Lfx</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Levofloxacin (Lfx), Initial DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>pTRWioGFFod</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST LM - Z</td>
        <td>Initial DST LM - Z</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Pyrazinamide (Z), Initial DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>Pvok4dVDC9n</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST LM - R</td>
        <td>Subsequent DST LM - R</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Rifampicin (R), Subsequent DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>pXViXBpKM6Y</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Control Question</td>
        <td>Control Question</td>
        <td></td>
        <td>Did the patient remember previous treatment for TB after these questions?</td>
        <td>default</td>
        <td>2020-06-26</td>
        <td>Q3sqPGI5Z55</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Cfz</td>
        <td>Cfz - WGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Clofazimine by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>QFU2ie7seWU</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Liquid Media)</td>
        <td>Date of Subsequent DST Inoculation (LM)</td>
        <td></td>
        <td>Date of Subsequent DST Inoculation (Liquid Media)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>qJH0R9qtDoA</td>
      </tr>
      <tr>
        <td>TB Lab: Culture in Solid Media (e.g. LJ)</td>
        <td>Culture in Solid Media (e.g. LJ)</td>
        <td></td>
        <td>Culture in solid media (e.g. LJ)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>QQEolquguCi</td>
      </tr>
      <tr>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Km</td>
        <td>LPA FQ/2LI - Km</td>
        <td></td>
        <td>Final LPA (FQ/2LI) Result for Kanamycin</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>qt2LpZN8Hb3</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST SM - H CB</td>
        <td>Subsequent DST SM - H CB</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Isoniazid - clinical breakpoint (H CB), Subsequent DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>R25K2kAAG4g</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST LM - Lzd </td>
        <td>Initial DST LM - Lzd </td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Linezolid (Lzd), Initial DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>R4Lknzhufeh</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST SM - R</td>
        <td>Initial DST SM - R</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Rifampicin (R), Initial DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>RAtv78ZXQec</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST LM - Dlm </td>
        <td>Subsequent DST LM - Dlm</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Delamanid (Dlm), Subsequent DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>rjMeZmOEivb</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Lzd</td>
        <td>Lzd - WGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Linezolid by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>RN3lGwZozL9</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Final Culture Result (Solid Media)</td>
        <td>Date of Final Culture Result (SM)</td>
        <td></td>
        <td>Date of Final Culture Result (Solid Media)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>rVKthrApqAq</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - E</td>
        <td>E - TGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Ethambutol by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>rVPpiiHMzTs</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Prior TB Registration</td>
        <td>Prior TB Registration</td>
        <td></td>
        <td>After extensive checking through the medical files and other documents available in the health centre, have you discovered that the patient has been registered for TB treatment before?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>rzts7X4mOUE</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Reasons for Failure</td>
        <td>WGS - reasons for failure</td>
        <td></td>
        <td>WGS - Reasons for Failure</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>SCWmNAXBBE7</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (FQ/2LI)</td>
        <td>LPA FQ/2LI</td>
        <td></td>
        <td>LPA (FQ/2LI)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>Sd91IsXISjp</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 4 Collection Date</td>
        <td>Sample 4 Collection Date</td>
        <td></td>
        <td>Sample 4 Collection Date</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>sdiW3OMXBHc</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Date of Targeted Gene Sequencing Results</td>
        <td>TGS - Date of Results</td>
        <td></td>
        <td>Date of Targeted Gene Sequencing Results</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>slD6pdIC4a6</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
        <td>WGS - Interpretable profiling for MTBc</td>
        <td></td>
        <td>Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
        <td>default</td>
        <td>2020-09-07</td>
        <td>SRB4upTdK46</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST LM - Mfx CB</td>
        <td>Subsequent DST LM - Mfx CB</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Moxifloxacin - clinical breakpoint (Mfx CB), Subsequent DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>TJLwFGwpGFU</td>
      </tr>
      <tr>
        <td>TB DRS CIF: HIV Test Result</td>
        <td>HIV Test Result</td>
        <td></td>
        <td>HIV Test Result</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>tlgvzxYlF2S</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - FQ</td>
        <td>FQ -WGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for FQ by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-08-18</td>
        <td>Tpwb8CJ8we0</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Cfz</td>
        <td>Cfz - TGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Clofazimine by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>tSe484MEuFG</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 2 DRS ID</td>
        <td>Sample 2 DRS ID</td>
        <td></td>
        <td>Sample 2 DRS ID</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>typK2Vw7WMj</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST in Liquid Media (e.g. MGIT)</td>
        <td>Subsequent DST in liquid media (e.g. MGIT)</td>
        <td></td>
        <td>Subsequent DST in Liquid Media (e.g. MGIT)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>uaewAATQgBJ</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 4 Additive</td>
        <td>Sample 4 Treatment</td>
        <td></td>
        <td>Sample 4 Additive</td>
        <td>default</td>
        <td>2020-06-26</td>
        <td>ucaLoGejB2M</td>
      </tr>
      <tr>
        <td>TB Lab: Date of Final Subsequent DST Results (Solid Media)</td>
        <td>Date of subsequent DST results (SM)</td>
        <td></td>
        <td>Date of Final Subsequent DST Results (Solid Media)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>uEV8flIOeYI</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Date of Samples Arrival at SRL</td>
        <td>Date of samples arrival at SRL</td>
        <td></td>
        <td>Date of samples arrival at SRL</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>uhrqXcvXURW</td>
      </tr>
      <tr>
        <td>TB Lab: Culture in Liquid Media (e.g. MGIT)</td>
        <td>Culture in Liquid Media (e.g. MGIT)</td>
        <td></td>
        <td>Culture in Liquid Media (e.g. MGIT)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>uI7p5xLE1C8</td>
      </tr>
      <tr>
        <td>TB Lab: Final LPA (RIF/INH) Result - H</td>
        <td>LPA RIF/INH - H</td>
        <td></td>
        <td>Final LPA (RIF/INH) Result for Isoniazid</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>UIzR3p4nlMI</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST LM - Lfx</td>
        <td>Subsequent DST LM - Lfx</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Levofloxacin (Lfx), Subsequent DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>un8hXdOPwzh</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pa</td>
        <td>Pa - TGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Pretomanid by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>uprsSY93zJA</td>
      </tr>
      <tr>
        <td>TB DRS CS: Date Samples Shipped to NRL</td>
        <td>Date Samples Shipped to NRL</td>
        <td></td>
        <td>Date samples shipped to Central Laboratory (NRL)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>vD3nvlSC6A6</td>
      </tr>
      <tr>
        <td>TB Lab: Date of LPA (FQ/2LI)</td>
        <td>Date of LPA FQ/2LI</td>
        <td></td>
        <td>Date of LPA (FQ/2LI)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>vezbpFOckNI</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF</td>
        <td></td>
        <td>Xpert MTB/RIF</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>VSuQ1rwL2nA</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Culture Result (Liquid Media)</td>
        <td>Culture Result (LM)</td>
        <td></td>
        <td>Final Culture Result (Liquid Media)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>vTvtuUqdhSg</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Eto</td>
        <td>WGS - Eto </td>
        <td></td>
        <td>Genotypic resistance profiling for Ethionamide by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-09-07</td>
        <td>VW74EEB0Ump</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 1 DRS ID</td>
        <td>Sample 1 DRS ID</td>
        <td></td>
        <td>Sample 1 DRS ID</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>vY0hDQBLuXA</td>
      </tr>
      <tr>
        <td>TB DRS SRL: Import .csv</td>
        <td>Import csv</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-02-04</td>
        <td>VYQY1CSTWHx</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Date of Results</td>
        <td>Date of WGS results</td>
        <td></td>
        <td>Date of WGS Results</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>w1r7ah3H7r7</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 3 DRS ID</td>
        <td>Sample 3 DRS ID</td>
        <td></td>
        <td>Sample 3 DRS ID</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>w2e9rGFLNIa</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - R</td>
        <td>R - TGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Rifampicin by Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>w3litCy0uoa</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Reasons for No Resistance Profiling Available</td>
        <td>WGS: Reasons for No Resistance Profiling Available</td>
        <td></td>
        <td>Reasons for No Resistance Profiling Available</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>w7z2AXGEc5o</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Final Xpert MTB/RIF Ultra Test Result</td>
        <td>Xpert MTB/RIF Ultra Result</td>
        <td></td>
        <td>Final Xpert MTB/RIF Ultra Test Result</td>
        <td>default</td>
        <td>2020-09-07</td>
        <td>w8t8k2IPqsB</td>
      </tr>
      <tr>
        <td>TB Lab: Date of Final Initial DST Results (Liquid Media)</td>
        <td>Date of initial DST results (LM)</td>
        <td></td>
        <td>Date of Final Initial Phenotypic DST Results (Liquid Media)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>Wg7Df5kgpaF</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST SM - H CB</td>
        <td>Initial DST SM - H CB</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Isoniazid - clinical breakpoint (H CB), Initial DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>wgEYFWwfv7z</td>
      </tr>
      <tr>
        <td>TB Lab: Date of Final Subsequent DST Results (Liquid Media)</td>
        <td>Date of subsequent DST results (LM)</td>
        <td></td>
        <td>Date of Final Subsequent DST Results (Liquid Media)</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>wi4NRarMSuv</td>
      </tr>
      <tr>
        <td>TB Lab: Final LPA (FQ/2LI) Result - E</td>
        <td>LPA FQ/2LI - E</td>
        <td></td>
        <td>Final LPA (FQ/2LI) Result for Ethambutol</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>WLaOsGs9ujA</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Treatment Over 1 Month</td>
        <td>Treatment over 1 month</td>
        <td></td>
        <td>Has patient been previously treated for TB for more than a month?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>WlAQcyJ0xW6</td>
      </tr>
      <tr>
        <td>TB DRS LAB: TGS - Reasons for Failure</td>
        <td>TGS - reasons for failure</td>
        <td></td>
        <td>Targeted Gene Sequencing: Reasons for Failure</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>wQqfoI8qTMX</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST LM - Dlm </td>
        <td>Initial DST LM - Dlm</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Delamanid (Dlm), Initial DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>wzPWimo6vO3</td>
      </tr>
      <tr>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - E</td>
        <td>E - WGS Genotypic resistance profiling</td>
        <td></td>
        <td>Genotypic resistance profiling for Ethambutol by Whole Genome Sequencing</td>
        <td>default</td>
        <td>2020-08-20</td>
        <td>Xmu74LffbOV</td>
      </tr>
      <tr>
        <td>TB DRS SRL: DRS ID</td>
        <td>Patient DRS ID</td>
        <td></td>
        <td>Patient DRS ID</td>
        <td>default</td>
        <td>2020-06-26</td>
        <td>xOhEOb1qLwJ</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST SM - Lzd</td>
        <td>Initial DST SM - Lzd </td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Linezolid (Lzd), Initial DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>xP5C3zmYXde</td>
      </tr>
      <tr>
        <td>TB Lab: Date of Sputum Smear Microscopy Result</td>
        <td>Date of microscopy result</td>
        <td></td>
        <td>Date of Sputum Smear Microscopy Result</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>xyczZvsuaWr</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST SM - Mfx CC</td>
        <td>Lab Subsequent DST SM - Mfx CC</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Moxifloxacin - critical concentration (Mfx CC), Subsequent DST SM</td>
        <td>default</td>
        <td>2020-08-13</td>
        <td>xZfTs7RfeIU</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST SM - Lfx</td>
        <td>Subsequent DST SM - Lfx</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Levofloxacin (Lfx), Subsequent DST SM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>Y1VpjCBrpEc</td>
      </tr>
      <tr>
        <td>TB DRS CS: Additional Comments and Remarks</td>
        <td>Additional Comments and Remarks</td>
        <td></td>
        <td>Additional comments and remarks</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>Y66pOFOYt6T</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST LM - Mfx CC</td>
        <td>Lab Initial DST LM - Mfx CC</td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Moxifloxacin CC (Mfx CC), Initial DST LM</td>
        <td>default</td>
        <td>2020-08-13</td>
        <td>yiGr4JTFLv3</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Prior Symptoms</td>
        <td>TB Prior symptoms</td>
        <td></td>
        <td>Did the patient have the same symptoms prior to this episode?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>yn0LMROuQwZ</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 4 DRS ID</td>
        <td>Sample 4 DRS ID</td>
        <td></td>
        <td>Sample 4 DRS ID</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>YNDJVRtDxbi</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (FQ/2LI) - MTB</td>
        <td>LPA FQ/2LI - MTB</td>
        <td></td>
        <td>LPA (FQ/2LI) - MTB</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>z0j1fZQHoSB</td>
      </tr>
      <tr>
        <td>TB DRS CS: Specify Other (Sample 2)</td>
        <td>Specify Other (Sample 2)</td>
        <td></td>
        <td>Specify other</td>
        <td>default</td>
        <td>2020-06-26</td>
        <td>z6hnMc1kBNO</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST LM - Bdq </td>
        <td>Subsequent DST LM - Bdq </td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Bedaquiline (Bdq), Subsequent DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>zcmsN575vwZ</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (RIF/INH) - MTB</td>
        <td>LPA RIF/INH - MTB</td>
        <td></td>
        <td>LPA (RIF/INH) - MTB</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>Zd7703kfnOC</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Targeted Gene Sequencing</td>
        <td>Targeted Gene Sequencing</td>
        <td></td>
        <td>Targeted Gene Sequencing</td>
        <td>default</td>
        <td>2020-06-26</td>
        <td>zfF3GMpuYAP</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST LM - Cfz </td>
        <td>Initial DST LM - Cfz </td>
        <td></td>
        <td>Drug susceptibility testing (Lab) for Clofazimine (Cfz), Initial DST LM</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>ZSL9PI7Kbsa</td>
      </tr>
      <tr>
        <td>TB DRS CS: Sample 2 Collection Date</td>
        <td>Sample 2 Collection Date</td>
        <td></td>
        <td>Sample 2 Collection Date</td>
        <td>default</td>
        <td>2020-09-24</td>
        <td>zVDnm2Bur06</td>
      </tr>
      <tr>
        <td>TB DRS CIF: Treatment History - Sputum Examinations</td>
        <td>Sputum Examinations</td>
        <td></td>
        <td>Did the patient have sputum examinations prior to this episode?</td>
        <td>default</td>
        <td>2020-03-18</td>
        <td>ZyxsK4KWkLQ</td>
      </tr>
    </table>
    <h2>Data Element Groups</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS</td>
        <td>2020-09-04</td>
        <td>SfwwoCbB1m3</td>
      </tr>
    </table>
    <h3>Data Element Groups - Data Elements</h3>
    <table>
      <tr>
        <th>Data Element Group</th>
        <th>Data Element</th>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST SM - H CC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Reasons for Sample Rejection or Loss</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - FQ</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST LM - Z</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST LM - Mfx CC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Eto</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Previous TB Registration Number</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL - Reasons for not Shipping Samples to SRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of Final Initial DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: HIV Test Date</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Am/Cm</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Xpert MTB/RIF Initial Screening Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - H</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Sample Rejected or Lost</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Specimen 2 Microscopy Test Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Test</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Pa</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST LM - Am</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Z</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Am</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST SM - Lzd </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST SM - E</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST SM - H CC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Fluoroquinolones</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Bdq</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Xpert MTB/RIF Ultra Quantitative Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - R</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST LM - H CC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - length of sickness - weeks</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST LM - R</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Names of Drugs</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST LM - Mfx CB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Bdq</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Solid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST SM - R</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Specimen Type used for LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Outcome</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Lzd</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 2 Additive</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Z</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Final LPA (RIF/INH) Result - R</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Storage Only</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Dlm</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Am</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST SM - Dlm </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - H</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Outcome Other</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST SM - Dlm</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Regimen</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Tuberculosis Drugs</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST LM - Am</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST SM - Mfx CB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Injections for TB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Specify Other (Sample 3)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST SM - Z</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST SM - Bdq </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST SM - Bdq</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Date of Xpert MTB/RIF Initial Screening Test</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Specify Other (Sample 4)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 3 Collection Date</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST SM - Mfx CC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST LM - H CB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Bacteriological Confirmation - Sputum Smear Microscopy</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Specify Other (Sample 1)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST LM - Lfx</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST SM - Mfx CB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST SM - Z</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST SM - E</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Culture Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - CIF Officer Name</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Test Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Speciation Results</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 1 Additive</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Date Samples Shipped to Supranational Laboratory (SRL)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 1 Collection Date</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST SM - Cfz</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST SM - Am</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Samples Shipped to SRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST LM - E</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Initial DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST SM - Cfz </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 3 Additive</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Date of Samples Arrival at NRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Xpert MTB/RIF Ultra Test</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST LM - H CB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Specimen 1 Microscopy Test Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Dlm</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST LM - Bdq </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Other Symptoms of Lung Disease</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST LM - E</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST LM - H CC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST LM - Cfz </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Specimen Type used for LPA (RIF/INH)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST SM - Am</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Bacteriological Confirmation - Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Xpert MTB/RIF Quantitative Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST LM - Lzd </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST SM - Lfx</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST LM - Z</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST LM - R</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Control Question</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Cfz</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Subsequent DST Inoculation (Liquid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Culture in Solid Media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - Km</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST SM - H CB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST LM - Lzd </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST SM - R</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST LM - Dlm </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Lzd</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Final Culture Result (Solid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - E</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Prior TB Registration</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 4 Collection Date</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Date of Targeted Gene Sequencing Results</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Is Interpretable Genetic Resistance Profiling for MTBc Available?</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST LM - Mfx CB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: HIV Test Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - FQ</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Cfz</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 2 DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 4 Additive</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of Final Subsequent DST Results (Solid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Date of Samples Arrival at SRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Culture in Liquid Media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Final LPA (RIF/INH) Result - H</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST LM - Lfx</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - Pa</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Date Samples Shipped to NRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of LPA (FQ/2LI)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Culture Result (Liquid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - Eto</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 1 DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: Import .csv</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Date of Results</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 3 DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Genotypic Resistance Profiling - R</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Reasons for No Resistance Profiling Available</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Final Xpert MTB/RIF Ultra Test Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of Final Initial DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST SM - H CB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of Final Subsequent DST Results (Liquid Media)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Final LPA (FQ/2LI) Result - E</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Treatment Over 1 Month</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: TGS - Reasons for Failure</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST LM - Dlm </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: WGS - Genotypic Resistance Profiling - E</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS SRL: DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST SM - Lzd</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Date of Sputum Smear Microscopy Result</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST SM - Mfx CC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST SM - Lfx</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Additional Comments and Remarks</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST LM - Mfx CC</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Prior Symptoms</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 4 DRS ID</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: LPA (FQ/2LI) - MTB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Specify Other (Sample 2)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Subsequent DST LM - Bdq </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: LPA (RIF/INH) - MTB</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS LAB: Targeted Gene Sequencing</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB Lab: Initial DST LM - Cfz </td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CS: Sample 2 Collection Date</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>TB DRS CIF: Treatment History - Sputum Examinations</td>
      </tr>
    </table>
    <h2 id="categoryCombos">Category Combinations</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
        <th>Categories</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2020-09-24</td>
        <td>bjDvmb4bfuf</td>
        <td>default</td>
      </tr>
    </table>
    <h2 id="categories">Data Element Categories</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
        <th>Category options</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2020-10-01</td>
        <td>GLevLNI9wkl</td>
        <td>default</td>
      </tr>
    </table>
    <h2 id="categoryOptions">Data Element Category Options</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2020-09-24</td>
        <td>xYerKDKCefk</td>
      </tr>
    </table>
    <h2 id="categoryOptionCombos">Category Option Combination</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2020-09-24</td>
        <td>HllvX50cXC0</td>
      </tr>
    </table>
    <h2 id="optionSets">Option Sets</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
        <th>Options</th>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>2020-03-18</td>
        <td>acANJTHfW9R</td>
        <td>Susceptible; Resistant; No Interpretable Result (i.e. insufficient quality); Indeterminate (i.e. mutation unknown / not graded)</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>2020-08-04</td>
        <td>bLA3AqDKdwx</td>
        <td>Yes; No; Unknown</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>2020-07-23</td>
        <td>cNBWQaZZQ8g</td>
        <td>Cured or treatment completed; Failed regimen as a new patient; Failed regimen as a previously treated patient; Lost to follow-up; Other; Unknown</td>
      </tr>
      <tr>
        <td>Positive/Negative/Unknown</td>
        <td>2020-03-18</td>
        <td>EAesHOyydJi</td>
        <td>Positive; Negative; Unknown</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>2020-08-13</td>
        <td>ekhfzhURD44</td>
        <td>Susceptible; Resistant; Contaminated; Indeterminate</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>2020-08-13</td>
        <td>eUBlAbh0g2h</td>
        <td>Detected; Not detected; Error/Invalid/No result</td>
      </tr>
      <tr>
        <td>TB DRS - Treatment Regimen</td>
        <td>2020-07-24</td>
        <td>hAdCLiy6j0y</td>
        <td>Drug-susceptible regimen; Drug-resistant regimen</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>2020-09-02</td>
        <td>hiQ3QFheQ3O</td>
        <td>Male; Female</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Genotypic Speciation Results</td>
        <td>2020-03-18</td>
        <td>KFLJiv8X5Uf</td>
        <td>MTBc; Mixed MTBc and Other; NTM; Contamination; Failed</td>
      </tr>
      <tr>
        <td>TB DRS LPA Specimen</td>
        <td>2020-08-04</td>
        <td>oKESbY0JpLt</td>
        <td>Sputum samples or sediments; MTB culture isolates</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>2020-08-18</td>
        <td>otxN1DQ61fV</td>
        <td>MTB detected (Rifampicin susceptible); MTB detected (Rifampicin resistant); MTB detected (Rifampicin indeterminate); MTB not detected; No result; Error; Invalid; Not done</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>2020-05-15</td>
        <td>pDOu7HaMvKJ</td>
        <td>None; CPC; Ethanol; PrimeStore; Other</td>
      </tr>
      <tr>
        <td>Susceptible/Resistant/Indeterminate</td>
        <td>2020-08-13</td>
        <td>q75AsvLUWVp</td>
        <td>Susceptible; Resistant; Indeterminate</td>
      </tr>
      <tr>
        <td>Yes/No/Not Applicable</td>
        <td>2020-06-26</td>
        <td>qIXXdwltkqk</td>
        <td>Yes; No; Not Applicable</td>
      </tr>
      <tr>
        <td>Yes/No</td>
        <td>2020-06-26</td>
        <td>qtswn9lMSXN</td>
        <td>Yes; No</td>
      </tr>
      <tr>
        <td>TB DRS Sputum Smear Microscopy Result</td>
        <td>2020-08-18</td>
        <td>qu5LpxbpHUa</td>
        <td>Negative; Scanty; +; ++; +++; Not done</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>2020-08-13</td>
        <td>rB88xT5ggFg</td>
        <td>MTB; NTM; No growth; Contaminated</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Quantitative Result</td>
        <td>2020-03-18</td>
        <td>Vh9kmO4yiKE</td>
        <td>Very Low; Low; Average; High; Unknown</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>2020-06-26</td>
        <td>ynHtyLDVeJO</td>
        <td>Afghanistan; Aland Islands; Albania; Algeria; American Samoa; Andorra; Angola; Anguilla; Antarctica; Antigua and Barbuda; Argentina; Armenia; Aruba; Australia; Austria; Azerbaijan; Bahamas; Bahrain; Bangladesh; Barbados; another 229 options not shown.</td>
      </tr>
    </table>
    <h2 id="options">Options</h2>
    <table>
      <tr>
        <th>Option Set Name</th>
        <th>Name</th>
        <th>Code</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Romania</td>
        <td>RO</td>
        <td>2020-06-29</td>
        <td>a5ayhZAtUe4</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Genotypic Speciation Results</td>
        <td>NTM</td>
        <td>NTM</td>
        <td>2020-08-13</td>
        <td>AADFw8OdflX</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tuvalu</td>
        <td>TV</td>
        <td>2020-06-29</td>
        <td>aGozKfvhGv6</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>Detected</td>
        <td>DETECTED</td>
        <td>2020-08-04</td>
        <td>aIKhwpm3xjg</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Brunei Darussalam</td>
        <td>BN</td>
        <td>2020-06-26</td>
        <td>AlKNJVD0Bqv</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Algeria</td>
        <td>DZ</td>
        <td>2020-06-29</td>
        <td>ALoq1vKJCDr</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Honduras</td>
        <td>HN</td>
        <td>2020-06-26</td>
        <td>ALX1BnV0GrW</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sao Tome and Principe</td>
        <td>ST</td>
        <td>2020-06-29</td>
        <td>AMFu6DFAqll</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guadeloupe</td>
        <td>GP</td>
        <td>2020-06-29</td>
        <td>AneyNa28ceQ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>India</td>
        <td>IN</td>
        <td>2020-06-26</td>
        <td>AObPqV4cHPb</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Estonia</td>
        <td>EE</td>
        <td>2020-06-29</td>
        <td>aOX23O03bBw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Malawi</td>
        <td>MW</td>
        <td>2020-06-26</td>
        <td>ApCSe2JdIUw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Andorra</td>
        <td>AD</td>
        <td>2020-06-29</td>
        <td>aslBaQPVe9V</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>Female</td>
        <td>FEMALE</td>
        <td>2020-08-04</td>
        <td>AZK4rjJCss5</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sweden</td>
        <td>SE</td>
        <td>2020-06-29</td>
        <td>ban72xOWClE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Central African Republic</td>
        <td>CF</td>
        <td>2020-06-29</td>
        <td>bANs6w1wFgV</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Iran (Islamic Republic of)</td>
        <td>IR</td>
        <td>2020-06-29</td>
        <td>bEj6P1jqHje</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kiribati</td>
        <td>KI</td>
        <td>2020-06-29</td>
        <td>BFMEIXmaqFE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>South Sudan</td>
        <td>SS</td>
        <td>2020-06-29</td>
        <td>bhfjgX8aEJQ</td>
      </tr>
      <tr>
        <td>Susceptible/Resistant/Indeterminate</td>
        <td>Indeterminate</td>
        <td>INDETERMINATE</td>
        <td>2020-08-04</td>
        <td>bOnWRnVw30P</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Marshall Islands</td>
        <td>MH</td>
        <td>2020-06-29</td>
        <td>BpqJwhPqI9O</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Chile</td>
        <td>CL</td>
        <td>2020-06-29</td>
        <td>bQX37dUQTAr</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>Other</td>
        <td>OTHER</td>
        <td>2020-06-29</td>
        <td>bxKZffLCvEp</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>Ethanol</td>
        <td>ETHANOL</td>
        <td>2020-03-18</td>
        <td>BZCqdbW974l</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Malta</td>
        <td>MT</td>
        <td>2020-06-26</td>
        <td>C2Ws5NctBqi</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Venezuela (Bolivarian Republic of)</td>
        <td>VE</td>
        <td>2020-06-29</td>
        <td>C3Mf3a5OJa3</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Curacao</td>
        <td>CW</td>
        <td>2020-06-29</td>
        <td>C5DXQidiMMc</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bahrain</td>
        <td>BH</td>
        <td>2020-06-29</td>
        <td>cc1JEMv0suu</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cyprus</td>
        <td>CY</td>
        <td>2020-06-29</td>
        <td>ccs1kikyZS3</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Helena, Ascension and Tristan da Cunha</td>
        <td>SH</td>
        <td>2020-06-29</td>
        <td>CCzBKhjSPFo</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>El Salvador</td>
        <td>SV</td>
        <td>2020-06-29</td>
        <td>CDBeT1lT7n2</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>Indeterminate (i.e. mutation unknown / not graded)</td>
        <td>INDETERMINATE</td>
        <td>2020-03-18</td>
        <td>cdwZvx6AcLV</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Dominican Republic</td>
        <td>DO</td>
        <td>2020-06-29</td>
        <td>CedH1TzSPgO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bulgaria</td>
        <td>BG</td>
        <td>2020-06-29</td>
        <td>cGLoDkT864j</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Burundi</td>
        <td>BI</td>
        <td>2020-06-29</td>
        <td>CIYwznedTto</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Latvia</td>
        <td>LV</td>
        <td>2020-06-29</td>
        <td>CkE4sCvC7zj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Viet Nam</td>
        <td>VN</td>
        <td>2020-06-29</td>
        <td>CndbUcexjyJ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Aland Islands</td>
        <td>AX</td>
        <td>2020-06-29</td>
        <td>CNnT7FC710W</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>China</td>
        <td>CN</td>
        <td>2020-06-29</td>
        <td>CQR9IijKrgo</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>Indeterminate</td>
        <td>INDETERMINATE</td>
        <td>2020-08-04</td>
        <td>cqyKiKWzg1m</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>Yes</td>
        <td>YES</td>
        <td>2020-08-04</td>
        <td>CvivP1rh4ii</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Falkland Islands (Malvinas)</td>
        <td>FK</td>
        <td>2020-06-29</td>
        <td>CWhuePZuC9y</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Genotypic Speciation Results</td>
        <td>MTBc</td>
        <td>MTBC</td>
        <td>2020-03-18</td>
        <td>cXeTwncrs81</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Germany</td>
        <td>DE</td>
        <td>2020-06-29</td>
        <td>CxKFBwhGuJr</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Macedonia (the former Yugoslav Republic of)</td>
        <td>MK</td>
        <td>2020-06-29</td>
        <td>cxvpqSjkTjP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Congo</td>
        <td>CG</td>
        <td>2020-06-29</td>
        <td>Cy4TaW1hskg</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>San Marino</td>
        <td>SM</td>
        <td>2020-06-29</td>
        <td>CysWbM6JFgj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Armenia</td>
        <td>AM</td>
        <td>2020-06-29</td>
        <td>CzdkfAxkAqe</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Uruguay</td>
        <td>UY</td>
        <td>2020-06-29</td>
        <td>CzJoxdewhsm</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Reunion</td>
        <td>RE</td>
        <td>2020-06-29</td>
        <td>D9h2axpYFx9</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cuba</td>
        <td>CU</td>
        <td>2020-06-29</td>
        <td>DEO4vDvhNEv</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Greenland</td>
        <td>GL</td>
        <td>2020-06-29</td>
        <td>dMRNgoCtogj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Belarus</td>
        <td>BY</td>
        <td>2020-06-29</td>
        <td>dUEKKaPFcVU</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Colombia</td>
        <td>CO</td>
        <td>2020-06-29</td>
        <td>e4CswJZAFBR</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Namibia</td>
        <td>NA</td>
        <td>2020-06-29</td>
        <td>e4HCJJlYOQP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ukraine</td>
        <td>UA</td>
        <td>2020-06-29</td>
        <td>E68TvHpnyp5</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Moldova (Republic of)</td>
        <td>MD</td>
        <td>2020-06-29</td>
        <td>EABP62Ce29b</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Isle of Man</td>
        <td>IM</td>
        <td>2020-06-29</td>
        <td>ecANXpkkcPT</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>PrimeStore</td>
        <td>PRIMESTORE</td>
        <td>2020-03-18</td>
        <td>eefJopL3w3t</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>Contaminated</td>
        <td>CONTAMINATED</td>
        <td>2020-08-04</td>
        <td>eeiCaPcf3ZX</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Hungary</td>
        <td>HU</td>
        <td>2020-06-29</td>
        <td>eGQJGkiLamm</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Pakistan</td>
        <td>PK</td>
        <td>2020-06-29</td>
        <td>eHKdzDVgEuj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Myanmar</td>
        <td>MM</td>
        <td>2020-06-29</td>
        <td>ElBqHdoLnsc</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guam</td>
        <td>GU</td>
        <td>2020-06-29</td>
        <td>ELm3SnuBHJZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sudan</td>
        <td>SD</td>
        <td>2020-06-29</td>
        <td>ELZXJ7i1DKL</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Gambia</td>
        <td>GM</td>
        <td>2020-06-29</td>
        <td>EQULu0IwQNE</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Quantitative Result</td>
        <td>Average</td>
        <td>AVERAGE</td>
        <td>2020-03-18</td>
        <td>Er3cOin8vnZ</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Failed regimen as a new patient</td>
        <td>FAILED_REGIMEN_NEW</td>
        <td>2020-07-23</td>
        <td>eRxCMA3E65a</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Jamaica</td>
        <td>JM</td>
        <td>2020-06-29</td>
        <td>etZCdyFxz4w</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Genotypic Speciation Results</td>
        <td>Contamination</td>
        <td>CONTAMINATION</td>
        <td>2020-03-18</td>
        <td>EzNcSEhsU1n</td>
      </tr>
      <tr>
        <td>TB DRS Sputum Smear Microscopy Result</td>
        <td>+++</td>
        <td>+++</td>
        <td>2020-03-18</td>
        <td>f0QayRDQJAw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Benin</td>
        <td>BJ</td>
        <td>2020-06-29</td>
        <td>fEV7BkjJi8V</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>New Caledonia</td>
        <td>NC</td>
        <td>2020-06-29</td>
        <td>fg3tUp5fFH1</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Turkey</td>
        <td>TR</td>
        <td>2020-06-29</td>
        <td>fmGjlRnf0AW</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Holy See</td>
        <td>VA</td>
        <td>2020-06-29</td>
        <td>FmIGl5AnbxN</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>Not done</td>
        <td>NOT_DONE</td>
        <td>2020-08-20</td>
        <td>fP6dG3rRLIW</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Finland</td>
        <td>FI</td>
        <td>2020-06-29</td>
        <td>fQzvkEY9chs</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Azerbaijan</td>
        <td>AZ</td>
        <td>2020-06-29</td>
        <td>FXk1MDI7CEJ</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Other</td>
        <td>OTHER</td>
        <td>2020-08-04</td>
        <td>fysHYlw4KDx</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Korea (Republic of)</td>
        <td>KR</td>
        <td>2020-06-29</td>
        <td>G9rNnfnVNcB</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Botswana</td>
        <td>BW</td>
        <td>2020-06-29</td>
        <td>ga22tvzYHEZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Grenada</td>
        <td>GD</td>
        <td>2020-06-29</td>
        <td>gDARdk8cZ3H</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bahamas</td>
        <td>BS</td>
        <td>2020-06-29</td>
        <td>GGWWOucyQ5L</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Rwanda</td>
        <td>RW</td>
        <td>2020-06-29</td>
        <td>gSPpYw9P7YO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Japan</td>
        <td>JP</td>
        <td>2020-06-29</td>
        <td>H65niFKFuSs</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Swaziland</td>
        <td>SZ</td>
        <td>2020-06-29</td>
        <td>HafX2zWjutb</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Genotypic Speciation Results</td>
        <td>Failed</td>
        <td>FAILED</td>
        <td>2020-06-29</td>
        <td>HAHhOpw9qIc</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tanzania, United Republic of</td>
        <td>TZ</td>
        <td>2020-06-29</td>
        <td>hB9kKEo5Jav</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Western Sahara</td>
        <td>EH</td>
        <td>2020-06-29</td>
        <td>hbiFi85xO2g</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Gabon</td>
        <td>GA</td>
        <td>2020-06-29</td>
        <td>hF9y363enrH</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Pierre and Miquelon</td>
        <td>PM</td>
        <td>2020-06-29</td>
        <td>hIGURTVsclf</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Togo</td>
        <td>TG</td>
        <td>2020-06-29</td>
        <td>HOiHQKzyA2h</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mauritania</td>
        <td>MR</td>
        <td>2020-06-29</td>
        <td>HScqQPe1X9u</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Peru</td>
        <td>PE</td>
        <td>2020-06-29</td>
        <td>hUQDnRc6BKw</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>Error/Invalid/No result</td>
        <td>ERROR</td>
        <td>2020-08-13</td>
        <td>Hv5WIheOqCR</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Korea (Democratic People's Republic of)</td>
        <td>KP</td>
        <td>2020-06-29</td>
        <td>i0Dl3gB8WuY</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guinea-Bissau</td>
        <td>GW</td>
        <td>2020-06-29</td>
        <td>I8A7Q4zi1YI</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Georgia</td>
        <td>GE</td>
        <td>2020-06-29</td>
        <td>I9v1TBhT3OV</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Niue</td>
        <td>NU</td>
        <td>2020-06-29</td>
        <td>ibFgvQscr1i</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Suriname</td>
        <td>SR</td>
        <td>2020-06-29</td>
        <td>IfwaYvRaIhp</td>
      </tr>
      <tr>
        <td>TB DRS LPA Specimen</td>
        <td>Sputum samples or sediments</td>
        <td>SPUTUM_SAMPLES_OR_SEDIMENTS</td>
        <td>2020-08-04</td>
        <td>io6qvQDAP8r</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Jordan</td>
        <td>JO</td>
        <td>2020-06-29</td>
        <td>IqyWsh1pbYf</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>No growth</td>
        <td>NO_GROWTH</td>
        <td>2020-09-24</td>
        <td>iRIdWqmsuhn</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cote d'Ivoire</td>
        <td>CI</td>
        <td>2020-06-29</td>
        <td>iwk6djvOBNV</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>Contaminated</td>
        <td>CONTAMINATED</td>
        <td>2020-08-04</td>
        <td>Ix8MPUuGZXD</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Macao</td>
        <td>MO</td>
        <td>2020-06-29</td>
        <td>IyBPcxO7hfB</td>
      </tr>
      <tr>
        <td>Positive/Negative/Unknown</td>
        <td>Negative</td>
        <td>NEGATIVE</td>
        <td>2020-06-29</td>
        <td>IYKMiif5Uno</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Quantitative Result</td>
        <td>High</td>
        <td>HIGH</td>
        <td>2020-03-18</td>
        <td>j2cnORcpi4l</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>MTB detected (Rifampicin resistant)</td>
        <td>MTB_DETECTED_RIFAMPICIN_RESISTANT</td>
        <td>2020-08-18</td>
        <td>Jbx4393qLtO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Slovenia</td>
        <td>SI</td>
        <td>2020-06-29</td>
        <td>Jl2tnw6dutF</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Taiwan, Province of China</td>
        <td>TW</td>
        <td>2020-06-29</td>
        <td>jLIOTZIi0Ou</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Norfolk Island</td>
        <td>NF</td>
        <td>2020-06-29</td>
        <td>jmZqHjwAKxJ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Norway</td>
        <td>NO</td>
        <td>2020-06-29</td>
        <td>JpY27WXUqOI</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mayotte</td>
        <td>YT</td>
        <td>2020-06-29</td>
        <td>jQ3mYwytyZn</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cameroon</td>
        <td>CM</td>
        <td>2020-06-29</td>
        <td>JqPKssESKSC</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>British Indian Ocean Territory</td>
        <td>IO</td>
        <td>2020-06-29</td>
        <td>JUY113J4COL</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>United States Minor Outlying Islands</td>
        <td>UM</td>
        <td>2020-06-29</td>
        <td>JwhF38ZDa7Y</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kazakhstan</td>
        <td>KZ</td>
        <td>2020-06-29</td>
        <td>JWIEjkUmsWH</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>Susceptible</td>
        <td>SUSCEPTIBLE</td>
        <td>2020-06-29</td>
        <td>jwk0lGLsonq</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Jersey</td>
        <td>JE</td>
        <td>2020-06-29</td>
        <td>JwslMKjECF2</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Somalia</td>
        <td>SO</td>
        <td>2020-06-29</td>
        <td>JYfvnvIzM84</td>
      </tr>
      <tr>
        <td>TB DRS - Treatment Regimen</td>
        <td>Drug-susceptible regimen</td>
        <td>DRUG_SUSCEPTIBLE_REGIMEN</td>
        <td>2020-07-23</td>
        <td>K568S90VzOF</td>
      </tr>
      <tr>
        <td>TB DRS Sputum Smear Microscopy Result</td>
        <td>++</td>
        <td>++</td>
        <td>2020-03-18</td>
        <td>K9PoNq9YiJw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bouvet Island</td>
        <td>BV</td>
        <td>2020-06-29</td>
        <td>k9qiH4Z3K6m</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Madagascar</td>
        <td>MG</td>
        <td>2020-06-29</td>
        <td>kaf9448wuv0</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Slovakia</td>
        <td>SK</td>
        <td>2020-06-29</td>
        <td>kdX0FFam8Vz</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Northern Mariana Islands</td>
        <td>MP</td>
        <td>2020-06-29</td>
        <td>KGoEICL7PmU</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sint Maarten (Dutch part)</td>
        <td>SX</td>
        <td>2020-06-29</td>
        <td>Kjon60bpcC4</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Svalbard and Jan Mayen</td>
        <td>SJ</td>
        <td>2020-06-29</td>
        <td>kNow7wcQT6z</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Equatorial Guinea</td>
        <td>GQ</td>
        <td>2020-06-29</td>
        <td>KNU7Tm8S245</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Indonesia</td>
        <td>ID</td>
        <td>2020-06-29</td>
        <td>kPQes5oG21J</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Lost to follow-up</td>
        <td>LOST_TO_FOLLOW_UP</td>
        <td>2020-07-08</td>
        <td>KRDPhShyFOe</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Malaysia</td>
        <td>MY</td>
        <td>2020-06-29</td>
        <td>KtR12m8FoT0</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Vincent and the Grenadines</td>
        <td>VC</td>
        <td>2020-06-29</td>
        <td>L1FmwJC0u3z</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guernsey</td>
        <td>GG</td>
        <td>2020-06-29</td>
        <td>l69MO3y6LuS</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cambodia</td>
        <td>KH</td>
        <td>2020-06-29</td>
        <td>l8WR0m3GGuB</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>New Zealand</td>
        <td>NZ</td>
        <td>2020-06-29</td>
        <td>lBZHFe8qxEL</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Montenegro</td>
        <td>ME</td>
        <td>2020-06-29</td>
        <td>lCww3l79Wem</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Liberia</td>
        <td>LR</td>
        <td>2020-06-29</td>
        <td>LfjyJpiu8dL</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Thailand</td>
        <td>TH</td>
        <td>2020-06-29</td>
        <td>lGIM5L1ldVZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Yemen</td>
        <td>YE</td>
        <td>2020-06-29</td>
        <td>lJBsaRbZLZP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kyrgyzstan</td>
        <td>KG</td>
        <td>2020-06-29</td>
        <td>LjRX17TMcTX</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Anguilla</td>
        <td>AI</td>
        <td>2020-06-29</td>
        <td>LMzYJEbDEN6</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Singapore</td>
        <td>SG</td>
        <td>2020-06-29</td>
        <td>loTOnrxGmCv</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Aruba</td>
        <td>AW</td>
        <td>2020-06-29</td>
        <td>LoTxSO186BO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Comoros</td>
        <td>KM</td>
        <td>2020-06-29</td>
        <td>LRjLr9oMe1M</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Nepal</td>
        <td>NP</td>
        <td>2020-06-29</td>
        <td>LRsQdDERp1f</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Barthalemy</td>
        <td>BL</td>
        <td>2020-06-29</td>
        <td>lufRQXPgcJ8</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Syrian Arab Republic</td>
        <td>SY</td>
        <td>2020-06-29</td>
        <td>LuMJaVKadYM</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Panama</td>
        <td>PA</td>
        <td>2020-06-29</td>
        <td>Lyu0GDGZLU3</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Luxembourg</td>
        <td>LU</td>
        <td>2020-06-29</td>
        <td>M2XM0PR40oH</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Christmas Island</td>
        <td>CX</td>
        <td>2020-06-29</td>
        <td>m9vCfHK0sLC</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Morocco</td>
        <td>MA</td>
        <td>2020-06-29</td>
        <td>MBVq67Tm1wK</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kuwait</td>
        <td>KW</td>
        <td>2020-06-29</td>
        <td>mCnaSMEODSz</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Belize</td>
        <td>BZ</td>
        <td>2020-06-29</td>
        <td>MdSOAa4C4gW</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>Resistant</td>
        <td>RESISTANT</td>
        <td>2020-06-29</td>
        <td>MhctAiVMO5v</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ecuador</td>
        <td>EC</td>
        <td>2020-06-29</td>
        <td>mJexWvdoaXE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>French Southern Territories</td>
        <td>TF</td>
        <td>2020-06-29</td>
        <td>MKmqLvOYWos</td>
      </tr>
      <tr>
        <td>Positive/Negative/Unknown</td>
        <td>Positive</td>
        <td>POSITIVE</td>
        <td>2020-06-29</td>
        <td>Mn39beDtXNS</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Dominica</td>
        <td>DM</td>
        <td>2020-06-29</td>
        <td>MpwuGzXBpAk</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Antarctica</td>
        <td>AQ</td>
        <td>2020-06-29</td>
        <td>mQ5FOz8JXKs</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Poland</td>
        <td>PL</td>
        <td>2020-06-29</td>
        <td>mTmjaDWUfDG</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ghana</td>
        <td>GH</td>
        <td>2020-06-29</td>
        <td>N9bYrawJaqR</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Micronesia (Federated States of)</td>
        <td>FM</td>
        <td>2020-06-29</td>
        <td>nDTKZYmGEvT</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>MTB detected (Rifampicin indeterminate)</td>
        <td>MTB_DETECTED_RIF_INDETERMINATE</td>
        <td>2020-08-18</td>
        <td>nIKou981NQB</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Portugal</td>
        <td>PT</td>
        <td>2020-06-29</td>
        <td>NlVuvr5WbKy</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mali</td>
        <td>ML</td>
        <td>2020-06-29</td>
        <td>nOMNxq2fHGq</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Philippines</td>
        <td>PH</td>
        <td>2020-06-29</td>
        <td>nTQRDVcTHr0</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Uganda</td>
        <td>UG</td>
        <td>2020-06-29</td>
        <td>NV1MNzAfPWE</td>
      </tr>
      <tr>
        <td>Susceptible/Resistant/Indeterminate</td>
        <td>Resistant</td>
        <td>RESISTANT</td>
        <td>2020-09-24</td>
        <td>O9zjp4LJUeu</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Heard Island and McDonald Islands</td>
        <td>HM</td>
        <td>2020-06-29</td>
        <td>OC0K30ETDLD</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guatemala</td>
        <td>GT</td>
        <td>2020-06-29</td>
        <td>Oh3CJhGeaoi</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Burkina Faso</td>
        <td>BF</td>
        <td>2020-06-29</td>
        <td>OIXRi2caf6J</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Pitcairn</td>
        <td>PN</td>
        <td>2020-06-29</td>
        <td>oMLQaRXOs1B</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Australia</td>
        <td>AU</td>
        <td>2020-06-29</td>
        <td>omWzNDmT2t7</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Cured or treatment completed</td>
        <td>CURED_TREATMENT_COMPLETED</td>
        <td>2020-06-11</td>
        <td>onqAZ9bio2t</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>South Africa</td>
        <td>ZA</td>
        <td>2020-06-29</td>
        <td>OozIOFXlUQB</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Seychelles</td>
        <td>SC</td>
        <td>2020-06-29</td>
        <td>Oprr3by24Zt</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>French Guiana</td>
        <td>GF</td>
        <td>2020-06-29</td>
        <td>otDBqUSWuzE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>American Samoa</td>
        <td>AS</td>
        <td>2020-06-29</td>
        <td>OvCy05DV6kt</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Papua New Guinea</td>
        <td>PG</td>
        <td>2020-06-29</td>
        <td>ovWqm6wr1dP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mozambique</td>
        <td>MZ</td>
        <td>2020-06-29</td>
        <td>OvzdfV1qrvP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Wallis and Futuna</td>
        <td>WF</td>
        <td>2020-06-29</td>
        <td>oZPItrH57Zf</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>No result</td>
        <td>NO_RESULT</td>
        <td>2020-03-18</td>
        <td>ozqzmmfyvu8</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Libya</td>
        <td>LY</td>
        <td>2020-06-29</td>
        <td>p0vsNlHuo7N</td>
      </tr>
      <tr>
        <td>Susceptible/Resistant/Indeterminate</td>
        <td>Susceptible</td>
        <td>SUSCEPTIBLE</td>
        <td>2020-09-24</td>
        <td>p3SXa0Go6cJ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saudi Arabia</td>
        <td>SA</td>
        <td>2020-06-29</td>
        <td>p8Tgra7YJ7h</td>
      </tr>
      <tr>
        <td>TB DRS - Treatment Regimen</td>
        <td>Drug-resistant regimen</td>
        <td>DRUG_RESISTANT_REGIMEN</td>
        <td>2020-07-23</td>
        <td>pB9Xbeotzhx</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>France</td>
        <td>FR</td>
        <td>2020-06-29</td>
        <td>pBNkmU3hDoT</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Unknown</td>
        <td>UNKNOWN</td>
        <td>2020-08-04</td>
        <td>PFLWg0jJAPV</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Lesotho</td>
        <td>LS</td>
        <td>2020-06-29</td>
        <td>PFq4nWHt0fM</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cabo Verde</td>
        <td>CV</td>
        <td>2020-06-29</td>
        <td>phN4setkIfq</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>No</td>
        <td>NO</td>
        <td>2020-09-24</td>
        <td>PLlPgcfbL1D</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Djibouti</td>
        <td>DJ</td>
        <td>2020-06-29</td>
        <td>PMSl473rekw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cayman Islands</td>
        <td>KY</td>
        <td>2020-06-29</td>
        <td>pQhtDfYHXlQ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Palestine, State of</td>
        <td>PS</td>
        <td>2020-06-29</td>
        <td>Publ7A7E6r3</td>
      </tr>
      <tr>
        <td>Yes/No/Not Applicable</td>
        <td>Not Applicable</td>
        <td>NOT_APPLICABLE</td>
        <td>2020-03-18</td>
        <td>pv1WdxdAZl8</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Montserrat</td>
        <td>MS</td>
        <td>2020-06-29</td>
        <td>q36uKrRjq1P</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>United Arab Emirates</td>
        <td>AE</td>
        <td>2020-06-29</td>
        <td>qCmj8zWn2RQ</td>
      </tr>
      <tr>
        <td>Yes/No/Not Applicable</td>
        <td>Yes</td>
        <td>YES</td>
        <td>2020-06-29</td>
        <td>qEd2VMWfhan</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Italy</td>
        <td>IT</td>
        <td>2020-06-29</td>
        <td>QIjTIxTedos</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sri Lanka</td>
        <td>LK</td>
        <td>2020-06-29</td>
        <td>qpv7jbqwNTN</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Monaco</td>
        <td>MC</td>
        <td>2020-06-29</td>
        <td>QT9Erxe7UaX</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Serbia</td>
        <td>RS</td>
        <td>2020-06-29</td>
        <td>QtjohlzA8cl</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Maldives</td>
        <td>MV</td>
        <td>2020-06-29</td>
        <td>Qtp6HW63yqV</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Greece</td>
        <td>GR</td>
        <td>2020-06-29</td>
        <td>QyJHXS44Xj9</td>
      </tr>
      <tr>
        <td>Positive/Negative/Unknown</td>
        <td>Unknown</td>
        <td>UNKNOWN</td>
        <td>2020-06-29</td>
        <td>QYtc2i3L8Jd</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Zimbabwe</td>
        <td>ZW</td>
        <td>2020-06-29</td>
        <td>r15gweUYYrk</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>Susceptible</td>
        <td>SUSCEPTIBLE</td>
        <td>2020-06-29</td>
        <td>R3xLm0LElMI</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Quantitative Result</td>
        <td>Very Low</td>
        <td>VERY_LOW</td>
        <td>2020-06-29</td>
        <td>R58K1QZRG4y</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cocos (Keeling) Islands</td>
        <td>CC</td>
        <td>2020-06-29</td>
        <td>Rb9W87URnVe</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Chad</td>
        <td>TD</td>
        <td>2020-06-29</td>
        <td>rBktLnj3vUY</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Nauru</td>
        <td>NR</td>
        <td>2020-06-29</td>
        <td>rbvEOlaNkUU</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Quantitative Result</td>
        <td>Unknown</td>
        <td>UNKNOWN</td>
        <td>2020-06-29</td>
        <td>RgKYvq8eYjq</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Gibraltar</td>
        <td>GI</td>
        <td>2020-06-29</td>
        <td>riIXFPTUnZX</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Martin (French part)</td>
        <td>MF</td>
        <td>2020-06-29</td>
        <td>rJTXccXhtTG</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Egypt</td>
        <td>EG</td>
        <td>2020-06-29</td>
        <td>RkxuXQTQjxk</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mauritius</td>
        <td>MU</td>
        <td>2020-06-29</td>
        <td>RmjKEjs388f</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bhutan</td>
        <td>BT</td>
        <td>2020-06-29</td>
        <td>RNUEujTD4AN</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tokelau</td>
        <td>TK</td>
        <td>2020-06-29</td>
        <td>roEWVrnX17w</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Angola</td>
        <td>AO</td>
        <td>2020-06-29</td>
        <td>rpzJ5jGkUAn</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>Resistant</td>
        <td>RESISTANT</td>
        <td>2020-09-24</td>
        <td>RrdcLAuvPke</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>United States of America</td>
        <td>US</td>
        <td>2020-06-29</td>
        <td>RvhGvhkGceD</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Cook Islands</td>
        <td>CK</td>
        <td>2020-06-29</td>
        <td>Rx05JdBEHIW</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Sierra Leone</td>
        <td>SL</td>
        <td>2020-06-29</td>
        <td>rXsByduwzcw</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Hong Kong</td>
        <td>HK</td>
        <td>2020-06-29</td>
        <td>S3Dt4ozhM8X</td>
      </tr>
      <tr>
        <td>TB DRS Previous Treatment Outcome</td>
        <td>Failed regimen as a previously treated patient</td>
        <td>FAILED_REGIMEN_PREV</td>
        <td>2020-07-23</td>
        <td>S4bXo4JsAbA</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Czech Republic</td>
        <td>CZ</td>
        <td>2020-06-29</td>
        <td>Scdk35fgY12</td>
      </tr>
      <tr>
        <td>Yes/No/Not Applicable</td>
        <td>No</td>
        <td>NO</td>
        <td>2020-06-29</td>
        <td>sEqMay8BGdJ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Virgin Islands (U.S.)</td>
        <td>VI</td>
        <td>2020-06-29</td>
        <td>sgvVI1jilCg</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mexico</td>
        <td>MX</td>
        <td>2020-06-29</td>
        <td>sK6lzdZiwIg</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Lao People's Democratic Republic</td>
        <td>LA</td>
        <td>2020-06-29</td>
        <td>SN9NeGsvfmM</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Senegal</td>
        <td>SN</td>
        <td>2020-06-29</td>
        <td>sPFJiL1BLTy</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Solomon Islands</td>
        <td>SB</td>
        <td>2020-06-29</td>
        <td>sQNVDVNINvY</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>Error</td>
        <td>ERROR</td>
        <td>2020-08-04</td>
        <td>sSxqp8mUH3o</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Lithuania</td>
        <td>LT</td>
        <td>2020-06-29</td>
        <td>SXD2EhrNaQu</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Spain</td>
        <td>ES</td>
        <td>2020-06-29</td>
        <td>SXeG3KaIkU8</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bangladesh</td>
        <td>BD</td>
        <td>2020-06-29</td>
        <td>t0fFxYw3Cg4</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guinea</td>
        <td>GN</td>
        <td>2020-06-29</td>
        <td>T0gujEdp3Z6</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Denmark</td>
        <td>DK</td>
        <td>2020-06-29</td>
        <td>t0mq3u8SNgz</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Guyana</td>
        <td>GY</td>
        <td>2020-06-29</td>
        <td>TfyHeFLDOKu</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Lebanon</td>
        <td>LB</td>
        <td>2020-06-29</td>
        <td>THKtWeVTuBk</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Puerto Rico</td>
        <td>PR</td>
        <td>2020-06-29</td>
        <td>ThLyMbT1IvD</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>French Polynesia</td>
        <td>PF</td>
        <td>2020-06-29</td>
        <td>THPEMRSnC4G</td>
      </tr>
      <tr>
        <td>TB DRS LAB: Genotypic Speciation Results</td>
        <td>Mixed MTBc and Other</td>
        <td>MIXED_MTBC_AND_OTHER</td>
        <td>2020-03-18</td>
        <td>tI2yNUx4RML</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ireland</td>
        <td>IE</td>
        <td>2020-06-29</td>
        <td>tiwJrxfBoHT</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>Unknown</td>
        <td>UNKNOWN</td>
        <td>2020-08-04</td>
        <td>TKD1XJ4ZhMO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Croatia</td>
        <td>HR</td>
        <td>2020-06-29</td>
        <td>tLn4hW3TbNZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Antigua and Barbuda</td>
        <td>AG</td>
        <td>2020-06-29</td>
        <td>TRETd1l7n1N</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Timor-Leste</td>
        <td>TL</td>
        <td>2020-06-29</td>
        <td>txfMqMjfmGK</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>Invalid</td>
        <td>INVALID</td>
        <td>2020-06-29</td>
        <td>U9s3LZ1Rp6E</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Kitts and Nevis</td>
        <td>KN</td>
        <td>2020-06-29</td>
        <td>uJH3wMNmMNO</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Kenya</td>
        <td>KE</td>
        <td>2020-06-29</td>
        <td>UJppzPKIQRv</td>
      </tr>
      <tr>
        <td>TB DRS Sputum Smear Microscopy Result</td>
        <td>Not done</td>
        <td>NOT_DONE</td>
        <td>2020-08-20</td>
        <td>uJXGqaQsBQZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Barbados</td>
        <td>BB</td>
        <td>2020-06-29</td>
        <td>uM1WgdIueNA</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Mongolia</td>
        <td>MN</td>
        <td>2020-06-29</td>
        <td>UmW7wmw0AX9</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tunisia</td>
        <td>TN</td>
        <td>2020-06-29</td>
        <td>uNt8kKM8azp</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Faroe Islands</td>
        <td>FO</td>
        <td>2020-06-29</td>
        <td>upfjuKBGHq9</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>Male</td>
        <td>MALE</td>
        <td>2020-08-04</td>
        <td>UrUdMteQzlT</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>MTB</td>
        <td>MTB</td>
        <td>2020-08-13</td>
        <td>UsugTEaeBhi</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Paraguay</td>
        <td>PY</td>
        <td>2020-06-29</td>
        <td>UvnjescFIbU</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Iraq</td>
        <td>IQ</td>
        <td>2020-06-29</td>
        <td>UXyOlL9FJ5o</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Niger</td>
        <td>NE</td>
        <td>2020-06-29</td>
        <td>UzC7hScynz0</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Eritrea</td>
        <td>ER</td>
        <td>2020-06-29</td>
        <td>v16FQ3xwnGN</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Martinique</td>
        <td>MQ</td>
        <td>2020-06-29</td>
        <td>V1nDCD6QvPs</td>
      </tr>
      <tr>
        <td>Yes/No</td>
        <td>No</td>
        <td>NO</td>
        <td>2020-06-29</td>
        <td>vak9GKjzzAP</td>
      </tr>
      <tr>
        <td>TB DRS Genotypic Resistance Profiling</td>
        <td>No Interpretable Result (i.e. insufficient quality)</td>
        <td>NO_INTERPRETABLE_RESULT</td>
        <td>2020-03-18</td>
        <td>vaxQgTZQXpM</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>None</td>
        <td>NONE</td>
        <td>2020-03-18</td>
        <td>vEL863qZ6HA</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Virgin Islands (British)</td>
        <td>VG</td>
        <td>2020-06-29</td>
        <td>VEulszgYUL2</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tonga</td>
        <td>TO</td>
        <td>2020-06-29</td>
        <td>vjJWFh1j9U5</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>South Georgia and the South Sandwich Islands</td>
        <td>GS</td>
        <td>2020-06-29</td>
        <td>vMAK8GtCXzE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Congo (Democratic Republic of the)</td>
        <td>CD</td>
        <td>2020-06-29</td>
        <td>VnmVMbf4mwL</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Turkmenistan</td>
        <td>TM</td>
        <td>2020-06-29</td>
        <td>vPk3xrZvimA</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Quantitative Result</td>
        <td>Low</td>
        <td>LOW</td>
        <td>2020-03-18</td>
        <td>vq8qUW3pu22</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Israel</td>
        <td>IL</td>
        <td>2020-06-29</td>
        <td>VQkdjFxCLNH</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bonaire, Sint Eustatius and Saba</td>
        <td>BQ</td>
        <td>2020-06-29</td>
        <td>vuiZtzbuwWx</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Iceland</td>
        <td>IS</td>
        <td>2020-06-29</td>
        <td>vzzPNV6Wu0J</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Samoa</td>
        <td>WS</td>
        <td>2020-06-29</td>
        <td>w0S8ngASwmq</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Ethiopia</td>
        <td>ET</td>
        <td>2020-06-29</td>
        <td>W4KroB1nw6P</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Costa Rica</td>
        <td>CR</td>
        <td>2020-06-29</td>
        <td>WBvTizbhaXP</td>
      </tr>
      <tr>
        <td>TB DRS Sputum Smear Microscopy Result</td>
        <td>Negative</td>
        <td>NEGATIVE</td>
        <td>2020-06-29</td>
        <td>WhaoVoBAFxG</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bolivia (Plurinational State of)</td>
        <td>BO</td>
        <td>2020-06-29</td>
        <td>WIleZf4Cua4</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Zambia</td>
        <td>ZM</td>
        <td>2020-06-29</td>
        <td>WPR1XicphAd</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Uzbekistan</td>
        <td>UZ</td>
        <td>2020-06-29</td>
        <td>WrnwBUl0Vzt</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Albania</td>
        <td>AL</td>
        <td>2020-06-29</td>
        <td>wuS7cVSEiYA</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Fiji</td>
        <td>FJ</td>
        <td>2020-06-29</td>
        <td>wVl5DoJmza2</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>MTB not detected</td>
        <td>MTB_NOT_DETECTED</td>
        <td>2020-08-18</td>
        <td>wxaK4PQwtar</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Saint Lucia</td>
        <td>LC</td>
        <td>2020-06-29</td>
        <td>x4Ohep6Q85T</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Russian Federation</td>
        <td>RU</td>
        <td>2020-06-29</td>
        <td>xF48L1VlFrZ</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Turks and Caicos Islands</td>
        <td>TC</td>
        <td>2020-06-29</td>
        <td>xIvocxUNJvn</td>
      </tr>
      <tr>
        <td>TB DRS Xpert MTB/RIF Test Result</td>
        <td>MTB detected (Rifampicin susceptible)</td>
        <td>MTB_DETECTED_RIFAMPICIN_SUSCEPTIBLE</td>
        <td>2020-08-18</td>
        <td>xq1DHmnRamj</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Liechtenstein</td>
        <td>LI</td>
        <td>2020-06-29</td>
        <td>XQZko5dUFGU</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Nigeria</td>
        <td>NG</td>
        <td>2020-06-29</td>
        <td>xsNVICc3jPD</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Palau</td>
        <td>PW</td>
        <td>2020-06-29</td>
        <td>xuUrPK5b7MP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Argentina</td>
        <td>AR</td>
        <td>2020-06-29</td>
        <td>xvYNdt7dLiM</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Nicaragua</td>
        <td>NI</td>
        <td>2020-06-29</td>
        <td>Y2ze1UBngud</td>
      </tr>
      <tr>
        <td>TB DRS Sample Additive</td>
        <td>CPC</td>
        <td>CPC</td>
        <td>2020-03-18</td>
        <td>Y85Yik3kfq6</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bosnia and Herzegovina</td>
        <td>BA</td>
        <td>2020-06-29</td>
        <td>Yf0Gb9nZiQ1</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>Not detected</td>
        <td>NOT_DETECTED</td>
        <td>2020-08-04</td>
        <td>YMFMcGchVjk</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>NTM</td>
        <td>NTM</td>
        <td>2020-08-13</td>
        <td>YoZDgCMUpJy</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Vanuatu</td>
        <td>VU</td>
        <td>2020-06-29</td>
        <td>yqQ0IiG9maE</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Oman</td>
        <td>OM</td>
        <td>2020-06-29</td>
        <td>yxbHuzqF6VS</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Tajikistan</td>
        <td>TJ</td>
        <td>2020-06-29</td>
        <td>yxvBpzHn9VN</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Afghanistan</td>
        <td>AF</td>
        <td>2020-06-29</td>
        <td>yyeQNBfmO7g</td>
      </tr>
      <tr>
        <td>TB DRS Sputum Smear Microscopy Result</td>
        <td>+</td>
        <td>+</td>
        <td>2020-03-18</td>
        <td>z6UTT4AESR8</td>
      </tr>
      <tr>
        <td>TB DRS LPA Specimen</td>
        <td>MTB culture isolates</td>
        <td>MTB_CULTURE_ISOLATES</td>
        <td>2020-08-04</td>
        <td>zAH62QSxRYh</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Switzerland</td>
        <td>CH</td>
        <td>2020-06-29</td>
        <td>ZcaE9JG9xrr</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Bermuda</td>
        <td>BM</td>
        <td>2020-06-29</td>
        <td>zITeQ1j7Jmz</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Trinidad and Tobago</td>
        <td>TT</td>
        <td>2020-06-29</td>
        <td>zJCV30f9Pix</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>United Kingdom of Great Britain and Northern Ireland</td>
        <td>GB</td>
        <td>2020-06-29</td>
        <td>ZOGqtsOOfdP</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Canada</td>
        <td>CA</td>
        <td>2020-06-29</td>
        <td>zonuQ6g4FFh</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Qatar</td>
        <td>QA</td>
        <td>2020-06-29</td>
        <td>zooDgQrnVkm</td>
      </tr>
      <tr>
        <td>Yes/No</td>
        <td>Yes</td>
        <td>YES</td>
        <td>2020-06-29</td>
        <td>zPVS0EAEwia</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Brazil</td>
        <td>BR</td>
        <td>2020-06-29</td>
        <td>ZqOOqkOV8Zm</td>
      </tr>
      <tr>
        <td>TB DRS Sputum Smear Microscopy Result</td>
        <td>Scanty</td>
        <td>SCANTY</td>
        <td>2020-03-18</td>
        <td>ZS5tTttku2i</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Belgium</td>
        <td>BE</td>
        <td>2020-06-29</td>
        <td>zsS0Xx2iUV6</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Netherlands</td>
        <td>NL</td>
        <td>2020-06-29</td>
        <td>ztgG5fQPur9</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Austria</td>
        <td>AT</td>
        <td>2020-06-29</td>
        <td>zTtjy8I0bcu</td>
      </tr>
      <tr>
        <td>Countries</td>
        <td>Haiti</td>
        <td>HT</td>
        <td>2020-06-29</td>
        <td>ZyGPejjzvGD</td>
      </tr>
    </table>
    <h2 id="indicatorGroups">Indicator Groups</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td></td>
        <td>2020-09-16</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td></td>
        <td>2020-08-14</td>
        <td>jMQBr2VRNuD</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td></td>
        <td>2020-08-14</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td></td>
        <td>2020-09-16</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td></td>
        <td>2020-08-14</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td></td>
        <td>2020-08-14</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td></td>
        <td>2020-09-21</td>
        <td>zcQDItYC8pL</td>
      </tr>
    </table>
    <h3>Indicator Groups - Indicators</h3>
    <table>
      <tr>
        <th>Indicator Group</th>
        <th>Indicator</th>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>DRS: Average number of days from sample collection to Xpert MTB/RIF Ultra test at NTRL</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>DRS: Patients with Xpert MTB/RIF Ultra test (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>DRS: LPA FQ/2LI: <=5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>DRS: LPA FQ/2LI: <=9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>DRS: LPA FQ/2LI: <=10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>DRS: LPA FQ/2LI: <=2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>DRS: Average number of days from sample collection to LPA FQ/2LI test at NTRL</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>DRS: LPA FQ/2LI: <=7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>DRS: LPA FQ/2LI: <=8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>DRS: LPA FQ/2LI: <=6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>DRS: LPA FQ/2LI: 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>DRS: LPA FQ/2LI: <=1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>DRS: LPA FQ/2LI: <=3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>DRS: LPA FQ/2LI: <=4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>DRS: LPA FQ/2LI: <=10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>DRS: Patients with LPA FQ/2LI test (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture SM: <= 4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA FQ/2LI: <=5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture SM: <= 10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture SM: <= 1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture SM: <= 9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture SM: <= 6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture SM: <= 10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture SM: <= 8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA FQ/2LI: <=9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA FQ/2LI: <=10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA FQ/2LI: <=2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture SM: <= 7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Average number of days from sample collection to LPA FQ/2LI test at NTRL</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture SM: <= 5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA FQ/2LI: <=7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA FQ/2LI: <=8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA FQ/2LI: <=6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Average number of days from sample collection to inoculation for culture SM at NTRL</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture SM: <= 2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture SM: 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Culture SM: <= 3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA FQ/2LI: 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA FQ/2LI: <=1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA FQ/2LI: <=3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA FQ/2LI: <=4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: LPA FQ/2LI: <=10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>DRS: Patients with LPA FQ/2LI test (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>DRS: Average number of days from sample collection to Xpert MTB/RIF test at NTRL</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>DRS: Xpert MTB/RIF: <=1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>DRS: Patients with Xpert MTB/RIF test (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td>DRS: LPA RIF/INH: <=8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td>DRS: LPA RIF/INH: <=4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td>DRS: LPA RIF/INH: <=3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td>DRS: LPA RIF/INH: <=6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td>DRS: Patients with LPA RIF/INH test (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td>DRS: LPA RIF/INH: <=1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td>DRS: LPA RIF/INH: <=2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td>DRS: LPA RIF/INH: <=10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td>DRS: LPA RIF/INH: <=7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td>DRS: LPA RIF/INH: 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td>DRS: Average number of days from sample collection to LPA RIF/INH test at NTRL</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td>DRS: LPA RIF/INH: <=5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td>DRS: LPA RIF/INH: <=9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td>DRS: LPA RIF/INH: <=10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Average number of days from sample collection to inoculation for culture LM at NTRL</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture LM: <= 5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture LM: <= 7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture LM: 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture LM: <= 2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture LM: <= 10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture LM: <= 4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture LM: <= 10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture LM: <= 3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture LM: <= 1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture LM: <= 9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture LM: <= 8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>DRS: Culture LM: <= 6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS - Samples turn-around time: <=3 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS - Average number of days from sample collection to sample arrival at NTRL</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS: Patients with initial DST LM test (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS - Samples turn-around time: <=2 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS - Samples turn-around time: 0 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS - Samples turn-around time: <=10+ days (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS: Patients with LPA RIF/INH test (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS: Sample Rejection/Loss Rate (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS - Samples turn-around time: <=10 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS - Samples turn-around time: <=4 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS: Patients with subsequent DST in SM test (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS: Patients with subsequent DST LM test (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS - Samples turn-around time: <=8 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS - Samples turn-around time: <=6 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS - Samples turn-around time: <=1 day (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS - Samples turn-around time: <=7 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS: Patients with initial DST SM test (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS - Samples turn-around time: <=5 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS: Patients with culture SM test (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS - Samples turn-around time: <=9 days (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS: Patients with culture LM test (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS: Patients with microscopy test (%)</td>
      </tr>
      <tr>
        <td>TB DRS</td>
        <td>DRS: Patients with LPA FQ/2LI test (%)</td>
      </tr>
    </table>
    <h2 id="indicators">Indicators</h2>
    <table>
      <tr>
        <th>UID</th>
        <th>Name</th>
        <th>Shortname</th>
        <th>Code</th>
        <th>Description</th>
        <th>Numerator</th>
        <th>Denominator</th>
        <th>Type</th>
        <th>Last updated</th>
        <th>Indicator group UID</th>
      </tr>
      <tr>
        <td>a8setUueamz</td>
        <td>DRS - Samples turn-around time: <=3 days (%)</td>
        <td>Turn-around time: <=3d (%)</td>
        <td></td>
        <td>Turn-around time: <=3 days - percentage of samples</td>
        <td>Turn-around time: <=3 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-08-13</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>AcHQyohvydu</td>
        <td>DRS: Average number of days from sample collection to inoculation for culture LM at NTRL</td>
        <td>Culture LM: turn-around time - mean</td>
        <td></td>
        <td>Average number of days from sample collection to culture inoculation in liquid media at NTRL</td>
        <td>Average number of days from sample collection to culture inoculation in liquid media at NTRL</td>
        <td>1</td>
        <td>Numerator only (number)</td>
        <td>2020-09-21</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>ae0oVqByDr1</td>
        <td>DRS: Xpert MTB/RIF: <=4 days (%)</td>
        <td>Xpert MTB/RIF: <=4d (%)</td>
        <td></td>
        <td>Percentage of samples with 4 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=4 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>aeK9KTMrpI1</td>
        <td>DRS: Average number of days from sample collection to Xpert MTB/RIF test at NTRL</td>
        <td>Xpert MTB/RIF: turn-around time - mean</td>
        <td></td>
        <td>Average number of days from sample collection to Xpert MTB/RIF test at NTRL</td>
        <td>Average number of days from sample collection to Xpert MTB/RIF test at NTRL</td>
        <td>1</td>
        <td>Numerator only (number)</td>
        <td>2020-09-21</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>am5DJHSAzK3</td>
        <td>DRS - Average number of days from sample collection to sample arrival at NTRL</td>
        <td>Days between collection and arrival (mean)</td>
        <td></td>
        <td>Average number of days from sample collection to sample arrival at NTRL</td>
        <td>Average number of days from sample collection to sample arrival at NTRL</td>
        <td>1</td>
        <td>Numerator only (number)</td>
        <td>2020-08-14</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>aS7bteRrJDZ</td>
        <td>DRS: Xpert MTB/RIF: <=3 days (%)</td>
        <td>Xpert MTB/RIF: <=3d (%)</td>
        <td></td>
        <td>Percentage of samples with 3 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=3 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>bffHR88vA98</td>
        <td>DRS: Xpert MTB/RIF Ultra: 0 days (%)</td>
        <td>Xpert MTB/RIF Ultra: 0d (%)</td>
        <td></td>
        <td>Percentage of samples with 0 days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: 0 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>Bn67IWVrBHi</td>
        <td>DRS: Culture SM: <= 4 days (%)</td>
        <td>Culture SM: <=4d (%)</td>
        <td></td>
        <td>Percentage of samples with 4 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 4 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>bSWNVWcyzwB</td>
        <td>DRS: Patients with initial DST LM test (%)</td>
        <td>Initial DST LM: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with inoculation date for initial DST LM out of all enrolled patients</td>
        <td>Patients with inoculation date for initial DST LM</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>cBQZ41II5Gc</td>
        <td>DRS: LPA FQ/2LI: <=5 days (%)</td>
        <td>LPA FQ/2LI: <=5d (%)</td>
        <td></td>
        <td>Percentage of samples with 5 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA FQ/2LI: <=5 days</td>
        <td>Processed LPA FQ/2LI samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>cCwNBsU06Ws</td>
        <td>DRS: Culture SM: <= 10+ days (%)</td>
        <td>Culture SM: <=10+d (%)</td>
        <td></td>
        <td>100% of samples</td>
        <td>Culture SM: <= 10+ days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>cjzSGuUsFi7</td>
        <td>DRS: Culture SM: <= 1 day (%)</td>
        <td>Culture SM: <=1d (%)</td>
        <td></td>
        <td>Percentage of samples with 1 or less day turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 1 day</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>Cuny2qjvQH8</td>
        <td>DRS: Culture SM: <= 9 days (%)</td>
        <td>Culture SM: <=9d (%)</td>
        <td></td>
        <td>Percentage of samples with 9 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 9 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>d7FmPC0FAyO</td>
        <td>DRS: Culture LM: <= 5 days (%)</td>
        <td>Culture LM: <=5d (%)</td>
        <td></td>
        <td>Percentage of samples with 5 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 5 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>dbWMLoaoRXt</td>
        <td>DRS: Culture SM: <= 6 days (%)</td>
        <td>Culture SM: <=6d (%)</td>
        <td></td>
        <td>Percentage of samples with 6 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 6 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>DOa8x2MeB7x</td>
        <td>DRS: LPA RIF/INH: <=8 days (%)</td>
        <td>LPA RIF/INH: <=8d (%)</td>
        <td></td>
        <td>Percentage of samples with 8 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA RIF/INH: <=8 days</td>
        <td>Processed LPA RIF/INH samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>dP9fGLr2xEJ</td>
        <td>DRS - Samples turn-around time: <=2 days (%)</td>
        <td>Turn-around time: <=2d (%)</td>
        <td></td>
        <td>Turn-around time: <=2 days - percentage of samples</td>
        <td>Turn-around time: <=2 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-08-13</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>EJkYRjUldf6</td>
        <td>DRS: Culture LM: <= 7 days (%)</td>
        <td>Culture LM: <=7d (%)</td>
        <td></td>
        <td>Percentage of samples with 7 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 7 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>eoGyZLFAHdV</td>
        <td>DRS: Xpert MTB/RIF: <=10+ days (%)</td>
        <td>Xpert MTB/RIF: <=10+d (%)</td>
        <td></td>
        <td>100% of samples</td>
        <td>Xpert MTB/RIF: <=10+ days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>eQ99BPBeFto</td>
        <td>DRS: Average number of days from sample collection to Xpert MTB/RIF Ultra test at NTRL</td>
        <td>Xpert MTB/RIF Ultra: turn-around time - mean</td>
        <td></td>
        <td>Average number of days from sample collection to Xpert MTB/RIF Ultra test at NTRL</td>
        <td>Average number of days from sample collection to Xpert MTB/RIF Ultra test at NTRL</td>
        <td>1</td>
        <td>Numerator only (number)</td>
        <td>2020-09-21</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>ESwnQHRtDaJ</td>
        <td>DRS: LPA RIF/INH: <=4 days (%)</td>
        <td>LPA RIF/INH: <=4d (%)</td>
        <td></td>
        <td>Percentage of samples with 4 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA RIF/INH: <=4 days</td>
        <td>Processed LPA RIF/INH samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>EZbmivyB7nr</td>
        <td>DRS: Xpert MTB/RIF: <=6 days (%)</td>
        <td>Xpert MTB/RIF: <=6d (%)</td>
        <td></td>
        <td>Percentage of samples with 6 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=6 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>f31IE1B3CKi</td>
        <td>DRS: LPA RIF/INH: <=3 days (%)</td>
        <td>LPA RIF/INH: <=3d (%)</td>
        <td></td>
        <td>Percentage of samples with 3 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA RIF/INH: <=3 days</td>
        <td>Processed LPA RIF/INH samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>fa9SQjryhX3</td>
        <td>DRS - Samples turn-around time: 0 days (%)</td>
        <td>Turn-around time: 0d (%)</td>
        <td></td>
        <td>Turn-around time: 0 days - percentage of samples</td>
        <td>Turn-around time: 0 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-08-13</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>FcQisyQ92Zg</td>
        <td>DRS: LPA RIF/INH: <=6 days (%)</td>
        <td>LPA RIF/INH: <=6d (%)</td>
        <td></td>
        <td>Percentage of samples with 6 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA RIF/INH: <=6 days</td>
        <td>Processed LPA RIF/INH samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>fE4zG1Hl59F</td>
        <td>DRS: Culture SM: <= 10 days (%)</td>
        <td>Culture SM: <=10d (%)</td>
        <td></td>
        <td>Percentage of samples with 10 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 10 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>FFQdb5RH6iS</td>
        <td>DRS: Culture SM: <= 8 days (%)</td>
        <td>Culture SM: <=8d (%)</td>
        <td></td>
        <td>Percentage of samples with 8 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 8 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>fH5JqlzYk2i</td>
        <td>DRS: LPA FQ/2LI: <=9 days (%)</td>
        <td>LPA FQ/2LI: <=9d (%)</td>
        <td></td>
        <td>Percentage of samples with 9 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA FQ/2LI: <=9 days</td>
        <td>Processed LPA FQ/2LI samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>FJA1FIsRWdV</td>
        <td>DRS: LPA FQ/2LI: <=10+ days (%)</td>
        <td>LPA FQ/2LI: <=10+d (%)</td>
        <td></td>
        <td>100% of samples</td>
        <td>LPA FQ/2LI: <=10+ days</td>
        <td>Processed LPA FQ/2LI samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>Fknk2pZQ6Tv</td>
        <td>DRS - Samples turn-around time: <=10+ days (%)</td>
        <td>Turn-around time: <=10d+ (%)</td>
        <td></td>
        <td>Turn-around time: <=10+ days - percentage of samples</td>
        <td>Turn-around time: <=10+ days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-08-13</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>flPa9otyXxL</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=2 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=2d (%)</td>
        <td></td>
        <td>Percentage of samples with 2 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=2 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>Fo2Cl7X69Tq</td>
        <td>DRS: LPA FQ/2LI: <=2 days (%)</td>
        <td>LPA FQ/2LI: <=2d (%)</td>
        <td></td>
        <td>Percentage of samples with 2 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA FQ/2LI: <=2 days</td>
        <td>Processed LPA FQ/2LI samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>g2mOHLxN0tZ</td>
        <td>DRS: Patients with LPA RIF/INH test (%)</td>
        <td>LPA RIF/INH: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with test result for LPA RIF/INH out of all enrolled patients</td>
        <td>Patients with result for LPA RIF/INH</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>VRDPmfz0bEE, zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>GGY0RHKlpM3</td>
        <td>DRS: Culture LM: 0 days (%)</td>
        <td>Culture LM: 0d (%)</td>
        <td></td>
        <td>Percentage of samples with 0 days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: 0 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>gnv4CbHeRJD</td>
        <td>DRS: Xpert MTB/RIF: <=5 days (%)</td>
        <td>Xpert MTB/RIF: <=5d (%)</td>
        <td></td>
        <td>Percentage of samples with 5 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=5 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>GS5pE9D9xkM</td>
        <td>DRS: Sample Rejection/Loss Rate (%)</td>
        <td>DRS: Sample rejection/loss rate (%)</td>
        <td></td>
        <td>Percentage of samples rejected on arrival out of all collected samples</td>
        <td>Samples rejected on arrival</td>
        <td>Sample processing events, total</td>
        <td>Percentage</td>
        <td>2020-09-24</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>gYtgemihOJi</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=9 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=9d (%)</td>
        <td></td>
        <td>Percentage of samples with 9 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=9 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>H0Y0qVB8UQQ</td>
        <td>DRS - Samples turn-around time: <=10 days (%)</td>
        <td>Turn-around time: <=10d (%)</td>
        <td></td>
        <td>Turn-around time: <=10 days - percentage of samples</td>
        <td>Turn-around time: <=10 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-08-13</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>H9MaiWTz15Q</td>
        <td>DRS: Culture SM: <= 7 days (%)</td>
        <td>Culture SM: <=7d (%)</td>
        <td></td>
        <td>Percentage of samples with 7 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 7 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>hAMicIaBmAM</td>
        <td>DRS: Culture LM: <= 2 days (%)</td>
        <td>Culture LM: <=2d (%)</td>
        <td></td>
        <td>Percentage of samples with 2 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 2 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>HdMIlgBYze3</td>
        <td>DRS - Samples turn-around time: <=4 days (%)</td>
        <td>Turn-around time: <=4d (%)</td>
        <td></td>
        <td>Turn-around time: <=4 days - percentage of samples</td>
        <td>Turn-around time: <=4 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-08-13</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>HERepQ0qswD</td>
        <td>DRS: Xpert MTB/RIF: 0 days (%)</td>
        <td>Xpert MTB/RIF: 0d (%)</td>
        <td></td>
        <td>Percentage of samples with 0 days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: 0 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>HH7cj34RWyK</td>
        <td>DRS: LPA RIF/INH: <=1 day (%)</td>
        <td>LPA RIF/INH: <=1d (%)</td>
        <td></td>
        <td>Percentage of samples with 1 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA RIF/INH: <=1 day</td>
        <td>Processed LPA RIF/INH samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>HqR09RvwsJN</td>
        <td>DRS: Patients with subsequent DST in SM test (%)</td>
        <td>Subsequent DST SM: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with inoculation date for subsequent DST SM out of all enrolled patients</td>
        <td>Patients with inoculation date for subsequent DST SM</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>i1LZPAYNwAt</td>
        <td>DRS: Culture LM: <= 10 days (%)</td>
        <td>Culture LM: <=10d (%)</td>
        <td></td>
        <td>Percentage of samples with 10 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 10 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>i3UxIqflvlW</td>
        <td>DRS: Xpert MTB/RIF: <=10 days (%)</td>
        <td>Xpert MTB/RIF: <=10d (%)</td>
        <td></td>
        <td>Percentage of samples with 10 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=10 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>iSMLdHROvWH</td>
        <td>DRS: Patients with subsequent DST LM test (%)</td>
        <td>Subsequent DST LM: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with inoculation date for subsequent DST LM out of all enrolled patients</td>
        <td>Patients with inoculation date for subsequent DST LM</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>j3HE4i1K8UX</td>
        <td>DRS: Average number of days from sample collection to LPA FQ/2LI test at NTRL</td>
        <td>LPA FQ/2LI: turn-around time - mean</td>
        <td></td>
        <td>Average number of days from sample collection to LPA FQ/2LI test at NTRL</td>
        <td>Average number of days from sample collection to LPA FQ/2LI test at NTRL</td>
        <td>1</td>
        <td>Numerator only (number)</td>
        <td>2020-09-21</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>JBUxyk3lCQ3</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=1 day (%)</td>
        <td>Xpert MTB/RIF Ultra: <=1d (%)</td>
        <td></td>
        <td>Percentage of samples with 1 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=1 day</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>JDVx65Xz6XT</td>
        <td>DRS - Samples turn-around time: <=8 days (%)</td>
        <td>Turn-around time: <=8d (%)</td>
        <td></td>
        <td>Turn-around time: <=8 days - percentage of samples</td>
        <td>Turn-around time: <=8 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-08-13</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>JnEvbkg7hv2</td>
        <td>DRS: LPA RIF/INH: <=2 days (%)</td>
        <td>LPA RIF/INH: <=2d (%)</td>
        <td></td>
        <td>Percentage of samples with 2 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA RIF/INH: <=2 days</td>
        <td>Processed LPA RIF/INH samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>jp238ubVDNg</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=10 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=10d (%)</td>
        <td></td>
        <td>Percentage of samples with 10 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=10 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>jv8wEnsQwUX</td>
        <td>DRS - Samples turn-around time: <=6 days (%)</td>
        <td>Turn-around time: <=6d (%)</td>
        <td></td>
        <td>Turn-around time: <=6 days - percentage of samples</td>
        <td>Turn-around time: <=6 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-08-13</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>LeRvQjCZlmn</td>
        <td>DRS - Samples turn-around time: <=1 day (%)</td>
        <td>Turn-around time: <=1d (%)</td>
        <td></td>
        <td>Turn-around time: <=1 day - percentage of samples</td>
        <td>Turn-around time: <=1 day</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-08-13</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>lFgVlJ9ofDP</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=4 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=4d (%)</td>
        <td></td>
        <td>Percentage of samples with 4 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=4 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>M5rzpqToNVY</td>
        <td>DRS: LPA RIF/INH: <=10 days (%)</td>
        <td>LPA RIF/INH: <=10d (%)</td>
        <td></td>
        <td>Percentage of samples with 10 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA RIF/INH: <=10 days</td>
        <td>Processed LPA RIF/INH samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>M9PODPpbKal</td>
        <td>DRS: LPA RIF/INH: <=7 days (%)</td>
        <td>LPA RIF/INH: <=7d (%)</td>
        <td></td>
        <td>Percentage of samples with 7 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA RIF/INH: <=7 days</td>
        <td>Processed LPA RIF/INH samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>Ma6eNUhAnlN</td>
        <td>DRS: Culture LM: <= 4 days (%)</td>
        <td>Culture LM: <=4d (%)</td>
        <td></td>
        <td>Percentage of samples with 4 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 4 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>MeMSwX9uZZp</td>
        <td>DRS: LPA RIF/INH: 0 days (%)</td>
        <td>LPA RIF/INH: 0d (%)</td>
        <td></td>
        <td>Percentage of samples with 0 days turn-around time between date of sample collection and test date</td>
        <td>LPA RIF/INH: 0 days</td>
        <td>Processed LPA RIF/INH samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>MfuvDUrnP6f</td>
        <td>DRS: Culture LM: <= 10+ days (%)</td>
        <td>Culture LM: <=10+d (%)</td>
        <td></td>
        <td>100% of samples</td>
        <td>Culture LM: <= 10+ days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>MlSNx9HU7TI</td>
        <td>DRS: Xpert MTB/RIF: <=7 days (%)</td>
        <td>Xpert MTB/RIF: <=7d (%)</td>
        <td></td>
        <td>Percentage of samples with 7 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=7 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>mzWxxsEh9og</td>
        <td>DRS: Culture SM: <= 5 days (%)</td>
        <td>Culture SM: <=5d (%)</td>
        <td></td>
        <td>Percentage of samples with 5 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 5 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>NhSYNUMNjNs</td>
        <td>DRS: Average number of days from sample collection to LPA RIF/INH test at NTRL</td>
        <td>LPA RIF/INH: turn-around time - mean</td>
        <td></td>
        <td>Average number of days from sample collection to LPA RIF/INH test at NTRL</td>
        <td>Average number of days from sample collection to LPA RIF/INH test at NTRL</td>
        <td>1</td>
        <td>Numerator only (number)</td>
        <td>2020-09-21</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>nkI1EXXVx6q</td>
        <td>DRS: Xpert MTB/RIF: <=8 days (%)</td>
        <td>Xpert MTB/RIF: <=8d (%)</td>
        <td></td>
        <td>Percentage of samples with 8 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=8 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>NTq2m5syKdO</td>
        <td>DRS: LPA FQ/2LI: <=7 days (%)</td>
        <td>LPA FQ/2LI: <=7d (%)</td>
        <td></td>
        <td>Percentage of samples with 7 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA FQ/2LI: <=7 days</td>
        <td>Processed LPA FQ/2LI samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>OdJf8tmZ1mj</td>
        <td>DRS - Samples turn-around time: <=7 days (%)</td>
        <td>Turn-around time: <=7d (%)</td>
        <td></td>
        <td>Turn-around time: <=7 days - percentage of samples</td>
        <td>Turn-around time: <=7 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-08-13</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>on52l0lUpel</td>
        <td>DRS: Culture LM: <= 3 days (%)</td>
        <td>Culture LM: <=3d (%)</td>
        <td></td>
        <td>Percentage of samples with 3 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 3 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>pPGxe6kKZlv</td>
        <td>DRS: LPA FQ/2LI: <=8 days (%)</td>
        <td>LPA FQ/2LI: <=8d (%)</td>
        <td></td>
        <td>Percentage of samples with 8 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA FQ/2LI: <=8 days</td>
        <td>Processed LPA FQ/2LI samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>qhYQV5iWnkt</td>
        <td>DRS: LPA FQ/2LI: <=6 days (%)</td>
        <td>LPA FQ/2LI: <=6d (%)</td>
        <td></td>
        <td>Percentage of samples with 6 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA FQ/2LI: <=6 days</td>
        <td>Processed LPA FQ/2LI samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>qq3lX3j1NZ3</td>
        <td>DRS: LPA RIF/INH: <=5 days (%)</td>
        <td>LPA RIF/INH: <=5d (%)</td>
        <td></td>
        <td>Percentage of samples with 5 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA RIF/INH: <=5 days</td>
        <td>Processed LPA RIF/INH samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>Qqt73P9tc9Z</td>
        <td>DRS: Xpert MTB/RIF: <=2 days (%)</td>
        <td>Xpert MTB/RIF: <=2d (%)</td>
        <td></td>
        <td>Percentage of samples with 2 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=2 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>qZAPndnoZsD</td>
        <td>DRS: Average number of days from sample collection to inoculation for culture SM at NTRL</td>
        <td>Culture SM: turn-around time - mean</td>
        <td></td>
        <td>Average number of days from sample collection to culture inoculation in solid media at NTRL</td>
        <td>Average number of days from sample collection to culture inoculation in solid media at NTRL</td>
        <td>1</td>
        <td>Numerator only (number)</td>
        <td>2020-09-21</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>QzGsx5yW3K0</td>
        <td>DRS: Culture SM: <= 2 days (%)</td>
        <td>Culture SM: <=2d (%)</td>
        <td></td>
        <td>Percentage of samples with 2 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 2 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>r1bYQSkX7S0</td>
        <td>DRS: Patients with Xpert MTB/RIF Ultra test (%)</td>
        <td>Xpert MTB/RIF Ultra:: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with test result for Xpert MTB/RIF Ultra out of all enrolled patients</td>
        <td>Patients with result for Xpert MTB/RIF Ultra</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>rNnAvLcQaDH</td>
        <td>DRS: Patients with initial DST SM test (%)</td>
        <td>Initial DST SM: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with inoculation date for initial DST SM out of all enrolled patients</td>
        <td>Patients with inoculation date for initial DST SM</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>rWU3OG0Hoes</td>
        <td>DRS: Culture SM: 0 days (%)</td>
        <td>Culture SM: 0d (%)</td>
        <td></td>
        <td>Percentage of samples with 0 days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: 0 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>s0N0628XJk4</td>
        <td>DRS: Culture LM: <= 1 day (%)</td>
        <td>Culture LM: <=1d (%)</td>
        <td></td>
        <td>Percentage of samples with 1 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 1 day</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>SLEcCUelmh4</td>
        <td>DRS: LPA RIF/INH: <=9 days (%)</td>
        <td>LPA RIF/INH: <=9d (%)</td>
        <td></td>
        <td>Percentage of samples with 9 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA RIF/INH: <=9 days</td>
        <td>Processed LPA RIF/INH samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>SP6CAQHWVAE</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=6 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=6d (%)</td>
        <td></td>
        <td>Percentage of samples with 6 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=6 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>sU03j4s9XdO</td>
        <td>DRS - Samples turn-around time: <=5 days (%)</td>
        <td>Turn-around time: <=5d (%)</td>
        <td></td>
        <td>Turn-around time: <=5 days - percentage of samples</td>
        <td>Turn-around time: <=5 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-08-13</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>SzaccE231ip</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=10+ days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=10+d (%)</td>
        <td></td>
        <td>100% of samples</td>
        <td>Xpert MTB/RIF Ultra: <=10+ days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>taM6ep0BP6M</td>
        <td>DRS: Patients with culture SM test (%)</td>
        <td>Culture SM: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with inoculation date for culture SM out of all enrolled patients</td>
        <td>Patients with inoculation date for culture SM</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>TMEDhCBGZ1y</td>
        <td>DRS: Culture SM: <= 3 days (%)</td>
        <td>Culture SM: <=3d (%)</td>
        <td></td>
        <td>Percentage of samples with 3 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture SM: <= 3 days</td>
        <td>Started culture SM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>Trcb8xHsjt6</td>
        <td>DRS - Samples turn-around time: <=9 days (%)</td>
        <td>Turn-around time: <=9d (%)</td>
        <td></td>
        <td>Turn-around time: <=9 days - percentage of samples</td>
        <td>Turn-around time: <=9 days</td>
        <td>Sample collection and arrival events</td>
        <td>Percentage</td>
        <td>2020-08-13</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>Tye8znCo2XQ</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=3 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=3d (%)</td>
        <td></td>
        <td>Percentage of samples with 3 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=3 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>TZWk9KMI4ZG</td>
        <td>DRS: LPA FQ/2LI: 0 days (%)</td>
        <td>LPA FQ/2LI: 0d (%)</td>
        <td></td>
        <td>Percentage of samples with 0 days turn-around time between date of sample collection and test date</td>
        <td>LPA FQ/2LI: 0 days</td>
        <td>Processed LPA FQ/2LI samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>U1hmoiM7tGC</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=5 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=5d (%)</td>
        <td></td>
        <td>Percentage of samples with 5 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=5 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>u8tyaQI2gZv</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=7 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=7d (%)</td>
        <td></td>
        <td>Percentage of samples with 7 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=7 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>UKG5rYhLzB9</td>
        <td>DRS: Xpert MTB/RIF: <=9 days (%)</td>
        <td>Xpert MTB/RIF: <=9d (%)</td>
        <td></td>
        <td>Percentage of samples with 9 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=9 days</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>vAxhDAwCETT</td>
        <td>DRS: LPA RIF/INH: <=10+ days (%)</td>
        <td>LPA RIF/INH: <=10d+ (%)</td>
        <td></td>
        <td>100% of samples</td>
        <td>LPA RIF/INH: <=10+ days</td>
        <td>Processed LPA RIF/INH samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>VRDPmfz0bEE</td>
      </tr>
      <tr>
        <td>VcyNL2HV7bm</td>
        <td>DRS: Culture LM: <= 9 days (%)</td>
        <td>Culture LM: <=9d (%)</td>
        <td></td>
        <td>Percentage of samples with 9 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 9 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>VPCubNFuzbt</td>
        <td>DRS: LPA FQ/2LI: <=1 day (%)</td>
        <td>LPA FQ/2LI: <=1d (%)</td>
        <td></td>
        <td>Percentage of samples with 1 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA FQ/2LI: <=1 day</td>
        <td>Processed LPA FQ/2LI samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>Vt3ZRTycjeI</td>
        <td>DRS: Patients with culture LM test (%)</td>
        <td>Culture LM: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with inoculation date for culture LM out of all enrolled patients</td>
        <td>Patients with inoculation date for culture LM</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>wjoodsLQE59</td>
        <td>DRS: LPA FQ/2LI: <=3 days (%)</td>
        <td>LPA FQ/2LI: <=3d (%)</td>
        <td></td>
        <td>Percentage of samples with 3 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA FQ/2LI: <=3 days</td>
        <td>Processed LPA FQ/2LI samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>Wxp1B8XNZzr</td>
        <td>DRS: Xpert MTB/RIF: <=1 day (%)</td>
        <td>Xpert MTB/RIF: <=1d (%)</td>
        <td></td>
        <td>Percentage of samples with 1 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF: <=1 day</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>x4A5M9cr9oq</td>
        <td>DRS: LPA FQ/2LI: <=4 days (%)</td>
        <td>LPA FQ/2LI: <=4d (%)</td>
        <td></td>
        <td>Percentage of samples with 4 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA FQ/2LI: <=4 days</td>
        <td>Processed LPA FQ/2LI samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>X6dO8wrnZGb</td>
        <td>DRS: Patients with microscopy test (%)</td>
        <td>Microscopy: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with test result for microscopy out of all enrolled patients</td>
        <td>Patients with result for microscopy</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>xAA3QjOSO6O</td>
        <td>DRS: Patients with Xpert MTB/RIF test (%)</td>
        <td>Xpert MTB/RIF: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with test result for Xpert MTB/RIF out of all enrolled patients</td>
        <td>Patients with result for Xpert MTB/RIF</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>tT9zlH1blFN</td>
      </tr>
      <tr>
        <td>xdmAAbHAvnI</td>
        <td>DRS: LPA FQ/2LI: <=10 days (%)</td>
        <td>LPA FQ/2LI: <=10d (%)</td>
        <td></td>
        <td>Percentage of samples with 10 or less days turn-around time between date of sample collection and test date</td>
        <td>LPA FQ/2LI: <=10 days</td>
        <td>Processed LPA FQ/2LI samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U</td>
      </tr>
      <tr>
        <td>xeDY5Q0nchY</td>
        <td>DRS: Culture LM: <= 8 days (%)</td>
        <td>Culture LM: <=8d (%)</td>
        <td></td>
        <td>Percentage of samples with 8 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 8 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
      <tr>
        <td>XOtwbmogZ0G</td>
        <td>DRS: Xpert MTB/RIF Ultra: <=8 days (%)</td>
        <td>Xpert MTB/RIF Ultra: <=8d (%)</td>
        <td></td>
        <td>Percentage of samples with 8 or less days turn-around time between date of sample collection and test date</td>
        <td>Xpert MTB/RIF Ultra: <=8 days</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>aMVNGUT1NrY</td>
      </tr>
      <tr>
        <td>YGEum9Spb2s</td>
        <td>DRS: Patients with LPA FQ/2LI test (%)</td>
        <td>LPA FQ/2LI: test rate (%)</td>
        <td></td>
        <td>Percentage of patients with test result for LPA FQ/2LI out of all enrolled patients</td>
        <td>Patients with result for LPA FQ/2LI</td>
        <td>Enrolled patients (cumulative)</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>jMQBr2VRNuD, tc99ZtxED2U, zcQDItYC8pL</td>
      </tr>
      <tr>
        <td>zvUK5ny3PP1</td>
        <td>DRS: Culture LM: <= 6 days (%)</td>
        <td>Culture LM: <=6d %)</td>
        <td></td>
        <td>Percentage of samples with 6 or less days turn-around time between date of sample collection and inoculation date</td>
        <td>Culture LM: <= 6 days</td>
        <td>Started culture LM tests</td>
        <td>Percentage</td>
        <td>2020-09-21</td>
        <td>x5vJqFVdnvJ</td>
      </tr>
    </table>
    <h2 id="indicatorTypes">Indicator types</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Factor</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Numerator only (number)</td>
        <td>1</td>
        <td>2020-06-29</td>
        <td>CqNPn5KzksS</td>
      </tr>
      <tr>
        <td>Percentage</td>
        <td>100</td>
        <td>2020-07-08</td>
        <td>e1jRVY5Mcq0</td>
      </tr>
    </table>
    <h2 id="programIndicatorGroups">Program Indicator Groups</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td></td>
        <td>2020-09-17</td>
        <td>BXnv12U5Jy3</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td></td>
        <td>2020-09-17</td>
        <td>eri8M3D4v6s</td>
      </tr>
      <tr>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td></td>
        <td>2020-09-17</td>
        <td>FiNCOjpEv2I</td>
      </tr>
      <tr>
        <td>TB DRS - LPA RIF/INH</td>
        <td></td>
        <td>2020-09-16</td>
        <td>INbRAyCAOc4</td>
      </tr>
      <tr>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td></td>
        <td>2020-09-17</td>
        <td>k9lwqiHfz2b</td>
      </tr>
      <tr>
        <td>TB DRS - General</td>
        <td></td>
        <td>2020-08-14</td>
        <td>kmqHGVM4yxV</td>
      </tr>
      <tr>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td></td>
        <td>2020-09-17</td>
        <td>Mvn7IXcHFo0</td>
      </tr>
      <tr>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td></td>
        <td>2020-09-17</td>
        <td>nSgYWeRLjRp</td>
      </tr>
      <tr>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td></td>
        <td>2020-09-17</td>
        <td>oBqt1YD4p9j</td>
      </tr>
      <tr>
        <td>TB DRS - Microscopy</td>
        <td></td>
        <td>2020-08-27</td>
        <td>os6mytOHLuy</td>
      </tr>
      <tr>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td></td>
        <td>2020-09-17</td>
        <td>qPEvRoiKifn</td>
      </tr>
      <tr>
        <td>TB DRS - LPA FQ/2LI</td>
        <td></td>
        <td>2020-09-16</td>
        <td>QTlcFCQucx2</td>
      </tr>
    </table>
    <h3>Program Indicator Groups - Program Indicators</h3>
    <table>
      <tr>
        <th>Prog.Ind. UID</th>
        <th>Program Indicator Group</th>
        <th>Program Indicator</th>
        <th>Program Indicator UID</th>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - error</td>
        <td>CBzjrquAv7v</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: patients - MTB not detected</td>
        <td>CWCpPgb2Y2r</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF - patients - RS</td>
        <td>FEiqi1Eorpi</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Samples with result for Xpert MTB/RIF</td>
        <td>GCs58vwZsyf</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 6 days</td>
        <td>GGmlMcmL9hd</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Patients with result for Xpert MTB/RIF</td>
        <td>gnSeNJoGz9T</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - invalid</td>
        <td>GxBSEkFVnml</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 1 day</td>
        <td>in2GZS5lUD5</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Patients with invalid Xpert MTB/RIF result</td>
        <td>JIZ6X5rD7OK</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: previously treated patients - RS</td>
        <td>l8EQ2Kz8HMy</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - RR</td>
        <td>MJNbrK0Q80m</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - MTB not detected</td>
        <td>n31mFHYciKv</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: patients - RIF indeterminate </td>
        <td>ncciXS4015B</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Processed Xpert MTB/RIF samples</td>
        <td>nhi2Mi5MXVW</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: previously treated patients - RR</td>
        <td>NZul7fh2R8B</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Days between sample collection and Xpert MTB/RIF test</td>
        <td>O81jVgPRPJZ</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: new patients - RS</td>
        <td>oOTpUbHvOxn</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 8 days</td>
        <td>OVysV7KptVe</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 10 days</td>
        <td>PdeRbkFtsIC</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - MTB detected, RIF indeterminate</td>
        <td>PDSh98oi6iG</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 5 days</td>
        <td>PvKoYkm2MCX</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: new patients - RIF indeterminate</td>
        <td>QvrvOrqNR9s</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: previously treated patients - RIF indeterminate</td>
        <td>S8lSfngoxu7</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 4 days</td>
        <td>TUguO2Ynxex</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Patients with valid Xpert MTB/RIF result</td>
        <td>VBrNPAkO9f1</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 3 days</td>
        <td>wHvQW41KS4c</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: new patients - RR</td>
        <td>Wq80cCyFEPj</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 9 days</td>
        <td>XqOkeUv3qn6</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 2 days</td>
        <td>Y9ecVYqq2wF</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 10+ days</td>
        <td>YLgDcklInvQ</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - no result</td>
        <td>ymjPwXARDTy</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: patients - RR</td>
        <td>YrnVXhFyLCd</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: samples - RS</td>
        <td>YsIIurLgmPo</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 0 days</td>
        <td>yw1VqE1IjSk</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: 7 days</td>
        <td>ZcZOvviknKv</td>
      </tr>
      <tr>
        <td>BXnv12U5Jy3</td>
        <td>TB DRS - Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF: patients - MTB detected</td>
        <td>ZWyfaOl5ga7</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: 1 day</td>
        <td>apEsA0h0WnR</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: new patients - NTM detected</td>
        <td>Bl0VfF5WWxe</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Days between sample collection and culture inoculation LM</td>
        <td>BwTuzAmHJY2</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: samples - MTB</td>
        <td>CgDIb7hgosn</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: 9 days</td>
        <td>CtUD7DpDhUt</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: 2 days</td>
        <td>cyOnOSTFAny</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: new patients - contaminated</td>
        <td>elHXs7QIHeg</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: patients - no growth</td>
        <td>emvCVU7nSyP</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: previously treated patients - MTB detected</td>
        <td>fq4aooEypot</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: patients - MTB detected</td>
        <td>hDf5GZVCh6b</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: samples - contaminated</td>
        <td>IV7jORMyeU0</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: 5 days</td>
        <td>JH0XVP5TaUz</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: patients - NTM detected</td>
        <td>K0Ni8uEHLXY</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: 10 days</td>
        <td>l0oQQUpCe0t</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: 7 days</td>
        <td>LKgEs168uwz</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Samples with result for culture LM</td>
        <td>lx4tkD2nyiv</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Patients with result for culture LM</td>
        <td>Nwoz37ThBzC</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: 3 days</td>
        <td>oE4qleMRIsc</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: samples - No growth</td>
        <td>pTDVLacJUAm</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Patients with inoculation date for culture LM</td>
        <td>R1AWAmtWXNh</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: previously treated patients - no growth</td>
        <td>R3JPrdIcmjs</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: 8 days</td>
        <td>RV2PlhWoox8</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: previously treated patients - contaminated</td>
        <td>sRaCkGSjiLt</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: 6 days</td>
        <td>STuGYEEZ6o5</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: new patients - MTB detected</td>
        <td>t3qthExhQKL</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: patients - contaminated</td>
        <td>tIgRROcdrWC</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Samples with inoculation date for culture LM</td>
        <td>vkspdWX0mzd</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: 10+ days</td>
        <td>WJwWEO1wLoD</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: new patients - no growth</td>
        <td>wQisEHlG43c</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: previously treated patients - NTM detected</td>
        <td>WTblEFaKYPi</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: samples - NTM</td>
        <td>xFN86BRI9Z6</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: 4 days</td>
        <td>YhbI5N1k81G</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Started culture LM tests</td>
        <td>yqSM0imyakl</td>
      </tr>
      <tr>
        <td>eri8M3D4v6s</td>
        <td>TB DRS - Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM: 0 days</td>
        <td>ZM7UpCaGTY1</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - R resistant</td>
        <td>B5d9eKm8nRR</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Z resistant</td>
        <td>bbvugBgfLh0</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Dlm resistant</td>
        <td>belqKaig0KY</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Bdq contaminated/indeterminate</td>
        <td>bIHg1wvFPuX</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Am contaminated</td>
        <td>bNdyJEAQZYH</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Mfx CB resistant</td>
        <td>BTG0cxe1miz</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Lfx susceptible</td>
        <td>btPg6w5CrOs</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - E susceptible</td>
        <td>BXayDcGzAQ5</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - H CB resistant</td>
        <td>bxVekLXvoG6</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Dlm contaminated/indeterminate</td>
        <td>BZapNkxbmGh</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Bdq contaminated</td>
        <td>bZiq1qPRaJM</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Mfx CB susceptible</td>
        <td>c0Z8dcZwA9o</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Bdq resistant</td>
        <td>c9iFIVVuVMD</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - R susceptible</td>
        <td>ccIrRzBwp6v</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Lzd contaminated/indeterminate</td>
        <td>CCqP9jWQpAH</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Dlm resistant</td>
        <td>ckCldwmEQAl</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Mfx CC resistant</td>
        <td>CR1sEF01MvB</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Am resistant</td>
        <td>D4I7CFxNoxO</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Dlm susceptible</td>
        <td>d4K0yZYr5sf</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Dlm indeterminate</td>
        <td>d5VDVBgpNff</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Cfz contaminated</td>
        <td>D9GN83zB1tB</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Lfx indeterminate</td>
        <td>dCXS1Srtvzz</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Mfx CC contaminated/indeterminate</td>
        <td>dflTpUL9TOd</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - H CC resistant</td>
        <td>dh2mOeE0ieM</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Mfx CC susceptible</td>
        <td>dNbYkrR3zua</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Lzd indeterminate</td>
        <td>doQ3NVOHYPH</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Mfx CC indeterminate</td>
        <td>DQ6TpILpwGm</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Z susceptible</td>
        <td>DQiw76Xw1r4</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Bdq susceptible</td>
        <td>DTPsQiXmWTp</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - R contaminated/indeterminate</td>
        <td>DXmiExPcVmJ</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Mfx CB susceptible</td>
        <td>EAwBFKFUQcM</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Z contaminated/indeterminate</td>
        <td>elpk5h0qKHQ</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Lzd resistant</td>
        <td>eLzDUToUdCS</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Lzd susceptible</td>
        <td>eohX6MLy3Pz</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - H CB contaminated/indeterminate</td>
        <td>epZELbYw3Dp</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Cfz resistant</td>
        <td>eZ7eIDHaYnM</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - R contaminated/indeterminate</td>
        <td>f7CKyOdJg01</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Lzd contaminated/indeterminate</td>
        <td>F9aDDuk2zH7</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - H CB resistant</td>
        <td>fcxcyNcQjzi</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - H CC resistant</td>
        <td>FFBHhpROVU4</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Lzd contaminated/indeterminate</td>
        <td>ffqUD3Dxlfs</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Bdq susceptible</td>
        <td>FI5yCrIHoow</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Mfx CC susceptible</td>
        <td>fkSqKvpD6PA</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Am resistant</td>
        <td>FNvQMKWecPh</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Mfx CC resistant</td>
        <td>fOxfV0W9xb1</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - H CB susceptible</td>
        <td>G5dwFp4FeUI</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Cfz indeterminate</td>
        <td>GCHhMllhJcW</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - E contaminated/indeterminate</td>
        <td>GGmrn3hUfJ1</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Bdq resistant</td>
        <td>GTJ6K25PdVV</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Bdq indeterminate</td>
        <td>GYiY3HvV1Gy</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Dlm susceptible</td>
        <td>HdRTHmCBN5P</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - E resistant</td>
        <td>hzrdf9T71sf</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - H CC contaminated</td>
        <td>IAyxc41e5Yy</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - H CB susceptible</td>
        <td>ijcH0gNXBx9</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Dlm resistant</td>
        <td>iKfKE7FhH9H</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - E contaminated/indeterminate</td>
        <td>IMmK1P6fBva</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - E contaminated</td>
        <td>IQbtsnDkfAq</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Bdq resistant</td>
        <td>J3ahtr4IVZn</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Z resistant</td>
        <td>j3vGe1RQoJ3</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - H CC resistant</td>
        <td>JBxsvdKtcZI</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Mfx CB contaminated/indeterminate</td>
        <td>jgpxNB7lUtw</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Lzd susceptible</td>
        <td>jihuemWnruh</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Bdq susceptible</td>
        <td>jR50rSWqk0y</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - H CB indeterminate</td>
        <td>jxvva3VcMqQ</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Bdq susceptible</td>
        <td>jZODNlINPVG</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Am contaminated/indeterminate</td>
        <td>k6SBsqcv8Pw</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Cfz susceptible</td>
        <td>KbOntu5fKTV</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Z contaminated/indeterminate</td>
        <td>KJe6BdMVXF3</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Mfx CB susceptible</td>
        <td>kn7mJ4XH40C</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Dlm susceptible</td>
        <td>kqrwj0JOJon</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Mfx CC resistant</td>
        <td>l9WK4N0BUzx</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Lfx contaminated/indeterminate</td>
        <td>LAsyN6saoOd</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Am susceptible</td>
        <td>lvGGYtdHr0u</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - H CB resistant</td>
        <td>lxX3YYtafD4</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - E susceptible</td>
        <td>lyaTr1HCOH2</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Mfx CC contaminated</td>
        <td>Me0P8Hywg5V</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Lzd contaminated</td>
        <td>mQmX7NJ2iWr</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - H CC contaminated/indeterminate</td>
        <td>mU0CgKC2iWM</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Z susceptible</td>
        <td>MVspOs3ajZ8</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - H CC resistant</td>
        <td>mZ25KRwF5Gy</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - R indeterminate</td>
        <td>NadcebWfg1z</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Z resistant</td>
        <td>nbNPEdgcXHR</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Z susceptible</td>
        <td>NJDQNJw2tGD</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - R contaminated</td>
        <td>NQXMN2Td6gk</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - H CB contaminated/indeterminate</td>
        <td>NXVfkJA7wg5</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - R resistant</td>
        <td>NyzaBaIm5jS</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Lfx susceptible</td>
        <td>nzj3O4baUVb</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Mfx CB contaminated</td>
        <td>oaIfTkuTRsC</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - E susceptible</td>
        <td>OlecwgQa57o</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Mfx CB susceptible</td>
        <td>Olrvc8Jhijd</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Cfz resistant</td>
        <td>ou4WNqCxMuu</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Bdq resistant</td>
        <td>Pc6xpNNg7LE</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Z resistant</td>
        <td>pEpZ5PTUhJz</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Bdq contaminated/indeterminate</td>
        <td>Pf9TOtsHmci</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Am susceptible</td>
        <td>pfmjHNJ9x6R</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Am susceptible</td>
        <td>phffikkxLSj</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Lfx contaminated/indeterminate</td>
        <td>Pi8ayoXTRKO</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - E contaminated/indeterminate</td>
        <td>pkgY5FqeFjb</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - R resistant</td>
        <td>PL2mZFknpzr</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Lzd susceptible</td>
        <td>plvxpzzpVzo</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Z indeterminate</td>
        <td>pqKUQg6IVks</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Cfz susceptible</td>
        <td>Pr1eRaFDtRG</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Cfz contaminated/indeterminate</td>
        <td>pvcjXzf476j</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Dlm resistant</td>
        <td>QEcUcHVFJho</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - R susceptible</td>
        <td>QGjAcTm4uv2</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Mfx CB contaminated/indeterminate</td>
        <td>QgZ5U6ocKbS</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Z contaminated/indeterminate</td>
        <td>qtJLBYBxHXE</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Cfz susceptible</td>
        <td>qUcV1AsyrjM</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Patients with result for initial DST LM</td>
        <td>QXiAL03hJjW</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Lzd resistant</td>
        <td>rb5UEJsvHMs</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - E indeterminate</td>
        <td>Rfz2wpp9wsI</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Lzd susceptible</td>
        <td>RK2d2KxY2ln</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Bdq contaminated/indeterminate</td>
        <td>RLMAFAjdM1P</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Am susceptible</td>
        <td>RsElKBSc1kB</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Mfx CC contaminated/indeterminate</td>
        <td>s4ojXwTRVMB</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Mfx CC susceptible</td>
        <td>sGLpHvkrJl0</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Mfx CB resistant</td>
        <td>SGT2z6fisYd</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Am resistant</td>
        <td>smBK9aQLZVt</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Lfx resistant</td>
        <td>Sn1Y3lTblQ2</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Mfx CB contaminated/indeterminate</td>
        <td>snExB8w3Gcm</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - H CB contaminated</td>
        <td>su6weiXSIti</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Cfz susceptible</td>
        <td>svpfoQw6O39</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Lfx contaminated</td>
        <td>tA5pYtchuWU</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - R contaminated/indeterminate</td>
        <td>TeRX9Z45EzR</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - E resistant</td>
        <td>tlmQ6gisAGh</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Dlm susceptible</td>
        <td>tois9I4EkY3</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Lfx contaminated/indeterminate</td>
        <td>TORYgaK1YUF</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Mfx CB indeterminate</td>
        <td>TOU4KSWSS1b</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - H CB susceptible</td>
        <td>TTy1mozDhty</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - H CC indeterminate</td>
        <td>tuy3A2HETxn</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Cfz resistant</td>
        <td>U0KbG9khPd5</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Cfz resistant</td>
        <td>U4YZsFclJlk</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Lzd resistant</td>
        <td>Uchb5CJcAOn</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - H CC susceptible</td>
        <td>uM6AKPkeUwQ</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Samples with result for initial DST LM</td>
        <td>VCucFY6roOu</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - R resistant</td>
        <td>VIgX0suMyw3</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Mfx CC resistant</td>
        <td>vIvpAQtmuvr</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Lfx susceptible</td>
        <td>vjf4N8MCOV3</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Cfz contaminated/indeterminate</td>
        <td>vnRU4p2WNZH</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - H CB contaminated/indeterminate</td>
        <td>VvwaGW8ihTk</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Cfz contaminated/indeterminate</td>
        <td>W8slaPHit8G</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - E resistant</td>
        <td>waI6zGdAC0L</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Lfx susceptible</td>
        <td>WAOO1PP801X</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Am resistant</td>
        <td>Wb7mB8gZmxS</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Am indeterminate</td>
        <td>weuEp8gEYiA</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - E susceptible</td>
        <td>Wh5ltuI2RdR</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - H CC contaminated/indeterminate</td>
        <td>WQ2ZlVJAL1d</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Mfx CC susceptible</td>
        <td>wSl9gzxcHBr</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Lfx resistant</td>
        <td>xCg1UJXJ5Yc</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - H CC susceptible</td>
        <td>XhNxSlnrws1</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Mfx CB resistant</td>
        <td>xLut6liwpel</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - H CB susceptible</td>
        <td>xmRYHCLPMTe</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - E resistant</td>
        <td>xMXHVJ3TGdP</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Samples with inoculation date for initial DST LM</td>
        <td>xRHkullgtDD</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Patients with inoculation date for initial DST LM</td>
        <td>xrpPtTU0Zkc</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - H CC contaminated/indeterminate</td>
        <td>xvIpBKT8S5R</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Z contaminated</td>
        <td>yFUJCbawmOX</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Am contaminated/indeterminate</td>
        <td>yi5Rehcel7M</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Dlm contaminated/indeterminate</td>
        <td>yLH2B6wc2uR</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - H CB resistant</td>
        <td>YOEdyHoPgPV</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Dlm contaminated</td>
        <td>YWOxEKIW5KB</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: previously treated patients - Dlm contaminated/indeterminate</td>
        <td>Z4MdCZDK7cg</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Mfx CC contaminated/indeterminate</td>
        <td>zB5B6o1lCXQ</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Lzd resistant</td>
        <td>ZBWtuPoGXl6</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Am contaminated/indeterminate</td>
        <td>ZCuphHumZGJ</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - Lfx resistant</td>
        <td>zD5P8ROnJci</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - R susceptible</td>
        <td>zd6SD8bbBl3</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Mfx CB resistant</td>
        <td>zgKh2FOhkSv</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - Z susceptible</td>
        <td>zIkLhe4NJc1</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: new patients - H CC susceptible</td>
        <td>ZlyejogmAYG</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - R susceptible</td>
        <td>zsxVBbRRx6D</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: samples - Lfx resistant</td>
        <td>ZUax8mb3Fht</td>
      </tr>
      <tr>
        <td>FiNCOjpEv2I</td>
        <td>TB DRS - Initial DST in liquid media (e.g. MGIT) </td>
        <td>Initial DST LM: patients - H CC susceptible</td>
        <td>ZY5fuX5XP7P</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: patients - INH indeterminate</td>
        <td>aRT2098p8t3</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>Samples with result for LPA RIF/INH</td>
        <td>bE3YcdNxA3g</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>Patients with invalid LPA RIF/INH result</td>
        <td>bUSPnAIXlHM</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: 2 days</td>
        <td>c2pvFmOjpxD</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: patients - RIF susceptible</td>
        <td>CHMTFoEGDYW</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: previously treated patients - INH indeterminate</td>
        <td>coaXGRyCvbg</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: 9 days</td>
        <td>Dh7a17admqQ</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: 5 days</td>
        <td>dIx2cpCkvtj</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: new patients - INH susceptible</td>
        <td>eqA9DYBlpOk</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>Processed LPA RIF/INH samples</td>
        <td>henuXSapu7A</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: new patients - RIF susceptible</td>
        <td>hfYRwQKgaXt</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: previously treated patients - RIF indeterminate</td>
        <td>iK1pi7QPSVA</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: 10+ days</td>
        <td>Ik9eYxKo6pQ</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: samples - INH resistant</td>
        <td>IQERFALbvVz</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: samples - RIF susceptible</td>
        <td>jnBglStivhT</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: 1 day</td>
        <td>JXTklB80mSZ</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>Days between sample collection and LPA RIF/INH test</td>
        <td>LaSMRgk7CXT</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: samples - INH susceptible</td>
        <td>lmfraes6AwW</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: previously treated patients - INH susceptible</td>
        <td>lMxeHgDnnYU</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: samples - INH indeterminate</td>
        <td>lNfI3Vav9ya</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: previously treated patients - INH resistant</td>
        <td>m9N36IcoG1l</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>Patients with result for LPA RIF/INH</td>
        <td>MJ93HUyctIa</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: samples - RIF indeterminate</td>
        <td>MmgqczjBy4x</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: patients - INH susceptible</td>
        <td>mXnpYGKvJOJ</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: 6 days</td>
        <td>NOwoUDobC82</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: patients - INH resistant</td>
        <td>pDr45R9KiqB</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: patients - MTB detected</td>
        <td>pytuZVI0ukZ</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: 4 days</td>
        <td>pYWJoY1zICY</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: new patients - RIF resistant</td>
        <td>qAaqiEtHFgB</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: samples - MTB detected</td>
        <td>qgRHOse57eS</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: samples - MTB not detected</td>
        <td>r1f4FeokEfS</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: 7 days</td>
        <td>s2MFQfmgwDR</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: new patients - INH resistant</td>
        <td>sHgmMnlbGOd</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: new patients - INH indeterminate</td>
        <td>SMQaa2FME9m</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: patients - RIF resistant</td>
        <td>spav9vMokn2</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: patients - RIF indeterminate</td>
        <td>sPBdvSLlJZY</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: 10 days</td>
        <td>u7o1DWalCtg</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: 3 days</td>
        <td>uNBJmNEtRBF</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: samples - Error/Invalid/No result</td>
        <td>VsbiIWP2J2F</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: 8 days</td>
        <td>w3AZnT9pW4i</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: 0 days</td>
        <td>WcDv2gi6Pek</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: previously treated patients - RIF resistant</td>
        <td>XoQx6SJPRTV</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: previously treated patients - RIF susceptible</td>
        <td>y0yp20p5Pfr</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: patients - MTB not detected</td>
        <td>Ym7g5TyBlyV</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: samples - RIF resistant</td>
        <td>yNQDN6Y7RRv</td>
      </tr>
      <tr>
        <td>INbRAyCAOc4</td>
        <td>TB DRS - LPA RIF/INH</td>
        <td>LPA RIF/INH: new patients - RIF indeterminate</td>
        <td>yw5erBUqN3l</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: samples - invalid</td>
        <td>bZYLsyngaPn</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 5 days</td>
        <td>Ccxbjmjx4DF</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 1 day</td>
        <td>CkH4cl9Ip25</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: samples - no result</td>
        <td>cKlPzK4efeq</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Days between sample collection and Xpert MTB/RIF Ultra test</td>
        <td>DVMln9sMq2c</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: patients - RIF indeterminate </td>
        <td>e33nRsNWbUl</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 0 days</td>
        <td>EbYQHywJJT7</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 9 days</td>
        <td>F790gdBXKhI</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Patients with result for Xpert MTB/RIF Ultra</td>
        <td>fpV3tkYm9rn</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: previously treated patients - RIF indeterminate</td>
        <td>gZCthbeejQI</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: new patients - RIF indeterminate</td>
        <td>Hbaf9zZw15P</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: samples - MTB detected, RIF indeterminate</td>
        <td>hHniKx89xJK</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Patients with invalid Xpert MTB/RIF Ultra result</td>
        <td>HTBvmWX11N2</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: new patients - RS</td>
        <td>IIRJBuBrOTJ</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 7 days</td>
        <td>jvvRyJ0orNz</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 4 days</td>
        <td>Kk7fwdFUnYo</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: previously treated patients - RS</td>
        <td>LRW1AeEUfTs</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 10 days</td>
        <td>LuoF6aB4C7j</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 6 days</td>
        <td>NkcFiEE3PpA</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Patients with valid Xpert MTB/RIF Ultra result</td>
        <td>nNXqEhYPq12</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 2 days</td>
        <td>NqXeQze1Q7b</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 8 days</td>
        <td>NVZjjPEo2QI</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 10+ days</td>
        <td>NyyAfu95mCo</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: patients - MTB not detected</td>
        <td>Poolb0bKeix</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: previously treated patients - RR</td>
        <td>pzTm4eHbXdp</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: samples - RR</td>
        <td>qQlS4yw9RaV</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: samples - MTB not detected</td>
        <td>QSa605mN246</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Samples with result for Xpert MTB/RIF Ultra</td>
        <td>rkXSq0Sf1Lc</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: samples - RS</td>
        <td>SH0iOmEe0AR</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: patients - MTB detected</td>
        <td>SJIgoySQSL9</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: 3 days</td>
        <td>tqXqhNzjbLK</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: samples - error</td>
        <td>v4o5oChYOcF</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: new patients - RR</td>
        <td>XBM747hHcXa</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Processed Xpert MTB/RIF Ultra samples</td>
        <td>Ydf2CAJR8of</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: patients - RR</td>
        <td>ykeijqKZSTD</td>
      </tr>
      <tr>
        <td>k9lwqiHfz2b</td>
        <td>TB DRS - Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra: patients - RS</td>
        <td>ZLg4V9cAXmw</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Missing data: age</td>
        <td>AIhr0Sqq0Nl</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Patients with negative HIV status</td>
        <td>dOXNXZWb32d</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Patients with positive HIV status</td>
        <td>FGsZGC28X8R</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Enrolled patients</td>
        <td>gTPmPsKLwdR</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Samples rejected on arrival</td>
        <td>hZP8QqW2Hgr</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Missing data: TB treatment history</td>
        <td>Ir4RiYE3Nke</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Previously treated patients (cumulative)</td>
        <td>J9VPfek4eYG</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Patients with unknown HIV status</td>
        <td>jhm47tAnQV8</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Patients with unknown treatment history (cumulative)</td>
        <td>nDbv7VbejeH</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Sample collection and arrival events</td>
        <td>P9K7xj7hHgZ</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>New patients (cumulative)</td>
        <td>PK5i0N7y7Ja</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Enrolled patients (cumulative)</td>
        <td>qd9PbhmNYnR</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Missing data: patients with no registered age, gender, HIV test result, or TB treatment history</td>
        <td>qGLJdB5Qg2I</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Missing data: gender</td>
        <td>vXwdB7fhkW5</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Missing data: HIV test result</td>
        <td>XOE7Mzfedq4</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Sample processing events, total</td>
        <td>Z0pHyvWCUNG</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Days between all lab sample collection and arrival, sum</td>
        <td>ZeEskzvKb72</td>
      </tr>
      <tr>
        <td>kmqHGVM4yxV</td>
        <td>TB DRS - General</td>
        <td>Patients with 1+ test started, cumulative</td>
        <td>zIR9P1JOf0P</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - E resistant</td>
        <td>AAaf1N6q9Kc</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Lzd contaminated</td>
        <td>ADNg2qsAAcK</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Mfx CB contaminated</td>
        <td>Ae5XHffdlOT</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - E susceptible</td>
        <td>ahmEPvvLdlB</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Cfz susceptible</td>
        <td>AhU8qnVRvyB</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - H CC indeterminate</td>
        <td>Aiy6br5cVtS</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - H CC contaminated</td>
        <td>aLoApEYPHN8</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - R resistant</td>
        <td>aQYGSuGN2yc</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Z indeterminate</td>
        <td>ASk2lczUEoC</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Mfx CC resistant</td>
        <td>ATlmsxFz21i</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Lfx susceptible</td>
        <td>AxJiEHXPR4O</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Samples with inoculation date for subsequent DST LM</td>
        <td>BAx8oO7z3BL</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Cfz resistant</td>
        <td>Bd06WGYcdgI</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Am contaminated/indeterminate</td>
        <td>bg6znd2CWYH</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - H CB susceptible</td>
        <td>BifclMTmRC8</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Bdq contaminated/indeterminate</td>
        <td>bPWnbBZ4zc1</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Am contaminated/indeterminate</td>
        <td>bSe8cLu9vaB</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - H CB susceptible</td>
        <td>bxokCBL7Fa6</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Dlm resistant</td>
        <td>bYO87TQdvrx</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - R contaminated/indeterminate</td>
        <td>cD6yomdezwR</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Am contaminated</td>
        <td>D1txAWeoz5n</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Bdq contaminated</td>
        <td>D2XDPZzaKjH</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Mfx CB resistant</td>
        <td>D74MdAoARVD</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Mfx CB contaminated/indeterminate</td>
        <td>dBGD2K40yW9</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Lfx resistant</td>
        <td>djuou80be4X</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Mfx CC resistant</td>
        <td>dkKIGNb3BPe</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Cfz indeterminate</td>
        <td>dvBHjZYq37O</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Mfx CC indeterminate</td>
        <td>eCIxImB6qsO</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - R contaminated</td>
        <td>ecuAlCQqOV0</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - H CC susceptible</td>
        <td>eId8rqyJur9</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Mfx CC susceptible</td>
        <td>enpdoV1nHk0</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - H CC susceptible</td>
        <td>EPdS0YCH90B</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Bdq susceptible</td>
        <td>EpspNpkl2xy</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Bdq susceptible</td>
        <td>erA6BTudlqi</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - R resistant</td>
        <td>eSVL9Sr7zpp</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Lfx contaminated/indeterminate</td>
        <td>F7BmHiwjier</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Lfx susceptible</td>
        <td>Fgoss6VRywe</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - R susceptible</td>
        <td>fmtrEnAYaRK</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Bdq resistant</td>
        <td>FNYTBE2wcLm</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Bdq contaminated/indeterminate</td>
        <td>frJyeMsmKYo</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Dlm resistant</td>
        <td>fUdI3Clnew1</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - R resistant</td>
        <td>fYERuvsUVki</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Mfx CC resistant</td>
        <td>fyw7CVbbp5r</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Cfz contaminated</td>
        <td>g9Sp1K9EgQZ</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Am resistant</td>
        <td>gCQxWn0enit</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Lzd resistant</td>
        <td>GGor2BR1Yq1</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Mfx CC contaminated/indeterminate</td>
        <td>GPMaGbyEjG4</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - H CC resistant</td>
        <td>htk2PaBn9n6</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Cfz susceptible</td>
        <td>HTYSiumflrW</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Mfx CC susceptible</td>
        <td>HuH9Wbdba4q</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Z susceptible</td>
        <td>hvqTrO9xqPC</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - E resistant</td>
        <td>HXeaRn0AaLL</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Bdq susceptible</td>
        <td>hZn5S7DWqzF</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Mfx CC contaminated</td>
        <td>HZQG39GLjUK</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Patients with result for subsequent DST LM</td>
        <td>I4aotZJ6il4</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - E contaminated/indeterminate</td>
        <td>IOIQueZoXmk</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - H CB resistant</td>
        <td>IpbcHr0Sl5m</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - R susceptible</td>
        <td>IZmFYcpgXBt</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - H CB contaminated</td>
        <td>j3G2AoTFI9u</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Lfx susceptible</td>
        <td>Je3u7mBTONj</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Dlm contaminated/indeterminate</td>
        <td>jFmQ13LrhXY</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - H CB susceptible</td>
        <td>jIlJF6otQaS</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Lfx resistant</td>
        <td>JuE3ZTRER0P</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Mfx CB susceptible</td>
        <td>JxdzwSOjm8A</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Mfx CB contaminated/indeterminate</td>
        <td>k1YfISnKxoF</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Mfx CB susceptible</td>
        <td>KBbgHraFGGs</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Cfz contaminated/indeterminate</td>
        <td>kBPPbfaHHLL</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Z susceptible</td>
        <td>kDH4tyBM6FG</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Lfx resistant</td>
        <td>kghHkgNoh1r</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Cfz susceptible</td>
        <td>KXylN7DLOAI</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Dlm contaminated/indeterminate</td>
        <td>l2og8x5vEYa</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - E resistant</td>
        <td>l9hGqsUThxS</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Lzd resistant</td>
        <td>Lc5HjAi5vyL</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Lfx contaminated</td>
        <td>lopaZTLHpyB</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - H CC contaminated/indeterminate</td>
        <td>LX5Y5X1ijjJ</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - E contaminated/indeterminate</td>
        <td>maRlEPKLrit</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Lfx susceptible</td>
        <td>mI5CLdPFdly</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - E contaminated/indeterminate</td>
        <td>MkaxSDtr5lN</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Bdq resistant</td>
        <td>MkpDzk0VVOn</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Bdq contaminated/indeterminate</td>
        <td>Ml5TUmEp9co</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Z contaminated</td>
        <td>MnhS9zbQTuz</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - R indeterminate</td>
        <td>MNQ2cVPKts0</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Mfx CB resistant</td>
        <td>MRE4oCbTgdp</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Lzd resistant</td>
        <td>mS4y1f2N2qr</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Cfz contaminated/indeterminate</td>
        <td>mUmuZc4YfoA</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Am susceptible</td>
        <td>MwMGpZDEsVq</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Am resistant</td>
        <td>mWVJ6NngcOg</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - H CC resistant</td>
        <td>N8T2Ka08phP</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Lzd susceptible</td>
        <td>NeWHeUHbtLY</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Mfx CB indeterminate</td>
        <td>nl8UjHDuOJp</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - E susceptible</td>
        <td>ntgkubZBIVR</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Mfx CC susceptible</td>
        <td>o2vVY3Tou4b</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Am resistant</td>
        <td>o5VfgMGlYLo</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - H CB resistant</td>
        <td>O6It7XLWzij</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Dlm resistant</td>
        <td>OebNebICI0h</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Bdq susceptible</td>
        <td>oftX0vZAM9r</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - E contaminated</td>
        <td>onZWy5SCjZ5</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - H CC resistant</td>
        <td>oqv395bpDv1</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Lzd contaminated/indeterminate</td>
        <td>PgBqxJAbupy</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Dlm susceptible</td>
        <td>phorDunwGXo</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - H CB contaminated/indeterminate</td>
        <td>PJZO3meSj8D</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Patients with inoculation date for subsequent DST LM</td>
        <td>PldVWpl9xeq</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Z contaminated/indeterminate</td>
        <td>pLUGwLLLQMF</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Lfx contaminated/indeterminate</td>
        <td>pMGwv0JLXEt</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Lzd susceptible</td>
        <td>PtpSwoTHmcG</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Z contaminated/indeterminate</td>
        <td>PUMHNoEubMR</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - H CB resistant</td>
        <td>pXysNcjM76l</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Cfz contaminated/indeterminate</td>
        <td>QjC1EgtnJAD</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Mfx CC resistant</td>
        <td>QmGU5r5l9Ab</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Mfx CC susceptible</td>
        <td>qoEyqH4wwwm</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - R contaminated/indeterminate</td>
        <td>QxlIXjaP09h</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Cfz susceptible</td>
        <td>REb86WxR7NW</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Dlm - contaminated</td>
        <td>rWJyTJVZl5s</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Am contaminated/indeterminate</td>
        <td>RZPj0Wrcnxn</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Z susceptible</td>
        <td>S33osVSK7bu</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Mfx CB susceptible</td>
        <td>SftNGftUtHI</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - H CC contaminated/indeterminate</td>
        <td>sg927BRQATg</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Dlm indeterminate</td>
        <td>sJxBmDVVRFI</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - H CB susceptible</td>
        <td>SNTw9Vpw8qb</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - H CC contaminated/indeterminate</td>
        <td>ss7bHfxhLrq</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Lzd susceptible</td>
        <td>stEHUWnoMq5</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Lfx contaminated/indeterminate</td>
        <td>Tcq1ZiYT7Yq</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Dlm susceptible</td>
        <td>Tegm0xLM4rn</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Dlm susceptible</td>
        <td>titK1r1BOlH</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Z resistant</td>
        <td>tJa81zjWUkG</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Am resistant</td>
        <td>TXzYZ5NUzGE</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Lfx indeterminate</td>
        <td>U5WRXT9rtyA</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Am susceptible</td>
        <td>UBxYSphJOOI</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - E susceptible</td>
        <td>UnMZYDDbWef</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Mfx CC contaminated/indeterminate</td>
        <td>uSojnfuocie</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Mfx CB contaminated/indeterminate</td>
        <td>uvQVPvXOXSK</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Lzd contaminated/indeterminate</td>
        <td>Uy0fdbBkqgV</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Cfz resistant</td>
        <td>V0x2p9VH7D8</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Z susceptible</td>
        <td>V4GWEENoVdy</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Am susceptible</td>
        <td>veREteT6hlg</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Z resistant</td>
        <td>VkB0mC22R4E</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Dlm susceptible</td>
        <td>VPiRrxWIeAu</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Am susceptible</td>
        <td>VrkQDJXIDDP</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - H CB resistant</td>
        <td>vSMBlVfDmft</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Mfx CB resistant</td>
        <td>vYwZAP4yu5U</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Am indeterminate</td>
        <td>WdtDDovKwwJ</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Lzd susceptible</td>
        <td>wfYOu1lx6Qa</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Lfx resistant</td>
        <td>WiIoqdGvg1M</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - E resistant</td>
        <td>wqHfPAv7vWy</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Samples with result for subsequent DST LM</td>
        <td>wsLnXY7LDlA</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Lzd indeterminate</td>
        <td>WzSjzok3JLp</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - R susceptible</td>
        <td>x0BuFyVqp5G</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - H CC resistant</td>
        <td>x2pAZdpQDUD</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - R resistant</td>
        <td>xEEDBnzahPe</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - H CB contaminated/indeterminate</td>
        <td>XGMW0GtBuNg</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Bdq resistant</td>
        <td>xMEWouqClFf</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - R susceptible</td>
        <td>xPHG0IoL3gy</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Bdq resistant</td>
        <td>XqdaRwwmYFx</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Mfx CB susceptible</td>
        <td>xQzcgF6mGZd</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - R contaminated/indeterminate</td>
        <td>xRxkG7NLgxN</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Dlm resistant</td>
        <td>XtISOg6IH58</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - H CC susceptible</td>
        <td>Xvi6xboD8rO</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Lzd resistant</td>
        <td>xWTCtUoYESr</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Bdq indeterminate</td>
        <td>Y3IoUjmY7AN</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Z resistant</td>
        <td>yEIeCX7IwVi</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - H CB contaminated/indeterminate</td>
        <td>YgU4PmqMkzP</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Z resistant</td>
        <td>YhxAkBpMTmd</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Dlm contaminated/indeterminate</td>
        <td>YRkeyxS2xir</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Mfx CB resistant</td>
        <td>YTfcpgyo1OW</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - Lzd contaminated/indeterminate</td>
        <td>zBFap1a5xsV</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - E indeterminate</td>
        <td>zdHSqAwHF7w</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - Mfx CC contaminated/indeterminate</td>
        <td>zdJzjF1oAzR</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Z contaminated/indeterminate</td>
        <td>ZEWoHGVMJHT</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: previously treated patients - Cfz resistant</td>
        <td>ZONe9AdoHYE</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - Cfz resistant</td>
        <td>zp3uN4hpm22</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: patients - H CC susceptible</td>
        <td>zq6n2KdR9yQ</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: samples - H CB indeterminate</td>
        <td>ZQk5pK5QPhu</td>
      </tr>
      <tr>
        <td>Mvn7IXcHFo0</td>
        <td>TB DRS - Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM: new patients - E susceptible</td>
        <td>Zvwpbgxmp94</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - H CC susceptible</td>
        <td>A4tOZ6DtOz6</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Dlm resistant</td>
        <td>A9gJNpnubW6</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - H CB contaminated/indeterminate</td>
        <td>abdl4RkyzwL</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Bdq resistant</td>
        <td>adnY7HmKOSi</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - R contaminated</td>
        <td>AnE9y3CTG55</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Dlm susceptible</td>
        <td>AoNRpuKHFIA</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Mfx CC resistant</td>
        <td>ap5DhakUaof</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Mfx CB susceptible</td>
        <td>APrBMG15JPD</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - H CC susceptible</td>
        <td>aqiSmfOO1Y8</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Cfz contaminated/indeterminate</td>
        <td>AUZxWKFQOIK</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Z contaminated/indeterminate</td>
        <td>aW1dvUXmJzF</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Lzd resistant</td>
        <td>b5ipTVVUxgZ</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - H CB resistant</td>
        <td>B9veWJCIhm3</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Lzd susceptible</td>
        <td>BDa3bpSHQfR</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Lzd susceptible</td>
        <td>booODOHpIFb</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Mfx CB susceptible</td>
        <td>bPfqNC7BOgJ</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Am contaminated/indeterminate</td>
        <td>BQ8ftQEraa4</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Mfx CC indeterminate</td>
        <td>bYFSgzsh4y2</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Mfx CC contaminated/indeterminate</td>
        <td>BzfUTfps4gS</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Mfx CB resistant</td>
        <td>c7A83DBkpom</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Z resistant</td>
        <td>cVY0RGqdI69</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Lzd contaminated/indeterminate</td>
        <td>cYQnmEGAuSH</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - R susceptible</td>
        <td>dEk1wwgfnnD</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Dlm indeterminate</td>
        <td>dlC6LusCW5i</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Lzd susceptible</td>
        <td>dZ0rHB1EkHD</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Z susceptible</td>
        <td>e9RjhGOu3Fz</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - H CB susceptible</td>
        <td>EELFTduH3M9</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - R contaminated/indeterminate</td>
        <td>EEQ0GjzL3Xl</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Lfx indeterminate</td>
        <td>EfhWg7dKNsv</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Z contaminated/indeterminate</td>
        <td>eHQizAJZuXK</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - R resistant</td>
        <td>EICJmQVZa2a</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Patients with inoculation date for subsequent DST SM</td>
        <td>EtO96EwY8GU</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Z resistant</td>
        <td>EvcKhBk9htx</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Dlm contaminated</td>
        <td>f8OaQON8Jug</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Dlm susceptible</td>
        <td>FMvbZg2LHhV</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Am susceptible</td>
        <td>FNMPwjQNg4U</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Am resistant</td>
        <td>FRGmGDJHpkM</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Cfz susceptible</td>
        <td>fxAlrUlm1GU</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - R susceptible</td>
        <td>g3oYfS8eQAq</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Am susceptible</td>
        <td>Gc2umtqZ1lY</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Mfx CB susceptible</td>
        <td>GCpLmFiy28k</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - H CC resistant</td>
        <td>GDUhrJPqy6w</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Bdq resistant</td>
        <td>gHTL2er7krj</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Bdq indeterminate</td>
        <td>GLSkgEz1sfT</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - E resistant</td>
        <td>gnJSzbNuMYw</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Dlm contaminated/indeterminate</td>
        <td>GStm6UzOQdq</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Mfx CC susceptible</td>
        <td>gvvZUXARGg0</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - E contaminated</td>
        <td>H0uraA1hI5d</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Am indeterminate</td>
        <td>H185R6OCh9r</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - E resistant</td>
        <td>h8kBZ3K0T2d</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - H CC contaminated/indeterminate</td>
        <td>hcnG8PMuECt</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Cfz resistant</td>
        <td>hhcHMksqM3z</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - H CC susceptible</td>
        <td>HkdrJSar6If</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Lzd resistant</td>
        <td>HLrMymgpoqI</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Mfx CB contaminated/indeterminate</td>
        <td>hLYwIBpo278</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Lzd indeterminate</td>
        <td>HqO6R44DBqY</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Lfx resistant</td>
        <td>HxB1sbrTKkv</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Mfx CB resistant</td>
        <td>IPCjhHOQMWl</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Cfz contaminated/indeterminate</td>
        <td>IWSzulLtcRU</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Z contaminated</td>
        <td>j1utfSEDGOO</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Cfz resistant</td>
        <td>J230BlAaQlK</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Lzd resistant</td>
        <td>J3wjJEF8aq0</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Z contaminated/indeterminate</td>
        <td>j89ph75ZaX8</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - E susceptible</td>
        <td>JCJ6UNRWuJi</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - H CB contaminated/indeterminate</td>
        <td>jcm5Bo8ve5A</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Mfx CB contaminated/indeterminate</td>
        <td>JDINMJYfpt8</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - H CB indeterminate</td>
        <td>jKYooU49mG4</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - H CC resistant</td>
        <td>JqBF765vRaI</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Mfx CC susceptible</td>
        <td>JsAylXp8loj</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - R susceptible</td>
        <td>jyLq8xUOZne</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - H CC contaminated/indeterminate</td>
        <td>K3RhiJId07S</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - H CB resistant</td>
        <td>kGnLALoufUa</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Z susceptible</td>
        <td>Kl1ONdPznGh</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - E contaminated/indeterminate</td>
        <td>kLiVVkPNcEG</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Lzd susceptible</td>
        <td>KNZKCM67NGi</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - R resistant</td>
        <td>KW0n6JUuqVn</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - H CB resistant</td>
        <td>lfHTvcRzmXT</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Bdq susceptible</td>
        <td>LhJkKbrTOOS</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - H CC resistant</td>
        <td>LOLIwqxd2wm</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Am contaminated</td>
        <td>LROUBwdzaVw</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Mfx CC resistant</td>
        <td>M2IinLZavHj</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Lzd contaminated/indeterminate</td>
        <td>m5nShXZwfvl</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - H CC contaminated/indeterminate</td>
        <td>M74bikagdCn</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Mfx CB susceptible</td>
        <td>M7Z1bApwb6J</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Bdq contaminated/indeterminate</td>
        <td>MAfGE8h9nR5</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Lzd contaminated/indeterminate</td>
        <td>MGHQjfJcv8i</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Am susceptible</td>
        <td>MlKowimCL4m</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Z indeterminate</td>
        <td>mqf825wSgBW</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Bdq resistant</td>
        <td>MQz9ho7oTxM</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Z susceptible</td>
        <td>MX0ZgqJRARO</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - H CB contaminated/indeterminate</td>
        <td>nAG3hPJLNRZ</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - H CC resistant</td>
        <td>nFdMqXBCHgs</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Lfx susceptible</td>
        <td>NfZJb3KTVAO</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Samples with result for subsequent DST SM</td>
        <td>NiZZuTnJcqI</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - R resistant</td>
        <td>NLogSNyPLrG</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Mfx CC contaminated/indeterminate</td>
        <td>nNgTAOUHVVf</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Bdq contaminated/indeterminate</td>
        <td>nvL2apj8ESp</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Lfx susceptible</td>
        <td>nVXSEczhAvM</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Bdq susceptible</td>
        <td>NYBeJuBeqD6</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Dlm susceptible</td>
        <td>NzGW6C58GkF</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Z resistant</td>
        <td>O9hhMPIUYZO</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Dlm resistant</td>
        <td>oeZepiNfmKj</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Lzd contaminated</td>
        <td>OLR2G7P2KLX</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Cfz contaminated/indeterminate</td>
        <td>OQeEjNs3Ho9</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - H CC contaminated</td>
        <td>oUz32KzStH0</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - R indeterminate</td>
        <td>oz7eO5DDvNa</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Mfx CB contaminated/indeterminate</td>
        <td>pDF9ROzD1cb</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Dlm susceptible</td>
        <td>PPl4KMHIJT3</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Mfx CC resistant</td>
        <td>PpTb1ERfg3Q</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Am resistant</td>
        <td>pwDBHevJNrL</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - E susceptible</td>
        <td>q76HsI6ClCd</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Cfz susceptible</td>
        <td>q9KghOGpcdq</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Cfz indeterminate</td>
        <td>QLdY9WHtJDz</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Cfz resistant</td>
        <td>qxFMe08GfWQ</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Dlm contaminated/indeterminate</td>
        <td>RBicbarJPl4</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Lfx contaminated/indeterminate</td>
        <td>rcICF38L7mE</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - R contaminated/indeterminate</td>
        <td>RCuCuQq8EVw</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - H CC susceptible</td>
        <td>rMKJMrIdwxU</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Bdq contaminated/indeterminate</td>
        <td>rocQB4VEATy</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Am resistant</td>
        <td>rShSocJ14lJ</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Am susceptible</td>
        <td>ruLVyeypubb</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Lfx resistant</td>
        <td>s8ca1kbNVCy</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Bdq susceptible</td>
        <td>SARbVYz3ovb</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - H CB susceptible</td>
        <td>SbfRyAQCsp4</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Mfx CC contaminated</td>
        <td>SkrMaOzuaOx</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Lfx contaminated/indeterminate</td>
        <td>srZG8NDtJ3h</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Bdq susceptible</td>
        <td>SwmPVQY2FJ3</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Am resistant</td>
        <td>sYiVV33usyC</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - H CB resistant</td>
        <td>SzYSBtaPujQ</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Mfx CC susceptible</td>
        <td>T1D14wQc6Pe</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Mfx CB contaminated</td>
        <td>TAJrVlUWA15</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Mfx CB resistant</td>
        <td>TePspFbeIA5</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - H CB susceptible</td>
        <td>TkKU87tvUfC</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Cfz resistant</td>
        <td>U61I4srgNTl</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - H CB contaminated</td>
        <td>Ugg2hcmNkv1</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Dlm resistant</td>
        <td>uHVdQW61TK6</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - E contaminated/indeterminate</td>
        <td>uOiAgPqfSca</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - H CC indeterminate</td>
        <td>Ur2unOu0ABe</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - E susceptible</td>
        <td>UuJnpUZEIMt</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Patients with result for subsequent DST SM</td>
        <td>uXexeo22Whu</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Lfx resistant</td>
        <td>UzmVwVcCDsP</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Dlm resistant</td>
        <td>V36JWd4DEwS</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Am contaminated/indeterminate</td>
        <td>V8h0smTVb4r</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Lfx susceptible</td>
        <td>vJljhgD71Ny</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - R contaminated/indeterminate</td>
        <td>VTQkjI3hSkm</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - Z resistant</td>
        <td>vWmY0yvNVfc</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Bdq contaminated</td>
        <td>VxJFIFNjhb4</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - E indeterminate</td>
        <td>W0OTsurXcBq</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Mfx CC resistant</td>
        <td>W3jcBVNTObT</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Lfx contaminated</td>
        <td>w4Oc9nvJwmg</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Lfx contaminated/indeterminate</td>
        <td>WaQFRJ0X8xv</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Lzd resistant</td>
        <td>WjpPcWta7Gz</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Samples with inoculation date for subsequent DST SM</td>
        <td>wxKzVyo48o2</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Lfx resistant</td>
        <td>Wyv5aIEB1Gl</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Dlm contaminated/indeterminate</td>
        <td>XdE897XapaW</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Mfx CC susceptible</td>
        <td>xDI1TZpYM8S</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Mfx CC contaminated/indeterminate</td>
        <td>XjFQ4NnAU7N</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Bdq resistant</td>
        <td>xLxjI8jmbas</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Cfz susceptible</td>
        <td>XRPgDH3Z3Fq</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - H CB susceptible</td>
        <td>YADgwHM5hbx</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Mfx CB indeterminate</td>
        <td>yb8FgBYSj32</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Z susceptible</td>
        <td>YCmTdM8P0s0</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Mfx CB resistant</td>
        <td>YGAd7tN7N6e</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Cfz susceptible</td>
        <td>yIGqQACwPj5</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - R resistant</td>
        <td>ylIA0CiL0uz</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - Am contaminated/indeterminate</td>
        <td>ymG3jrd4Aba</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - E susceptible</td>
        <td>YOjNYg1yUIh</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: previously treated patients - E resistant</td>
        <td>YqnFKRIK0VQ</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: samples - Cfz contaminated</td>
        <td>YVm2y4ROVLo</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - E contaminated/indeterminate</td>
        <td>YytrJOimdR2</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - Lfx susceptible</td>
        <td>ZiA5jXTrmaY</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: patients - E resistant</td>
        <td>ZiVkPofyVfW</td>
      </tr>
      <tr>
        <td>nSgYWeRLjRp</td>
        <td>TB DRS - Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM: new patients - R susceptible</td>
        <td>ZZoPud9wM6I</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: previously treated patients - contaminated</td>
        <td>aLyPlwg2jot</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: patients - contaminated</td>
        <td>BRoeNFPYHhT</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Started culture SM tests</td>
        <td>bXTRrrObrqh</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Patients with inoculation date for culture SM</td>
        <td>c5whDMhSvRT</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Days between sample collection and culture inoculation SM</td>
        <td>dGKwqxO3eKj</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: 0 days</td>
        <td>EqAuIAkWriW</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Samples with inoculation date for culture SM</td>
        <td>eSmBD2Ihlyp</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: patients - MTB detected</td>
        <td>EU2sU2GqFEJ</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: 7 days</td>
        <td>fFuaaoUS5fC</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: 8 days</td>
        <td>FrIJvXbBKJ9</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: 10+ days</td>
        <td>h3ZPbULlyUP</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Patients with result for culture SM</td>
        <td>HRT8j3uimEB</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: new patients - contaminated</td>
        <td>HT5df1hXx46</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: 4 days</td>
        <td>hyoQv9Zr56m</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: 6 days</td>
        <td>JCsNAS3pqZZ</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: patients - no growth</td>
        <td>JxcokEnr3xj</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: 5 days</td>
        <td>kgPgADkI9De</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: previously treated patients - NTM detected</td>
        <td>l3xgbTao9qK</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: 10 days</td>
        <td>Lje8dx9lWYQ</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Samples with result for culture SM</td>
        <td>lZ1tOjYHm2t</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: 2 days</td>
        <td>mNIzirHVwvO</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: new patients - NTM detected</td>
        <td>MuqppHWlVvW</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: samples - NTM</td>
        <td>NuvmZiORoOd</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: samples - no growth</td>
        <td>oXa3DtiSYe0</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: 1 day</td>
        <td>Rlbs4UiZydq</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: samples - contaminated</td>
        <td>RX5YwuS9RbM</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: patients - NTM detected</td>
        <td>snFxSirfErx</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: previously treated patients - MTB detected</td>
        <td>UrPUE2i8GAU</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: 9 days</td>
        <td>utTgYdaTGrb</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: previously treated patients - no growth</td>
        <td>vlhg0jTKrsH</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: 3 days</td>
        <td>x9RZw5fD8fa</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: new patients - MTB detected</td>
        <td>xDByzKWh8B5</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: new patients - no growth</td>
        <td>XZiRvxDYZTg</td>
      </tr>
      <tr>
        <td>oBqt1YD4p9j</td>
        <td>TB DRS - Culture in solid media (e.g. LJ)</td>
        <td>Culture SM: samples - MTB</td>
        <td>ZPXThwLCqnd</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS - Microscopy</td>
        <td>Microscopy: previously treated patients - negative</td>
        <td>by5T3Wqf1Yx</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS - Microscopy</td>
        <td>Microscopy: patients - positive</td>
        <td>G3yAX5ER7E3</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS - Microscopy</td>
        <td>Microscopy: patients - negative</td>
        <td>HDPycwY4BhS</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS - Microscopy</td>
        <td>Microscopy: new patients - positive</td>
        <td>HxgMmSOXRO9</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS - Microscopy</td>
        <td>Samples with result for microscopy</td>
        <td>rV8cfZVEqZK</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS - Microscopy</td>
        <td>Microscopy: previously treated patients - positive</td>
        <td>RZEpC4Mmmsp</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS - Microscopy</td>
        <td>Microscopy: new patients - negative</td>
        <td>YkUfHLCaQMC</td>
      </tr>
      <tr>
        <td>os6mytOHLuy</td>
        <td>TB DRS - Microscopy</td>
        <td>Patients with result for microscopy</td>
        <td>ZxM3pubMWLI</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Z contaminated/indeterminate</td>
        <td>A6hImpJUCnp</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Mfx CB susceptible</td>
        <td>aEQVSqDQ91m</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Mfx CC indeterminate</td>
        <td>AJ626bsdSe7</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Lfx contaminated</td>
        <td>ATMaMtQexcy</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - H CC resistant</td>
        <td>AZuK40TqYeX</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Bdq contaminated/indeterminate</td>
        <td>BaMzkG7QFr3</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - E resistant</td>
        <td>BBfev9dl9RM</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Mfx CC susceptible</td>
        <td>bibTiiTflBW</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - H CC contaminated/indeterminate</td>
        <td>bLhO4Hh4j7O</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Am resistant</td>
        <td>C2bwEfFwiBX</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Cfz susceptible</td>
        <td>c2PFlkVS4Zz</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Samples with inoculation date for initial DST SM</td>
        <td>cJ9JXbZ0itN</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Bdq contaminated</td>
        <td>cKpRfFeeqeK</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - H CC contaminated/indeterminate</td>
        <td>cOFUIqdayX1</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - E contaminated/indeterminate</td>
        <td>cyJiS3rV7KV</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Cfz contaminated/indeterminate</td>
        <td>d2CN7zcwQq2</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - E resistant</td>
        <td>d5iwto9PKqu</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Dlm resistant</td>
        <td>DesYHcLzFQQ</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - H CC susceptible</td>
        <td>dhS0qZCbUgr</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Mfx CB contaminated/indeterminate</td>
        <td>DmK5rIflVja</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Lfx resistant</td>
        <td>dU8neclU24g</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Bdq susceptible</td>
        <td>dZZHJma1Kge</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Am contaminated/indeterminate</td>
        <td>e0cJcbD47aQ</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - R susceptible</td>
        <td>e0gi9i7AftL</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - H CB susceptible</td>
        <td>E4zdpgEfh2D</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Lzd susceptible</td>
        <td>EGNwXUQWIKb</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Mfx CB resistant</td>
        <td>EhnADaDfnTB</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Lzd contaminated/indeterminate</td>
        <td>ePD0F8obRs8</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - E contaminated/indeterminate</td>
        <td>EtQJDbQppQI</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Z resistant</td>
        <td>EUoIM0Gbjcq</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Dlm resistant</td>
        <td>Ew0ZLYwvP0N</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Lfx resistant</td>
        <td>exwSqqUbu1i</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Am indeterminate</td>
        <td>f5iJzjQNKc0</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Cfz resistant</td>
        <td>F8DmuEmfrYR</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - H CB resistant</td>
        <td>FaO1ALEZbWD</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - H CB resistant</td>
        <td>fEZeFn8VTpk</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Mfx CC contaminated/indeterminate</td>
        <td>FHU4eNjE5FD</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Z contaminated/indeterminate</td>
        <td>fIbds4Nfw1i</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - H CB contaminated</td>
        <td>fITjLSEGjiq</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - H CB susceptible</td>
        <td>fkva9qgQzv1</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Lzd resistant</td>
        <td>fpXisLGhJfK</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Am resistant</td>
        <td>FzvIunVITV7</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Cfz susceptible</td>
        <td>g8HOqnoSNJ9</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Mfx CB contaminated</td>
        <td>glxNdJrAU4x</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Lfx indeterminate</td>
        <td>gpcKhKQvKWR</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Z indeterminate</td>
        <td>GUWNoDKwVeB</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - H CB susceptible</td>
        <td>gwJnPsEhIvZ</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - E contaminated/indeterminate</td>
        <td>gYdixn3rVl7</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Mfx CC susceptible</td>
        <td>H3TqQeEo9MY</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - E susceptible</td>
        <td>h4iCiDYGYwR</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Bdq resistant</td>
        <td>H8hAkVy6cc6</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - H CB contaminated/indeterminate</td>
        <td>H9pBIDDmvRF</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Bdq susceptible</td>
        <td>Hb3NQ6s8obq</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Am contaminated/indeterminate</td>
        <td>HJ7yxI5uok5</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Am susceptible</td>
        <td>hL4mwtjHRFZ</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Lfx resistant</td>
        <td>HNLM0vPGidN</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Mfx CC contaminated</td>
        <td>i14osWxv3vs</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - H CB indeterminate</td>
        <td>I64mYichCJ7</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - E susceptible</td>
        <td>i7BNLtz6jEk</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Mfx CB contaminated/indeterminate</td>
        <td>ibm1blKTuPA</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - H CC resistant</td>
        <td>ic0VoKRJi8V</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Mfx CB susceptible</td>
        <td>iNHCjhXr71r</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Lfx susceptible</td>
        <td>JBEHF7dwqbE</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - R resistant</td>
        <td>jEFlq5DrhmK</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Mfx CC resistant</td>
        <td>jGOj77I7ivr</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - H CB resistant</td>
        <td>jmASgzacESm</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Bdq resistant</td>
        <td>JMJzISQzRK2</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - H CB contaminated/indeterminate</td>
        <td>JzIoXaU5gc7</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Lzd resistant</td>
        <td>K0pjdy1M4eD</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Bdq indeterminate</td>
        <td>k1b1mUVqTvK</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - E resistant</td>
        <td>K59BIxT2i6P</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Dlm contaminated/indeterminate</td>
        <td>KDMYnCVSgTk</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - H CB susceptible</td>
        <td>KeCuEyh87Ga</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - E resistant</td>
        <td>KiRnQZDm9hc</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Mfx CB indeterminate</td>
        <td>kRJlr5MFMSh</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - H CB contaminated/indeterminate</td>
        <td>KVMYPcUq22W</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Cfz contaminated/indeterminate</td>
        <td>L26pzli6SQ3</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - H CC contaminated</td>
        <td>L2Sv0Lmeke5</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Am contaminated</td>
        <td>l76u70Y8RNm</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - R resistant</td>
        <td>lAFXVyIOz59</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Lzd contaminated</td>
        <td>lQnrHEMWAee</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Lzd susceptible</td>
        <td>ltuLoYVJ4yN</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - H CC susceptible</td>
        <td>luMcMB4YiL9</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Bdq susceptible</td>
        <td>lWEOXjxUbwf</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Lfx resistant</td>
        <td>lwr3AChFg30</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Mfx CC resistant</td>
        <td>m6bgoNYcG12</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - H CC resistant</td>
        <td>m8N1dCCrsaT</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Am susceptible</td>
        <td>M9mlpuwMiJ8</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - H CC susceptible</td>
        <td>mBK3lYq8HO8</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Mfx CB susceptible</td>
        <td>mdIjVH1NUaF</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Z susceptible</td>
        <td>mgyXxutltWj</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - E susceptible</td>
        <td>MIDce43XVMU</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - R contaminated/indeterminate</td>
        <td>MT7aEWVXFBf</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Patients with inoculation date for initial DST SM</td>
        <td>MTU6QAz2cpX</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Lfx contaminated/indeterminate</td>
        <td>N7o1Xqjimlj</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - R resistant</td>
        <td>nea65dZOQfp</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Lfx contaminated/indeterminate</td>
        <td>npECBAtnX10</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Am susceptible</td>
        <td>nQp5mF3EWSv</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Dlm contaminated/indeterminate</td>
        <td>NQyWPTJyzhL</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Dlm indeterminate</td>
        <td>O07GF4PWILB</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Bdq contaminated/indeterminate</td>
        <td>o0r6wVvQT1H</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Bdq resistant</td>
        <td>O6sByxTUSCg</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Lfx contaminated/indeterminate</td>
        <td>OSIs8OpyxVO</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Cfz resistant</td>
        <td>oyDpKH5EAxE</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - H CC resistant</td>
        <td>P1wRsnQDSoO</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Cfz resistant</td>
        <td>pg04Amkdg8w</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - H CC contaminated/indeterminate</td>
        <td>PHv62Yu06oi</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - E susceptible</td>
        <td>pnT5LoEQyzr</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Lzd contaminated/indeterminate</td>
        <td>QBlVFZk3DBu</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - R indeterminate</td>
        <td>QBTDDGn35IH</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Mfx CC contaminated/indeterminate</td>
        <td>qhTaRzXxdgE</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Lfx susceptible</td>
        <td>QLOD6SMC2A0</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Mfx CC resistant</td>
        <td>qogSzR2VXkK</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Samples with result for initial DST SM</td>
        <td>QPGYhthplln</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Lzd susceptible</td>
        <td>r35T9E2eN0J</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Cfz susceptible</td>
        <td>rAIsq8tQ0rL</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Lzd susceptible</td>
        <td>RBKOeLO8kFs</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - R resistant</td>
        <td>RFUHj0EVvIW</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Am susceptible</td>
        <td>rq7eOFDLmQK</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Mfx CB resistant</td>
        <td>rQXzjEVe3c2</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Mfx CB susceptible</td>
        <td>RTLLeqWAffq</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Dlm contaminated</td>
        <td>rUvdF2y3yQV</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Z susceptible</td>
        <td>RyF9HEzgBBn</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Cfz resistant</td>
        <td>s560uws0IhG</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - R susceptible</td>
        <td>sh8xXpr7SOC</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Z contaminated</td>
        <td>Smx6TYW3634</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Dlm contaminated/indeterminate</td>
        <td>sqp1Bv70e3U</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Mfx CB resistant</td>
        <td>t2EcSOcA09t</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Cfz susceptible</td>
        <td>tDKHvNwKNRL</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Dlm susceptible</td>
        <td>thTqoznl0K7</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - H CC indeterminate</td>
        <td>ToEpkaCnJuf</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - H CC susceptible</td>
        <td>TSS4Ymmu0qa</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Dlm resistant</td>
        <td>ttyarOal7wI</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Dlm susceptible</td>
        <td>tuFTLk3Q0ss</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Mfx CC susceptible</td>
        <td>U4mKeK8i4Hk</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - R susceptible</td>
        <td>UfEFCBuifbO</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - R contaminated/indeterminate</td>
        <td>ulABEq4nBsW</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Lzd indeterminate</td>
        <td>VFwlYCRpKT8</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - R contaminated</td>
        <td>VIGJElSLwE6</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Cfz indeterminate</td>
        <td>vMpjSJHqaNa</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Mfx CB resistant</td>
        <td>vpFUsKTHw7C</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Cfz contaminated/indeterminate</td>
        <td>vPjEMOUrOiA</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Am resistant</td>
        <td>VsaE6AEggjD</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Mfx CC resistant</td>
        <td>VxTMToeTQsg</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Mfx CC susceptible</td>
        <td>vxy56EFkTrH</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - E indeterminate</td>
        <td>w2AaUjwDGui</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Am contaminated/indeterminate</td>
        <td>wjQ7CrAeA6p</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - R contaminated/indeterminate</td>
        <td>WLH2VJO0PkN</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Dlm susceptible</td>
        <td>wMrYlXritKK</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Z contaminated/indeterminate</td>
        <td>wnmc8YIahud</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - R susceptible</td>
        <td>Won3WS3jgBz</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Bdq contaminated/indeterminate</td>
        <td>WwLq06C7iTC</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Lfx susceptible</td>
        <td>WYIKQdnWj8v</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Lzd contaminated/indeterminate</td>
        <td>X1OWCAaNwhw</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Mfx CB contaminated/indeterminate</td>
        <td>XbDlCbLLMWa</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Cfz contaminated</td>
        <td>XCJmxcszJ4E</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Z susceptible</td>
        <td>xHZKn549ZRN</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Z resistant</td>
        <td>XJom38gElVN</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Dlm susceptible</td>
        <td>xjqlj9qGNwf</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Z susceptible</td>
        <td>XQluYa6a41F</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - E contaminated</td>
        <td>YeU707qWYqZ</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Am resistant</td>
        <td>yj67gy58tvc</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - H CB resistant</td>
        <td>yw1mFlZWAMP</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Dlm resistant</td>
        <td>ywEgFe3CmDN</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Lfx susceptible</td>
        <td>Z28tLWyehWi</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Lzd resistant</td>
        <td>z4w7a7VHWsr</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: new patients - Bdq resistant</td>
        <td>ZhWUJgUGMzD</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Bdq susceptible</td>
        <td>Zie6OAMjczP</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Patients with result for initial DST SM</td>
        <td>ZMo9mf0LfWt</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: samples - Z resistant</td>
        <td>zN38C55xHYZ</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Mfx CC contaminated/indeterminate</td>
        <td>Ztm42od2b6y</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: previously treated patients - Lzd resistant</td>
        <td>zwG40huDp6Q</td>
      </tr>
      <tr>
        <td>qPEvRoiKifn</td>
        <td>TB DRS - Initial DST in solid media (e.g. LJ) </td>
        <td>Initial DST SM: patients - Z resistant</td>
        <td>ZWGzbjgAKMS</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: new patients - Km resistant</td>
        <td>afmIU4uXULr</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>Samples with result for LPA FQ/2LI</td>
        <td>BP1h0h5Fcsc</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: previously treated patients - Am/Cm resistant</td>
        <td>BpRbOc95EiZ</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - Am/Cm indeterminate</td>
        <td>cjamO4QmiQl</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>Patients with invalid LPA FQ/2LI result</td>
        <td>cMcje1sf4Pn</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: new patients - Am/Cm indeterminate</td>
        <td>CVHpNLwyPw9</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - Km indeterminate</td>
        <td>dFWU6kNKodU</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: 6 days</td>
        <td>eMQxOQjYOAk</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - Km susceptible</td>
        <td>EXziKxYBfcC</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: previously treated patients - Km susceptible</td>
        <td>FBfIl9ERVVt</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: new patients - E resistant</td>
        <td>fE6l4xcNtLq</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - Km indeterminate</td>
        <td>FeaSAdlKno2</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - Km susceptible</td>
        <td>fI46ToIG10v</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - E resistant</td>
        <td>FLYNb9akyHF</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: new patients - E indeterminate</td>
        <td>GAPMlTbDkXb</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: 10+ days</td>
        <td>GLQZXhtNL52</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - Am/Cm resistant</td>
        <td>gSD4sqSzgGL</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: 4 days</td>
        <td>H8hl6NVdcGi</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: previously treated patients - E indeterminate</td>
        <td>HfuHrxdatgU</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: 5 days</td>
        <td>HicWDsLR7Nj</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - Am/Cm susceptible</td>
        <td>HkAV7ShttEV</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>Days between sample collection and LPA FQ/2LI test</td>
        <td>ibSDbrIrEph</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - Am/Cm susceptible</td>
        <td>IkHjK7xP7Xf</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - E susceptible</td>
        <td>jRlXrgXU6gg</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: new patients - FQ indeterminate</td>
        <td>jZM5koLMnTL</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: previously treated patients - Km resistant</td>
        <td>k3dVli6pjex</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: 8 days</td>
        <td>KaGNXiu65VF</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - FQ resistant</td>
        <td>KDdD36jnouX</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - FQ resistant</td>
        <td>lHv7SkxUIi0</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - MTB detected</td>
        <td>M65WBBPkgIF</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - FQ susceptible</td>
        <td>mg6xbOMevpk</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: 1 day</td>
        <td>mmAog6SHRqH</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - FQ indeterminate</td>
        <td>mSoVmSlOATC</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - Am/Cm indeterminate</td>
        <td>mx7q7B3ZSpH</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - FQ susceptible</td>
        <td>n6Rrth8edSM</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: new patients - FQ susceptible</td>
        <td>NbEBOhJFhBx</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: previously treated patients - FQ resistant</td>
        <td>nVrp5WyTpvb</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: previously treated patients - FQ indeterminate</td>
        <td>NWJoPKtoVSu</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - E indeterminate</td>
        <td>nYuAYvmgfbs</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: previously treated patients - Km indeterminate</td>
        <td>oLyx8mPsMUU</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - Km resistant</td>
        <td>OxtZda8ABPq</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: new patients - Am/Cm resistant</td>
        <td>P8GK4wGFFTE</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: new patients - Km susceptible</td>
        <td>PCemW9SgW7M</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: previously treated patients - E resistant</td>
        <td>pcyI2L4i2bS</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: 0 days</td>
        <td>PD1r3kjNsEZ</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - MTB detected</td>
        <td>q6rKTcc0b4G</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: 7 days</td>
        <td>QarDtlid8zk</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - E resistant</td>
        <td>Qfhf25Oce5X</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: 2 days</td>
        <td>rnxWrZanCtV</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: 3 days</td>
        <td>rSrlFohRGM1</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>Processed LPA FQ/2LI samples</td>
        <td>rxuYRTJZ2ej</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: previously treated patients - FQ susceptible</td>
        <td>s9gdW5R4nj1</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: new patients - E susceptible</td>
        <td>SjJygt0PwVc</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - Km resistant</td>
        <td>SKYQM109VlR</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: previously treated patients - E susceptible</td>
        <td>SmerIApsjMN</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - FQ indeterminate</td>
        <td>tiuKqMsWxrw</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - Error/Invalid/No result</td>
        <td>tja5fRSuTBE</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: 10 days</td>
        <td>tYLvtd2eq1T</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - E indeterminate</td>
        <td>u8hqJ0vFyDx</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: 9 days</td>
        <td>uu0066KEVEY</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - Am/Cm resistant</td>
        <td>uvyU5oBD2oz</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: patients - MTB not detected</td>
        <td>VCfBUEMSE8h</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - MTB not detected</td>
        <td>VVv5IQaPrdI</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: previously treated patients - Am/Cm indeterminate</td>
        <td>W2V43bhnDpW</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: previously treated patients - Am/Cm susceptible</td>
        <td>XmzqEJb0w79</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: samples - E susceptible</td>
        <td>XNFmjjFC52a</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>Patients with result for LPA FQ/2LI</td>
        <td>Yb4I8XsLvAC</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: new patients - Am/Cm susceptible</td>
        <td>yXTY7DS9wuu</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: new patients - Km indeterminate</td>
        <td>Z0nNQL81cpK</td>
      </tr>
      <tr>
        <td>QTlcFCQucx2</td>
        <td>TB DRS - LPA FQ/2LI</td>
        <td>LPA FQ/2LI: new patients - FQ resistant</td>
        <td>zo63zcpBZCV</td>
      </tr>
    </table>
    <h2 id="userGroups">User Groups</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB DRS data capture</td>
        <td>2020-09-29</td>
        <td>byS9SDFsd9p</td>
      </tr>
      <tr>
        <td>TB DRS access</td>
        <td>2020-09-29</td>
        <td>LHhbGJKXmzz</td>
      </tr>
      <tr>
        <td>TB DRS admin</td>
        <td>2020-09-29</td>
        <td>vN3X85Hxzno</td>
      </tr>
    </table>
    <h2>Users</h2>
    <table>
      <tr>
        <th>Username</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>who</td>
        <td>2020-07-07</td>
        <td>vUeLeQMSwhN</td>
      </tr>
    </table>
  </body>

</html>